[{"nctId":"NCT07552610","OrgName":"Xuanwu Hospital, Beijing","Titlefull":"Efficacy and Safety of Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy in Acute Anterior Circulation Large-Vessel Occlusion: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study","BriefSummary":"Stroke remains a major global health burden, with acute ischemic stroke (AIS) accounting for more than 65% of all cases. Endovascular thrombectomy (EVT) has been established as a standard treatment for large vessel occlusion (LVO) stroke; however, \"futile recanalization\" remains common, with many patients failing to achieve favorable functional outcomes despite successful vessel reperfusion. Increasing evidence indicates that neutrophils and neutrophil extracellular traps (NETs) play important roles in post-reperfusion inflammation, thrombosis, and microcirculatory dysfunction, which may contribute to thrombolysis resistance and poor prognosis. Neutrophil elastase (NE), a key component associated with NETs, may further aggravate vascular injury and thrombus formation.\n\nSivelestat Sodium is a selective NE inhibitor that has demonstrated anti-inflammatory and organ-protective effects in patients with acute respiratory distress syndrome and in experimental models of cerebral ischemia. It may help preserve blood-brain barrier integrity, reduce brain edema, and improve neurological outcomes. Based on these findings, this study is designed as a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of sivelestat sodium as an adjunct to EVT in patients with acute anterior circulation large-vessel occlusive stroke within 24 hours of onset. The results of this study are expected to provide further clinical evidence for anti-inflammatory adjunctive treatment strategies aimed at reducing futile recanalization and improving functional outcomes in AIS.","ExperimentalDrugs":"[\"sivelestat sodium\",\"procedure: endovascular thrombectomy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":23,"Phase":"NA","lastUpdateDate":"2026-04-20"},{"nctId":"NCT07333950","OrgName":"Beijing Tiantan Hospital","Titlefull":"The Efficacy and Safety of Endovascular Therapy for Acute Ischemic Stroke Due to Large Core Infarction -- A Multicenter, Prospective, Open-label, Blind Endpoint, Randomized Controlled Trial","BriefSummary":"This study assesses the efficacy and safety of endovascular therapy in patients with acute basilar artery occlusion with large core infarction within a multicenter, prospective, open-label, blinded endpoint, randomized controlled trial","ExperimentalDrugs":"[\"procedure: endovascular recanalization strategy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"NA","lastUpdateDate":"2025-12-30"},{"nctId":"NCT05225961","OrgName":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","Titlefull":"Randomized Multi-center Clinical Trial to Assess Effectiveness and Safety of Tirofiban Versus Intravenous Aspirin in Patients With Acute Ischemic Stroke Secondary to Tandem Injury, Subject to Recanalization Therapy Through Endovascular Treatment","BriefSummary":"Patients with tandem lesions (TL) are defined as patients with an acute ischemic stroke (AIS) with occlusion of an intracranial vessel of the anterior circulation and an occlusion or severe stenosis (70-99%) of the origin of the ipsilateral internal carotid artery (ICA). The greatest current limitation in the management of this type of lesion is the use of antithrombotic medication (double antiaggregation) in the acute phase that is required in case of placing extracranial stent to stabilize the atheroma plaque. In relation to this antiplatelet regimen, the latest clinical practice guidelines warn about the risk of combining intravenous fibrinolysis with antiplatelet medication in the acute phase, since it seems to increase the risk of symptomatic intracranial hemorrhage (sICH). However, the non-stabilization of the carotid atheroma plaque is associated with higher rates of cervical reocclusion, poorer functional prognosis, and higher mortality.\n\nTherefore, the use of a single antiplatelet agent could be a reasonable alternative. To establish the best protocol for mono-antiaggregant therapy in the acute phase of TL, the investigators propose to carry out a prospective multicenter randomized clinical trial.\n\n1. All patients with ischemic stroke secondary to TL in the anterior circulation candidates for mechanical thrombectomy in whom cervical endoprosthesis will be placed in the acute phase, will be included, randomized to two groups: 500 mg of intravenous (iv) Aspirin vs Low dose regimen of Tirofiban iv.\n2. Carotid reocclusion rates and sICH rates will be evaluated within the first 24 hours after mechanical thrombectomy . As a secondary objective, the functional prognosis at 3 months in both groups will be analyzed, as well as a panel of biomarkers predictors of reocclusion in both groups. Establishing an antiplatelet management protocol in the acute phase in these patients would be an innovative strategy not developed by any other group worldwide, and would place us at the forefront of research in the field. Likewise, developing a clinical-biological predictive model of carotid reocclusion will allow us to establish risk patients in which to plan alternative treatments. Reference hospitals in the treatment of ischemic stroke at the national level with sufficient experience in the management of this pathology will participate in the project.","ExperimentalDrugs":"[\"tirofiban\",\"acetylsalicylic acid\"]","Allcountries":"[\"Spain\"]","FirstAdminInter":"Other","TreatDur":"Day 1 only","Status":"COMPLETED","Add_on":"EVT mandatory; IVT optional","Endpoint":"Early efficacy","total_Score":16,"Phase":"PHASE4","lastUpdateDate":"2026-03-30"},{"nctId":"NCT07521930","OrgName":"Johns Hopkins University","Titlefull":"Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)","BriefSummary":"The goal of this clinical trial is to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different areas of the brain to allow adults affected by disabling paralysis (see Eligibility for more details) to control and receive feedback from assistive devices.","ExperimentalDrugs":"[\"device: intent neural interface system\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":8,"Phase":"NA","lastUpdateDate":"2026-04-02"},{"nctId":"NCT07401784","OrgName":"Second Affiliated Hospital of Nanchang University","Titlefull":"Efficacy and Safety Evaluation of Remote Ischemic Adaptation ( Intermittent Pressure Stimulation ) in the Treatment of Insomnia After Stroke","BriefSummary":"The incidence of post-stroke depression is high, which will affect the rehabilitation of neurological function, damage cognitive function, and increase the risk of subsequent stroke recurrence. The guidelines recommend that in addition to antiplatelet, blood pressure control, lipid-lowering and other treatments, secondary prevention of post-stroke depression should also be strengthened. Moreover, after the occurrence of post-stroke depression, methods such as medication and psychotherapy have their own limitations, such as potential adverse drug reactions and limited psychotherapy. Therefore, it is necessary to pay attention to the prevention of post-stroke depression.\n\nThe remote ischemic adaptation therapy applied in our study is a safe, non-invasive and convenient physical therapy. By transiently and repeatedly applying ischemia-reperfusion stimulation to both upper arms, it induces a systemic protective response, improves the brain 's tolerance to ischemia and hypoxia, and exerts a protective effect on multiple organs such as the brain and heart. The RIC therapeutic instrument has been national patented and has been maturely applied to the prevention and treatment of acute cerebral infarction, which can promote the rehabilitation of neurological function. In addition, it also has certain curative effect in the treatment of cerebrovascular stenosis, refractory hypertension, depression, insomnia, anxiety and so on.","ExperimentalDrugs":"[\"device: automatic ischemic preconditioning therapeutic apparatus\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":9,"Phase":"NA","lastUpdateDate":"2026-02-03"},{"nctId":"NCT07516522","OrgName":"Tang-Du Hospital","Titlefull":"Intra-arterial Methylprednisolone After Successful Endovascular Thrombectomy Anterior Circulation Large Vessel Occlusion","BriefSummary":"The purpose of IMPACT-LVO trial is to investigate the efficacy and safety of early adjunctive intra-arterial combined with intravenous administration methylprednisolone sodium succinate after successful endovascular thrombectomy in anterior circulation large vessel occlusion patients.\n\nThis is a multicenter, randomized, double-blind, placebo-controlled trial. Acute ischemia stroke patients with anterior circulation large vessel occlusion within 24 hours from last known well will be screened for this trial. Successful recanalization after mechanical thrombectomy (eTICI 2b-3) patients will be randomized 1:1 to either methylprednisolone sodium succinate group or placebo group. The methylprednisolone sodium succinate group patients will receive intra-arterial methylprednisolone sodium succinate 40mg immediately after the recanalization. Then, intravenous administration with methylprednisolone sodium succinate 2mg/kg in the next 3 days. The placebo group patients will receive intra-arterial and intravenous sterile water for injection.\n\nThe shift on modified Rankin Scale score is designed to detect in the present trial. A sample size of n = 178 patients (n=89 per group) is required. The intention-to-treat principle will be applied to the primary analysis, therefore, to safeguard against dilution of the treatment effect associated with an approximate 15% non-adherence rate (due to loss to follow-up, consent withdrawal and other reasons), we planned to enrol n=210 patients (n=105 per group) for this study. The findings of IMPACT-LVO are likely to have a direct impact on clinical practice.","ExperimentalDrugs":"[\"the methylprednisolone sodium succinate group\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Safety","total_Score":24,"Phase":"PHASE2","lastUpdateDate":"2026-03-31"},{"nctId":"NCT07398612","OrgName":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","Titlefull":"Clinical Study on the Safety and Efficacy of Human Adipose-Derived Stem Cell Exosomes in the Treatment of Acute Ischemic Stroke","BriefSummary":"This is a Phase I/II, randomized, double-blind, placebo-controlled, single/multiple ascending dose clinical study (Investigator-Initiated Trial, IIT) evaluating the safety and efficacy of Human Adipose-Derived Stem Cell Exosomes (ADSC-exo, STX11102 Nasal Spray) in treating acute ischemic stroke (AIS). The study consists of two sequential parts: a Single-Ascending Dose (SAD) study and a Multiple-Ascending Dose (MAD) study.\n\nThe SAD part will enroll 12 subjects with mild stroke (NIHSS 1-4). They will be sequentially enrolled into three dose cohorts (4 subjects each: 2×10⁹, 4×10⁹, and 8×10⁹ particles/mL) to receive a single nasal spray dose alongside standard care, with safety monitoring for 14 days. Dose escalation is contingent upon the safety review of the preceding cohort.\n\nUpon confirming safety, the study proceeds to the MAD part, which will enroll 48 subjects with moderate stroke (NIHSS 5-12). They will be randomized into two dose groups (Low and High Dose), each containing an active treatment arm and a placebo arm (saline) in a 2:1 ratio (16 active:8 placebo per group). Subjects will self-administer the nasal spray daily for 14 days, with follow-up until Day 90. The primary objective is to evaluate safety, with secondary objectives assessing efficacy via neurological function scales (NIHSS, mRS, BI) and infarct volume change on MRI.","ExperimentalDrugs":"[\"biological: human adipose-derived stem cell exosomes\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"Safety","total_Score":16,"Phase":"PHASE1","lastUpdateDate":"2026-02-09"},{"nctId":"NCT07127484","OrgName":"First Affiliated Hospital of Wannan Medical College","Titlefull":"Efficacy and Safety of Hemoadsorption for Severe Ischemic Stroke","BriefSummary":"This is a multicenter, randomized-controlled, open-label, blinded endpoint clinical trial that aims to evaluate the efficacy and safety of hemoadsorption for severe ischemic stroke","ExperimentalDrugs":"[]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":20,"Phase":"NA","lastUpdateDate":"2026-05-13"},{"nctId":"NCT07436156","OrgName":"Route 92 Medical, Inc.","Titlefull":"SUMMIT RISE Study of Acute Ischemic Stroke Patients Evaluating the Route 92 Medical Reperfusion Systems.","BriefSummary":"SUMMIT RISE Study of Acute Ischemic Stroke Patients","ExperimentalDrugs":"[\"device: route 92 medical reperfusion systems\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 6 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":29,"Phase":"PHASE4","lastUpdateDate":"2026-02-25"},{"nctId":"NCT07528456","OrgName":"Nanfang Hospital, Southern Medical University","Titlefull":"Efficacy and Safety of Butylphthalide in Improving Cerebral Edema After Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Double-Blind, Double-Dummy, Randomized Controlled Trial","BriefSummary":"This is a prospective, multicenter, randomized controlled clinical study aimed at evaluating the efficacy of butylphthalide in improving the severity of cerebral edema and prognosis in patients with acute anterior circulation large vessel occlusion after endovascular treatment.","ExperimentalDrugs":"[\"butylphthalide\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":19,"Phase":"PHASE4","lastUpdateDate":"2026-04-07"},{"nctId":"NCT06038136","OrgName":"Medical University of South Carolina","Titlefull":"Post-Stroke Enhancement of Delirium Outcomes With Reduction in Neuro-checks","BriefSummary":"There have been limited studies on delirium in patients hospitalized with acute stroke. There have been no studies on the potential impact of overnight neuro-checks and resulting sleep disruption on delirium or other outcomes. Additional research is needed to determine if overnight checks are necessary or even harmful. We aim to find out if stopping overnight neuro checks may prevent delirium and benefit the patient.","ExperimentalDrugs":"[\"behavioral: decreased neuro checks overnight\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"SUSPENDED","Add_on":"Other","Endpoint":"Early efficacy","total_Score":5,"Phase":"NA","lastUpdateDate":"2026-04-03"},{"nctId":"NCT06858436","OrgName":"Taichung Veterans General Hospital","Titlefull":"The Role of SGLT2 Inhibitors in Stroke-reperfusion Injury:A Multi-Center, Randomized, Open-Label, Controlled Trial","BriefSummary":"Background:\n\nReperfusion therapies, including intravenous rt-PA and mechanical thrombectomy, significantly improve outcomes in acute ischemic stroke. However, these interventions also increase the risk of hemorrhagic transformation and malignant edema. Preclinical studies have demonstrated that Canagliflozin, an SGLT2 inhibitor, reduces astrocyte swelling and brain edema in a transient middle cerebral artery occlusion (tMCAo) model. While SGLT2 inhibitors have shown neuroprotective effects in the acute phase of ischemic stroke, their potential to mitigate hemorrhagic transformation and malignant edema following reperfusion therapy in humans remains unexamined.\n\nAims:\n\nThis study aims to evaluate the effect of SGLT2 inhibitors on hemorrhagic transformation and malignant edema in patients undergoing reperfusion therapy for acute ischemic stroke.\n\nMethods:\n\nThis is a multi-center, randomized, open-label, controlled study enrolling ischemic stroke patients aged 18 years or older who meet predefined inclusion and exclusion criteria. Participants will be randomized to receive Canagliflozin 100 mg once daily for 14 days or no additional treatment before undergoing mechanical thrombectomy. Clinical data collection will include baseline demographics, medical and medication history, NIHSS scores at admission and 24 hours post-reperfusion, stroke subtype, modified Thrombolysis in Cerebral Infarction (TICI) scores, laboratory results, and modified Rankin Scale (mRS) scores at discharge and 3 months post-stroke.\n\nThe primary outcome is to assess the association between Canagliflozin use and the severity of hemorrhagic transformation and malignant edema. Hemorrhagic transformation will be classified using the Heidelberg criteria, and malignant edema will be defined as a midline shift of ≥5 mm. Brain imaging, including CT scans at 24 hours post-intervention and additional scans as clinically indicated, will be reviewed by blinded radiologists. Brain MRA will also be performed to assess infarct size and edema progression.\n\nImportance:\n\nThis study aims to explore the potential for repurposing SGLT2 inhibitors as a therapeutic strategy in acute ischemic stroke. If Canagliflozin is shown to reduce hemorrhagic transformation and malignant edema, it could offer a novel adjunctive treatment to improve patient outcomes following reperfusion therapy.","ExperimentalDrugs":"[\"canagliflozin 100mg\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":19,"Phase":"PHASE4","lastUpdateDate":"2026-03-30"},{"nctId":"NCT07598799","OrgName":"Shanghai Jiao Tong University Affiliated Sixth People's Hospital","Titlefull":"Rapid Local Ischemic Postconditioning Following Successful Recanalization After Endovascular Thrombectomy in Large Ischemic Core Stroke","BriefSummary":"The main goal of this study is to find out if a new, quick \"brain rescue\" procedure can help people recover better from a severe stroke caused by a large vessel occlusion.\n\nWhen someone has this type of stroke, doctors often perform a procedure called an endovascular thrombectomy (EVT). In EVT, they thread a thin tube through a blood vessel up to the brain to remove the clot and restore blood flow. This is a highly effective treatment.\n\nHowever, for some patients, suddenly restoring blood flow can cause additional, unexpected injury to the brain. This is called \"reperfusion injury.\" This study tests a technique called rapid local ischemic postconditioning (RL-IPostC) that might prevent this extra damage. It's a very simple additional step performed immediately after the clot is successfully removed.\n\nThe doctor would briefly inflate and deflate a tiny balloon inside the proximal brain artery after recanalization, creating very short, controlled \"pauses\" in blood flow. This is believed to give brain cells a gentler \"wake-up\" call, helping them tolerate the return of oxygen-rich blood.\n\nThe study will test two different \"doses\" of this procedure (meaning different numbers of inflation/deflation cycles) against the standard care (no additional procedure).\n\nPhase IIb (the first part): Which dose of RL-IPostC (high or low) is more promising for reducing early brain swelling (measured by whether the brain's midline has shifted less than 3 mm on a 24-hour scan)? Phase III (the main part): Using the best dose from Phase IIb, does RL-IPostC improve a patient's functional recovery three months later, specifically enabling them to walk and manage daily activities without help? A total of 288 participants who have had a large-vessel occlusion stroke and successful clot removal will be enrolled. If early results look promising but not quite conclusive, the study can increase the total number of participants up to 448 to get a clearer answer.\n\nIf successful, this study could identify a simple, low-cost add-on procedure to a standard stroke treatment that improves long-term recovery and quality of life for thousands of stroke patients. It's a potential new tool to protect the brain after blood flow is restored. This is a carefully designed study testing a gentle \"on/off\" blood flow technique right after clot removal, to see if it can reduce brain injury and help people walk and live more independently after a severe stroke.","ExperimentalDrugs":"[\"procedure: high-dose rl-ipostc\",\"procedure: low-dose rl-ipostc\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"NA","lastUpdateDate":"2026-06-03"},{"nctId":"NCT07627399","OrgName":"University of Malaga","Titlefull":"Effectiveness of Implementing Best Care Practices in the Management of Patients With Acute Stroke in Conventional Hospitalization: A Cluster-Randomized, Open, Stepped-Wedge Controlled Trial.","BriefSummary":"The goal of this clinical trial is to evaluate whether a multicomponent nurse-led intervention (BEST CARE ICTUS\\_HC) can reduce stroke-related complications and improve recovery in adults (18 years and older) hospitalized with an acute ischemic or hemorrhagic stroke in hospitals without specialized Stroke Units. The main questions it aims to answer are:\n\n1. Does the implementation of the program increase the early and correct detection of swallowing difficulties (dysphagia) to prevent pneumonia?\n2. Does the program reduce the severity of attention problems (hemineglect) and improve the patients' quality of life up to 6 months after discharge?\n\nResearchers will compare patients receiving the BEST CARE ICTUS\\_HC program to patients receiving usual hospital care to see if this new approach improves patient safety and long-term functional recovery.\n\nParticipants will:\n\n* Receive either the usual hospital care for stroke or the BEST CARE ICTUS\\_HC nursing program, depending on the study phase of the hospital.\n* Be screened for swallowing problems using a standardized test before receiving any food or drink.\n* Be cared for in an adapted environment (FLECHA Project) that uses visual signs and room organization to help with orientation and safety.\n* Have their temperature, blood sugar, and blood pressure monitored under a strict specialized protocol.\n* Be contacted by phone 30 days and 6 months after leaving the hospital to answer questions about their health and quality of life.","ExperimentalDrugs":"[\"other: best care ictus_hc bundle\"]","Allcountries":"[\"Spain\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Other","total_Score":8,"Phase":"NA","lastUpdateDate":"2026-05-29"},{"nctId":"NCT07216170","OrgName":"Microvention-Terumo, Inc.","Titlefull":"REVascularization In Large VEssel Occlusion for Acute Ischemic Stroke","BriefSummary":"The objective of this study is to evaluate the safety and effectiveness of the SOFIA Flow 88 Aspiration Catheter for treatment of acute ischemic stroke.","ExperimentalDrugs":"[\"device: sofia flow 88 aspiration catheter\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Safety","total_Score":24,"Phase":"NA","lastUpdateDate":"2026-05-21"},{"nctId":"NCT07203625","OrgName":"Xuanwu Hospital, Beijing","Titlefull":"Intravenous Tenecteplase Before Interhospital Transfer for Thrombectomy in Acute Basilar Artery Occlusion at 4.5 to 24 Hours","BriefSummary":"This study is designed to investigate the efficacy and safety of intravenous tenecteplase before interhospital transfer from a non-endovascular capable center(nECC) to an endovascular capable center (ECC) for thrombectomy in patients with acute ischemic stroke (AIS) caused by neuroimaging-confirmed acute basilar artery occlusion (BAO) between 4.5-24 hours of symptom onset.","ExperimentalDrugs":"[\"tenecteplase thrombolysis\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"PHASE4","lastUpdateDate":"2026-03-16"},{"nctId":"NCT07610291","OrgName":"National University of Malaysia","Titlefull":"APPLICATION OF COGNITIVE CARE BUNDLE TO ISCHAEMIC STROKE PATIENTS AND ITS EFFECT ON POST-STROKE COGNITIVE OUTCOME: A PILOT RANDOMISED CONTROLLED TRIAL","BriefSummary":"The goal of this clinical trial is to learn if a set of treatments, called a \"cognitive care bundle,\" can help preserve cognitive ability in people who have had a stroke. This study will also test how feasible it is for people to follow this care bundle.\n\nThe main questions it aims to answer are:\n\n1. Do people find it feasible to follow the care bundle, which includes daily home blood pressure checks (and blood sugar checks for those with diabetes), along with referrals to specialists like dietitians, eye doctors, hearing specialists, and mental health professionals?\n2. Do people who receive the cognitive care bundle have better cognitive scores 3 months after their stroke, compared to those who receive standard care?\n\nResearchers will compare two groups of stroke survivors. One group will receive the cognitive care bundle plus standard medical care. The other group will receive standard medical care alone. This comparison will help researchers see if the care bundle works better to prevent cognitive decline.\n\nParticipants in the intervention (care bundle) group will:\n\nCheck and record their blood pressure daily at home (and their blood sugar too, if they have diabetes). Talk with a doctor weekly over the phone to review their readings and adjust medications if needed\n\nSee a dietitian for a personalized eating plan\n\nHave a hearing test by an audiologist\n\nHave a basic vision test by the research team\n\nAnswer a short questionnaire about their mood to screen for depression\n\nAll participants (in both groups) will undergo physiotherapy and cognitive training. Participants will be followed up with blood tests, examination by a doctor and questionnaires after 3 months.\n\nThis is a pilot study to see if this approach works and is practical to do in a larger future study.","ExperimentalDrugs":"[\"other: cognitive care bundle\",\"other: standard medical care (smc)\"]","Allcountries":"[\"Malaysia\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":10,"Phase":"NA","lastUpdateDate":"2026-05-20"},{"nctId":"NCT07414732","OrgName":"Massachusetts General Hospital","Titlefull":"The \"Savvy for Stroke Survivors\" Study: Testing a Novel Tool to Help Stroke Survivors Take Their Medication","BriefSummary":"The goal of this study is to test if Savvy, a multimodal intervention (consisting of psychological exercises, a weekly pill organizer, and a text message reminder system) can improve medication adherence in stroke survivors.\n\nThe main questions it aims to answer are:\n\n* Can the Savvy tool improve medication adherence in stroke survivors compared to usual care?\n* Does the use of the Savvy tool lead to better blood pressure control after a stroke?\n\nThe investigators will compare the use of the Savvy intervention to a control group that receives usual care, including a package of educational materials.\n\nThe study consists of the following components:\n\n* Participants will receive the Savvy intervention or usual care. The intervention package consists of short psychological exercises over the phone, a weekly medication organizer to support daily medication intake, and text message reminders to take medication and refill the medication box. Participants in the control group will receive usual care, including educational materials about the importance of blood pressure and medication.\n* All participants will receive a free home blood pressure monitor and will be requested to measure their blood pressure at certain time points during the study.\n* Participants will be enrolled in the study for 6 months and will have virtual follow-up calls at 3 and 6 months.","ExperimentalDrugs":"[\"behavioral: savvy medication adherence intervention\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":6,"Phase":"NA","lastUpdateDate":"2026-05-19"},{"nctId":"NCT07174414","OrgName":"Stanford University","Titlefull":"Cilostazol for Prevention of Recurrent Stroke Trial","BriefSummary":"The goal of this clinical trial is to learn whether adding cilostazol to aspirin or clopidogrel prevents stroke and heart attack in people who have had a stroke or mini-stroke.","ExperimentalDrugs":"[\"cilostazol 100 mg\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":15,"Phase":"PHASE3","lastUpdateDate":"2025-09-12"},{"nctId":"NCT07311304","OrgName":"Assiut University","Titlefull":"A Randomized Controlled Trial on the Efficacy of Early Task-Oriented Rehabilitation in Acute Stroke Recovery Compared to Traditional Rehabilitation","BriefSummary":"Stroke is one of the leading causes of long-term disability worldwide, and early rehabilitation is considered crucial for improving functional recovery. Traditional physiotherapy mainly focuses on mobility, strength, and general exercises, while task-oriented rehabilitation emphasizes practicing meaningful, goal-directed activities related to daily life. This randomized controlled trial aims to evaluate the efficacy of early task-oriented rehabilitation compared to traditional rehabilitation in acute stroke patients. Patients admitted with ischemic or hemorrhagic stroke within 48 hours will be randomly assigned to either a task-oriented rehabilitation program or conventional physiotherapy. Interventions will be delivered 3-4 times per week, 45-60 minutes per session, during hospitalization and continued in outpatient follow-up. The primary outcome will be functional independence assessed at 3 months. Secondary outcomes will include stroke severity, quality of life, and patient-reported outcomes. The findings are expected to provide evidence for improving rehabilitation strategies in Egypt.","ExperimentalDrugs":"[\"behavioral: task-oriented rehabilitation\",\"behavioral: traditional physiotherapy rehabilitation\"]","Allcountries":"[]","FirstAdminInter":"Within first 2 days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":15,"Phase":"NA","lastUpdateDate":"2025-12-21"},{"nctId":"NCT07335107","OrgName":"Beijing Tiantan Hospital","Titlefull":"Intravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion (RESCUE-AS): A Multicenter, Randomized, Open Label, Blinded Endpoint Study","BriefSummary":"The investigators propose to assess the efficacy and safety of intravenous tirofiban after bridging therapy (endovascular therapy \\[EVT\\] following intravenous Tenecteplase) for acute ischemic stroke due to intracranial atherosclerotic disease related large vessel occlusion (ICAD related LVO). This study will recruit 564 patients from about 50 hospitals in China. Inclusion criteria for the trial are: (1)age ≥18 years old, (2)Pre-mRS 0-2, (3)Baseline NIHSS 6-30 points, (4) Baseline ASPECTS ≥6 points, (5) Baseline CTA/MRA diagnosed: the ICA or MCA-M1/M2 occlusion, (6) Receiving bridging therapy (EVT following IV Tenecteplase) within 24 hours from stroke onset (7) Baseline DSA diagnosed: ICAD related LVO(if any one the following criteria is fulfilled: 1) absence of atrial fibrillation; 2) truncal-type occlusion; 3) residual stenosis ≥30% on DSA after the first retriever; 4) researchers determined it to be ICAD-related LVO based on the TOAST classification, (8) Have achieved successful reperfusion after EVT (mTICI ≥2b). Patients with previously known permanent, persistent, or paroxysmal atrial fibrillation, permanent stenting during EVT, severe bleeding or had a higher bleeding risk in the last 6 months, imaging examination before randomization showed the Heidelberg hemorrhage type 1c, 2, or 3 ICH with or without clinical exacerbation, infarct area greater than 50% of the middle cerebral artery blood supply area or infarct volume ≥70ml, cerebral hernia signs, and some other severe organic diseases and an expected survival time of less than 90 days, severe liver insufficiency or renal insufficiency will be excluded. Patients will be randomly assigned to the experimental group or control group at a 1:1 ratio. Experimental group will receive intravenous tirofiban of a dose of 0.4 μg/kilo/min for 30 minutes after the completion of bridging therapy, followed by a continuous infusion of 0.1 μg/kilo/min for up to 24 hours. Then the patient will transition to standard medical therapy, with no restrictions on the antiplatelet regimen but is advised to receive loading dose dual antiplatelet therapy (oral aspirin 100 mg and clopidogrel 300 mg four hours before the end of intravenous tirofiban and daily oral aspirin 100 mg and clopidogrel 75 mg for 30 days). Control group will receive standard medical therapy after bridging treatment. The primary endpoint is the proportion of modified Rankin Scale (mRS) score 0 to 2 at 90±7 days after onset. The primary safety outcome is the symptomatic intracerebral hemorrhage (sICH) within 48 hours after randomization according to ECASS III criteria. This trial will provide important information for the standardization of antiplatelet medication regimens after bridging therapy for improving functional outcomes in patients with acute large vessel atherosclerotic occlusive ischemic stroke.","ExperimentalDrugs":"[\"intravenous tirofiban\",\"standard medical therapy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT mandatory; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":27,"Phase":"PHASE3","lastUpdateDate":"2026-01-12"},{"nctId":"NCT07557485","OrgName":"Beijing Tiantan Hospital","Titlefull":"Safety and Efficacy of Endovascular Treatment for Progressive Stroke Due to Vertebrobasilar Artery Occlusion: A Multicenter, Prospective, Open-Label Randomized Controlled Trial With Blinded Endpoint Assessment","BriefSummary":"This multicenter, prospective, open-label randomized controlled trial with blinded assessment was designed to assess the efficacy and safety of endovascular treatment for progressive stroke due to vertebrobasilar artery occlusion.","ExperimentalDrugs":"[\"procedure: endovascular recanalization\",\"medical therapy alone\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"NA","lastUpdateDate":"2026-04-23"},{"nctId":"NCT07626450","OrgName":"Beijing Tiantan Hospital","Titlefull":"HyperBaric Oxygen Therapy After ACute Thrombectomy in Acute Ischemic strOke Due to Large Vessel occlusioN","BriefSummary":"The purpose of this RCT trial is to evaluate whether the sequential hyperbaric oxygen therapy can improve the 90-day functional outcome in patients with acute large vessel occlusion ischemic stroke after endovascular treatment.","ExperimentalDrugs":"[\"other: hyperbaric oxygen therapy plus standard medical treatment\",\"other: standard medical treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"NA","lastUpdateDate":"2026-06-02"},{"nctId":"NCT07585058","OrgName":"Shandong Provincial Hospital","Titlefull":"Safety and Efficacy of Early Brain-Computer Interface Training After Reperfusion Therapy in Acute Ischemic Stroke","BriefSummary":"This is a multicenter, prospective, randomized controlled trial designed to evaluate the efficacy, safety, and feasibility of early EEG-based non-invasive brain-computer interface (EEG-BCI) training as an add-on to standard early rehabilitation in patients with acute ischemic stroke (AIS) after reperfusion therapy. Eligible participants are adults aged 18 to 80 years with unilateral limb motor dysfunction after intravenous thrombolysis (IVT) and/or mechanical thrombectomy (MT). Participants will be randomized to receive either standard early rehabilitation plus closed-loop EEG-BCI dual-module virtual hand and gait training, or standard early rehabilitation alone.\n\nThe EEG-BCI intervention includes upper-limb virtual hand training and lower-limb gait/ankle dorsiflexion training, delivered twice daily for approximately 20 minutes per session over 5 consecutive days. The primary outcome is the change in Fugl-Meyer Assessment for Upper Extremity (FMA-UE) score from baseline (T0) to Day 30. Secondary outcomes include upper- and lower-limb motor function, ambulation, neurological status, disability, and activities of daily living. Safety and feasibility outcomes will also be assessed.","ExperimentalDrugs":"[\"device: eeg-based non-invasive brain-computer interface (bci) virtual hand/gait training system\",\"behavioral: standard early rehabilitation\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-05-08"},{"nctId":"NCT07386262","OrgName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","Titlefull":"Efficacy and Safety of the Adacolumn® Granulocyte and Monocyte/Macrophage Apheresis Device for Cerebral Edema After Acute Anterior Circulation Occlusive Cerebral Infarction: A Prospective, Randomized, Controlled Clinical Trial","BriefSummary":"The primary objective is to investigate whether treatment with Adacolumn can ameliorate the progression of cerebral edema within 72 hours in patients with anterior circulation ischemic stroke. The secondary objective is to explore if Adacolumn could improve acute neurologic status, functional outcomes, treatment requirements and safety in patients with anterior circulation ischemic stroke.","ExperimentalDrugs":"[\"device: adacolumn®\",\"procedure: endovascular thrombectomy\",\"standard medical management\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"Other","total_Score":22,"Phase":"NA","lastUpdateDate":"2026-05-03"},{"nctId":"NCT07520630","OrgName":"Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine","Titlefull":"Neurophysiological Markers for Developing an Integrative Model of Rehabilitation Prognosis in Patients With Ischemic Stroke","BriefSummary":"The goal of this randomized controlled study is to develop and validate an integrated neurophysiological model for predicting rehabilitation potential in patients with ischemic stroke. The study focuses on identifying objective markers of brain activity associated with motor preparation and recovery.\n\nThe project includes two stages. First, healthy volunteers will participate in experimental motor and mental tasks to establish reference patterns of brain activity using electroencephalography and transcranial magnetic stimulation. These data will be used to define stable neurophysiological markers of motor network function.\n\nIn the second stage, patients in the acute and early recovery phases after ischemic stroke will be randomly assigned to receive either active intermittent theta-burst stimulation of the motor cortex or a sham procedure, in addition to standard rehabilitation. Brain activity and clinical motor function will be assessed before and after the intervention.\n\nThe study aims to determine which neurophysiological measures are sensitive to neuromodulation and are associated with clinical improvement, in order to construct a predictive model of rehabilitation outcome.\n\nParticipants will \\[describe the main tasks participants will be asked to do, interventions they'll be given and use bullets if it is more than 2 items\\].","ExperimentalDrugs":"[\"device: intermittent theta burst stimulation\"]","Allcountries":"[\"Russia\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2026-04-02"},{"nctId":"NCT06784518","OrgName":"Rennes University Hospital","Titlefull":"Stroke Cerebral Reorganization Pathways Longitudinal Study After Stroke of the Clinical Motor Pattern and the Cerebral Reorganization According to the Different Damaged Motor Pathways (Main and Accessory) (SPECTRE)","BriefSummary":"SPECTRE is a prospective longitudinal study in order to identify whether patients with different degrees of motor recovery are distinguished by distinct brain post-stroke plasticity patterns in the acute and sub-acute phases. This study allows close longitudinal follow-up of patients with severe clinical motor impairment using functional MRI to study cerebral neuroplasticity after ischemic stroke in the acute and sub-acute phase in patients with upper limb motor impairement, taking into account prognostic criteria used in current practice.","ExperimentalDrugs":"[\"other: clinical scores and functional mri\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Late efficacy","total_Score":11,"Phase":"NA","lastUpdateDate":"2026-03-27"},{"nctId":"NCT07511868","OrgName":"VASCage GmbH","Titlefull":"Evaluating a Digital Health Application for Post-stroke Care and Vascular Risk Factor Management - a Multicenter Randomized Controlled Clinical Investigation","BriefSummary":"Stroke is a leading cause of death and long-term disability worldwide. Despite substantial advances in acute stroke care, there remains a lack of evidence-based digital solutions to support patients after hospital discharge. This study evaluates the effectiveness of a digital health application (StrokeApp) designed to support patients with ischemic or hemorrhagic stroke or transient ischemic attack (TIA) in secondary prevention and recovery.\n\nIn this multicenter, randomized, controlled, open-label trial, 500 patients will be assigned in a 1:1 ratio to receive either standard care alone or standard care in combination with StrokeApp. The primary objective is to assess the impact of the application on health-related quality of life three months after discharge. Secondary and exploratory outcomes include health literacy, medication adherence, vascular risk factors, health-related behaviors, psychosocial outcomes, long-term recovery up to twelve months, as well as safety and user experience.","ExperimentalDrugs":"[\"device: strokeapp\",\"other: standard care\"]","Allcountries":"[\"Austria\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Other","total_Score":6,"Phase":"NA","lastUpdateDate":"2026-03-30"},{"nctId":"NCT07507097","OrgName":"West China Hospital","Titlefull":"Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke","BriefSummary":"Stroke is the second leading cause of death and the third leading cause of disability worldwide, with an increasing incidence. Reperfusion therapy after cerebral ischemia is one of the most practical and effective treatments for ischemic stroke globally. However, the nursing care and management of hemodynamics during the acute phase after reperfusion therapy for ischemic stroke have always been key and challenging aspects of clinical work. Stable hemodynamic status can prevent hypoperfusion or hyperperfusion of brain tissue, reduce damage to the ischemic core and penumbra areas, and consequently decrease cerebral edema, elevated intracranial pressure, and the associated neurological damage and worsening clinical outcomes.\n\nHead positioning, as a simple, economical, and effective adjunctive treatment for managing patients undergoing reperfusion therapy, has gradually received attention. During the acute phase of stroke, brain tissue is in a state of ischemia and hypoxia. Lying flat may increase blood and oxygen supply to the brain tissue, providing a certain degree of protection, but it may also have some impact on swallowing and lung function. Raising the head of the bed can help venous blood return from the head and may reduce cerebral edema to some extent, but it can also affect perfusion of ischemic brain tissue to a certain degree. In the acute phase after successful reperfusion, it remains a clinical challenge to maintain stable cerebral blood supply (hemodynamic stability) through nursing care. Head positioning (lying flat or elevating the head of the bed) is a simple, economical nursing measure that may affect cerebral blood flow. However, for severely affected stroke patients like you, there is no clear international consensus on whether maintaining a flat position (0°) or elevating the head of the bed 30° within the first 24 hours after treatment is more beneficial for long-term recovery. Previous studies have shown inconsistent results, so more rigorous research is needed to answer this question.\n\nThe primary purpose of this study is to determine that a 30° position during the acute phase of severe ischemic stroke is safe. The secondary purpose is to evaluate whether a 30° position in the acute phase improves 90-day outcomes compared to a 0° position (assessed using the modified Rankin Scale).\n\nThis study is a randomized controlled trial. This means you will be randomly assigned (like a coin toss) to one of the following two groups: Experimental group: within 24 hours of admission, maintain the head and bed elevated at 30°. Control group: within 24 hours of admission, remain completely flat (0°). Interventions and methods: Both head positions are commonly used basic nursing measures in neurological intensive care. Lying flat may help increase blood supply to the brain, while elevating the head of the bed may help reduce cerebral edema and the risk of aspiration. This study aims to scientifically compare which angle is better for your long-term recovery. Procedures: Research nurses will use a special angle ruler to ensure your head position is accurate. During the 24-hour intervention, we need you to maintain the assigned position as much as possible. Considering your comfort and necessary medical care (such as back patting and skin inspection), brief interruptions are allowed (no more than three times for the flat position group, with each interruption less than 30 minutes). Legal Compliance: Head positioning management is a routine nursing procedure. This study only conducted standardization and comparative research on it, and did not involve the use of any experimental drugs or high-risk devices. It has passed ethical review.","ExperimentalDrugs":"[\"behavioral: head position\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Day 1 only","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":20,"Phase":"NA","lastUpdateDate":"2026-03-29"},{"nctId":"NCT06911385","OrgName":"University of Alberta","Titlefull":"Augmenting Cerebral Blood Flow Using a Novel Combined Treatment Approach in Patients With Ischemic Stroke: Protocol Development","BriefSummary":"The most common type of stroke is ischemic (lack of blood flow to the brain due to a clot blocking a blood vessel). Time is brain and an average of 1.9 million brain nerve cells per minute are destroyed in patients experiencing a typical LVO. The main goal of treatment is to help restore blood flow as quickly as possible and prevent brain tissue and cell death. Acute treatments like clot-busting medication or clot removal by wire are standard of care but are available in comprehensive stroke centers in a few urban centers. Often, patients need to be transferred to these centers via ground or air ambulance, sometimes over hours, and no active treatment can be provided during these transfers.\n\nEnhancing or increasing blood flow to the brain is associated with good outcomes in stroke. This study involves an innovative approach combining two treatment interventions - Remote ischemic conditioning (arms) and Air compression therapy (legs, applied simultaneously to all four limbs, that may help improve blood flow to the brain. Remote Ischemic Conditioning is a type of treatment delivered with the help of a regular blood pressure machine. This does not involve any drug. A typical treatment involves the application of a blood pressure cuff followed by brief sessions of compressions and relaxation on the arm muscles, much akin to blood pressure measurement, but for 5 min. It leads to a transient safe state of less blood flow in arm muscles which initiates the release of molecules and signals transmitted by blood. These signals may then go on to improve blood flow in the brain. Air Compression is delivered by a commercially available device (Normatech Elite). They are inflatable sleeves resembling puffy thigh-high boots that deliver compressive pulses stimulating blood flow in the legs, in a graded manner from the ankles to the thighs. We believe this air compression device may help improve and divert blood flow to stroke-affected areas in the brain.","ExperimentalDrugs":"[\"device: arm remote ischemic conditioning plus pneumatic compression lower limb\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":11,"Phase":"PHASE1","lastUpdateDate":"2026-05-05"},{"nctId":"NCT07407790","OrgName":"Sorlandet Hospital HF","Titlefull":"The Southern-Norway Post-Stroke Atrial Fibrillation Study","BriefSummary":"This study evaluates whether a procedure using a new wireless heart sensor patch is equal to or better than the standard hospital procedures and equipment at detecting an irregular heartbeat called Atrial Fibrillation (AF) after an ischemic stroke. Atrial fibrillation is a major cause of stroke, but it can be difficult to catch because it often comes and goes.\n\nThe study will include approximately 450 adults who have had a stroke or a transient \"mini-stroke\" (TIA) within the last two weeks. Participants will be assigned by chance (randomized) to one of two groups:\n\n* Group 1 (Intervention): Participants wear the \"ECG247 Smart Heart Sensor.\" This is a small patch that sticks to the chest and connects to a smartphone. It is worn continuously for up to 14 days, even after leaving the hospital.\n* Group 2 (Standard Care): Participants receive the standard hospital check-up. This typically involves using a \"Holter monitor\" (a device with wires and electrodes) for a period of about 24 to 48 hours some time after leaving the hospital.\n\nThe main goal is to see if the procedure using the patch is equal to the standard procedure in detecting atrial fibrillation in participants. The study will also measure how quickly doctors can start the correct medication and how easy the patients find the devices to use.","ExperimentalDrugs":"[\"device: patch ecg\"]","Allcountries":"[\"Norway\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":5,"Phase":"NA","lastUpdateDate":"2026-02-05"},{"nctId":"NCT07514949","OrgName":"Beijing Tiantan Hospital","Titlefull":"The Feasibility and Safety of RK-4 Injection Bypassing Blood-brain Barrier in the Treatment of Acute Large Hemispheric Infarction Using Intracalvariosseous Injection Device","BriefSummary":"A pilot study confirmed the feasibility and safety of neuroprotectant RK-4 intracalvariosseous(ICO) injection in patients with malignant middle cerebral artery infarction (mMCAI), showing a trend in improving 90-day functional scores compared to conventional treatment. The aim of this trial is to investigate the feasibility and safety of neuroprotective agent RK-4 injection using intracalvariosseous injection device in patients with acute large hemispheric infarction (LHI) who has contraindications of reperfusion therapy or have got poor reperfusion therapy outcomes.","ExperimentalDrugs":"[\"device: rk-4 ico injection\",\"other: conventional treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"3 days or less","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Safety","total_Score":20,"Phase":"NA","lastUpdateDate":"2026-03-31"},{"nctId":"NCT07635498","OrgName":"Hospital Universitario Virgen Macarena","Titlefull":"Virtual Stroke Units Versus Conventional Stroke Unit Care in Non-Thrombectomy-Candidate Patients: A Non-Inferiority Prospective Cohort Study","BriefSummary":"Stroke is the leading cause of acquired disability in adults and a major cause of mortality worldwide; in Spain, Andalusia shows the highest stroke-related mortality rate. Comprehensive Stroke Units (SU) are the gold-standard organizational model for acute stroke care; however, only a fraction of patients have direct access to an SU, particularly those not eligible for mechanical thrombectomy who are admitted to regional or district hospitals without on-site SU capacity.\n\nThe Virtual Stroke Unit (VSU) concept extends specialized stroke care to non-SU hospitals by combining standardized in-hospital monitoring boxes with synchronous remote multidisciplinary assessment by a stroke neurologist and stroke nurse from a reference center, via the regional telemedicine platform (CATI).\n\nThis prospective, multicenter, non-inferiority cohort study compares effectiveness, safety, and feasibility of VSU care versus conventional SU care in patients with acute ischemic or hemorrhagic stroke who are not candidates for mechanical thrombectomy. Recruitment targets 363 patients per arm (726 total). The primary outcome is death or dependency at 3 months (modified Rankin Scale 3-6) - the canonical measure of stroke-unit effectiveness - with functional independence (mRS 0-2), adherence to the stroke-unit care quality bundle, safety, mortality, recurrence, length of stay, satisfaction (TUQ/TSQ/TMPQ) and cost-effectiveness as secondary outcomes.","ExperimentalDrugs":"[\"other: (healthcare organizational model)\",\"other: conventional care\"]","Allcountries":"[\"Spain\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"mRS at 90 days","total_Score":17,"Phase":"NA","lastUpdateDate":"2026-06-03"},{"nctId":"NCT06825897","OrgName":"University of Iowa","Titlefull":"Delay Avoiding Primary Evaluation for Thrombectomy for Acute Stroke Patients With Large Vessel Occlusion in the Angiography Suite (DIRECT) Trial","BriefSummary":"The purpose of this study is to compare two strategies for treating adults with suspected large vessel occlusion stroke within 7 hours of symptom onset. Researchers will evaluate whether direct transfer to the neurointerventional angiography suite improves recovery and reduces disability compared to the conventional approach of first being evaluated in the emergency department. The study will also assess safety and other health outcomes to guide care for stroke patients.","ExperimentalDrugs":"[\"other: conventional triage for mechanical thrombectomy\",\"other: direct transfer to angiography suite (dtas\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":22,"Phase":"NA","lastUpdateDate":"2026-03-11"},{"nctId":"NCT07509645","OrgName":"Capital Medical University","Titlefull":"Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial-3","BriefSummary":"This is an investigator-initiated phase III clinical trial employing a randomized, double-blind, placebo-controlled design. The primary objective of this study is to investigate the efficacy and safety of an interleukin-6 inhibitor (tocilizumab) combined with endovascular therapy in patients with acute posterior circulation large-vessel occlusion stroke.","ExperimentalDrugs":"[\"tocilizumab\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":34,"Phase":"PHASE3","lastUpdateDate":"2026-04-29"},{"nctId":"NCT07558577","OrgName":"Xuanwu Hospital, Beijing","Titlefull":"Research on the Application of Sigma Radiopharmaceutical FBFP in Cerebral Stroke","BriefSummary":"This clinical research, aims to investigate the uptake of \\[18F\\]FBFP, a Sigma-1 receptor (Sig 1R) PET imaging agent, in stroke participants, compare differences with healthy controls, and evaluate its diagnostic efficacy, providing objective basis for clinical diagnosis and treatment.\n\nThe study will recruit 30 stroke participants (with specific inclusion criteria for unilateral ICA stenosis cases) and 20 gender- and age-matched healthy controls from January 2025 to December 2026. Exclusion criteria cover various neurological and systemic diseases that may affect results, as well as conditions preventing cooperation with examinations.\n\nNo intervention measures are involved. Follow-ups will be conducted at 6 and 12 months to collect clinical data and observe neurological symptom progression. Key measurements include clinical information (via questionnaires and scales like NIHSS and mRS) and PET/MR imaging data (analyzed using PMOD software to calculate SUVmean and uptake differences with cerebellar cortex as reference).\n\nStatistical analysis will use SPSS 21.0, applying descriptive statistics, t-test, ANOVA, regression models, ROC curves, etc., with P \\< 0.05 as significant. Safety evaluation notes PET/MR radiation dose (3-5mSv) is much lower than the safe threshold.\n\nParticipant protection includes ethical approval, informed consent, voluntary participation, risk disclosure, no fees for related exams, and privacy protection. The research team and institution have sufficient resources and qualifications, with outputs including a clinical research cohort and a high-quality paper.","ExperimentalDrugs":"[\"diagnostic test: pet/mr multimodality imaging\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":10,"Phase":"NA","lastUpdateDate":"2026-04-26"},{"nctId":"NCT07566598","OrgName":"Centre Hospitalier Universitaire de Nice","Titlefull":"Measuring Absolute Brain Flow and Brain Microcirculation Resistance by Continuous Thermodilution: a Pilot Study - RESISTANCE","BriefSummary":"Worldwide, cerebrovascular accidents (also known as strokes) are the leading cause of acquired disability, the second-leading cause of dementia (after Alzheimer's disease) and the second-leading cause of death (but the leading cause of death among women). A mechanical thrombectomy (MT) allows the recanalization of the occluded cerebral artery during an acute ischemic stroke, by removing the blood clot with a mechanical device inserted endovascularly under image guidance. MTs are the optimal treatment for a large number of patients presenting an occlusion in an anterior artery (the internal carotid artery and the proximal segment of the middle cerebral artery). Reperfusion is considered satisfactory if the mTICI score at the end of the procedure is of mTICI 2c or mTICI 3. Despite these scores having been obtained by 71% of patients during the randomized trials, showing the superiority of MT over intravenous thrombolysis, only 27% of these patients were free of neurological deficits at 3 months . Therefore, there is a discrepancy between the high rate of macroscopic recanalization and clinical results. One hypothesis to explain this discrepancy is that despite high quality macroscopic recanalization, reperfusion of the cerebral microcirculation remains insufficient: macroscopic recanalization is not equivalent to microscopic reperfusion. This discrepancy also exists in cardiology: despite a high rate of coronary artery recanalization when patients with an ST- segment elevation myocardial infarction are in emergency care, half of these patients later exhibit coronary microvascular dysfunction. The absence of reperfusion is associated with an increased risk of cardiovascular death, recurring myocardial infarctions, cardiogenic shock and heart failure one year after the coronary recanalization for an ST-segment elevation myocardial infarction. It has been shown that continuous intracoronary thermodilution can be used to quantify coronary blood flow and the absolute value of microcirculatory resistance (in Wood units). There are not currently any tools that can quantify cerebral microcirculation immediately after an MT.\n\nThe aim of this study is to evaluate the feasibility and safety of using a pressure/temperature sensing guidewire to measure cerebral microcirculatory resistance using thermodilution in patients with a score of mTICI 2c or 3 after MT for the management of acute ischemic stroke in the anterior circulation.","ExperimentalDrugs":"[\"device: measuring absolute cerebral flow and microvascular resistance by thermodilution\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":9,"Phase":"NA","lastUpdateDate":"2026-05-11"},{"nctId":"NCT03176498","OrgName":"Sclnow Biotechnology Co., Ltd.","Titlefull":"The Effects of Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neurological Function for Cerebral Infarction Patients in Convalescent Period.","BriefSummary":"This is a randomized, double-blind study. Human umbilical cord mesenchymal stem cells (hUC-MSC) will be treated on cerebral infarction patients, and evaluates their neurological function of convalescent period.","ExperimentalDrugs":"[\"biological: allogeneic umbilical cord mesenchymal stem cell\",\"aspirin enteric-coated tablets & atorvastatin calcium\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"SUSPENDED","Add_on":"Other","Endpoint":"Late efficacy","total_Score":15,"Phase":"PHASE1","lastUpdateDate":"2026-04-22"},{"nctId":"NCT07253181","OrgName":"Xuanwu Hospital, Beijing","Titlefull":"Tenecteplase Before inteRhospital Transfer for Endovascular Treatment in pAtientS With acUte Anterior ciRculation Large vEssel Occlusion at 4.5 to 24 Hours","BriefSummary":"This study will address the efficacy and safety of Tenecteplase administered in non-endovascular capable center (nECC) in patients with acute ischemic stroke (AIS) caused by anterior circulation large vessel occlusion (acLVO) who present in the 4.5- to 24-hour time window before interhospital transfer to an endovascular capable center (ECC) for endovascular treatment (EVT).\n\n* Primary objective: To evaluate the efficacy and safety of Tenecteplase administration at a nECC before EVT transfer compared with standard of care\n* Secondary objective: To evaluate the impact of time from needle-to-arterial puncture on clinical outcomes Patients who meet inclusion criteria will be randomized to Tenecteplase (0.25mg/kg, maximum 25mg) before transfer or standard of care. A single bolus dose should be injected over 5 seconds.","ExperimentalDrugs":"[\"tenecteplase (tnk) (0.25 mg/kg, to maximum of 25mg)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"PHASE3","lastUpdateDate":"2026-03-16"},{"nctId":"NCT07396337","OrgName":"Changzhou Qianhong Bio-pharma Co., Ltd.","Titlefull":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIb Clinical Trial of QHRD106 Injection for the Treatment of Acute Ischemic Stroke","BriefSummary":"The purpose of this study is to determine the efficacy and safety of QHRD106 injection in treating acute ischemic stroke.","ExperimentalDrugs":"[\"qhrd106 injection (low-dose group)\",\"qhrd106 injection (middle-dose group)\",\"qhrd106 injection (high-dose group)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":30,"Phase":"PHASE2","lastUpdateDate":"2026-02-01"},{"nctId":"NCT03186456","OrgName":"Sclnow Biotechnology Co., Ltd.","Titlefull":"Study the Safety and Efficacy of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Acute Cerebral Infarction","BriefSummary":"The purposes of the study is to determine the safety and efficacy of treating acute ischemic stroke patients with human umbilical cord mesenchymal stem cells (hUC-MSC).","ExperimentalDrugs":"[\"biological: allogeneic umbilical cord mesenchymal stem cells (sclnow 19#)\",\"aspirin tablet\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"SUSPENDED","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Safety","total_Score":18,"Phase":"PHASE1","lastUpdateDate":"2026-04-22"},{"nctId":"NCT07115940","OrgName":"University Hospitals Cleveland Medical Center","Titlefull":"Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well - SELECT LATE Trial","BriefSummary":"SELECT LATE trial aims to evaluate if addition of endovascular thrombectomy to medical management in patients presenting with acute ischemic stroke and a proximal large vessel occlusion in the anterior circulation between 24 and 72 hours of stroke onset results in achieving better functional outcomes (measured using modified Rankin Scale Scores) at 90-day follow-up (± 15 days).","ExperimentalDrugs":"[\"device: endovascular thrombectomy\",\"other: medical management\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"NA","lastUpdateDate":"2026-04-02"},{"nctId":"NCT07316049","OrgName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","Titlefull":"Construction and Evaluation of an Intelligent Decision System for Reperfusion Therapy in Acute Ischemic Stroke","BriefSummary":"This multicenter, cluster-randomized controlled trial will evaluate the effectiveness and safety of the LingBao System, an AI-enabled clinical decision support platform for reperfusion therapy in acute ischemic stroke (AIS). Twenty certified stroke centers will be randomized 1:1 to LingBao-assisted care or standard care. Consecutive patients aged 18 years or older who present within 24 hours of symptom onset or last-known-well and are evaluated for intravenous thrombolysis and/or endovascular therapy will be prospectively enrolled.\n\nThe study initially plans to enroll approximately 3,000 patients from about 20 certified stroke centers, with approximately 150 patients per center. Because this is a cluster-randomized trial, a pre-specified blinded sample size re-estimation will be performed after approximately 40% of participants have completed the 90-day mRS assessment. The re-estimation will be based only on pooled, blinded information, including cluster size, cluster-size variability, intracluster correlation, follow-up completeness, missingness of the primary outcome, and the overall distribution of the 90-day mRS. No between-group treatment effect will be examined, and any sample size adjustment will only allow an increase in enrollment.\n\nAt intervention sites, clinicians may use the LingBao System during their routine workflows. The platform integrates routinely available clinical and imaging data, automatically estimates onset-to-treatment windows, screens contraindications, and provides evidence-based, guideline-concordant recommendations for reperfusion therapy; all treatment decisions remain at physician discretion.\n\nThe primary endpoint is the 90-day modified Rankin Scale (mRS) score analyzed by ordinal shift. Secondary endpoints include workflow metrics (door-to-needle time and door-to-puncture time), reperfusion treatment rates, early neurological improvement, symptomatic intracranial hemorrhage, and mortality.\n\nThe findings will provide real-world evidence on the clinical value of AI-assisted decision support for reperfusion therapy in AIS and inform broader implementation of intelligent stroke management systems.","ExperimentalDrugs":"[\"other: lingbao system\",\"other: standard care\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Day 1 only","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":20,"Phase":"NA","lastUpdateDate":"2026-06-02"},{"nctId":"NCT07231380","OrgName":"Vanderbilt University Medical Center","Titlefull":"Plunger Stroke Trial: A Comparison of Cyclic Manual Direct Aspiration Thrombectomy (Plunger Technique) vs. Static Manual Direct Aspiration Thrombectomy for Treatment of Acute Large Vessel Occlusion Stroke With the Raptor Aspiration Catheter","BriefSummary":"This prospective, randomized controlled trial will compare two manual aspiration techniques for treating acute ischemic stroke due to large vessel occlusion: cyclic aspiration (Plunger technique) and static aspiration. Both techniques use FDA-approved devices (Raptor Aspiration Catheters and VacLok syringes) and are standard of care. Approximately 500 participants across 20 sites will be randomized to one of the two techniques. The primary endpoint is First Pass Effect (TICI 2c/3 after first attempt), with secondary endpoints including overall recanalization and 90-day functional outcomes. Results will address a critical gap in optimizing aspiration thrombectomy techniques.","ExperimentalDrugs":"[\"procedure: plunger technique\",\"procedure: static manual aspiration thrombectomy\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"EVT mandatory; IVT optional","Endpoint":"Other","total_Score":19,"Phase":"NA","lastUpdateDate":"2026-05-15"},{"nctId":"NCT07552818","OrgName":"IGEA","Titlefull":"Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Effect of I-NIC Therapy in Patients With Acute Ischemic Stroke.","BriefSummary":"The goal of this clinical trial is to evaluate whether low-frequency, low-intensity transcranial magnetic stimulation (ELF-MF), delivered by the I-NIC medical device, is effective and safe in treating patients with acute ischemic stroke.\n\nThe study aims to answer the following questions:\n\nDoes ELF-MF stimulation with the I-NIC device improve outcomes in patients with acute cerebral ischemia? Is the treatment safe and well tolerated?\n\nResearchers will compare the I-NIC device to a placebo device (identical in appearance but without active stimulation), both in addition to standard care, to determine its effectiveness.\n\nParticipants will:\n\n* Be randomly assigned to receive either standard care plus I-NIC treatment or standard care plus a placebo device\n* Start treatment within 48 hours of symptom onset\n* Receive daily treatment sessions of 120 minutes for 5 consecutive days\n* Undergo clinical and neurological evaluations at baseline, 7 days, and 90 days (the 90-day visit may be conducted remotely)\n* Provide clinical and demographic data during the study\n\nThis is a phase 3, multicenter, randomized, double-blind, placebo-controlled study involving 364 patients across 14 centers in Italy, with a total study duration of 3 months per participant.","ExperimentalDrugs":"[\"device: treatment with the i-nic medical device for neuroprotection\"]","Allcountries":"[]","FirstAdminInter":"Within first 2 days","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"NA","lastUpdateDate":"2026-04-20"},{"nctId":"NCT07609654","OrgName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","Titlefull":"A Prospective, Multicenter, Randomized Controlled Trial of Anticoagulation Therapy After Ischemic Stroke in Patients With Previous Intracerebral Hemorrhage and Atrial Fibrillation","BriefSummary":"This prospective, multicenter, randomized controlled trial aims to evaluate the efficacy and safety of initiating direct oral anticoagulants (DOACs) in patients with a history of spontaneous intracerebral hemorrhage (ICH) and non-valvular atrial fibrillation (AF) who have recently suffered an acute ischemic stroke. Existing evidence regarding the optimal antithrombotic strategy for this specific high-risk \"double-jeopardy\" population remains largely undefined. Eligible participants will be randomized in a 1:1 ratio to either receive oral anticoagulation therapy or a non-anticoagulation standard of care. The primary objective is to assess the incidence of a composite endpoint consisting of recurrent ischemic stroke and recurrent ICH over a 12-month follow-up period.","ExperimentalDrugs":"[\"direct oral anticoagulants (doacs)\",\"antiplatelet therapy or no antithrombotic therapy\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"PHASE4","lastUpdateDate":"2026-05-20"},{"nctId":"NCT07577336","OrgName":"Children's Mercy Hospital Kansas City","Titlefull":"Ultralow-Field Portable MRI for Detection of Pediatric Hypoxic Ischemic Brain Injury","BriefSummary":"This study will evaluate the sensitivity and specificity of low field portable MRI (pMRI) for detection of hypoxic ischemic brain injuries in pediatric patients compared to clinically obtained neuroimaging to define pediatric diagnostic limitations and to determine the diagnostic capabilities of this neuroimaging modality following optimization of image acquisition. The results of this study will help determine optimal clinical implementation opportunities in pediatric patients.","ExperimentalDrugs":"[\"device: portable mri\",\"other: scavenged sample collection\"]","Allcountries":"[]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":4,"Phase":"NA","lastUpdateDate":"2026-05-03"},{"nctId":"NCT07318948","OrgName":"West China Hospital","Titlefull":"BALANCE Trial Protocol - Blood Pressure Lowering and Thrombolysis: Concurrent vs Sequential Management in Acute Ischemic Stroke","BriefSummary":"Elevated blood pressure (BP) is nearly universal in acute ischemic stroke (AIS) and critically influences eligibility for intravenous thrombolysis; however, current guidelines-requiring BP reduction to below 185/110 mmHg before treatment-lack robust evidence and may delay reperfusion in a time-sensitive therapy, potentially worsening outcomes. Emerging data suggest that aggressive pre-thrombolysis BP lowering does not reduce hemorrhage risk and might impair recovery, highlighting the need to avoid large BP fluctuations. Yet it remains uncertain whether initiating thrombolysis concurrently with antihypertensive therapy is safer and more effective than the standard sequential approach, particularly in patients with markedly elevated but not extreme BP (systolic \\<220 mmHg).\n\nTo address this gap, the BALANCE trial is a prospective, multicenter, randomized controlled study enrolling AIS patients within 4.5 hours of onset whose pre-thrombolysis BP exceeds regional guideline thresholds (e.g., \\>180/100 mmHg in China or \\>185/110 mmHg internationally) but is \\<220 mmHg and who are otherwise eligible for thrombolysis. Patients are randomized to either: (1) concurrent management-immediate thrombolysis with simultaneous IV antihypertensive therapy to gradually lower BP-or (2) sequential management-antihypertensive treatment first, followed by thrombolysis only after BP reaches target. The primary endpoint is a hierarchical composite analyzed using the win ratio, prioritizing: (1) functional outcome (90-day mRS distribution), (2) major safety (symptomatic intracerebral hemorrhage within 7 days per SITS-MOST criteria), and (3) process efficiency (door-to-needle time).\n\nConducted across 80-100 global stroke centers, BALANCE aims to provide definitive evidence to optimize BP management and improve outcomes in AIS patients with elevated BP.","ExperimentalDrugs":"[\"other: concurrent thrombolysis\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Day 1 only","Status":"NOT_YET_RECRUITING","Add_on":"IVT mandatory; EVT optional","Endpoint":"mRS at 90 days","total_Score":26,"Phase":"NA","lastUpdateDate":"2025-12-20"},{"nctId":"NCT07517263","OrgName":"Novartis","Titlefull":"A Single Arm, Multicenter, Open-label Extension (OLE) Trial to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) in Participants Who Completed the Parent Lp(a)HORIZON Trial","BriefSummary":"This open-label extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).","ExperimentalDrugs":"[\"pelacarsen (tqj230)\"]","Allcountries":"[\"Argentina\",\"Australia\",\"Austria\",\"Belgium\",\"Brazil\",\"Bulgaria\",\"Canada\",\"China\",\"Colombia\",\"Czechia\",\"Denmark\",\"France\",\"Germany\",\"Greece\",\"Hong Kong\",\"Hungary\",\"India\",\"Israel\",\"Italy\",\"Japan\",\"Netherlands\",\"Norway\",\"Poland\",\"Portugal\",\"Puerto Rico\",\"Romania\",\"Russia\",\"Slovakia\",\"South Africa\",\"South Korea\",\"Spain\",\"Sweden\",\"Switzerland\",\"Taiwan\",\"Turkey (Türkiye)\",\"United Kingdom\",\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":21,"Phase":"PHASE3","lastUpdateDate":"2026-06-08"},{"nctId":"NCT07616622","OrgName":"University of Faisalabad","Titlefull":"Comparison Between Roods Facilitatory Techniques and Sequential PNF Pattern on Upper Limb Function in Acute Phase of Middle Cerebral Artery Stroke Patients","BriefSummary":"Middle cerebral artery (MCA) stroke often causes weakness or stiffness in the arm and hand, making daily activities difficult. This study compares two physical therapy approaches - Rood's facilitatory techniques (using touch, quick stretch, and ice to activate muscles) and PNF sequential patterns (using diagonal movement patterns) - to improve arm function in acute stroke patients. Both groups will also receive neuromuscular electrical stimulation (NMES). A total of 28 patients will be randomly assigned to one of two groups and receive treatment three times per week for eight weeks. Arm function will be measured using the Fugl-Meyer Assessment, and muscle stiffness will be measured using the Modified Ashworth Scale before and after treatment.","ExperimentalDrugs":"[\"device: neuromuscular electrical stimulation\",\"procedure: rood's facilitatory techniques\",\"procedure: proprioceptive neuromuscular facilitation\"]","Allcountries":"[\"Pakistan\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"ENROLLING_BY_INVITATION","Add_on":"Other","Endpoint":"Late efficacy","total_Score":14,"Phase":"NA","lastUpdateDate":"2026-05-23"},{"nctId":"NCT07404371","OrgName":"University of Lahore","Titlefull":"Efficacy of Sensory Reweighting Techniques for Balance and Risk of Fall in Chronic Ischemic Stroke Patients","BriefSummary":"This randomized controlled trial will evaluate the effectiveness of sensory reweighting techniques on balance and risk of falls in individuals with chronic ischemic stroke. A total of 46 participants will be recruited using purposive sampling and randomly assigned into two groups through the sealed envelope method. Balance and fall risk will be assessed using the Berg Balance Scale and the Timed Up and Go test at baseline and after completion of the intervention. Participants in the experimental group will receive sensory reweighting-based balance training three times per week for eight weeks, incorporating altered sensory conditions such as reduced visual input, unstable surfaces, and vestibular challenges. The control group will receive conventional balance training of similar duration and intensity without sensory manipulation. Both groups will also receive standard physiotherapy throughout the intervention period. Ethical approval will be obtained prior to data collection, written informed consent will be secured from all participants, and confidentiality and voluntary participation will be ensured.","ExperimentalDrugs":"[\"behavioral: sensory reweighting balance training\",\"behavioral: conventional balance training\"]","Allcountries":"[\"Pakistan\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-02-11"},{"nctId":"NCT07364344","OrgName":"Capital Medical University","Titlefull":"A Single-Center,Open-Label Clinical Study on the Safety and Preliminary Efficacy of Hibernation-Like Therapy (Chlorpromazine and Promethazine) in Patients With Acute Ischemic Stroke (AIS) Eligible for Reperfusion Therapy.","BriefSummary":"This is a single-center, dose-escalation and dose-expansion Phase I study designed to evaluate the safety of hibernation-like therapy (Chlorpromazine and Promethazine, C+P) and observe improvements in infarct volume in patients with AIS eligible for reperfusion therapy.","ExperimentalDrugs":"[\"hibernation-like therapy (chlorpromazine and promethazine, c+p)\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Safety","total_Score":20,"Phase":"NA","lastUpdateDate":"2026-01-15"},{"nctId":"NCT07635758","OrgName":"Chinese PLA General Hospital","Titlefull":"A Phase I/IIa Clinical Trial on the Safety, Tolerability, and Preliminary Efficacy of Human Placental-Derived 3D Mesenchymal Stem Cell Injection Administered Via the Intravenous Route in Patients With Acute Ischemic Stroke (AIS): A Randomized, Double-Blind, Placebo-Controlled Study","BriefSummary":"This is a Phase I/IIa clinical trial evaluating human placental-derived 3D mesenchymal stem cell (MSC) injection in patients with acute ischemic stroke (AIS). Phase I is a single-dose escalation study to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). Phase IIa explores preliminary efficacy. Each participant undergoes screening (up to 72 hours before treatment), a single-day treatment period, and follow-up for up to 720 days (24 months).","ExperimentalDrugs":"[\"biological: human placenta-derived 3d mesenchymal stem cells (guojiangqingke)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"mRS at 90 days","total_Score":20,"Phase":"PHASE1","lastUpdateDate":"2026-06-03"},{"nctId":"NCT07379190","OrgName":"Weifang Medical University","Titlefull":"Efficacy and Safety of Tirofiban Therapy in Acute Ischemic Stroke Patients Beyond the Time Window Guided by High-Resolution Magnetic Resonance Imaging","BriefSummary":"This study aims to address the existing clinical challenges by introducing high-resolution magnetic resonance vessel wall imaging (HR-MRI), an advanced imaging technology, to achieve precise etiological classification in patients with acute ischemic stroke (AIS) beyond the time window. HR-MRI allows clear visualization of intracranial arterial wall structures and direct identification of key pathological features of the culprit vessel, including atherosclerotic plaques, vascular wall remodeling, and intracranial hemorrhage, thereby enabling reliable differentiation between intracranial atherosclerotic large artery atherosclerosis (ICAS-LAA) stroke and other etiological subtypes such as cardiogenic embolism. Based on the latest clinical demands and advances in imaging technology, this study intends to evaluate the efficacy and safety of tirofiban in patients with ICAS-LAA stroke beyond the time window under the precise guidance of HR-MRI. It is expected to provide high-level evidence-based medical evidence for this specific patient population and further optimize clinical diagnosis and treatment strategies.","ExperimentalDrugs":"[\"tirofiban\",\"dual antiplatelet therapy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":23,"Phase":"PHASE3","lastUpdateDate":"2026-01-31"},{"nctId":"NCT07640360","OrgName":"University Hospital, Brest","Titlefull":"WATCH-STEP : Pilot Trial: Smartwatch-Guided Secondary Prevention After Stroke Randomized Trial of Nurse-led Program With Active vs Passive Smartwatch in Minor Stroke. A Randomized Controlled Trial Evaluating a Nurse-led Secondary Prevention and Physical Activity Program Supported by Either an Active Smartwatch (Structured Feedback) or Passive Smartwatch in Patients With Minor Stroke.","BriefSummary":"After a first stroke or transient ischemic attack (TIA), the risk of recurrence is high in the weeks and months following the initial event. There are several modifiable risk factors that can reduce this risk, such as blood pressure, diet, physical activity, and smoking. Many stroke patients (NIHSS \\< 5) have a low daily step count during the early recovery period, despite a good functional prognosis.\n\nActive smartwatches provide real-time feedback, track progress, and set personalized walking goals, thereby boosting motivation and adherence to physical activity recommendations.\n\nThe combination of advice provided by nurses and active behavioral coaching supported by a smartwatch, compared to passive monitoring, could significantly increase daily step counts over a 12-week period. The results of this research will help guide future large-scale secondary prevention strategies integrating digital health and structured nursing support.","ExperimentalDrugs":"[\"other: smartwatch-guided secondary prevention after stroke\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":10,"Phase":"NA","lastUpdateDate":"2026-06-05"},{"nctId":"NCT07603440","OrgName":"Assistance Publique - Hôpitaux de Paris","Titlefull":"Intravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicenter Randomized Controlled Trial (IVT-ALL-IN)","BriefSummary":"Stroke is a frequent and severe disease worldwide, representing the second leading cause of death and the leading cause of acquired disability. Over the last thirty years, reperfusion therapies have transformed the prognosis of ischemic stroke. For patients with acute ischemic stroke due to large-vessel occlusion (LVOS) and a small- to moderate-sized irreversibly injured tissue (core), the recommended treatment consists of intravenous thrombolysis (IVT) followed by mechanical thrombectomy (MT). However, for the fifth of LVOS patients with large core, MT has demonstrated its effectiveness, but the benefits of prior IVT remain unclear. In fact, no randomized trial has compared IVT+MT and MT alone in this population.\n\nTenecteplase is increasingly replacing alteplase for LVOS due to two key advantages. First, it is administered as a single intravenous bolus, which speeds up treatment and transfers. Second, it improves reperfusion and functional outcomes in LVOS patients without large core. Emerging real-world evidence with tenecteplase reports lower rates of symptomatic intracranial hemorrhage than alteplase, suggesting superior overall efficacy. To date, no randomized trial has explored the benefit of tenecteplase in LVOS patients with large core.\n\nThe IVT ALL IN trial is a French multicenter open randomized controlled trial with two parallel groups (IVT with tenecteplase followed by MT \\[IVT+MT\\] vs MT alone) and blinded endpoint assessment following a PROBE design. Its main objective is to assess which treatment strategy between IVT+MT and MT alone has a superior efficacy in terms of 3-month good functional outcome, defined as a modified Rankin scale (mRS) score ≤ 3 at 3 months, for LVOS patients with large core of the anterior circulation. Our trial will provide high-level evidence on the optimal reperfusion treatment strategy for LVOS patients with large ischemic core, who currently still have a low likelihood of achieving a favorable neurological outcome.","ExperimentalDrugs":"[\"intravenous administration\",\"procedure: mt alone\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":33,"Phase":"PHASE3","lastUpdateDate":"2026-05-18"},{"nctId":"NCT07597031","OrgName":"Insel Gruppe AG, University Hospital Bern","Titlefull":"Feasibility Study of a Digital Interactive Life-style Platform for Individuals After Rehabilitation","BriefSummary":"The goal of this clinical trial is to evaluate the feasibility and usability of a digital lifestyle platform designed to support patients after discharge from inpatient rehabilitation. It will also assess patient engagement and the potential of the platform to support long-term self-management and healthy lifestyle behaviors in an outpatient setting.\n\nThe main questions it aims to answer are:\n\nIs the platform feasible and acceptable for patients after rehabilitation? Do patients engage with and regularly use the platform over time? Can personalized digital recommendations support adherence to healthy behaviors and self-management?\n\nResearchers will evaluate a telemedicine platform that delivers individualized suggestions, including lifestyle applications, educational content, and advice from healthcare professionals. The content is tailored to patient needs and continuously adapted based on patient feedback.\n\nParticipants will:\n\nUse the digital platform after discharge from inpatient rehabilitation for a defined follow-up period Receive personalized recommendations through the platform Rate the usefulness of recommendations to enable continuous adaptation Attend study visits or remote assessments to evaluate usability, engagement, and outcomes Continue standard outpatient care alongside the intervention","ExperimentalDrugs":"[\"behavioral: digital lifestyle platform\",\"behavioral: usual care (standard post-rehabilitation care)\"]","Allcountries":"[\"Switzerland\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":5,"Phase":"NA","lastUpdateDate":"2026-05-18"},{"nctId":"NCT07495722","OrgName":"Columbia University","Titlefull":"Safely Quenching Complement in Stroke Subjects: A Phase 1 Safety Trial","BriefSummary":"This study will include adults (ages 18-80) who have had a stroke caused by a large blood clot blocking blood flow in the brain. All patients in the study must have already had a treatment called a thrombectomy, where doctors remove the clot to help blood flow return to the brain.\n\nThe goal of this study is to test the safety of a drug called EMPAVELI (pegcetacoplan). This drug is meant to lower swelling and inflammation that can happen after blood flow returns. The hope is that it may help protect the brain from more damage and improve recovery.\n\nPeople in the study will get three doses of EMPAVELI through an EMPAVELI-designed pump 0-3 hours post thrombectomy surgery and 24 and 48 hours after the initial dose. Doctors will check them with exams, blood tests, brain scans, and other tests while they are there. Patients will also have follow-up visits at 30 and 90 days to see how they are doing, per the usual standard of care.\n\nThis research is important because, even with current stroke treatments, many patients still have problems like disability. If this drug is found to be safe, it could lead to better treatments to protect the brain and help people recover more fully after a stroke.","ExperimentalDrugs":"[\"pegcetacoplan injection [empaveli]\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"3 days or less","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Safety","total_Score":24,"Phase":"PHASE1","lastUpdateDate":"2026-04-24"},{"nctId":"NCT07584681","OrgName":"Northwell Health","Titlefull":"Connectomic Alterations Following Acute Ischemic Stroke in the Middle Cerebral Artery Territory: A Pilot Study of Prognostic Value and Structural Disruption","BriefSummary":"This study seeks to use safe, powerful, non-invasive computing tools, including machine learning and advanced neuroimaging analysis, to better understand how stroke affects the brain's network of connections. Using structural MRI, including diffusion-weighted imaging, this study will generate a detailed map of brain pathways to evaluate how strokes in the middle cerebral artery (MCA) territory disrupt the brain's structural networks. In the future, this approach may help physicians better predict recovery, monitor neuroplasticity, and guide rehabilitation decisions after stroke.","ExperimentalDrugs":"[]","Allcountries":"[\"United States\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Other","total_Score":6,"Phase":"NA","lastUpdateDate":"2026-05-07"},{"nctId":"NCT07485283","OrgName":"Herlev and Gentofte Hospital","Titlefull":"A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia in Adults Aged 65 Years or Above","BriefSummary":"DAN-ZOSTER is a nationwide randomized study investigating whether vaccination against herpes zoster (shingles) can reduce the risk of cardiovascular disease and dementia in older adults. Herpes zoster is caused by reactivation of the varicella-zoster virus and becomes more common with increasing age. Some observational studies have suggested that vaccination against herpes zoster may also lower the risk of heart attacks, strokes, and dementia, but this has not been confirmed in randomized clinical trials.\n\nIn this study, approximately 162,000 adults aged 65 years or older living in Denmark will be randomly assigned to either receive the recombinant herpes zoster vaccine (Shingrix®) or receive no vaccine. Participants in the vaccine group will receive two doses given 2-6 months apart.\n\nParticipants will be identified and invited using Danish national registries and digital mail systems. Information about health outcomes will be collected through nationwide health registries during follow-up.\n\nThe main outcomes of the study are major cardiovascular events (heart attack, stroke, or cardiovascular death) and new diagnoses of dementia. The goal of the study is to determine whether herpes zoster vaccination can help prevent these conditions in older adults.","ExperimentalDrugs":"[\"biological: recombinant herpes zoster vaccine (shingrix)\"]","Allcountries":"[\"Denmark\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":8,"Phase":"PHASE4","lastUpdateDate":"2026-04-28"},{"nctId":"NCT07336927","OrgName":"West China Hospital","Titlefull":"Efficacy and Safety of Endovascular Therapy With Intra-Arterial Thrombolysis for Medium Vessel Occlusion Stroke--the IAT-MeVO Trial","BriefSummary":"IAT-MeVO is an international, multicenter, prospective, randomised, open-label, blinded end-point assessed (PROBE) trial, to evaluate the efficacy and safety of endovascular therapy (EVT) \\[intra-arterial thrombolysis (IAT)-based\\] versus best medical management (BMT) in patients with acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) who are ineligible for intravenous thrombolysis (IV) within 24 h of onset.","ExperimentalDrugs":"[\"procedure: endovascular treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":27,"Phase":"NA","lastUpdateDate":"2026-01-13"},{"nctId":"NCT07613970","OrgName":"Vrije Universiteit Brussel","Titlefull":"Investigating the Causal Contribution of Neural Oscillations to Neuromuscular Fatigue After Stroke Using tACS","BriefSummary":"The goal of this interventional study is to understand the contribution of the central components to the manifestation of neuromuscular fatigue in stroke survivors. The study will include adults with a first-ever stroke in the subacute phase.\n\nThe main question it aims to answer:\n\n• How does the brain activity contribute to the manifestation of neuromuscular fatigue in stroke survivors?\n\nResearchers will compare stroke participants receiving active vs sham tACS in a single session before the fatiguing contractions to determine whether central changes can influence fatigue onset/progression.\n\nParticipants will:\n\n* Perform repeated leg muscle contractions until fatigue while seated in an experimental setup\n* Receive either active or sham tACS for 20 minutes before the fatiguing contractions.\n* Wear non-invasive sensors to record brain activity (EEG) and muscle activity (EMG) during the task\n* Complete the study during a single experimental session in which fatigue-related changes will be measured throughout the task","ExperimentalDrugs":"[\"device: transcranial alternating current stimulation (tacs)\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":7,"Phase":"PHASE1","lastUpdateDate":"2026-05-21"},{"nctId":"NCT07380490","OrgName":"Sahajanand Medical Technologies Limited","Titlefull":"Randomised Controlled Trial Comparing the Safety and EfficAcy of the Cocoon PFO Occluder Versus Amplatzer PFO ClosurE Device for Percutaneous Closure of Patent Foramen Ovale in Patients With a History of Stroke or Transient Ischemic Attack A Non-Profit, Single-blind, Investigator Driven Trial","BriefSummary":"This study is a prospective, multicenter, randomized, controlled, single-blind, investigator-driven, non-profit clinical trial designed to compare the safety and efficacy of the Cocoon PFO Occluder with the Amplatzer PFO Occluder family in patients requiring percutaneous closure of a patent foramen ovale (PFO). Eligible participants are adults with a history of cryptogenic embolic stroke or neurologically confirmed transient ischemic attack (TIA) within the previous 12 months and a PFO suitable for transcatheter closure.\n\nA total of up to 1260 subjects will be enrolled across multiple European centers. Participants will be randomly assigned in a 3:1 ratio to receive either the Cocoon PFO Occluder (experimental group) or an Amplatzer PFO closure device (control group). The procedure will be performed as soon as possible after randomization, preferably within 14 days and no later than 45 days.\n\nThe primary endpoint is a non-inferiority comparison of a composite outcome at 12 months, including recurrent ischemic stroke, TIA, or all-cause death. Secondary endpoints include PFO closure rate at 6 months, assessed by echocardiographic imaging, and other measures of safety, device performance, and clinical outcomes.\n\nThe study is conducted in a single-blind fashion: patients will not be informed of the device they receive unless they explicitly request this information. Any patient who chooses to be unblinded will continue to participate without affecting eligibility or follow-up, and the date of unblinding will be documented to allow appropriate sensitivity analyses.\n\nThis trial aims to provide robust comparative evidence on the clinical performance of the Cocoon PFO Occluder relative to the Amplatzer PFO Occluder to guide optimal device selection in patients with cryptogenic stroke or TIA associated with PFO.","ExperimentalDrugs":"[\"device: pfo closure procedure\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":22,"Phase":"NA","lastUpdateDate":"2026-03-23"},{"nctId":"NCT07503301","OrgName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","Titlefull":"the Role and Mechanism of Distant Ischemic Adaptation in Improving Cognitive Impairment in Cerebral Infarction and Cerebral Small Vessel Disease","BriefSummary":"Cerebral infarction (ischemic stroke) and cerebral small vessel disease (CSVD) represent major global causes of disability, cognitive decline, and mortality. Despite advances in reperfusion therapies, many patients experience residual neurological deficits and remain at high risk for recurrent stroke and vascular dementia. Effective adjunctive treatments that are safe, accessible, and capable of improving long-term outcomes are urgently needed.\n\nDistant ischemic adaptation (also known as remote ischemic conditioning, RIC) is a non-invasive, safe, and cost-effective intervention that induces endogenous protection against ischemic injury by applying brief, intermittent ischemia to a remote limb. While several large-scale clinical trials (e.g., RICAMIS, RECAST) have demonstrated promising neuroprotective effects of RIC in acute ischemic stroke, results remain inconsistent across studies, particularly in patients with CSVD. Key challenges include the lack of standardized RIC protocols and the absence of specific biomarkers to predict treatment response and elucidate underlying mechanisms.\n\nTo address these gaps, this study aims to identify potential effector proteins and specific biomarkers that mediate the therapeutic effects of RIC in patients with cerebral infarction and CSVD. By collecting and analyzing serum samples from RIC-treated patients and controls, we seek to uncover molecular mechanisms underlying RIC-induced neuroprotection and cognitive preservation. The findings may establish a theoretical foundation for optimizing RIC therapy, provide novel drug targets, and ultimately improve clinical outcomes for patients suffering from ischemic stroke and small vessel disease.","ExperimentalDrugs":"[\"device: medical-grade ischemic preconditioning training instrument\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Other","Status":"ENROLLING_BY_INVITATION","Add_on":"Other","Endpoint":"NIHSS","total_Score":16,"Phase":"NA","lastUpdateDate":"2026-03-25"},{"nctId":"NCT07639632","OrgName":"The University of Texas Health Science Center, Houston","Titlefull":"Reduce Inefficiencies in Management of Spasticity","BriefSummary":"The purpose of this study is to evaluate the effectiveness of a spasticity screener and to determine if the spasticity screener results are useful to healthcare providers and impact clinical decision making","ExperimentalDrugs":"[\"other: screener\",\"other: standard of care\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":4,"Phase":"NA","lastUpdateDate":"2026-06-10"},{"nctId":"NCT07511543","OrgName":"Population Health Research Institute","Titlefull":"A Multicentre, Prospective, Randomized, Open-label, Blinded Endpoint, Pilot Clinical Trial Evaluating Subcutaneous Semaglutide in Patients With Acute Ischaemic Stroke Due to Anterior Circulation Large Vessel Occlusion Treated With Endovascular Thrombectomy","BriefSummary":"Endovascular thrombectomy (EVT) is a procedure that improves recovery for people who suffer from a stroke by removing blood clots from large blood vessels in the brain. However, even with this treatment, over half of the patients either pass away or are left with serious disabilities within three months. This is partly because, even in cases of a successful EVT, brain tissue damage continues to grow. Extent of brain damage is a major factor in how well a patient recovers. Studies in animals have shown that a drug called semaglutide might help protect the brain and improve recovery after a stroke. Semaglutide is currently used for the treatment of diabetes and obesity and is given as a weekly injection under the skin.\n\nThe investigators are hoping to test whether giving semaglutide to stroke patients undergoing EVT can improve their recovery. A very large study at many hospitals is needed to answer this question. The investigators are starting with a smaller study to gain information on whether it is possible to perform a larger definitive one, and if so, how best to plan for it. In this first step the investigators will study 100 patients with stroke who are scheduled for EVT in approximately 10 stroke centers across Canada. These patients will be randomly divided (like flipping a coin) into two groups: one will receive weekly semaglutide injections for 12 weeks, while the other will not receive the drug. The investigators will track how many patients agree to participate, how many stay in the study, and how well they follow the treatment plan. The investigators will also monitor the patients' recovery, overall health, and any side effects from the treatment. These results will provide important information to plan the larger study with the goal of reducing death rates and long-term disability in stroke patients undergoing EVT.","ExperimentalDrugs":"[\"semaglutide\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":16,"Phase":"PHASE2","lastUpdateDate":"2026-04-15"},{"nctId":"NCT07555977","OrgName":"Shanghai Jiao Tong University Affiliated Sixth People's Hospital","Titlefull":"Super Large Bore Catheter Aspiration Versus Stent Retriever Thrombectomy as First Line Technique for Anterior Circulation Large Vessel Occlusion in Acute Ischemic Stroke","BriefSummary":"This is a multicenter, open-label, blinded-endpoint, randomized controlled trial comparing super large bore catheter aspiration versus stent retriever thrombectomy as the first-line technique for anterior circulation large vessel occlusion in acute ischemic stroke. Eligible patients with acute ischemic stroke due to internal carotid artery intracranial segment and/or middle cerebral artery M1 occlusion will be randomized 1:1 to receive either aspiration using a super large bore catheter (inner diameter ≥0.080 inch) or stent retriever thrombectomy (allowing balloon guiding catheters or intermediate catheters with inner diameter \\<0.080 inch). The primary outcome is the ordinal modified Rankin Scale score at 90 days post-procedure. Key secondary outcomes include the proportion of patients with mRS 0-2 at 90 days, change in NIHSS at 24 hours and 7 days, and various angiographic and safety endpoints. The trial plans to enroll 708 patients across approximately 30 centers in China. The total study duration is 24-36 months, with each patient participating for 3 months.","ExperimentalDrugs":"[\"procedure: super large bore catheter\",\"procedure: stent retriever thrombectomy\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"NA","lastUpdateDate":"2026-06-02"},{"nctId":"NCT07365475","OrgName":"Tianjin Huanhu Hospital","Titlefull":"Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Multicenter, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial (AMASS2)","BriefSummary":"Stroke remains a predominant global public health challenge, ranking as the third leading cause of death and the fourth leading contributor to disability-adjusted life years (DALYs). According to the Global Burden of Disease Study 2021, there are approximately 93.8 million prevalent stroke cases and 11.9 million new cases worldwide. China bears one of the heaviest burdens, with over 2 million new cases annually. Acute ischemic stroke (AIS), caused by acute cerebrovascular occlusion, accounts for 80% of all strokes. Approximately 30% of AIS cases result from large vessel occlusion (LVO), which typically carries a poor prognosis due to the extensive area of infarction . Research indicates that early recanalization significantly improves clinical outcomes. Currently, intravenous thrombolysis (IVT) and mechanical thrombectomy (MT) are the standard treatments for achieving recanalization . For LVO-related AIS, MT has become the preferred clinical approach due to its extended therapeutic window and superior recanalization rates . However, despite successful recanalization in over 70% of patients, nearly 50% fail to achieve functional independence at 90 days, and mortality remains above 15% . Therefore, enhancing long-term functional outcomes in post-MT patients is a critical unmet clinical need. Human albumin is the most abundant protein in plasma. Beyond maintaining colloid osmotic pressure, it also possesses multiple biological effects, including anti-inflammatory, anti-platelet aggregation, antioxidant, and endothelial protective properties. We conducted a Phase I clinical trial (AMASS-1) for patients post-mechanical thrombectomy, administering human albumin via the internal carotid artery. The results showed that intra-arterial infusion of 20% human albumin at a dose of 0.60 g/kg was safe, with no significant differences in serious adverse reactions such as mortality \\[Albumin group (6.7%) vs Control group (6.7%), P \\> 0.05\\] and symptomatic intracranial hemorrhage \\[Albumin group (6.7%) vs Control group (13.3%), P \\> 0.05\\] compared to the control group. In summary, albumin adjunctive therapy demonstrates good safety and potential neuroprotective effects in patients after mechanical thrombectomy. To further systematically evaluate its efficacy and safety, we plan to conduct a Phase II clinical trial of mechanical thrombectomy combined with intra-arterial albumin infusion for acute ischemic stroke. This is a multicenter, prospective, open-label, endpoint-blinded, randomized controlled trial designed to evaluate the efficacy and safety of intra-arterial infusion of 20% human serum albumin combined with mechanical thrombectomy versus mechanical thrombectomy alone in patients with acute ischemic stroke due to anterior circulation large vessel occlusion who have achieved recanalization after mechanical thrombectomy. A total of 306 patients are planned to be enrolled and randomly assigned in a 1:1 ratio using a dynamic minimization method to two groups: the Albumin Group (0.6 g/kg 20% human serum albumin plus Mechanical Thrombectomy) and the Control Group (Mechanical Thrombectomy alone). The primary efficacy objective of this study is to evaluate whether immediate intra-arterial infusion of 20% human albumin (0.6 g/kg) via the internal carotid artery following successful recanalization (eTICI ≥2b) improves clinical outcomes in patients with acute anterior circulation large vessel occlusion stroke, compared with mechanical thrombectomy alone. The study also aims to evaluate the safety and feasibility of immediate intra-arterial infusion of 20% human albumin (0.6 g/kg) via the internal carotid artery in patients with acute anterior circulation large vessel occlusion stroke who have achieved successful recanalization (eTICI ≥2b) following standard mechanical thrombectomy.","ExperimentalDrugs":"[\"20% human serum albumin\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":31,"Phase":"PHASE2","lastUpdateDate":"2026-01-16"},{"nctId":"NCT07475949","OrgName":"First Affiliated Hospital of Guangxi Medical University","Titlefull":"Intravenous Tenecteplase for Acute Ischemic Stroke With Unknown Time of Onset Under Non-Contrast CT Selection: A Multicenter, Prospective, Randomized, Open-label, Blinded Endpoint Trial","BriefSummary":"The benefit of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, e.g. wake-up stroke, remains uncertain. This randomized study aims to assess the efficacy and safety of intravenous tenecteplase following non-contrast CT screening for acute ischemic stroke with unknown time of onset.","ExperimentalDrugs":"[\"tenecteplase (tnk) (0.25 mg/kg, to maximum of 25mg)\",\"other: standard medical treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"PHASE3","lastUpdateDate":"2026-03-13"},{"nctId":"NCT07367100","OrgName":"Neuravi Limited","Titlefull":"A Prospective, First in Human Pivotal Study to Evaluate the Adaptive Tip Catheter Used to Treat Acute Ischemic Stroke Patients During Mechanical Thrombectomy","BriefSummary":"The purpose of this study is to assess the safety and the effectiveness of the Adaptive Tip Catheter (ATC) used as a first line direct aspiration thrombectomy technique for patients suffering of an acute ischemic stroke.","ExperimentalDrugs":"[\"procedure: adaptive tip catheter\"]","Allcountries":"[\"Belgium\",\"France\",\"Germany\",\"Ireland\",\"Netherlands\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":28,"Phase":"NA","lastUpdateDate":"2026-06-04"},{"nctId":"NCT07369648","OrgName":"Hanoi Medical University","Titlefull":"Effects of Repetitive Transcranial Magnetic Stimulation Combined With Motor Rehabilitation on Motor and Functional Outcomes in Patients With Ischemic Stroke: A Randomized Sham-Controlled Trial","BriefSummary":"Ischemic stroke is a leading cause of long-term motor disability, frequently resulting in hemiplegia and limitations in daily activities and quality of life. Motor rehabilitation is a fundamental component of post-stroke care across all stages of recovery; however, functional outcomes may vary, particularly in patients with persistent motor impairment.\n\nRepetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that has been used as an adjunct to rehabilitation to modulate cortical excitability and potentially support motor recovery.\n\nThe purpose of this study is to evaluate the effects of low-frequency rTMS combined with conventional motor rehabilitation compared with sham rTMS combined with conventional motor rehabilitation in patients with first-ever ischemic stroke during the acute, subacute, and chronic stages. Motor function, balance, functional mobility, activities of daily living, and stroke-specific quality of life will be assessed at baseline, after the intervention, and at 3-month and 6-month follow-up.","ExperimentalDrugs":"[\"device: active repetitive transcranial magnetic stimulation\",\"other: conventional motor rehabilitation\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-02-06"},{"nctId":"NCT07049692","OrgName":"Beijing Chao Yang Hospital","Titlefull":"Evaluation of the Efficacy and Safety of Hyperbaric Oxygen in Patients After Endovascular Treatment for Acute Ischemic Stroke: A Multicenter, Open-label, Randomized Controlled Clinical Trial","BriefSummary":"1. The goal of this clinical trial is to evaluate the efficacy and safety of hyperbaric oxygen (HBO)in stroke patients after endovascular treatment\n2. The main questions it aims to answer is:\n\n   Whether HBO can improve the prognosis of ischemic stroke patients after endovascular treatment?\n3. Participants will:\n\nreceive HBO (1.6 Atmosphere Absolute，1.6ATA)，Once a day, for 1 hour each time, for 5 days a week (it can be non-consecutive days), the total course of treatment is 10 times.\n\nundergo three scheduled face to face or telephone follow-up assessments during the 12-month period following HBO.","ExperimentalDrugs":"[\"other: hyperbaric oxygen therapy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":19,"Phase":"NA","lastUpdateDate":"2025-12-25"},{"nctId":"NCT07621796","OrgName":"Hackensack Meridian Health","Titlefull":"Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant (ESTER-DOAC)","BriefSummary":"The study will randomize patients with acute ischemic stroke and Direct Oral AntiCoagulants (DOAC) ingestion within 48 hours from enrollment (but otherwise eligible for thrombolysis) to administration of intravenous tenecteplase vs. placebo (1:1).\n\nParticipants will be enrolled at NIH StrokeNet sites across the US and followed for 90-days.\n\nThe primary aim is to determine the efficacy of intravenous tenecteplase (TNK) vs placebo among acute ischemic stroke patients and to determine the safety of TNK among acute ischemic stroke patients within 4.5 hours of last known well who used DOAC within 48 hours prior to thrombolysis. Efficacy and safety endpoints will be the focus of this proposed Phase III study.","ExperimentalDrugs":"[\"intravenous tenecteplase (tnk)\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT mandatory; EVT optional","Endpoint":"mRS at 90 days","total_Score":32,"Phase":"PHASE3","lastUpdateDate":"2026-05-26"},{"nctId":"NCT07369999","OrgName":"Xiangya Hospital of Central South University","Titlefull":"Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke -A Prospective, Multicenter, Randomized, Double-blind, Active-controlled Trial","BriefSummary":"Abstract Background Intravenous thrombolysis is the cornerstone of early treatment for acute ischemic stroke (AIS), but some still have a poor prognosis, especially in patients with mild disabling stroke. Tenecteplase (TNK), a novel thrombolytic agent with favorable pharmacokinetic profiles, and butylphthalide (NBP), a multi-targeted neuroprotective drug, have shown promising efficacy in separate clinical applications. However, evidence for their combined use in mild disabling AIS is lacking.\n\nAim To determine whether TNK combined with NBP can improve functional outcomes compared with TNK monotherapy in patients with mild disabling AIS who receive thrombolysis within 4.5 hours of onset.\n\nDesign BENEFIT-2 is a prospective, multicenter, randomized, double-blind, active-controlled trial. Eligible patients are randomized 1:1 to receive either TNK plus NBP (combination group) or TNK plus placebo (control group) via stratified block randomization. The combination group receives sequential NBP sodium chloride injection (25mg/100ml, twice daily for 7 days) and oral NBP soft capsules (0.2g, three times daily) until day 14; the control group receives matching placebos.\n\nEligibility criteria include age 18-80 years, onset time ≤4.5 hours, NIHSS score 2-5 with disabling manifestations (hemianopia, aphasia, or limb weakness), and pre-stroke modified Rankin Scale (mRS) score ≤1.\n\nStudy outcomes The primary outcome is the proportion of patients with mRS score 0-1 at 90±7 days. Secondary outcomes include changes in NIHSS score, recurrence of ischemic stroke, composite vascular events, quality of life (assessed by EQ-5D scale), and ischemic penumbra salvage rate. Safety outcomes include symptomatic intracranial hemorrhage (sICH), vascular death, all-cause death, and adverse events within 90 days.\n\nDiscussion BENEFIT-2 is the first large-scale randomized trial to evaluate the synergistic effect of \"vascular recanalization + neuroprotection\" in mild disabling AIS. By combining TNK and NBP, this study aims to fill the evidence gap and provide a new therapeutic option to improve functional recovery in this specific population.","ExperimentalDrugs":"[\"combination group\"]","Allcountries":"[]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":26,"Phase":"PHASE3","lastUpdateDate":"2026-02-11"},{"nctId":"NCT07469293","OrgName":"Southwest Hospital, China","Titlefull":"Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO): A Multicenter, Prospective, Randomized Controlled, Open-label, Blinded-Endpoint Clinical Trial","BriefSummary":"DATE-MeVO is an investigator-initiated, multicenter, prospective, randomized controlled, open-label, blinded endpoint (PROBE) clinical trial aiming at evaluating the efficacy and safety of tenecteplase combined with standard medications in acute ischemic stroke patients with medium vessel occlusion stroke within 24 hours of onset.","ExperimentalDrugs":"[\"procedure: intra-arterial thrombolysis\",\"other: standard medical treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":32,"Phase":"PHASE3","lastUpdateDate":"2026-03-18"},{"nctId":"NCT07550296","OrgName":"General Hospital of Shenyang Military Region","Titlefull":"Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Prourokinase (RITIS-PUK): a Prospective, Randomized, Open Label, Blinded Assessment of Outcome, and Multi-center Study","BriefSummary":"Ischemic cerebrovascular disease is a common neurological disorder with high incidence, mortality, and disability. Early reperfusion to salvage the ischemic penumbra is the cornerstone of acute ischemic stroke (AIS) treatment. Current reperfusion strategies include intravenous thrombolysis (IVT) and endovascular therapy (EVT). Although alteplase is the first-line thrombolytic agent, its recanalization rate for large vessel occlusion (LVO) is only 10-20%, and for medium vessel occlusion (MeVO), approximately 50% of patients fail to achieve recanalization, leading to poor outcomes. Prourokinase has recently been shown to be non-inferior to alteplase with a better safety profile, and studies suggest that repeated thrombolysis may improve recanalization rates in patients without early clinical improvement after standard IVT. Therefore, this study aims to evaluate the efficacy and safety of an additional intravenous infusion of prourokinase in AIS patients with confirmed medium or large vessel occlusion who show no significant clinical improvement at 1 hour after standard IVT (within 4.5 hours of symptom onset). Patients without early neurological improvement (e.g., \\<2-point reduction in NIHSS) and persistent vessel occlusion on imaging will receive a second dose of prourokinase. The primary outcomes include 24-hour recanalization rate (by CTA/MRA), 90-day functional outcome (modified Rankin Scale), and safety endpoints (symptomatic intracranial hemorrhage, mortality). The hypothesis is that additional prourokinase following standard IVT in non-improving patients with medium or large vessel occlusion will significantly increase recanalization rates and improve clinical outcomes without an unacceptable increase in symptomatic intracranial hemorrhage.","ExperimentalDrugs":"[\"prourokinase\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"Early efficacy","total_Score":21,"Phase":"PHASE2","lastUpdateDate":"2026-04-19"},{"nctId":"NCT07433972","OrgName":"Mahidol University","Titlefull":"Changes in Hemodynamic Response Following Transcranial Electrical Stimulation in Sroke Individuals","BriefSummary":"The present study will use transcranial electrical stimulation (tES) which are transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS) combined with conventional physical therapy and cognitive-motor dualt ask gait training in sub-acute (at least 2 weeks after stroke onset) to chronic stroke (within 5 years post-stroke) to investigate changes in brain hemodynamics (oxy-hemoglobin and deoxy-hemoglobin concentration) as measured by functional near infrared spectroscopy (fNIRS). The findings may provides insights changes in combining tES with rehabilitation on improvements in brain hemodynamics in sub-acute to chronic stroke.","ExperimentalDrugs":"[\"device: transcranial direct current stimulation\",\"other: rehabilitation program\",\"device: transcranial alternating current stimulation\"]","Allcountries":"[\"Thailand\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":10,"Phase":"NA","lastUpdateDate":"2026-02-19"},{"nctId":"NCT07343284","OrgName":"University of Santiago de Compostela","Titlefull":"Effect of a Nursing Intervention Based on Health Education on Functionality, Depression Symptoms, and Quality of Life in Patients With Ischemic Stroke: A Quasi-Experimental, Longitudinal, and Prospective Clinical Trial","BriefSummary":"This study is titled \"Effect of a Nursing Intervention Based on Health Education on Functionality, Depression Symptoms, and Quality of Life in Patients with Ischemic Stroke.\" It is a quasi-experimental, longitudinal, prospective clinical trial that will beconducted with patients who have suffered an ischemic stroke and were treated in the neurology unit of the Lucus Augusti University Hospital, the same center where this study will take place.\n\nThe primary objective of the study is to determine the effect of a nursing intervention based on health education on quality of life and depression symptoms in individuals who have experienced an ischemic stroke.\n\nTo achieve this objective, variables such as cognitive status, depression symptoms, autonomy and ability to perform basic activities of daily living, neurological deficits, and quality of life will be assessed.\n\nRegarding the total number of subjects to be studied, according to the Stroke Atlas in Galicia published by the Spanish Society of Neurology in 2018, the autonomous community of Galicia had a population of 2,701,819 inhabitants. Applying an incidence rate of 187.4 cases per 100,000 inhabitants according to the IBERICTUS study, an estimated 5,064 new stroke cases occur each year in Galicia. The province of Lugo had 324,842 inhabitants as of January 1, 2024, according to the INE; therefore, applying the same incidence rate, an estimated 609 new stroke cases occur per year. Considering the proportion of ischemic strokes compared to other types of strokes (80:20), the estimated number of ischemic stroke cases in Lugo would be 487. The representative sample size of stroke patients in the province of Lugo would be 70 patients, with 35 patients receiving the intervention and 35 serving as controls.\n\nIndependent Variables:\n\nSociodemographic: sex, age, event date. Clinical: stroke type, treatment modality (rt-PA or thrombectomy), falls, pain, pressure ulcers, aspiration, pneumonia, dysphagia, vital signs.\n\nHealth education: received vs. not received.\n\nDependent Variables:\n\nCognitive status (MMSE). Depression symptoms (BDI). Autonomy and ADL performance (Barthel Index). Neurological deficits (NIHSS). Quality of life (European Quality of Life Scale).\n\nInstruments Mini-Mental State Examination (MMSE) Beck Depression Inventory (BDI) Barthel Index NIH Stroke Scale (NIHSS) Visual Analogue Scale (VAS) European Quality of Life Scale (EQLS)","ExperimentalDrugs":"[\"behavioral: health education program\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":9,"Phase":"NA","lastUpdateDate":"2026-01-07"},{"nctId":"NCT07324837","OrgName":"Supergene, LLC","Titlefull":"A Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of the Recombinant Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset (FRIDA-CT)","BriefSummary":"Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus injection of the recombinant non-immunogenic staphylokinase (Fortelyzin®, LLC \"SuperGene\", Russia) or placebo.","ExperimentalDrugs":"[\"non-immunogenic staphylokinase\"]","Allcountries":"[\"Russia\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":32,"Phase":"PHASE3","lastUpdateDate":"2026-06-10"},{"nctId":"NCT07591883","OrgName":"Guangdong Provincial Hospital of Traditional Chinese Medicine","Titlefull":"Spatiotemporal Evolution of Traditional Chinese Medicine Mechanisms in Acute Ischemic Stroke Treated With Dengzhan Xixin and Dengzhan Shengmai","BriefSummary":"To integrate large-scale RCT data on clinical symptoms, TCM syndromes, prognosis, and multi-omics profiles, construct a spatiotemporal dynamic network for disease-syndrome evolution of acute ischemic stroke (AIS) in the acute and recovery phases, evaluate the efficacy and safety of sequential treatment with Erigeron breviscapus-Dengzhan Shengmai for AIS, and provide evidence for precise syndrome differentiation and individualized therapy.Secondary Objective:To investigate the optimal time window and key intervention targets of sequential treatment with Erigeron breviscapus-Dengzhan Shengmai for AIS.","ExperimentalDrugs":"[\"dengzhan shengmai - erigeron breviscapus sequential intervention\"]","Allcountries":"[]","FirstAdminInter":"Within first 2 days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"mRS at 90 days","total_Score":22,"Phase":"PHASE2","lastUpdateDate":"2026-05-11"},{"nctId":"NCT07537933","OrgName":"Shandong Provincial Hospital","Titlefull":"Efficacy and Safety of Immediate Intra-Arterial Tirofiban After Mechanical Thrombectomy Recanalization in Acute Intracranial Large-Vessel Occlusion","BriefSummary":"The goal of this clinical trial is to learn if immediate intra-arterial tirofiban after complete recanalization can improve recovery in adults with acute ischemic stroke caused by anterior circulation large-vessel occlusion. It will also learn about the safety of this treatment. The main questions it aims to answer are:\n\nDoes immediate intra-arterial tirofiban after complete recanalization increase the number of participants with good functional outcome at 90 days? Does this treatment increase the risk of symptomatic intracranial hemorrhage or other important bleeding events?\n\nResearchers will compare immediate intra-arterial tirofiban with no intra-arterial tirofiban after complete recanalization to see if tirofiban improves recovery and is safe.\n\nParticipants will:\n\nBe enrolled after mechanical thrombectomy achieves complete recanalization Be randomly assigned to receive intra-arterial tirofiban or no intra-arterial tirofiban Receive follow-up assessments during hospitalization and at 90 days","ExperimentalDrugs":"[\"tirofiban\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":32,"Phase":"PHASE3","lastUpdateDate":"2026-04-17"},{"nctId":"NCT06771024","OrgName":"Associação para o Desenvolvimento do Centro Académico de Investigação e Formação Biomédica do Algarv","Titlefull":"Effectiveness of Community Physical Exercise Program in Chronic Disease (CPEP - Chronic Disease), a Clinical Randomized Controlled Trial","BriefSummary":"This study focuses on promoting physical activity (PA) through the implementation of a Community Physical Exercise Program for Chronic Diseases (CPEP-CD), targeting individuals aged 50 years and older with at least two of the following conditions: cardiovascular and/or cerebrovascular disease or risk (CVD), overweight, diabetes mellitus (DM), and musculoskeletal diseases. The primary objective is to improve muscle and cardiorespiratory health and well-being, while also contributing to a more objective and evidence-based exercise prescription for these pathological conditions.\n\nPopulation ageing is a global challenge associated with an increased prevalence of chronic diseases that compromise quality of life (QoL). A sedentary lifestyle is linked to declines in muscle function and cardiorespiratory fitness and is considered a major risk factor for morbidity and mortality. Consequently, physical exercise is widely recommended as a key non-pharmacological intervention across multiple chronic diseases.\n\nAccording to World Health Organization (WHO) guidelines, regular PA is a protective factor in the prevention and management of non-communicable diseases, including cardiovascular and cerebrovascular diseases and DM. In addition, PA provides mental health benefits, supports healthy weight maintenance, and enhances overall well-being. In adults, regular PA is associated with reductions in all-cause mortality, cardiovascular mortality, and the incidence of hypertension.\n\nWithin this context, the aim of this project is to implement a community-based physical exercise program for individuals with chronic disease and multimorbidity, focusing on CVD and cerebrovascular disease or risk, DM, and OA. The program integrates existing exercise prescription guidelines while personalizing exercise progression according to both disease-specific and multimorbidity profiles. The primary outcomes include improvements in cardiorespiratory fitness, muscular strength, bone health, functional capacity, and QoL. Additionally, through individualized training monitoring, this study seeks to establish an exercise prescription tailored to the most prevalent combinations of chronic diseases, thereby providing more objective and practical guidance for family physicians, exercise professionals, and rehabilitation specialists, and supporting more personalized and targeted exercise-based strategies for chronic disease prevention and management.","ExperimentalDrugs":"[\"behavioral: physical exercise\"]","Allcountries":"[\"Portugal\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":12,"Phase":"NA","lastUpdateDate":"2026-02-04"},{"nctId":"NCT07578779","OrgName":"Riphah International University","Titlefull":"Combined Effects of Frenkels Exercises and Electrical Muscle Stimulation on Balance, Coordination and Proprioception in Stroke Patients","BriefSummary":"To determine the combined effects of frenkel's exercises and electrical muscle stimulation on coordination, balance and proprioception in stroke patients.","ExperimentalDrugs":"[\"other: frenkels exercise with ems\",\"other: conservative treatment\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-06-08"},{"nctId":"NCT07510919","OrgName":"Isala","Titlefull":"Continuous Glucose Monitoring for Enhanced Management of Hyperglycemia in Persons With Type 2 Diabetes Undergoing Endovascular Therapy for Acute Ischemic Stroke: a Randomized Controlled Trial.","BriefSummary":"The goal of this randomized clinical trial is to evaluate whether continuous glucose monitoring (CGM) can be used to guide glucose management in patients with type 2 diabetes who are admitted with an acute ischemic stroke and undergo endovascular therapy. Hyperglycemia frequently occurs during hospitalization in stroke and is associated with worse neurological and clinical outcomes. In current clinical practice, glucose levels are monitored using intermittent point-of-care testing (POCT) with finger-prick measurements, which may miss clinically relevant glucose fluctuations. CGM provides continuous glucose measurements and may allow earlier detection of hyperglycemia and more timely glucose management.\n\nThis study is designed as a non-inferiority randomized controlled trial comparing CGM-guided glucose management with standard POCT-guided glucose management. The primary objective is to determine whether CGM-guided glucose management is non-inferior to POCT-guided management in terms of percentage time spent in hyperglycemia (glucose \\>10 mmol/L) during the first 72 hours of hospitalization.\n\nResearchers will compare CGM-guided glucose management to POCT-guided glucose management to evaluate whether CGM can be used as an alternative strategy to guide glucose control in hospitalized stroke patients.\n\nParticipants will:\n\n* Be randomly assigned to either CGM-guided glucose management or standard POCT-guided glucose management\n* Have their glucose levels continuously monitored (blinded in the POCT-guided group) during hospitalization\n* Receive glucose management according to the assigned monitoring strategy, based on the hospital insulin protocol","ExperimentalDrugs":"[\"device: continuous glucose monitoring\",\"diagnostic test: point-of-care testing\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":15,"Phase":"NA","lastUpdateDate":"2026-03-31"},{"nctId":"NCT07563673","OrgName":"Beijing Chao Yang Hospital","Titlefull":"Safety and Efficacy of Treatment With Early Low-dose ASpirin Use After Intravenous Thrombolysis for Acute Ischemic Cerebral Infarction (ELASTIC): A Randomized, Open-label, Blinded Endpoint, Clinical Trial","BriefSummary":"This study evaluates whether early administration of low-dose aspirin (100mg) at 2 hours post-intravenous thrombolysis, compared to the standard timing of 24 hours, improves functional outcomes in patients with acute ischemic stroke. Intravenous thrombolysis is effective for very early treatment of acute ischemic stroke. However, current guidelines recommend starting antiplatelet therapy 24 hours after thrombolysis to avoid symptomatic intracranial hemorrhage (SICH), a recommendation not based on prospective clinical studies. Early re-occlusion of recanalized arteries due to platelet aggregation occurs in 14-34% of cases and is associated with poor prognosis. The average incidence of SICH is 2.4%, with fatal SICH occurring in only 0.28%. Thus, the impact of re-occlusion on poor prognosis may outweigh the risk of SICH. In this prospective, randomized, open-label trial with blinded endpoint evaluation, participants are assigned to receive aspirin 100mg either at 2 hours (early group) or at 24 hours (standard group) after thrombolysis. The primary outcome is the proportion of patients with a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-2 at 3 months. Safety outcomes include the incidence of SICH and all-cause mortality at 3 months. This study will provide clinical evidence regarding the optimal timing for initiating antiplatelet therapy after thrombolysis in acute ischemic stroke.","ExperimentalDrugs":"[\"aspirin (early, 2h)\",\"aspirin (standard, 24h)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT mandatory; EVT optional","Endpoint":"mRS at 90 days","total_Score":23,"Phase":"PHASE4","lastUpdateDate":"2026-05-05"},{"nctId":"NCT07414446","OrgName":"St. Antonius Hospital","Titlefull":"Novel Approach For The Non-Invasive Detection of Pulmonary Right-to-Left Shunts","BriefSummary":"The goal of this clinical trial is to learn how well the SONAS ultrasound device can detect right-to-left shunts of adults with hereditary hemorrhagic telangiectasia (HHT) who are already scheduled for a contrast bubble echocardiogram (TTCE). The main questions it aims to answer are:\n\n1. How accurately does SONAS detect right-to-left shunts compared to the standard TTCE test?\n2. Can SONAS results help tell the difference between shunts in the heart and shunts in the lungs?\n\nParticipants will wear a headband with the SONAS device on the head while they undergo their routine TTCE bubble test. They will receive the usual contrast (agitated saline) through a vein, and both SONAS and TTCE signals will be recorded at the same time. There will be one examination in rest, and one during a breathing exercise (the Valsalva manoeuvre).","ExperimentalDrugs":"[\"device: transcranial ultrasound device\"]","Allcountries":"[\"Netherlands\"]","FirstAdminInter":"Not AIS","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":10,"Phase":"NA","lastUpdateDate":"2026-02-10"},{"nctId":"NCT07468448","OrgName":"Population Health Research Institute","Titlefull":"Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)","BriefSummary":"CATIS-ICAS is a double-blind, randomized, placebo-controlled (RCT), phase III study seeking to demonstrate that oral rivaroxaban 2.5 mg twice daily plus aspirin daily is superior to clopidogrel 75 mg daily plus aspirin daily for 90 days followed by placebo plus aspirin daily for preventing recurrent stroke in those with ischemic stroke secondary to intracranial atherosclerotic disease (ICAD) of 30-99%, when started within 30 days of index stroke.","ExperimentalDrugs":"[\"rivaroxaban\",\"asa\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":15,"Phase":"PHASE3","lastUpdateDate":"2026-03-09"},{"nctId":"NCT05871606","OrgName":"Wake Forest University Health Sciences","Titlefull":"Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy: A Phase I Drug Pilot Research Plan","BriefSummary":"The purpose of this study is to determine the safety and feasibility of using inhaled nitric oxide (iNO) in patients undergoing intra-arterial mechanical thrombectomy (blood clot extraction or IAMT) for treatment of acute ischemic (non-bleeding) stroke (AIS).","ExperimentalDrugs":"[\"ino\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Safety","total_Score":23,"Phase":"PHASE1","lastUpdateDate":"2026-04-22"},{"nctId":"NCT07279259","OrgName":"Shanghai East Hospital","Titlefull":"Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management, EAST-BP","BriefSummary":"This study is a Phase II, exploratory, prospective, multicenter, open-label, randomized controlled clinical trial with blinded endpoint assessment setting on the safety of an adjusted versus a conventional blood pressure management strategy during intravenous thrombolysis in AIS patients, with a key focus on the incidence of symptomatic intracranial hemorrhage (sICH).","ExperimentalDrugs":"[\"procedure: adjusted bp management group\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT mandatory; EVT optional","Endpoint":"Safety","total_Score":23,"Phase":"PHASE2","lastUpdateDate":"2026-01-18"},{"nctId":"NCT07619885","OrgName":"Shanghai CureGene Pharmaceutical Co., Ltd.","Titlefull":"A Pivotal Comparative Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of CG-0255 Besylate and Plavix® in Healthy Participants","BriefSummary":"CG-0255 is a novel investigational prodrug of the active metabolite of Plavix®， but with different active metabolite conversion routes. This is a randomized, open-label and Plavix®-controlled study to compare the PK and PD of CG-0255 Besylate and Plavix® in healthy participants.","ExperimentalDrugs":"[\"cg-0255 besylate capsule\",\"cg-0255 besylate for injection\",\"clopidogrel\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":13,"Phase":"PHASE1","lastUpdateDate":"2026-06-03"},{"nctId":"NCT07347626","OrgName":"Xinqiao Hospital of Chongqing","Titlefull":"Efficacy and Safety of Eptifibatide Therapy Following Intravenous Thrombolysis in Acute Ischemic Stroke Patients Within 4.5 to 24 Hours After Onset: A Multicenter, Randomized Controlled Trial","BriefSummary":"This is a multicenter, randomized, open-label, blinded-endpoint clinical trial designed to evaluate the efficacy and safety of early administration of eptifibatide following intravenous thrombolysis in patients with acute ischemic stroke who present 4.5 to 24 hours after symptom onset.","ExperimentalDrugs":"[\"eptifibatide (integrilin)\",\"standard medical therapy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Day 1 only","Status":"NOT_YET_RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"PHASE3","lastUpdateDate":"2026-01-15"},{"nctId":"NCT07483281","OrgName":"China-Japan Union Hospital","Titlefull":"Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke","BriefSummary":"This study is a multicentre, randomized, blinded-endpoint trial that aims to evaluate the efficacy and safety of human urinary kallidinogenase combined with reteplase intravenous thrombolysis in the treatment of acute ischemic stroke","ExperimentalDrugs":"[\"human urinary kallidinogenase\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":21,"Phase":"NA","lastUpdateDate":"2026-03-25"},{"nctId":"NCT07004790","OrgName":"Clinica Mexico","Titlefull":"Prognostic Value of Transcranial Doppler Ultrasound in the Clinical Evolution of Patients With Acute Ischemic Stroke: A Prospective Observational Study","BriefSummary":"This prospective observational study aims to determine whether specific parameters measured by transcranial Doppler ultrasound (TCD) can predict clinical outcomes in patients with acute ischemic stroke (AIS). The primary objective is to evaluate the association between middle cerebral artery (MCA) flow velocities and short-term neurological improvement. Secondary outcomes include the presence of collateral flow and flow patterns in relation to functional recovery measured by NIHSS and modified Rankin Scale (mRS) scores.","ExperimentalDrugs":"[]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"NIHSS","total_Score":12,"Phase":"NA","lastUpdateDate":"2025-09-13"},{"nctId":"NCT07466251","OrgName":"Peking Union Medical College Hospital","Titlefull":"PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke (PISTIAS-3): a Randomized, Double-blind, Placebo-controlled Trial","BriefSummary":"This study is a prospective, multicenter, double-blind, randomized, placebo-controlled clinical trial designed to evaluate whether early administration of PCSK9 inhibitors can effectively improve functional outcomes at 90 days in patients with ischemic stroke (AIS) associated with intracranial atherosclerotic stenosis (ICAS), primarily assessed using the modified Rankin Scale at 90 days.","ExperimentalDrugs":"[\"rucacuzumab plus standard therapy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":18,"Phase":"PHASE4","lastUpdateDate":"2026-03-11"},{"nctId":"NCT07307001","OrgName":"President Premium Medcenter","Titlefull":"Vojta Therapy Versus Conservative Therapy for Patients With Ischemic Stroke in Regaining Functional Independence","BriefSummary":"Main hypothesis: Vojta Therapy shows significantly better results in regaining functional independence for patients with ischemic stroke than the Conservative Therapy\n\nThe present study wishes to bring evidence that Vojta Therapy is superior in regaining functional independence for patients with ischemic stroke, whether it is solely used in the intervention, or as a complementary tool along with the Conservative Therapy.","ExperimentalDrugs":"[\"procedure: conservative therapy\",\"procedure: vojta therapy\"]","Allcountries":"[\"Romania\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-01-06"},{"nctId":"NCT07318714","OrgName":"Astellas Pharma Inc","Titlefull":"A Phase 1/2 Multicenter, Open-label, Dose Escalation Study Followed by a Randomized, Double-blind Sham-controlled Dose Expansion Study to Evaluate the Safety, Tolerability and Efficacy of ASP2246 in Adult Participants Who Have Motor Dysfunction Associated With Late Subacute to Chronic Ischemic Stroke Due to Supratentorial Perforator Area Infarction","BriefSummary":"This study is for adults who have difficulty moving a few months after a stroke. In this study, ASP2246 will be given to people for the first time. This is known as a \"first in human\" study.\n\nThe main aims of the study are to check the safety of ASP2246, how well people tolerate it, and to find suitable doses of ASP2246 to use later in this study and in future studies.\n\nThis study has 2 parts. In Part 1, people will have brain surgery. During the surgery, different small groups of people will receive a lower to a higher dose of ASP2246. Each dose will be given slowly through a special tube to the damaged part of the brain (intracerebral parenchymal infusion). Any medical problems will be recorded at each dose. This is done to find suitable doses to use in Part 2 of the study.\n\nIn Part 2, other different groups of people will undergo the same type of brain surgery. Some people will receive a higher dose of ASP2246, and some people will receive a lower dose of ASP2246. These are the doses from Part 1. Also, another group of people won't be given ASP2246 during brain surgery. This is known as a sham procedure. This is done so neither the people taking part in Part 2, nor the study doctors (apart from the surgeons) know who will be given ASP2246.\n\nAfter brain surgery, people will be observed for about 2 weeks. For people in Part 1, this will take place in the hospital. For people in Part 2, the observation in hospital may be longer or shorter, depending on the results from Part 1. People in both Parts 1 and 2 will have physical therapy for 12 weeks after surgery and continue to have safety checks for about 1 year after their brain surgery.","ExperimentalDrugs":"[\"asp2246\",\"procedure: brain surgery\",\"other: rehabilitation therapy\"]","Allcountries":"[\"Japan\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":24,"Phase":"PHASE1","lastUpdateDate":"2026-06-09"},{"nctId":"NCT07594301","OrgName":"Tongji Hospital","Titlefull":"Safety and Efficacy of Adjunctive Minocycline After Successful Endovascular Thrombectomy Recanalization for Acute Posterior Circulation Arterial Occlusion - A Multicenter, Prospective, Double-blind, Randomized Trial","BriefSummary":"Acute ischemic stroke (AIS) is a leading cause of mortality and long-term disability worldwide. Among these, stroke caused by large vessel occlusion (LVO) are associated with particularly poor outcomes. Multiple randomized controlled trials have demonstrated that endovascular thrombectomy (EVT) significantly improves clinical outcomes in patients with acute LVO and is recommended as the standard of care by current guidelines. Posterior circulation strokes account for approximately 20% of all ischemic strokes and are generally associated with worse prognosis than anterior circulation strokes, especially in patients with basilar artery occlusion, who have a markedly increased risk of death or severe disability. Despite EVT treatment, more than three-quarters of these patients remain dead or functionally dependent at 90 days, indicating substantial room for improvement.\n\nSuccessful recanalization and restoration of effective cerebral perfusion are critical for achieving favorable outcomes. However, although recanalization rates exceed 80% with current thrombectomy techniques, fewer than 40 of patients achieve good functional outcomes at 90 days, suggesting a high incidence of futile recanalization. The underlying mechanisms may include no-reflow, reperfusion injury, and microcirculatory dysfunction, all of which are closely associated with post-recanalization neuroinflammation.\n\nMinocycline is a second-generation tetracycline with pleiotropic neuroprotective properties, including inhibition of microglial activation, reduction of inflammatory mediators, suppression of matrix metalloproteinases, attenuation of oxidative stress, and preservation of blood-brain barrier integrity. Preclinical and clinical studies suggest that minocycline may improve neurological outcomes in patients with AIS.\n\nThis study is a multicenter, prospective, double-blind, randomized controlled trial designed to evaluate the safety and efficacy of adjunctive minocycline in patients with acute posterior circulation arterial occlusion who achieve successful recanalization after EVT. The trial will assess whether early administration of minocycline improves functional outcomes and reduces the incidence of futile recanalization.","ExperimentalDrugs":"[\"minocycline hydrochloride capsule\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":27,"Phase":"PHASE2","lastUpdateDate":"2026-05-19"},{"nctId":"NCT07283159","OrgName":"General Hospital of Shenyang Military Region","Titlefull":"Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS): a Prospective, Randomized, Double Blinded and Multi-center Study","BriefSummary":"Human urinary kallidinogenase (HUK) is a tissue kallikrein extracted from human urine. Under certain conditions, tissue kallikrein can convert kininogen into kallidin and kinins, thereby promoting vascular endothelial function, and exerting anti-inflammatory and antioxidant effects. Preclinical and clinical studies have demonstrated that HUK can salvage the ischemic penumbra and significantly promote the establishment of collateral circulation. Existing research suggests that the combination of HUK with intravenous alteplase significantly improves neurological function in patients with acute ischemic stroke (AIS) without increasing the risk of hemorrhage. However, whether its combination with tenecteplase can further enhance neurological recovery in patients remains unreported. Based on the above discussion, this study aims to investigate the efficacy and safety of combining tenecteplase with HUK in the treatment of AIS.","ExperimentalDrugs":"[\"human urinary kallidinogenase\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"PHASE2","lastUpdateDate":"2026-01-22"},{"nctId":"NCT07631078","OrgName":"Magnetic Tides","Titlefull":"kTMP-Enhanced Motor Rehabilitation for Chronic Stroke Recovery","BriefSummary":"kTMP, kilohertz transcutaneous magnetic perturbations, is a low intensity transcranial magnetic stimulation technique that will be used in this study to promote arm/hand rehabilitation in patients who have been disabled by stroke.","ExperimentalDrugs":"[\"device: ktmp\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":14,"Phase":"NA","lastUpdateDate":"2026-06-01"},{"nctId":"NCT07404852","OrgName":"Washington University School of Medicine","Titlefull":"Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct 2","BriefSummary":"This is a randomized open-label, with blinded outcome pilot study to evaluate the effect on inflammatory and brain injury laboratory values and explore clinical outcomes in patients who present with ischemic strokes due to large vessel occlusions and are treated with either current accepted management, or accepted management in addition to transcutaneous auricular vagal nerve stimulation.","ExperimentalDrugs":"[\"device: transcutaneous auricular vagal nerve stimulation\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":15,"Phase":"NA","lastUpdateDate":"2026-04-08"},{"nctId":"NCT07335185","OrgName":"Gravity Medical Technology, INC","Titlefull":"Gravity Stroke System for Recanalization of Large Vessel Occlusion Strokes","BriefSummary":"Supernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours of symptom onset or from last known well time.","ExperimentalDrugs":"[\"device: supernova revascularization device\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":22,"Phase":"NA","lastUpdateDate":"2026-01-05"},{"nctId":"NCT07448454","OrgName":"Assiut University","Titlefull":"Role of Vessel Wall MRI in Differentiaition Between Intrcranial Atherosclerotic Disease and Vasculitis as Causes of Ischemic Stroke","BriefSummary":"This work aims to clarify the diagnostic ability of vessel wall MRI to differentiate between intracranial atherosclerotic disease and vasculitis as causes of ischemic stroke, thereby guiding appropriate treatment and improving patient outcomes.","ExperimentalDrugs":"[]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":5,"Phase":"NA","lastUpdateDate":"2026-02-28"},{"nctId":"NCT07618052","OrgName":"Beijing Tiantan Hospital","Titlefull":"Efficacy and Safety of Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Intracranial Atherosclerotic Large Vessel Occlusion: A Clinical Trial Combining a Randomized Controlled Trial and a Concurrent Prospective Observational Cohort","BriefSummary":"A multicenter, randomized, open-label, blinded-endpoint trial with a concurrent prospective observational cohort to compare bailout intracranial angioplasty or stenting versus standard therapy on functional outcome, stroke recurrence, and mortality in patients with acute intracranial atherosclerotic stenosis-related large vessel occlusion after thrombectomy.","ExperimentalDrugs":"[\"procedure: bailout intracranial angioplasty or stenting\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"NA","lastUpdateDate":"2026-05-25"},{"nctId":"NCT07430917","OrgName":"Abrexa Pharmaceuticals, Inc.","Titlefull":"A Phase II, Randomized, Placebo-Controlled, Double-Blind, Adaptive Study to Assess the Safety and Efficacy of Intravenous J147 Combined With Endovascular Therapy in Patients With Acute Ischemic Stroke","BriefSummary":"The goal of this clinical trial is to find out if the drug J147 improves outcomes for persons who have had an ischemic stroke. It also will learn about the safety of J147 when given by injection to stroke patients. Researchers will compare the outcomes of those who receive J147 after therapy to clear the blood clot to those who don't receive J147. Participants will be asked to undergo a series of three to four magnetic resonance imaging (MRI) brain scans, and blood samples will be collected at several time points. Participants will also be evaluated to measure several aspects of brain function.","ExperimentalDrugs":"[\"j147 emulsion for injection\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"Safety","total_Score":26,"Phase":"PHASE2","lastUpdateDate":"2026-04-01"},{"nctId":"NCT07237048","OrgName":"Maimonides Medical Center","Titlefull":"Effect of Oral Minocycline in Patients With Acute Stroke - a Randomized, Open Label, Prospective Trial","BriefSummary":"The goal of this study is to determine if Minocycline, when added to standard care, can improve survival and functional outcomes in patients with moderate acute stroke (ischemic or hemorrhagic) aged 18 years and older.\n\nThe main questions it aims to answer are:\n\n1. Does Minocycline improve \\*National Institutes of Health Stroke Scale\\* (NIHSS) scores at hospital discharge and 90 days post-stroke?\n2. Does Minocycline reduce stroke-related disability, all-cause in hospital mortality (mRS -\\*Modified Rankin Scale\\* = 6) and at 90 days besides reducing brain bleeding complications compared to standard care?\n\nResearchers will compare patients receiving oral Minocycline plus standard care to those receiving standard care only to see if Minocycline leads to better neurological outcomes and lower mortality.\n\nParticipants will:\n\n1. Be randomly assigned by block to receive either:\n\n   Minocycline 200 mg orally once daily for five days within 24 hours from symptoms onset + Standard Care, or Standard Care only\n2. Undergo neurological assessments using NIHSS \\*National Institutes of Health Stroke Scale\\* and Modified Rankin Scale (mRS) at admission, discharge, 30 days post-stroke, 90 days post-stroke\n3. Be monitored for: a) hemorrhagic transformation of ischemic strokes; b) Adverse events and mortality outcomes; c) Safety and efficacy signals through interim analyses\n\nNIHSS: \\*National Institutes of Health Stroke Scale\\*, which is stroke severity scale,\n\nmRS: \\*Modified Rankin Scale\\*, which is stroke disability scale","ExperimentalDrugs":"[\"minocycline 200mg\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"NIHSS","total_Score":21,"Phase":"PHASE2","lastUpdateDate":"2026-03-18"},{"nctId":"NCT07323368","OrgName":"Beijing Tiantan Hospital","Titlefull":"Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Perfusion-guided Endovascular Intervention for Medium Vessel Occlusion Therapy (PIVOT)","BriefSummary":"The investigators initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of perfusion-guided endovascular treatment (EVT) compared to standard medical care for patients with acute ischemic stroke due to medium vessel occlusion (MeVO) within 24 hours from symptom onset.","ExperimentalDrugs":"[\"procedure: endovascular treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"NA","lastUpdateDate":"2026-02-08"},{"nctId":"NCT07415655","OrgName":"University Hospital Hradec Kralove","Titlefull":"Modulation of the Extent of Ischemic Brain Damage by Protecting the Endothelial Glycocalyx With Low-Dose Albumin Administration","BriefSummary":"A single-center, open-label, randomized, placebo-controlled, prospective phase II clinical trial to investigate the efficacy of low-dose albumin in patients with ischemic stroke with an indication for vasographic intervention. The clinical trial consists of the following phases: Screening, randomization, treatment phase - administration of albumin/placebo and vasographic intervention (with the duration of all these 3 phases in the order of hours) and a follow-up phase, which takes place first in the intensive care unit (ICU) and then in a standard ward and lasts 90 (±7) days. The clinical trial ends with the End of Study/Day 90 visit. The total maximum duration of patient participation in the clinical trial is therefore 97 days, including Follow-up.\n\nIschemic stroke is caused by local perfusion impairment due to thromboembolism or thrombosis at the site of perfusion impairment. The damaged brain area is projected into the patient's neurological clinical picture. The primary stroke cannot be influenced by therapeutic procedures, however, the area of the so-called penumbra (the surroundings of the ischemic lesion, where vasoreactivity is impaired and the blood-brain barrier is more or less damaged) can be, which is the main goal of therapy, as well as improving the neurological clinical outcome of patients as much as possible (thrombolysis, neuroangiointervention). Research over the past 20 years has highlighted the importance of the endothelial glycocalyx (EG) and has proposed a number of concepts and substances with a protective and reparative effect.\n\nAlbumin has come to the forefront of interest. The study assumes a benefit for patients in the form of non-circulatory effects of administered albumin: improvement of EG condition in the penumbra area of the ischemic focus, improvement of microrheology, and antioxidant protection. Albumin therapy has been used for 80 years and is generally well tolerated. Allergy to albumin is rare, as it is a protein of the body's own from healthy donors. The concomitantly used medicinal products are highly purified. The selected dosage should not endanger the patient in any way in terms of circulatory overload, pulmonary edema, and, we assume, also in terms of bleeding into the ischemic focus of the brain.\n\nStudy drug: albumin. Any albumin available on the market in the dose and strength specified in the protocol can be used. The reference SmPC is Alburex (manufacturer CSL Behring). Placebo: Fresenius Kabi 0.9% saline solution.\n\nIt is planned to enroll 100 patients.","ExperimentalDrugs":"[\"albumin infusion\"]","Allcountries":"[\"Czechia\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":17,"Phase":"PHASE2","lastUpdateDate":"2026-04-30"},{"nctId":"NCT07498777","OrgName":"National Taiwan University Hospital","Titlefull":"Individual Alpha Frequency-Based rTMS for Post-Stroke Motor Recovery: Efficacy and Neurophysiological Mechanisms","BriefSummary":"The goal of this clinical trial is to evaluate the efficacy of a personalized brain stimulation technique, Individual Alpha Frequency (IAF)-based rTMS, for motor function recovery in adult patients with a first-ever ischemic stroke.\n\nThe main questions it aims to answer are:\n\n1. Does IAF-based rTMS improve upper and lower limb motor recovery better than a sham (placebo) stimulation?\n2. How does this personalized stimulation affect brain wave activity (cortical oscillatory dynamics) as measured by EEG?\n\nResearchers will compare active IAF-based rTMS with a sham stimulation control in a crossover design to see if the active treatment leads to better clinical motor outcomes and beneficial changes in brain activity.\n\nParticipants will:\n\n1. Be randomly assigned to one of two sequences: receiving two weeks of active IAF-rTMS followed by two weeks of sham stimulation, or vice versa.\n2. Attend 30-minute brain stimulation sessions, targeted at the motor cortex, 5 days a week for a total of 4 weeks.\n3. Undergo clinical motor function assessments (including NIHSS, FMA-UE, and FMA-LE) and EEG recordings at three time points: at baseline, after 2 weeks, and at the end of the 4-week study.","ExperimentalDrugs":"[\"device: active individual alpha frequency-based repetitive transcranial magnetic stimulation (iaf-rtms)\",\"device: sham individual alpha frequency-based repetitive transcranial magnetic stimulation (iaf-rtms)\"]","Allcountries":"[\"Taiwan\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"NIHSS","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-03-23"},{"nctId":"NCT07626541","OrgName":"Capital Medical University","Titlefull":"Clinical Study of Fructose Injection in the Treatment of Acute Ischemic Stroke","BriefSummary":"This is a single-center, prospective, randomized, open-label, blinded-endpoint exploratory clinical study enrolling 46 patients with acute ischemic stroke. All eligible patients have symptom onset within 4.5 hours, meet intravenous thrombolysis indications, and receive standard thrombolysis and routine stroke treatment. Participants are randomly assigned to two groups: the intervention group receives early intravenous infusion of 10% fructose injection plus standard treatment, while the control group receives only standard treatment without fructose. The study mainly evaluates changes in neurological function via NIHSS scores within 7 days after thrombolysis, assesses cerebral infarct lesion volume and brain edema using multimodal MRI including DWI, T2WI and MRS, detects cerebral neuronal metabolic markers, and conducts 1-month follow-up of neurological function by NIHSS score as well as functional prognosis using the mRS score. The research also comprehensively monitors adverse events and safety indicators to explore the clinical efficacy, neuronal metabolic regulation effect and safety of early fructose injection combined with intravenous thrombolysis in acute ischemic stroke patients, aiming to provide clinical evidence for early neuroprotective intervention.","ExperimentalDrugs":"[\"10% fructose injection\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Only once","Status":"ACTIVE_NOT_RECRUITING","Add_on":"IVT mandatory; EVT optional","Endpoint":"NIHSS","total_Score":29,"Phase":"PHASE2","lastUpdateDate":"2026-06-17"},{"nctId":"NCT06442631","OrgName":"University of Pennsylvania","Titlefull":"An Individualized Video-based Stroke Education Platform for Stroke Survivors and Caregivers","BriefSummary":"The goal of this multicenter randomized trial is to evaluate the impact of a personalized video-based stroke education platform on patient-centered and health system-centered outcomes. The main questions this study aims to address are:\n\n1. Does a personalized, video-based educational platform improve stroke knowledge?\n2. Does a personalized, video-based educational platform reduce post-discharge health system utilization?\n3. Do different strategies of nudging improve engagement with educational material after hospital discharge?\n\nIn order to determine the effect of this personalized stroke education strategy, researchers will compare subjects who receive standard stroke education with those who receive the personalized stroke education platform in addition to standard standard education. Patient knowledge will be assessed 90-days after discharge. Study participants will include both stroke patients and caregivers, who will:\n\n1. Receive standard education during the stroke hospitalization\n2. Complete a survey on the day of hospital discharge to assess their baseline knowledge.\n3. Half of the subjects will be randomly assigned to also receive access to the personalized stroke education platform on the day of discharge.\n4. All subjects will complete two follow-up study visits (7 and 90 days after discharge) in order to complete surveys.","ExperimentalDrugs":"[\"behavioral: mystroke\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":10,"Phase":"NA","lastUpdateDate":"2026-01-05"},{"nctId":"NCT07423975","OrgName":"Beijing Tiantan Hospital","Titlefull":"Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke (SAFE)","BriefSummary":"The investigators initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to explore the safety and efficacy of different dose of Anakinra compared to standard medical care for patients with acute ischemic stroke who have achieved successful recanalization after endovascular thrombectomy.","ExperimentalDrugs":"[\"high-dose anakinra\",\"low-dose anakinra\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"3 days or less","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":25,"Phase":"PHASE2","lastUpdateDate":"2026-02-14"},{"nctId":"NCT04701619","OrgName":"Fondation Ophtalmologique Adolphe de Rothschild","Titlefull":"Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies","BriefSummary":"IMMUNOSTROKE study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the course of AIC management by reperfusion treatment and to monitor changes in these different parameters over time. Post-hoc analyses will make it possible to correlate the immuno-inflammatory and thrombo-inflammatory profiles and their evolution with the clinical outcome in terms of post-AIC functional and cognitive disability.","ExperimentalDrugs":"[]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Other","total_Score":9,"Phase":"NA","lastUpdateDate":"2026-01-16"},{"nctId":"NCT07375953","OrgName":"General Hospital of Shenyang Military Region","Titlefull":"Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK): a Prospective, Randomized, Open Label, Blinded Assessment of Outcome, and Multi-center Study","BriefSummary":"Despite being the standard pharmacological reperfusion therapy for acute ischemic stroke, intravenous thrombolysis is limited by suboptimal recanalization rates. Tenecteplase (TNK), a newer thrombolytic agent, offers practical advantages over alteplase, including single bolus administration. However, a significant proportion of patients fail to achieve early clinical improvement after standard thrombolysis, likely due to persistent vessel occlusion.\n\nThis study proposes to investigate a rescue strategy for patients who do not show significant neurological improvement within one hour after receiving standard intravenous tenecteplase within 3 hours of stroke onset. The primary objective is to evaluate the safety and feasibility of administering a second dose of tenecteplase in this scenario. The study will also explore the potential efficacy of this approach in improving recanalization and functional outcomes.","ExperimentalDrugs":"[\"tenecteplase\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":30,"Phase":"PHASE2","lastUpdateDate":"2026-03-31"},{"nctId":"NCT07091994","OrgName":"Nanfang Hospital, Southern Medical University","Titlefull":"A Prospective, Multicentre, Randomized Controlled Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy","BriefSummary":"This multicenter randomized controlled trial aims to evaluate the efficacy and safety of edaravone dexborneol injection in patients with acute ischemic stroke (AIS) complicated by active malignancies. The study will primarily investigate whether this combined antioxidant and anti-inflammatory treatment can improve neurological functional recovery and assess its safety profile in this high-risk population. Investigators will compare outcomes between the edaravone dexborneol treatment group and a control group receiving standard therapy to determine if the intervention provides superior neuroprotective effects. Participants will receive the assigned treatment regimen, undergo serial neurological assessments and imaging studies to monitor stroke progression and recovery, and be closely followed for safety evaluations. The findings may offer evidence-based therapeutic options for managing this challenging clinical scenario where current treatment alternatives are limited.","ExperimentalDrugs":"[\"edaravone dexborneol injection\",\"standard therapeutic protocol\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"NIHSS","total_Score":16,"Phase":"PHASE4","lastUpdateDate":"2026-04-13"},{"nctId":"NCT07449910","OrgName":"The First Affiliated Hospital of University of Science and Technology of China","Titlefull":"Safety and Efficacy of Baricitinib Combined With Acute Large Vessel Occlusion Recanalization : A Multicenter, Randomized Controlled Clinical Trial","BriefSummary":"The primary purpose of this study is to evaluate the efficacy and safety of Baricitinib combined with endovascular therapy in patients with acute anterior circulation large vessel occlusion, to address futile recanalization with priority, and to elucidating the mechanism of JAK/STAT pathway inhibition on neuroprotection and inflammatory regulation.","ExperimentalDrugs":"[\"2mg baricitinib\",\"other: guideline-based therapy\",\"4mg baricitinib\",\"placebo\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":26,"Phase":"PHASE2","lastUpdateDate":"2026-02-27"},{"nctId":"NCT07497542","OrgName":"Tianjin Medical University General Hospital","Titlefull":"Safety and Efficacy of Immediate Abundant Intravenous Normal Saline Infusion for Stroke After Intravenous Thrombolysis: a Multi-centre Randomized Controlled Phase III Trial","BriefSummary":"The intravenous administration of abundant normal saline is an easy-to-use strategy commonly employed to expand the blood volume. This study aimed to evaluate the efficacy and safety of the early administration of an abundant normal saline infusion after intravenous thrombolysis for promoting functional independence in patients with acute ischemic stroke. This multicenter, randomized, phase III clinical trial intends to enroll stroke participants who have undergone intravenous thrombolysis. Eligible patients are randomized to receive either abundant intravenous normal saline infusion (2,000-2,500 mL; normal saline group) or a small volume of intravenous normal saline infusion (≤600 mL; control group) immediately after thrombolysis. The primary outcome is the comparison of the ordinal modified Rankin Scale score at 90 days (±3) after randomization between the treatment groups.","ExperimentalDrugs":"[\"normal saline\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":26,"Phase":"PHASE3","lastUpdateDate":"2026-04-19"},{"nctId":"NCT07540065","OrgName":"National Taiwan University Hospital","Titlefull":"AI-Assisted Workflow for Occult Atrial Fibrillation Detection After Ischemic Stroke: A Prospective Randomized Trial","BriefSummary":"We hypothesize that an AI-guided AF risk stratification approach, particularly when combined with intensified rhythm monitoring using wearable devices and extended ECG patches, will significantly increase AF detection rates compared with standard care. By enabling earlier identification of patients who may benefit from anticoagulation therapy, this strategy has the potential to improve clinical outcomes while minimizing unnecessary exposure to anticoagulant-related bleeding risks. Ultimately, this trial seeks to provide robust clinical evidence supporting the integration of AI-assisted ECG analysis into routine post-stroke care, advancing precision medicine and optimizing resource allocation for patients with ischemic stroke.","ExperimentalDrugs":"[\"device: active follow-up group\",\"other: standard follow-up group\"]","Allcountries":"[\"Taiwan\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":4,"Phase":"NA","lastUpdateDate":"2026-04-16"},{"nctId":"NCT07628933","OrgName":"BOE Technology Group Co., Ltd.","Titlefull":"A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Human Umbilical Cord-derived Mesenchymal Stromal Cell Injection in Patients With Acute Ischemic Stroke (AIS)","BriefSummary":"Study Methods: The trial consists of two phases, both including a placebo control.\n\nPhase Ia (single-dose, dose-escalation): Three dose groups (low, medium, high) are set. This is a multicenter, randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial. Dose escalation to the next level is permitted only after safety assessment at 28 days post-dose in the previous group.\n\nPhase Ib (multiple-dose): Based on Phase Ia results, two dose groups will be selected. The product is administered on Day 0, Day 7, and Day 14 (3 doses total). The trial remains randomized, double-blind, and placebo-controlled.","ExperimentalDrugs":"[\"human umbilical cord mesenchymal stem cells injection\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"Safety","total_Score":22,"Phase":"PHASE1","lastUpdateDate":"2026-06-01"},{"nctId":"NCT07540416","OrgName":"The First Affiliated Hospital of Zhengzhou University","Titlefull":"Tenecteplase Thrombolysis for Acute Ischemic Stroke in the 4.5-9-Hour Window Guided by DWI-FLAIR Mismatch: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial","BriefSummary":"The goal of this clinical trial is to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in patients with acute ischemic stroke (AIS) guided by DWI-FLAIR mismatch on MRI. The main questions it aims to answer are:\n\n1. Does tenecteplase improve functional outcomes at 90 days compared with standard treatments in AIS patients administered 4.5-9 hours after stroke onset guided by DWI-FLAIR mismatch?\n2. The safety of tenecteplase thrombolysis for AIS patients in the 4.5-9 hours guided by DWI-FLAIR mismatch.\n\nResearchers will compare tenecteplase to placebo to see if it is effective and safe for these patients.\n\nParticipants will be randomly assigned (1:1) immediately after randomization:\n\n* Tenecteplase group: received tenecteplase, intravenously as a bolus administered over a period of 5 to 10 seconds at a dose of 0.25 mg per kilogram (maximum dose, 25 mg), plus aspirin placebo (300 mg).\n* Control group: aspirin (300 mg) plus tenecteplase placebo. From day 2 to day 90, all patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.","ExperimentalDrugs":"[\"tnk-tpa\",\"placebo\",\"aspirin\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":27,"Phase":"PHASE3","lastUpdateDate":"2026-04-17"},{"nctId":"NCT07367633","OrgName":"Population Health Research Institute","Titlefull":"A Pragmatic, Multicentre, Adaptive, Prospective, Open-label, Blinded Endpoint Randomized Clinical Trial Assessing the Impact of Head-of-bed Positioning at 0-degrees Versus 30-degrees or More on Functional Recovery Following Endovascular Thrombectomy for Anterior Circulation Large Vessel Occlusion Stroke.","BriefSummary":"Endovascular thrombectomy (EVT), also known as clot retrieval, is a procedure that improves recovery for people who suffer a stroke by removing blood clots from large blood vessels in the brain. However, half of the patients undergoing EVT to remove the clot from a brain vessel still face lasting disabilities or even die within three months.\n\nThe investigators of the HoBIT trial are trying to find out if the position of the head of bed improves recovery in patients who undergo EVT after suffering from a stroke.\n\nThe purpose of this study is to establish the benefit of head of bed positioning at 0-degrees compared with 30-degrees or more after EVT for improving functional outcomes in adults that suffer from a stroke.","ExperimentalDrugs":"[\"other: head of bed position of 0-degrees\"]","Allcountries":"[\"Canada\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-02-03"},{"nctId":"NCT06396858","OrgName":"Brazilian Clinical Research Institute","Titlefull":"A 2 x 2 Factorial Randomized Clinical Trial Evaluating Anti-inflammatory and Anti-thrombotic Strategy in Acute Ischemic Stroke","BriefSummary":"The ARCHIMEDES study (Anti-inflammatory and anti-thRombotic therapy with colCHicine and low dose rIvaroxaban for Major adverse cardiovascular Events reDuction in ischEmic Stroke) will be a randomized, double-blind, 2x2 factorial clinical trial, which will include at least 3000 and up to a maximum of 4500 patients with ischemic stroke without indication of oral anticoagulation.","ExperimentalDrugs":"[\"rivaroxaban 2.5 mg oral tablet\",\"colchicine 0.5 mg\",\"placebo colchicine\",\"placebo rivaroxaban\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Other","total_Score":10,"Phase":"PHASE4","lastUpdateDate":"2026-02-10"},{"nctId":"NCT07476898","OrgName":"First Hospital of China Medical University","Titlefull":"A Multicenter, Randomized, Open-Label, Blinded-Endpoint Trial of Tenecteplase Versus Dual Antiplatelet Therapy in Mild Disabling Ischemic Stroke With Large Vessel Occlusion Beyond 4.5 Hours (TIME-MINOR Trial)","BriefSummary":"To verify the efficacy and safety of intravenous tenecteplase (TNK) in patients with disabling minor stroke and large vessel occlusion (LVO) within a 4.5-24 hour time window.","ExperimentalDrugs":"[\"tenecteplase (0.25mg/kg)\",\"standard medical management\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"PHASE3","lastUpdateDate":"2026-03-12"},{"nctId":"NCT07361302","OrgName":"Boehringer Ingelheim","Titlefull":"TENACITY - A Phase III, Prospective, Randomized, Open-label, Blinded Endpoint Assessment (PROBE) to Assess Efficacy and Safety of i.v. Tenecteplase vs Standard of Care in Patients With Acute Ischemic Stroke (Including Wake-up Stroke), Last Known Well >4.5 h With Imaging Evidence of Salvageable Ischemic Tissue","BriefSummary":"This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke). This study is for people who had an acute stroke or woke up with a stroke and were last seen well more than 4.5 hours before joining the study. Participants need to have imaging that shows there is brain tissue that can still be saved. They also should not be planned to receive a procedure to remove the blood clot.\n\nThe purpose of this study is to find out whether a medicine called tenecteplase helps people recover from an acute stroke. Tenecteplase is already used to treat people within 4.5 hours after they had a stroke. This study tests if tenecteplase also helps if it is given more than 4.5 hours after the stroke.\n\nParticipants are put into 2 groups randomly, which means by chance. One group gets tenecteplase as a single injection into a vein. The other group receives standard medical practice. Participants have an equal chance of receiving tenecteplase or the standard treatment.\n\nParticipants are in the study for about 3 months. In the beginning, participants stay in the hospital for about 1 week. During the study, participants have 7 clinical examinations or visits. The last 2 of these visits will likely be done from home, allowing participants to complete certain assessments remotely. Doctors regularly test participants' recovery using a scale that measures the level of disability or dependence in daily activities. The results are compared between the 2 groups to see whether the treatment works. The doctors also check participants' health and take note of any unwanted effects.","ExperimentalDrugs":"[\"tenecteplase\",\"standard of care treatment\"]","Allcountries":"[\"Argentina\",\"Australia\",\"Bulgaria\",\"China\",\"Greece\",\"Hungary\",\"India\",\"Indonesia\",\"Kazakhstan\",\"Malaysia\",\"Norway\",\"Romania\",\"Spain\",\"Taiwan\",\"Thailand\",\"Vietnam\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":33,"Phase":"PHASE3","lastUpdateDate":"2026-06-08"},{"nctId":"NCT07496645","OrgName":"Dr. Ram Manohar Lohia Hospital","Titlefull":"EFFECT OF ANODAL TRANSCRANIAL DIRECT CURRENT STIMULATION ON NAMING IN APHASIC PATIENTS WITH ACUTE ISCHEMIC STROKE","BriefSummary":"The use of transcranial direct current stimulation (tDCS) for the management of deficits developed in stroke is a relatively new type of management option. Many of the studies performed using tDCS have focused on improvements noted in hemiplegia as compared to aphasia, which is an equally disabling outcome of strokes. The results of these studies have not been conclusive and concordant with each other.\n\nIn aphasia management, the majority of the studies have focused on chronic strokes. Since the use of tDCS is relatively new, the studies have not focused on a particular type of deficit or stroke. Very few studies have focused on the impact of solely using tDCS. Very few studies have focused on acute to subacute strokes. The results of the studies have, nevertheless, been encouraging.\n\nImprovements in aspects of language tested after a single session of tDCS are short-lived. There is an unmet need to probe the utility of repetitive tDCS on aspects of language function in patients who are aphasic due to acute stroke. There is also a paucity of data in the Indian scenario regarding the same.","ExperimentalDrugs":"[\"device: transcranial direct current stimulation\"]","Allcountries":"[\"India\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":11,"Phase":"PHASE3","lastUpdateDate":"2026-03-21"},{"nctId":"NCT07454707","OrgName":"Sunnybrook Health Sciences Centre","Titlefull":"Randomized Trial to Evaluate the Efficacy and Safety of Very Low Dose Anticoagulant Therapy Added to Standard-Care Single Antiplatelet Therapy for Prevention of Recurrent Strokes in Patients With Ischemic Stroke Aged 75+ Years","BriefSummary":"The overall aim of this research is to improve secondary stroke prevention for older patients with stroke.\n\nIn current practice, patients with stroke are often prescribed antiplatelet therapy with either aspirin or clopidogrel to help prevent recurrent strokes. However, an antiplatelet medication may not be effective enough for some patients.\n\nA promising new treatment strategy to enhance stroke prevention involves a very low dose of an anticoagulant (anti-clotting medication) added to the standard antiplatelet therapy. In a previous study, this approach cut stroke risk in half among patients with heart/vascular disease, but it has not yet been formally tested in an older stroke population. The STROKE75+ trial is now being conducted to carefully evaluate the potential benefits and potential risks of this type of treatment strategy for secondary stroke prevention.\n\nThe medication being tested in the STROKE75+ trial is a commonly used anticoagulant called edoxaban -- at a reduced dose of 15mg once daily (one-quarter of its full dose) to minimize the chance of bleeding. In previous research, edoxaban 15mg daily has been shown to be safe and effective for preventing strokes in patients with atrial fibrillation, but it has not been studied in stroke patients without atrial fibrillation.\n\nThis trial aims to answer the following questions:\n\n1. Does the addition of edoxaban 15mg once a day to standard antiplatelet therapy reduce the risk of recurrent strokes more than standard antiplatelet therapy alone?\n2. Does the addition of edoxaban 15mg daily reduce the risk of severe (disabling) strokes, dementia, or heart attacks?\n3. What is the incidence of bleeding with/without edoxaban 15mg daily?\n\nThese questions will be addressed using a Randomized Clinical Trial design. Eligible participants are randomly assigned (50/50 chance) to one of two study groups. Participants in Group 1 are treated with edoxaban 15 mg once a day by mouth (tablet) in addition to their usual standard antiplatelet medication. Participants in Group 2 will continue to take their standard antiplatelet medication (aspirin or clopidogrel) without edoxaban.\n\nParticipants are monitored closely for the duration of the study (approx.. 2-4 years). Every 3 months, participants will receive a phone call to check on their health status and assess if they have experienced any new strokes, bleeding, or other medical problems. Once a year, and at the start and end of the study, participants will also be asked questions about their symptoms, functioning, memory, and quality of life. At the end of the study, patient outcomes between the two groups will be compared and the results will be published.\n\nThe information gained from this study will increase knowledge and help inform future stroke care for the aging population. The ultimate goal of this research is to prevent more strokes, save lives, and reduce the growing public health burden of stroke.","ExperimentalDrugs":"[\"edoxaban 15 mg\",\"aspirin or clopidogrel\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":15,"Phase":"PHASE3","lastUpdateDate":"2026-03-03"},{"nctId":"NCT07390032","OrgName":"Beijing Tiantan Hospital","Titlefull":"The Efficacy and Safety of Endovascular Treatment for Acute Mild Basilar Artery Occlusion: A Multicenter, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial","BriefSummary":"This study assesses the efficacy and safety of endovascular treatment for acute mild basilar artery occlusion within a multicenter, prospective, open-label, endpoint-blinded, randomized controlled clinical trial.","ExperimentalDrugs":"[\"procedure: endovascular recanalization strategy\",\"best medical management\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"NA","lastUpdateDate":"2026-01-28"},{"nctId":"NCT07526649","OrgName":"Auckland City Hospital","Titlefull":"Head Cooling in Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy: A Phase 2 Randomised Controlled Trial (COOLHEAD-2b)","BriefSummary":"COOLHEAD-2b is a multicentre, phase 2, prospective, randomised, controlled, open-label, blinded-endpoint trial evaluating the safety and efficacy of non-invasive convective head cooling as an adjunct to endovascular thrombectomy (EVT) in patients with acute anterior circulation ischaemic stroke. Head cooling is initiated as early as possible, including during inter-hospital transfer, and continued until one hour after reperfusion. The primary efficacy endpoint is final infarct volume at 24 hours.","ExperimentalDrugs":"[\"device: non-invasive convective head cooling\",\"other: standard of care (soc)\"]","Allcountries":"[\"New Zealand\"]","FirstAdminInter":"Other","TreatDur":"Day 1 only","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-04-09"},{"nctId":"NCT07637825","OrgName":"Jiangsu Taizhou People's Hospital","Titlefull":"Transcranial Focused Ultrasound Neuromodulation in Post-Stroke Motor Dysfunction","BriefSummary":"This study aims to evaluate how transcranial focused ultrasound (tFUS) technology can promote neural network remodeling and functional recovery after stroke. By integrating signals from electroencephalography (EEG) and magnetic resonance imaging (MRI), the study will investigate how activating or inhibiting specific brain regions affects motor and cognitive recovery. The goal is to improve patients' motor and cognitive functions, reduce long-term disability, and enhance quality of life. The study also seeks to optimize stimulation parameters to maximize rehabilitation outcomes and explore the mechanisms underlying neuroprotection and functional reconstruction after stroke.\n\nThis is a case-control study involving a total of 60 participants. Participants will be ischemic stroke survivors aged 18-75 years, with first-ever stroke onset between 21 days and 6 months, stable vital signs, no consciousness disorders, and the ability to provide informed consent and cooperate with assessments. Eligible participants must have unilateral limb motor impairment, with an upper extremity modified Ashworth score ≤3, Brunnstrom stage II-V, and an upper extremity Fugl-Meyer Assessment (FMA-UE) score between 15 and 60.\n\nParticipants will be assigned to either a neuromodulation group (receiving multi-modal neuromodulation targeting specific brain regions) or a control group (receiving sham stimulation or conventional treatment). Primary outcome measures include changes in FMA-UE scores, neuroimaging data (CT/MRI), EEG measurements (resting-state and task-state spectral power, functional connectivity), and laboratory markers (complete blood count, CRP, IL-6, S100β, BDNF). Secondary outcome measures include Brunnstrom stage, Ashworth grade, muscle strength, and patient comfort ratings. Safety will be monitored through blood routine tests, blood biochemistry, and coagulation function.\n\nStatistical analysis will compare key indicator changes between the neuromodulation and control groups before and after intervention. Independent t-tests (for two groups) or ANOVA (for multiple groups) will be used to assess between-group differences, with non-parametric tests applied for data not following a normal distribution.","ExperimentalDrugs":"[\"device: transcranial focused ultrasound neuromodulation\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":7,"Phase":"NA","lastUpdateDate":"2026-06-05"},{"nctId":"NCT07460713","OrgName":"Beijing Tiantan Hospital","Titlefull":"Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Direct Transfer to Angiography Suite (DTAS) for Patients With Suspected Large Vessel Occlusion","BriefSummary":"The investigators initiated a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of the direct transfer to angiography suite (DTAS) triage strategy compared to the conventional triage strategy with CT/MRI in patients with suspected large artery occlusive (LVO) within 6 hours of symptom onset.","ExperimentalDrugs":"[\"procedure: direct transfer to angiography suite\",\"procedure: conventional ct/mri triage strategy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 6 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"NA","lastUpdateDate":"2026-03-10"},{"nctId":"NCT05723926","OrgName":"Javelin Medical","Titlefull":"Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation","BriefSummary":"Patients with atrial fibrillation (AF) who have had a prior stroke are at very high risk of recurrent ischemic stroke. About 40% of these strokes are due to large emboli which result in large cerebral vessel occlusion (LVO). This randomized control trial aims to address this unmet need by testing whether use of bilateral carotid filter implants in addition to OAC will reduce the risk of stroke in AF patients with recent (e.g. within 12 months) ischemic stroke vs. only OAC.","ExperimentalDrugs":"[\"device: vine filter\"]","Allcountries":"[\"Canada\",\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":14,"Phase":"NA","lastUpdateDate":"2026-06-07"},{"nctId":"NCT07376447","OrgName":"iVascular S.L.U.","Titlefull":"Confirmation of the Performance and Safety of the iNstroke 6F and 4F Thromboaspiration Catheter for the Treatment of Acute Ischemic Stroke","BriefSummary":"Prospective, single-arm, multi-center study to confirm the performance and safety of the iNstroke 6F and 4F thromboaspiration catheter for the treatment of acute ischemic stroke","ExperimentalDrugs":"[]","Allcountries":"[\"France\",\"Germany\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":29,"Phase":"NA","lastUpdateDate":"2026-01-29"},{"nctId":"NCT07471282","OrgName":"First Hospital of China Medical University","Titlefull":"Effectiveness and Safety of Intra-arterial Tenecteplase Bridging Therapy Following Incomplete Recanalization After Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","BriefSummary":"To evaluate the efficacy and safety of intra-arterial TNK bridging therapy following incomplete recanalization (2b ≤ eTICI \\< 3) after mechanical thrombectomy for acute anterior circulation large vessel occlusion.","ExperimentalDrugs":"[\"tenecteplase (0.0938mg/kg)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"EVT mandatory; IVT optional","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"PHASE3","lastUpdateDate":"2026-03-10"},{"nctId":"NCT07576647","OrgName":"McMaster University","Titlefull":"Optimized Recruitment to Drive Equitable Research in Stroke, Empowering Decision-making (ORDERed)","BriefSummary":"Stroke is a major health issue, especially for women, who are more likely than men to have worse outcomes and lower quality of life after a stroke. Yet, women are under-represented in stroke research, which limits how well treatments work for them. This study aims to change that by testing a new way to recruit women into stroke research using the ORDER toolkit, a set of easy-to-understand, women-focused materials like brochures and videos co-designed with patients. This new approach will be compared to the usual way of recruiting patients. The study will track how many people join, how long it takes to make a decision, and what influences participation. Patients and research coordinators will also share their feedback on the process. Our goal is to make stroke studies more inclusive so that research findings benefit everyone equally.","ExperimentalDrugs":"[\"other: supported, women-centred and aphasia-friendly recruitment process (ordered)\"]","Allcountries":"[\"Canada\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":5,"Phase":"NA","lastUpdateDate":"2026-04-30"},{"nctId":"NCT07520565","OrgName":"Biocells (Beijing) Biotech Co.,Ltd","Titlefull":"A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.","BriefSummary":"The purpose of this study was to evaluate the efficacy of early administration of BXOS110 for injection in reducing overall disability in patients with acute ischaemic stroke","ExperimentalDrugs":"[\"bxos110\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":34,"Phase":"PHASE3","lastUpdateDate":"2026-04-02"},{"nctId":"NCT07357987","OrgName":"Beijing Tiantan Hospital","Titlefull":"Intra-arterial Tenecteplase for Acute Medium Vessel Occlusion Stroke: the ANGEL-MeVO-TNK Randomized Clinical Trial","BriefSummary":"The ANGEL-MeVO-TNK is a multicentered, prospective, randomized, open label, blinded endpoint (PROBE) phase III trial. A total of 488 AIS patients (age ≥18 years) with acute MeVO-AIS (occlusion of the M2/M3, the A1/A2/A3, the P1/P2/P3, and with baseline NIHSS score \\>5 or disabling stroke with NIHSS score 3-5 \\[such as neurological deficits in motor strength, language, vision, etc\\]), will be enrolled. Patients fulfilling all the inclusion criteria and none of the exclusion criteria will be randomized 1:1 into the IA TNK group or the control group after offering informed content.\n\n* The IA TNK group：1) If the patient has not received IVT, IA TNK will be administered as a slow, continuous infusion for super-selective contact thrombolysis in a stepwise manner: an initial dose of 0.0625 mg/kg with a duration of 15 minutes. A repeat angiographic assessment will then be performed; if recanalization is not achieved, an additional dose of 0.0625 mg/kg will be administered over a further 15 minutes (maximum dose 12.5 mg) .\n\n  2\\) If the patient has received IVT, intra-arterial TNK will be administered as a slow infusion for super-selective contact thrombolysis at a dose of 0.0625 mg/kg (maximum dose 6.25 mg) with a duration of 15 minutes.\n* The control group will be given standard medical management.\n\nThe study consists of four visits including the day of randomization, 48±12 hours after randomization, and 90±7 days after randomization. Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment neurological function rating scale will be recorded during the program.\n\nThe primary outcome is the modified Rankin Scale (mRS) score of 0 to 1 at 90±7 days after onset. The primary safety outcome is the incidence of sICH within 48±12 hours after randomization (ECASS III).","ExperimentalDrugs":"[\"procedure: intra-arterial tenecteplase\",\"standard medical management\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":33,"Phase":"PHASE3","lastUpdateDate":"2026-04-26"},{"nctId":"NCT07556887","OrgName":"Maastricht University Medical Center","Titlefull":"Clinical Impact of the Use of IMPROVE for Selection of Patients for Carotid Revascularisation: a Randomized Controlled Multicentre Non-inferiority Trial in Symptomatic Patients With 30-99% Carotid Stenosis","BriefSummary":"Narrowing of the carotid artery due to atherosclerosis with an unstable plaque can cause a stroke. Patients with carotid artery disease who have had a TIA or minor stroke and are at high risk of another stroke are often treated with surgery or stenting to remove the plaque. For lower-risk patients, medication alone is the better option, as surgery also carries risks. A new decision method, based on MRI detection of unstable plaques (IMPROVE), can better assess stroke risk and help determine which patients do or do not need surgery. We are investigating whether this method is at least as effective as the standard approach, which mainly considers the degree of narrowing. We expect that this new method will help reduce strokes and lower healthcare costs.\n\nPatients will be followed for several years to compare which method is better for health and costs.","ExperimentalDrugs":"[\"other: improve risk model\"]","Allcountries":"[\"Netherlands\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":9,"Phase":"NA","lastUpdateDate":"2026-05-12"},{"nctId":"NCT07606807","OrgName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","Titlefull":"rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window: A Multicenter, Prospective, Randomized Controlled, Open-label, Blinded-Endpoint Trial","BriefSummary":"The PEARL-SIMPLIFIED trial is a multicenter, prospective, randomized controlled, open-label, blinded-endpoint study. It aims to evaluate the efficacy and safety of intravenous tenecteplase (TNK) in patients with acute ischemic stroke (AIS) presenting in the extended 4.5-24 hour window, using a simplified imaging selection strategy based solely on non-contrast CT (NCCT).","ExperimentalDrugs":"[\"tenecteplase (rhtnk-tpa) (0.25 mg/kg, to maximum of 25mg)\",\"standard medical treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"PHASE3","lastUpdateDate":"2026-06-11"},{"nctId":"NCT07356284","OrgName":"ProMedica Health System","Titlefull":"Emergent Large Vessel Occlusion Endovascular Rescue Therapy With Underlying Intracranial Stenosis","BriefSummary":"The study objective is to establish the safety and efficacy of endovascular adjunct stenting for patients undergoing mechanical thrombectomy (MT) that are found to have residual stenosis (70-99%) following attempted clot retrieval with either aspiration catheters or stent retrievers, per device instructions for use and device labeling.","ExperimentalDrugs":"[\"procedure: mechanical thrombectomy plus adjunct stenting\",\"device: mechanical thrombectomy\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":34,"Phase":"PHASE3","lastUpdateDate":"2026-05-20"},{"nctId":"NCT07419087","OrgName":"Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de Kerpape","Titlefull":"Trunk Impairment Scale - Adaptation and Validation in French","BriefSummary":"The objective of this project is to verify the validity and determine the clinimetric properties after translation and adaptation into French of the Trunk Impairment Scale (TIS), a scale for measuring trunk control and seated balance.","ExperimentalDrugs":"[\"other: evaluation by the tis\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":5,"Phase":"NA","lastUpdateDate":"2026-02-10"},{"nctId":"NCT07371455","OrgName":"Longwood Pharmaceuticals (Hangzhou) Co., Ltd.","Titlefull":"A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants","BriefSummary":"This study is a randomized, double-blind, placebo-controlled clinical trial featuring both single ascending dose (SAD), food effect and multiple ascending dose (MAD) phases intended to evaluate the safety, tolerability, PK, PD, and active metabolites of LWP779 after oral administration in healthy participants.","ExperimentalDrugs":"[\"lwp779\",\"placebo of lwp779\"]","Allcountries":"[\"Australia\"]","FirstAdminInter":"Not AIS","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":23,"Phase":"PHASE1","lastUpdateDate":"2026-03-18"},{"nctId":"NCT05470478","OrgName":"VA Office of Research and Development","Titlefull":"Enhancement and Optimization of a Mobile iBCI for Veterans With Paralysis","BriefSummary":"VA research has been advancing a high-performance brain-computer interface (BCI) to improve independence for Veterans and others living with tetraplegia or the inability to speak resulting from amyotrophic lateral sclerosis, spinal cord injury or stoke. In this project, the investigators enhance deep learning neural network decoders and multi-state gesture decoding for increased accuracy and reliability and deploy them on a battery-powered mobile BCI device for independent use of computers and touch-enabled mobile devices at home. The accuracy and usability of the mobile iBCI will be evaluated with participants already enrolled separately in the investigational clinical trial of the BrainGate neural interface.","ExperimentalDrugs":"[\"device: mobile neural decoding platform (mobile ibci)\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":3,"Phase":"NA","lastUpdateDate":"2026-02-19"},{"nctId":"NCT07533253","OrgName":"Centre hospitalier de l'Université de Montréal (CHUM)","Titlefull":"Treatment of Persistent Distal Occlusion After Successful Proximal Recanalization in Thrombectomy - A PHASE II Trial","BriefSummary":"The goal of this clinical trial is to determine whether rescue distal mechanical thrombectomy can improve outcomes in patients with persistent distal occlusions after successful proximal mechanical thrombectomy for acute ischemic stroke.\n\nMany patients with acute ischemic stroke caused by large vessel occlusion undergo emergency treatment with proximal mechanical thrombectomy, which removes the main clot and restores flow in a large artery. However, in some patients, one or more smaller distal arteries remain occluded after successful proximal recanalization. It is not yet known whether treating these persistent distal occlusions improves angiographic or clinical outcomes.\n\nThis study will compare two approaches:\n\nRescue distal mechanical thrombectomy: an additional distal mechanical thrombectomy procedure is performed during the same endovascular session.\n\nConservative management: no additional distal endovascular intervention is performed after successful proximal mechanical thrombectomy.\n\nThe main questions the study aims to answer are:\n\n* Is rescue distal mechanical thrombectomy feasible in this setting?\n* Is it safe?\n* Does it improve angiographic and clinical outcomes?\n\nParticipants will be randomly assigned during the index endovascular procedure to one of the two study groups and will be followed with imaging and clinical assessments during hospitalization and at 90 days.\n\nApproximately 72 participants will take part in this study at the Centre hospitalier de l'Université de Montréal (CHUM).","ExperimentalDrugs":"[\"procedure: proximal mechanical thrombectomy\",\"other: conservative management\",\"procedure: rescue distal mechanical thrombectomy\"]","Allcountries":"[\"Canada\"]","FirstAdminInter":"Other","TreatDur":"Day 1 only","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":17,"Phase":"NA","lastUpdateDate":"2026-04-14"},{"nctId":"NCT07420374","OrgName":"University Hospital Heidelberg","Titlefull":"Ambulatory Stroke Unit Treatment for Elderly Patients: A Prospective, Randomized, Controlled, Exploratory Non-Inferiority Trial (ARTIFICE)","BriefSummary":"ARTIFICE is a prospective, multicenter, randomized, controlled, exploratory non-inferiority trial evaluating whether an ambulatory stroke unit model (aSU) is non-inferior to conventional inpatient stroke unit care (SU) in patients aged 60 years or older with acute ischemic stroke, transient ischemic attack (TIA), or retinal ischemia and non-disabling neurological deficits.\n\nEligible patients are randomized 1:1 to same-day comprehensive ambulatory multiprofessional stroke evaluation (aSU) or guideline-based inpatient stroke unit treatment (SU). The primary endpoint is favorable functional outcome at 90 days, defined as modified Rankin Scale (mRS) 0-2 or return to pre-stroke mRS. Endpoint assessment at 90 days is performed by blinded assessors (PROBE design).\n\nSecondary outcomes include early neurological deterioration, recurrent stroke, delirium, mortality, health-related quality of life, healthcare utilization, and cost-effectiveness. A mixed-methods process evaluation examines feasibility, acceptability, and implementation aspects of the ambulatory care model.","ExperimentalDrugs":"[\"other: ambulatory stroke unit care\",\"other: conventional stroke unit care\"]","Allcountries":"[\"Germany\"]","FirstAdminInter":"Beyond two days","TreatDur":"Day 1 only","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":15,"Phase":"NA","lastUpdateDate":"2026-03-25"},{"nctId":"NCT07526987","OrgName":"Beijing Tiantan Hospital","Titlefull":"Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis (EMPHASIS-2): A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Trial","BriefSummary":"The aim of this study is to assess the efficacy and safety of minocycline in improving functional outcome among patients with acute ischaemic stroke receiving intravenous thrombolysis.","ExperimentalDrugs":"[\"minocycline hydrochloride capsule (50 mg per capsule)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":26,"Phase":"PHASE3","lastUpdateDate":"2026-04-14"},{"nctId":"NCT07430956","OrgName":"Regeneron Pharmaceuticals","Titlefull":"A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention With REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, Versus Placebo in Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE)","BriefSummary":"This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called \"study drugs\"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. When this happens, blood cannot move smoothly through the heart; it can slow down or pool in one spot, which can lead to the formation of blood clots.\n\nREGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how effective and safe REGN7508 and REGN9933, individually, are in preventing ischemic stroke or systemic embolism in people with atrial fibrillation who cannot or may choose to not take blood thinners.\n\nThe study is looking at several other research questions, including:\n\n* What side effects may happen from taking REGN7508 or REGN9933\n* How well does REGN7508 or REGN9933 lower the risk of having an ischemic stroke and/or systemic embolism compared to the placebo\n* How well does REGN7508 or REGN9933 lower the risk of having a major health problem affecting heart and blood circulation compared to placebo\n* How well does REGN7508 or REGN9933 lower the risk of death compared to placebo\n* How much REGN7508 or REGN9933 is in the blood at different times\n* Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the study drugs less effective or could lead to side effects)","ExperimentalDrugs":"[\"regn7508\",\"regn9933\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":19,"Phase":"PHASE3","lastUpdateDate":"2026-05-26"},{"nctId":"NCT06975696","OrgName":"Region Skane","Titlefull":"Fusion Imaging in Endovascular Thrombectomy for Acute Ischemic Stroke","BriefSummary":"Endovascular thrombectomy (EVT) is the standard of care for acute ischemic stroke (AIS) caused by a large vessel occlusion.\n\nSuccessful recanalization is one of the most important factors for a good patient outcome, especially when obtained within 30 minutes from groin puncture, and the procedural success-rate reaches above 90% at treating centers of excellence. There are however a portion of cases where recanalization is not achieved, which in some cases are attributed to difficult arterial anatomy affecting the ability to catheterize the precerebral target vessel.\n\nIn the latest angiography platforms, 3D reconstructions of the aortic, cervical and intracranial arteries from the preprocedural CT angiography can be fused with periprocedural 2D digital subtraction angiography and/or fluoroscopy images, so called 2D/3D Fusion imaging. The preparation steps can be done before patient arrival to the angiography suite and the image fusion can be done in less than a minute during patient preparation. Previous observational studies have shown that the use of fusion imaging during EVT procedures may decrease failed target vessel access and increase procedural success rate and first-pass recanalization rate, without prolonging the procedure.\n\nThe purpose of this study is to assess the use of fusion imaging in EVT procedures and its effect on target vessel access, recanalization success-rate and procedure times.","ExperimentalDrugs":"[\"procedure: standard evt without fusion\",\"procedure: standard endovascular thrombectomy with fusion\"]","Allcountries":"[\"Finland\",\"Sweden\"]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":21,"Phase":"NA","lastUpdateDate":"2026-03-02"},{"nctId":"NCT07341958","OrgName":"Beijing Tiantan Hospital","Titlefull":"INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)：A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial","BriefSummary":"The research team is conducting a randomized, double-blind, placebo-controlled, multicenter clinical study aimed at evaluating the impact of adding Tolecilimab (a PCSK9 inhibitor) to standard lipid-lowering therapy (statins ± ezetimibe) on serum lipoprotein(a) \\[Lp(a)\\] levels and the risk of stroke recurrence within 90 days in patients with ischemic stroke or high-risk TIA (ABCD² ≥ 4) accompanied by elevated lipoprotein(a) levels (≥50 mg/dL).","ExperimentalDrugs":"[\"tafolecimab\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Other","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-01-06"},{"nctId":"NCT07232082","OrgName":"First Affiliated Hospital of Wannan Medical College","Titlefull":"Assessing Local Hypothermia and Endovascular Recanalization for Acute Stroke With a Large Core Infarction-A Multicenter, Prospective, Open-label, Blinded-Endpoint, Randomized Controlled Trial","BriefSummary":"A multicenter, prospective, open-label, blinded-endpoint, randomized controlled trial to assess the effectiveness and safety of catheter-based focal intracranial hypothermia combined with endovascular reperfusion therapy for acute patients with a Large Core Infarction.","ExperimentalDrugs":"[\"other: control (normal saline)\",\"other: intra-arterial local therapeutic hypothermia\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Day 1 only","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":27,"Phase":"NA","lastUpdateDate":"2026-04-27"},{"nctId":"NCT07617870","OrgName":"The First Affiliated Hospital of Zhengzhou University","Titlefull":"Pro-urokinase for Reperfusion in Acute pOsterior Circulation ischeMIc Stroke in the Extended Window (the PROMISE Trail): A Randomized, Double-blind, Baseline Treatment-controlled Study","BriefSummary":"This study aims to evaluate whether, in patients with imaging-confirmed acute ischemic stroke of the posterior circulation presenting within 4.5-24 hours after symptom onset and not scheduled for endovascular thrombectomy, intravenous thrombolysis with recombinant human prourokinase (rhPro-UK), compared with standard medical treatment, can achieve superior 90-day functional outcomes with a higher level of safety.","ExperimentalDrugs":"[\"rhpro-uk\",\"placebo\",\"aspirin\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Day 1 only","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":26,"Phase":"PHASE3","lastUpdateDate":"2026-05-26"},{"nctId":"NCT07242599","OrgName":"Beijing Tiantan Hospital","Titlefull":"A Multicenter, Randomized, Open-label, Parallel-controlled, Event-driven, Blinded-endpoint Trial Evaluating the Efficacy and Safety of Ongericimab Injection in High-risk Stroke Patients With Intracranial or Extracranial Atherosclerotic Stenosis.","BriefSummary":"The Oris trial aims to evaluate whether the use of Ongericimab injection in patients with atherosclerotic ischemic cerebrovascular disease within 3 months of onset can reduce the risk of recurrent major cardiovascular events by achieving lower lipid-lowering target values (LDL-C \\< 1.4 mmol/L).","ExperimentalDrugs":"[\"combination product: high target group\",\"combination product: low target group\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":18,"Phase":"PHASE3","lastUpdateDate":"2026-04-15"},{"nctId":"NCT07594314","OrgName":"Tongji Hospital","Titlefull":"Safety and Efficacy of Adjunctive Minocycline After Successful Endovascular Thrombectomy Recanalization for Acute Anterior Circulation Large Vessel Occlusion - A Multicenter, Prospective, Double-blind, Randomized Trial","BriefSummary":"Endovascular thrombectomy (EVT) improves outcomes in patients with acute large vessel occlusion (LVO). However, despite successful recanalization rates exceeding 80%, fewer than 50% of patients achieve favorable functional outcomes at 90 days, indicating a high rate of futile recanalization. Potential mechanisms include no-reflow, reperfusion injury, and microcirculatory dysfunction, which are closely associated with post-recanalization neuroinflammation.\n\nMinocycline is a second-generation tetracycline with pleiotropic neuroprotective effects, including inhibition of microglial activation, reduction of inflammatory mediators, suppression of matrix metalloproteinases, attenuation of oxidative stress, and preservation of blood-brain barrier integrity. Prior preclinical and clinical studies suggest that minocycline may improve neurological outcomes in acute ischemic stroke.\n\nThis study is a multicenter, prospective, double-blind, randomized controlled trial designed to evaluate the safety and efficacy of adjunctive minocycline in patients with acute anterior circulation LVO who achieve successful recanalization after EVT. The trial will assess whether early administration of minocycline improves functional outcomes and reduces futile recanalization.","ExperimentalDrugs":"[\"minocycline hydrochloride capsule\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":27,"Phase":"PHASE2","lastUpdateDate":"2026-05-22"},{"nctId":"NCT07456956","OrgName":"Fenerbahce University","Titlefull":"The Effect of High-Intensity Interval Training Versus Moderate-Intensity Continuous Training on Sarcopenia and Clinical Outcomes in Patients With Ischemic Stroke: A Single-Blind Randomized Controlled Trial","BriefSummary":"The aim of this study is to investigate the effect of post-stroke sarcopenia on prognosis and clinical outcomes in patients with ischemic stroke and to compare the effects of High Intensity Interval Training (HIIT) and Moderate Intensity Continuous Training (MCIT) exercise programs on muscle mass, as well as on functional capacity, quality of life, and clinical outcomes.","ExperimentalDrugs":"[\"behavioral: high-intensity interval training (hiit)\",\"behavioral: moderate-intensity continuous training (mcit)\"]","Allcountries":"[\"Turkey (Türkiye)\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":11,"Phase":"NA","lastUpdateDate":"2026-03-22"},{"nctId":"NCT07302971","OrgName":"Capital Medical University","Titlefull":"Telemedicine-supported Management of Acute Ischemic Stroke in the Basic-level Hospitals","BriefSummary":"Telemedicine-supported stroke care can provide standardized guidance to hospitals and regions with limited medical resources, thereby improving treatment outcomes for stroke patients in these areas. While this approach has been widely adopted in many developed countries, its efficacy in guiding basic-level hospitals to manage acute ischemic stroke requires further investigation through large-scale, high-quality studies.\n\nThis study focused on patients with acute ischemic stroke who sought treatment at basic-level hospitals, aiming to investigate the efficacy and safety of treating acute ischemic stroke with telemedicine-supported management. Hospitals assigned to the experimental group received remote consultation guidance, quality control and professional training from expert teams at leading stroke centers, China National Center for Neurological Disorders. Hospitals in the control group did not receive telemedicine-supported management.","ExperimentalDrugs":"[\"other: telemedicine-supported management\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Day 1 only","Status":"RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":26,"Phase":"NA","lastUpdateDate":"2026-02-02"},{"nctId":"NCT07389460","OrgName":"First Affiliated Hospital Xi'an Jiaotong University","Titlefull":"Intravenous rhPro-UK Versus Placebo Before Endovascular Thrombectomy For Stroke Patient With Large Vessel Occlusion In The Extended Time Window: the Randomized, Placebo-controlled, Double-blind Trial (BRIDGE-PUK EXTEND )","BriefSummary":"This randomized, double-blind, placebo-controlled phase III clinical trial aims to evaluate the efficacy and safety of intravenous recombinant human Prourokinase (rhPro-UK) in acute ischemic stroke patients with large vessel occlusion presenting 4.5-24 hours after last known well. The study will address two primary questions: 1) Whether rhPro-UK enhances pre-thrombectomy reperfusion rates and improves 90-day functional outcomes compared to placebo; 2) Whether rhPro-UK increases the risk of symptomatic intracranial hemorrhage and mortality.\n\nParticipants will be randomized to receive an intravenous bolus of rhPro-UK or matching placebo, with a total dose of 35mg (15mg administered as an intravenous push within 5 minutes, and the remaining 20mg continuously infused intravenously over 30 minutes). Key assessments include repeat neuroimaging (CT/CTA or MRI/MRA) at 24 hours post-treatment to evaluate reperfusion, NIH Stroke Scale score at day 5-7, and modified Rankin Scale score assessment at 90 days. Safety monitoring will focus on hemorrhagic transformation and mortality events throughout the study period.","ExperimentalDrugs":"[\"intravenous rhpro-uk\",\"procedure: endovascular thrombectomy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":27,"Phase":"PHASE3","lastUpdateDate":"2026-02-04"},{"nctId":"NCT07403149","OrgName":"Assistance Publique - Hôpitaux de Paris","Titlefull":"Evaluating the Improvement of Stepping Quality by Using Adapted Shoes","BriefSummary":"Stroke is the leading cause of acquired disability in adults. Stroke causes death in 10% of patients, disability and functional handicap in 60% of cases. Sequelea of hemiplegia include spasticity resulting in great difficulty and slowness in walking, gait instability, increasing the risk of falls.\n\nDeambulation may need help (cane, crutch, tripod cane, walker). Lower limb spasticity includes hypertonia of extensors (gluteus maximus, quadriceps, posterior gastrocnemius) resulting in equinovarus. A neurology deficit may be present on ipsilateral lower limb flexors. Hence the patient walks with rubbing of the tip of the foot (tip-toeing gait), resulting in a \"mowing wheatslike\" movement of the leg as described in the French literature. Walking is then slowed down, unstable, with increased risk of falls.\n\nIn post stroke, during the period of rehabilitation and beyond, it is advisable to wear sports shoes although custom-made shoes improve walking and are reimbursed by the French social security system after prior agreement. Most of patients only wear conventional shoes.","ExperimentalDrugs":"[\"device: remarche® shoes\"]","Allcountries":"[]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2026-02-04"},{"nctId":"NCT07185022","OrgName":"The Second Hospital of Anhui Medical University","Titlefull":"a Multicenter Prospective Randomized Controlled Trial of Intra-artErial thrombolysiS for aCUte Ischemic strokE With Medium Vessel Occlusion (RESCUE MeVO)","BriefSummary":"Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has shown promise in clinical experience, robust evidence supporting its efficacy in MeVO or severe stenosis-related AIS is still absent. To fill this gap, the RESCUE MeVO trial has been designed as a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study to evaluate the efficacy and safety of intra-arterial thrombolysis in patients with AIS caused by MeVO or severe stenosis.","ExperimentalDrugs":"[\"procedure: intra-arterial thrombolysis\",\"best medical treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Day 1 only","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"NA","lastUpdateDate":"2026-04-13"},{"nctId":"NCT07375966","OrgName":"General Hospital of Shenyang Military Region","Titlefull":"Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Tenecteplase (RITIS-TNK2): a Prospective, Randomized, Open Label, Blinded Assessment of Outcome, and Multi-center Study","BriefSummary":"While intravenous thrombolysis (IVT) within 4.5 hours is the standard medical reperfusion therapy, its efficacy is limited, particularly for large or medium vessel occlusions (LVO/MeVO), with low recanalization rates for IVT with rt-PA. The newer thrombolytic agent, tenecteplase (TNK), offers practical advantages-including single bolus administration, a longer half-life, and potentially higher fibrin specificity-and has been shown to be non-inferior to rt-PA.\n\nDespite advances, a significant proportion of patients with LVO/MeVO do not achieve early clinical improvement after standard IVT, likely due to persistent occlusion from a high thrombus burden. Endovascular therapy, while highly effective for LVO, has limited accessibility. Therefore, there is an urgent need for more effective and widely accessible pharmacological strategies.\n\nThis study proposes a rescue strategy based on the hypothesis that a second dose of IVT may improve outcomes in patients with imaging-confirmed LVO or MeVO who show no significant neurological improvement one hour after standard TNK thrombolysis (administered within 4.5 hours of stroke onset). The primary aim of this study is to formally evaluate the efficacy and safety of a repeated dose of intravenous tenecteplase in this specific patient population.","ExperimentalDrugs":"[\"tenecteplase\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"Early efficacy","total_Score":27,"Phase":"PHASE2","lastUpdateDate":"2026-03-31"},{"nctId":"NCT07628283","OrgName":"Jiangsu Province (Suqian) Hospital","Titlefull":"A Prospective, Open-Label, Cluster Randomized Controlled Trial to Evaluate the Efficacy of a Rural Doctor-Led, Telemedicine-Supported Integrated Care Model for Reducing Cardiovascular and Cerebrovascular Events in Elderly Adults at High Risk of Stroke in China","BriefSummary":"This cluster randomized controlled trial aims to evaluate the effectiveness of a novel telemedicine-enabled integrated care model led by rural doctors in reducing cardiovascular and cerebrovascular events among elderly adults (≥65 years) at high risk of stroke in rural China. A total of 39 village clinics will be randomized to either the intervention group (digital health platform-supported integrated care) or the control group (enhanced usual care). The primary outcome is a composite of cardiovascular death, stroke, and hospitalization for heart failure or acute coronary syndrome at 36 months.","ExperimentalDrugs":"[\"behavioral: digital health platform-supported integrated stroke management\",\"behavioral: enhanced usual stroke care\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":9,"Phase":"NA","lastUpdateDate":"2026-05-28"},{"nctId":"NCT07013396","OrgName":"Virginia Commonwealth University","Titlefull":"A Prospective Evaluation of Clinical Outcomes in Acute Ischemic Stroke After Endovascular Treatment Using Transcranial","BriefSummary":"Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \\[1\\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.","ExperimentalDrugs":"[\"other: tcd measurement\",\"other: tcd parameters\",\"other: baseline characteristics\",\"other: clinical data will be collected\",\"other: all follow-up patients receive a phone call\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":10,"Phase":"NA","lastUpdateDate":"2025-11-21"},{"nctId":"NCT07630090","OrgName":"Jinling Hospital, China","Titlefull":"Comparing Early Post-pyloric Feeding Versus Gastric Feeding for the Prevention of Stroke-Associated Pneumonia in Patients With Severe Ischemic Stroke","BriefSummary":"This randomized controlled trial aims to compare the effectiveness of early post-pyloric feeding versus gastric feeding in preventing SAP in patients with severe ischemic stroke. The main question to answer is whether post-pyloric feeding group is better than the gastric feeding group for preventing SAP.","ExperimentalDrugs":"[\"procedure: post-pyloric feeding\",\"procedure: gastric feeding\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":10,"Phase":"PHASE4","lastUpdateDate":"2026-06-01"},{"nctId":"NCT07513233","OrgName":"Capital Medical University","Titlefull":"Safety and Efficacy of Anisodine Hydrobromide in Patients With Ischemic Stroke Undergoing Endovascular Treatment","BriefSummary":"This study is an investigator-initiated Phase 1b clinical trial employing an open-label, non-randomized, dose-escalation design. The primary objective is to evaluate the safety and tolerability of the investigational intervention and to determine the recommended dose for subsequent clinical studies.","ExperimentalDrugs":"[\"anisodine hydrobromide\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Safety","total_Score":23,"Phase":"PHASE1","lastUpdateDate":"2026-05-17"},{"nctId":"NCT07495969","OrgName":"Beijing Tiantan Hospital","Titlefull":"Endovascular Recanalization Versus Aggressive Medical Management Alone for Symptomatic Non-Acute Intracranial Artery Occlusion: A Multicenter, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial","BriefSummary":"A multicenter, randomized, open-label, endpoint-blinded trial to compare the effects of endovascular recanalization plus aggressive medical management with aggressive medical management alone on stroke recurrence and mortality in patients with symptomatic non-acute intracranial artery occlusion.","ExperimentalDrugs":"[\"procedure: endovascular recanalization strategy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Late efficacy","total_Score":21,"Phase":"NA","lastUpdateDate":"2026-03-22"},{"nctId":"NCT07392450","OrgName":"Takeda","Titlefull":"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke","BriefSummary":"Acute ischemic stroke (AIS) is a medical emergency that happens because of a sudden stop of blood flow to a part of the brain. This happens when a blood clot forms within the vessel (known as thrombotic occlusion) or a clot originating from somewhere else blocks a blood vessel (known as embolic occlusion). Strokes can cause serious health problems, death, and affect one's quality of life. To reduce long-term damage, it is important to restore blood flow to the brain as soon as possible.\n\nThe main aim of this study is to check how safe TAK-755 is, and how well adults with AIS tolerate it. Other aims are to check how well TAK-755 helps participants to manage their everyday activities and to understand whether it helps reduce the seriousness of their stroke symptoms when compared to placebo. A placebo looks like TAK-755, but does not have any medicine in it, to make sure participants do not know which treatment they are taking.\n\nThe participants will receive TAK-755 or placebo once; afterwards, their health will be monitored for about 3 months (90 days). All participants, regardless of their assignment to either TAK-755 or placebo, will receive the usual treatment for AIS as per the hospital's normal practice.","ExperimentalDrugs":"[\"biological: tak-755\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Safety","total_Score":42,"Phase":"PHASE2","lastUpdateDate":"2026-04-15"},{"nctId":"NCT06953726","OrgName":"VA Office of Research and Development","Titlefull":"CSP #2037T - Veterans Affairs Learning Health System Initiative to Assess Novel Screening vs. Usual Care and Treatment With Apixaban vs. Rivaroxaban in Veterans With Atrial Fibrillation (VALIANT-AF-T) Trial","BriefSummary":"* The trial will compare two anticoagulants (\"blood thinners\") that are currently used in the VA and are considered standard care to prevent strokes in patients with atrial fibrillation. The two most commonly-used anticoagulants will be compared: apixaban (Eliquis) and rivaroxaban (Xarelto). They are considered by many doctors to have similar benefits and risks, but no one knows for sure.\n* The trial only enrolls patients with a diagnosis of atrial fibrillation (\"A Fib\") or atrial flutter. Most participants will be age 65 or older, and should already be taking apixaban or rivaroxaban.\n* The investigators will measure, in about 10,000 VA patients nationally, whether the rates of stroke, major bleeding, or death differ between these two drugs.\n* The trial will last about 7 years, but after the first prescription, all information will be collected from electronic medical records.","ExperimentalDrugs":"[\"apixaban\",\"rivaroxaban\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":12,"Phase":"PHASE4","lastUpdateDate":"2026-04-03"},{"nctId":"NCT07053917","OrgName":"Johns Hopkins University","Titlefull":"Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability","BriefSummary":"The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.","ExperimentalDrugs":"[\"psilocybin (usona institute)\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Day 1 only","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":18,"Phase":"PHASE1","lastUpdateDate":"2026-02-11"},{"nctId":"NCT07553416","OrgName":"Beijing Tiantan Hospital","Titlefull":"A Prospective, Randomized, Parallel-Controlled Clinical Study Protocol of Non-Invasive Brain Computer Interface Robot Based on Mirror Rehabilitation Theory in the Treatment of Upper Limb Motor Function Disorder After Stroke","BriefSummary":"This study aims to utilize non-invasive brain-computer interface technology in conjunction with mirror therapy to design a new paradigm for rehabilitation robots to induce compensatory movements on the healthy side in stroke patients, evaluate the potential rehabilitation value of this paradigm for patients with severely impaired motor areas on the affected side, explore the neural rehabilitation compensation mechanism, and provide more personalized rehabilitation treatment strategies for patients with post-stroke motor dysfunction.","ExperimentalDrugs":"[\"device: brain computer interface-robotic mirror therapy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-04-22"},{"nctId":"NCT07519044","OrgName":"Xuanwu Hospital, Beijing","Titlefull":"Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study-IAT-GIANT (Ganglioside GM1 to Improve Outcomes in Anterior CirculatioN Thrombectomy)","BriefSummary":"Stroke is a leading cause of global mortality and morbidity, with acute ischemic stroke (AIS) accounting for approximately 65.3% of cases and resulting in roughly 3.4 million new cases annually in China. While endovascular thrombectomy (EVT) is the recommended first-line therapy for large vessel occlusion (LVO), achieving 80-90% recanalization, fewer than 50% of patients reach functional independence (mRS 0-2) due to \"futile recanalization\" caused by mechanisms like no-reflow and reperfusion injury. Monosialotetrahexosylganglioside (GM1) is a unique glycosphingolipid that crosses the blood-brain barrier to provide neuroprotection by suppressing oxidative stress, excitotoxicity, and apoptosis while promoting neurogenesis. Although Phase III trials like the FOCUS study confirmed GM1's safety and efficacy in AIS populations, its benefit specifically for patients undergoing mechanical thrombectomy remains unkown. Therefore, the IAT-GIANT study is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of adjunctive GM1 in improving 90-day functional outcomes for AIS-LVO patients treated with EVT.","ExperimentalDrugs":"[\"intravenous gm1 therapy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"PHASE4","lastUpdateDate":"2026-05-20"},{"nctId":"NCT07571954","OrgName":"iVascular S.L.U.","Titlefull":"Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the Instroke 5F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke.","BriefSummary":"Prospective, single-arm, multi-centre study to evaluate the efficacy and safety of the iNstroke 5F thromboaspiration catheter in patients with acute ischaemic stroke","ExperimentalDrugs":"[]","Allcountries":"[\"France\",\"Spain\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":29,"Phase":"NA","lastUpdateDate":"2026-05-08"},{"nctId":"NCT07527013","OrgName":"Beijing Tiantan Hospital","Titlefull":"Stratified Blood Pressure Management After Endovascular Treatment for Acute Ischemic Stroke (RESCUE-BP)","BriefSummary":"The RESCUE-BP is a multi-centered, prospective, randomized, open label, blinded endpoint (PROBE) phase III trial. In patients with acute ischemic stroke who have undergone endovascular treatment and achieved successful recanalization, the evaluation will compare a stratified blood pressure management strategy based on the collateral circulation status with the guideline-recommended conventional blood pressure management strategy. Within each stratum, participants will be randomized in a 1:1 ratio to either the stratified blood pressure management strategy group or the guideline-recommended conventional blood pressure management group. The goal is to determine whether this can improve good functional outcomes at 90 days (90-day Modified Rankin Scale \\[mRS\\] score 0-2).\n\nThe study consists of four visits including the day of randomization, 24±4 hours after randomization, 7±1 days after randomization and 90±7 days after randomization. Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment, neurological function rating scale will be recorded during the program.\n\nThe primary outcome is the modified Rankin Scale (mRS) score of 0 to 2 at 90±7 days after randomization. The primary safety outcome is the incidence of sICH within 24±4 hours after randomization.","ExperimentalDrugs":"[\"other: stratified blood pressure management\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"PHASE3","lastUpdateDate":"2026-04-17"},{"nctId":"NCT06953778","OrgName":"VA Office of Research and Development","Titlefull":"CSP #2037S - Veterans Affairs Learning Health System Initiative to Assess Novel Screening vs. Usual Care and Treatment With Apixaban vs. Rivaroxaban in Veterans With Atrial Fibrillation (VALIANT-AF-S) Trial","BriefSummary":"* The goal of the screening trial is to determine whether early screening for atrial fibrillation improves outcomes, including lowering the chance of death, hospitalization for stroke, blood clots, heart failure, heart attack, and severe bleeding reduces the risk of stroke or heart failure.\n* Atrial fibrillation is a common heart condition in which one of the heart chambers doesn't follow a normal rhythm. Blood clots can form as a result, and they can travel to the brain and cause strokes, or to other organs.\n* Almost everyone with atrial fibrillation is treated with drugs called anticoagulants (\"blood thinners\") to reduce the risk of stroke. These drugs also increase the risk of bleeding.\n* Testing for atrial fibrillation is usually done for patients who have symptoms of an irregular or unusually fast or slow heartbeat, often called \"palpitations\" or a sensation of the heart pounding or stopping for a short period of time.\n* What is not known is whether screening people who do not have symptoms of atrial fibrillation, but who are at above-average risk of getting atrial fibrillation, will reduce death, hospitalization for stroke, blood clots, heart failure more than it increases hospitalization for severe bleeding.\n* People who participate in the trial who are selected by chance to receive screening will wear a small heart-rate monitor (Zio Patch) on their skin for 14 days and then return it to the manufacturer. Their doctors will be notified about the results and will make decisions about any treatment to recommend.\n* The screening trial is expected to enroll about 24,000 VA patients nationwide and to last 7 years, but each person's active participation in the trial is completed after sending in the Zio Patch. After that, the study team will just collect information from the participant's electronic medical records.","ExperimentalDrugs":"[\"device: zio xt® patch\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":6,"Phase":"NA","lastUpdateDate":"2025-04-23"},{"nctId":"NCT07125157","OrgName":"Lincoln University College","Titlefull":"Effect Of Task-Specific Training With And Without Biofeedback On Balance And Risk Of Falls In Chronic Ischemic Stroke Patients Of Central Lahore, Pakistan, A Randomized Controlled Trial","BriefSummary":"This randomized controlled trial aims to evaluate the effects of task-specific training with and without biofeedback compared to conventional physical therapy on balance and fall risk in chronic ischemic stroke patients in Lahore, Pakistan. Sixty-six participants will be randomly allocated into three groups: Group 1 (task-specific training with biofeedback), Group 2 (task-specific training without biofeedback), and Group 3 (conventional physical therapy). The intervention will span 12 weeks, consisting of 36 sessions. Key outcome measures include the Berg Balance Scale, Timed Up and Go Test, and the Barthel Index. Assessments will be conducted at baseline, post-intervention, and three-month follow-up. The study hypothesizes that the use of biofeedback in task-specific training will produce significantly greater improvements in balance and reduced fall risk compared to conventional rehabilitation strategies. The study is being conducted at Shadman Medical Center in Lahore and is part of a PhD project from Lincoln University College.","ExperimentalDrugs":"[\"behavioral: task-specific training with biofeedback\",\"behavioral: task-specific training without biofeedback\",\"behavioral: conventional stroke rehabilitation\"]","Allcountries":"[\"Pakistan\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":14,"Phase":"NA","lastUpdateDate":"2026-02-17"},{"nctId":"NCT06437431","OrgName":"Fondation Ophtalmologique Adolphe de Rothschild","Titlefull":"Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy","BriefSummary":"Until recently, acute ischemic stroke (AIS) patients with a baseline large infarct core have been generally excluded from clinical trials of endovascular therapy (EVT). A first multicenter randomized trial (Rescue Japan Limit trial) found a significant benefit of EVT in AIS patients with large infarct core (DWI-ASPECTS of 3-5). Another non-randomized multicenter prospective study found a positive association of EVT with 3-month outcome in AIS patients with a baseline CTP ischemic core volume \\>70mL. More recently, 2 additional randomized trials were published. They both confirmed a strong efficacy of EVT in patients with large infarct core. However, even with EVT, the proportion of good outcome (3-month mRS score of 0-3), remains low in these highly severe AIS patients ranging from 8-30%. Almost 75% of EVT-treated patients are still severely disabled or dead at 3 months. In experimental studies, we and others described the pathophysiological features of the downstream microvascular thrombosis (DMT) in AIS setting highlighting its immediate occurrence and the pivotal role of platelet activation and aggregation. In recent clinical studies, it has been shown that, even with a complete angiographic recanalization after EVT, up to 40% of patients presented no-reflow (NR), a failure of downstream microvascular reperfusion, visible on perfusion imaging performed after EVT. Some clinical studies reported the clinical impact of NR after successful EVT. We found that DMT participated to the development of neurovascular lesions in AIS with both an early ischemic lesion growth risk evolving towards a delayed hemorrhagic transformation (HT) and vasogenic edema risks and therefore worse outcome. Our results suggested that an antiplatelet therapy infused early in AIS patients could reduce both the ischemic lesion but also the risk of delayed vasogenic edema and HT. Platelet glycoprotein VI (GPVI) is a key receptor for collagen and fibrin and plays a major role in platelet activation, platelet recruitment and thrombosis. Furthermore, inhibition of the GPVI does not impair haemostasis and subjects with a genetic or acquired GPVI deficiency are not prone to excessively bleed.\n\nGlenzocimab is a monoclonal antibody directed against the GPVI. It has been developed as an immediate antiplatelet agent with minimal bleeding risk for treating AIS. The ACTIMIS trial, a phase IB/IIA clinical study that assessed for the first time the glenzocimab IV infusion in AIS patients found very promising safety data including a significant reduce of symptomatic HT (1% vs. 7.8%) and mortality rates (7.8% vs. 18.7%), especially in severe AIS patients. Our hypothesis is that IV glenzocimab infusion would improve good functional outcome in large ischemic core AIS patients treated with EVT by reducing the DMT, ischemic lesion growth, and the HT rate.","ExperimentalDrugs":"[\"glenzocimab\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"PHASE2","lastUpdateDate":"2025-06-19"},{"nctId":"NCT07531394","OrgName":"Capital Medical University","Titlefull":"Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic Stroke","BriefSummary":"Introduction: The management of acute myocardial injury following acute ischemic stroke (AMI-AIS), a frequent complication that severely worsens prognosis, is challenging. Remote ischemic conditioning (RIC) has demonstrated therapeutic potential in separate cardiac and cerebrovascular diseases, and preliminary single-center evidence suggests its safety and efficacy in patients with acute ischemic stroke (AIS) complicating acute myocardial infarction. Therefore, we propose to conduct a multicenter, randomized controlled trial to definitively evaluate the safety and efficacy of RIC in patients with AMI-AIS.\n\nMethods: This is a multicenter, randomized, double-blind, sham-controlled trial of 580 participants with AMI-AIS. Participants will be randomized to receive either the RIC procedures or sham RIC procedures twice daily for 14 consecutive days. A 3-month follow-up will be conducted to assess the safety and efficacy of RIC in AMI-AIS patients. The primary study outcome is the incidence of major adverse cardio-cerebrovascular events (MACCEs). The secondary outcomes include mortality, neurological and cardiac function, cerebral infarct volume, and cerebral perfusion.","ExperimentalDrugs":"[\"device: remote ischemic conditioning\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Late efficacy","total_Score":21,"Phase":"PHASE3","lastUpdateDate":"2026-04-09"},{"nctId":"NCT07638462","OrgName":"Wake Forest University Health Sciences","Titlefull":"RIsEStroke (Recovery Insights Into Early Mobility Post Stroke)","BriefSummary":"This study is designed to better understand how patients with severe stroke move during their hospital stay. It will track their activity using a small wearable device (activPAL) along with standard mobility information already collected in clinical care. The goal is to learn what typical movement patterns look like early after a stroke and how well patients meet mobility goals while in the hospital. What is learned from this study may allow determination of how treatment for stroke patients may be improved to improve patient long-term mobility.","ExperimentalDrugs":"[\"device: activpal device\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":6,"Phase":"NA","lastUpdateDate":"2026-06-04"},{"nctId":"NCT06156059","OrgName":"Hospital San Carlos, Madrid","Titlefull":"Oral Bedtime Melatonin in Critically Ill Patients","BriefSummary":"Oxidative stress is one of the main mechanisms causing harm in severe infection with septic shock, ischemia-reperfusion injury in resuscitated cardiac arrest and ischemic and hemorrhagic stroke.\n\nMelatonin is a potent scavenger of the mediators of oxidative stress, oxygen and nitrogen-reactive species, which directly injure cell structures like walls and DNA and thus cause organ dysfunction.\n\nIn a previous study we have observed that high-dose oral bedtime melatonin (OBM) is associated with improved organ function in severe Covid-19 patients","ExperimentalDrugs":"[\"oral bedtime melatonin\"]","Allcountries":"[]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Late efficacy","total_Score":10,"Phase":"PHASE4","lastUpdateDate":"2024-02-28"},{"nctId":"NCT06883110","OrgName":"Tongji Hospital","Titlefull":"A Single-Center, Open-Label, Non-Inferiority Clinical Study of Angong Niuhuang Pills With Different Bovine Bezoar Formulation Sources in the Treatment of Acute Ischemic Stroke","BriefSummary":"This study is a single-center, open-label, controlled clinical trial that prospectively enrolls 100 participants (40 in the Z11020076 group, 40 in the Z20063878 group, and 20 in the blank control group) to collect clinical data, imaging data, and biospecimens over an 84-day follow-up period. The primary objective is to compare the efficacy and safety of Angong Niuhuang Pills from Beijing Tongrentang (Approval No. Z11020076) and Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd. (Approval No. Z20063878) in improving clinical functional outcomes and prognosis in acute ischemic stroke (AIS) patients. The secondary objective is to evaluate the interventional effects of Angong Niuhuang Pills with different bovine bezoar formulation sources on gut microbiota diversity and composition, peripheral blood immune function, and inflammatory status in AIS patients.","ExperimentalDrugs":"[\"z11020076\",\"z20063878\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":18,"Phase":"NA","lastUpdateDate":"2026-01-09"},{"nctId":"NCT07042490","OrgName":"The First Hospital of Jilin University","Titlefull":"Efficacy and Safety of Plasma Adsorption Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation: A Multicenter, Randomized, Parallel-controlled Clinical Trial","BriefSummary":"The purpose of this study is to determine the efficacy and safety of plasma adsorption for patients of acute ischemic stroke who underwent endovascular thrombectomy due to large vessel occlusion of anterior circulation.","ExperimentalDrugs":"[\"procedure: plasma adsorption\",\"procedure: endovascular thrombectomy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 12 hours","TreatDur":"3 days or less","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"NA","lastUpdateDate":"2025-06-27"},{"nctId":"NCT06895005","OrgName":"Fundación Cardiovascular de Colombia","Titlefull":"Effectiveness of Transcutaneous Auricular Vagus Nerve Stimulation on Upper Limb Motor Recovery After Stroke","BriefSummary":"This study will evaluate the effects of transcutaneous vagus nerve stimulation in combination with physical rehabilitation on upper limb motor function of patients with stroke.","ExperimentalDrugs":"[\"device: transcutaneous auricular vagus nerve stimulation + rehabilitation therapy\"]","Allcountries":"[\"Colombia\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":8,"Phase":"NA","lastUpdateDate":"2025-03-25"},{"nctId":"NCT07290751","OrgName":"Beijing Anzhen Hospital","Titlefull":"Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke: A Multicenter, Prospective, Double-Blind, Placebo-Controlled, Randomized Controlled Trial","BriefSummary":"This multicenter, prospective, double-blind, placebo-controlled, randomized trial (ANGEL-DRUG2) aims to evaluate the efficacy and safety of intravenous tirofiban following intravenous thrombolysis in patients with acute ischemic stroke who show insufficient neurological improvement after initial treatment. Eligible patients (≥18 years, baseline NIHSS ≥4, within 4.5 hours from last known well) will be randomized 1:1 to receive either tirofiban or placebo infusion for 24 hours, followed by standard oral antiplatelet therapy. The primary endpoint is the proportion of patients achieving functional independence (mRS 0-2) at 90 days. Secondary outcomes include changes in NIHSS score, vessel recanalization, infarct volume, distribution of mRS scores, recurrent stroke, and health-related quality of life. Safety outcomes focus on symptomatic intracranial hemorrhage and all-cause mortality. Approximately 976 patients will be enrolled across 30 sites in China.","ExperimentalDrugs":"[\"tirofiban\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":23,"Phase":"PHASE4","lastUpdateDate":"2025-12-22"},{"nctId":"NCT07085390","OrgName":"University of South Florida","Titlefull":"Balloon Guide Versus Conventional Guide Catheter in Stroke Thrombectomy","BriefSummary":"The purpose of this clinical trial is to study the two main types of approaches used in stroke thrombectomy and to investigate if one approach is more effective than the other, as this is currently not known. This study will be conducted in adults who have been diagnosed with an acute ischemic stroke and who are undergoing a thrombectomy for the treatment of their stroke. The main questions it aims to answer are:\n\n* Does the use of a balloon guide catheter versus a conventional guide catheter lower the time needed to restore blood flow in the blocked vessel in the brain\n* To help researchers better understand the technical, clinical, and procedural outcomes associated with using a balloon guide catheter versus a conventional guide catheter in stroke thrombectomy\n\nParticipants will be asked to\n\n* Share their medical history and imaging data that is collected as part of their routine medical care\n* Undergo a mechanical thrombectomy as part of their routine medical care\n* Answer some questions about their neurological functioning at 3 months (90 days) post hospitalization","ExperimentalDrugs":"[]","Allcountries":"[\"United States\"]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":14,"Phase":"NA","lastUpdateDate":"2025-09-15"},{"nctId":"NCT07135089","OrgName":"General Hospital of Shenyang Military Region","Titlefull":"Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban (INSIST-IT2): a Prospective, Randomized, Double Blinded, Multi-center Study","BriefSummary":"It remains uncertain whether intravenous tirofiban administered before endovascular thrombectomy could improve disability severity for patients with LVO due to intracranial atherosclerosis.The current study aimed to assess the efficacy and safety of administering intravenous tirofiban before endovascular thrombectomy for improving clinical outcomes in patients with anterior circulation LVO due to intracranial atherosclerosis.","ExperimentalDrugs":"[\"intravenous tirofiban before endovascular thrombectomy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 12 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":34,"Phase":"PHASE3","lastUpdateDate":"2025-12-02"},{"nctId":"NCT06748703","OrgName":"Nanjing Medical University","Titlefull":"Optic Nerve Injury and the Effect of CPAP Treatment in Obstructive Sleep Apnea Patients","BriefSummary":"Ischemic optic neuropathy (ION) is damage to the optic nerve caused by ischemia and hypoxia of the optic nerve due to an impairment of the blood supply to the optic nerve from the arteries. Obstructive Sleep Apnea Hypoventilation Syndrome (OSAHS) is a sleep-breathing disorder characterized by recurrent upper airway obstruction and apnea during sleep, leading to recurrent intermittent hypoxemia with fragmented sleep and daytime sleepiness. Due to the lack of accurate methods to evaluate blood flow, the correlation between the two is unclear and uncertain. The study will enroll 80 patients from the First Affiliated Hospital of Nanjing Medical University and categorize them into mild, moderate, and severe OSA groups according to their apnea-hypopnea index (AHI). Participants will undergo a baseline evaluation, including polysomnography (PSG) and ophthalmologic examinations such as optic nerve and macular blood flow OCT, visual acuity, refraction, intraocular pressure, and visual fields. Eligible patients will be treated with CPAP for 3 months, after which their PSG and ophthalmologic examination-related results will be re-evaluated to assess treatment efficacy.","ExperimentalDrugs":"[\"device: cpap treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":10,"Phase":"NA","lastUpdateDate":"2025-06-24"},{"nctId":"NCT06900725","OrgName":"National Taiwan University Hospital","Titlefull":"Low-Dose Edoxaban Versus Very-Low-Dose Edoxaban in Elderly Patients With Atrial Fibrillation and a History of Stroke (LEAVE-Stroke): A Pragmatic Randomized Clinical Trial","BriefSummary":"This prospectively enrolled, pragmatic randomized trial aims to investigate whether very low dose edoxaban regimen (15 mg daily) achieves similar edoxaban concentrations as low dose edoxaban regimen (30 mg daily), while maintaining a comparable risk of clinical outcomes and reducing major bleeding in elderly patients with atrial fibrillation and a history of ischemic stroke or transient ischemic attack.","ExperimentalDrugs":"[\"edoxaban 30 mg\",\"edoxaban\"]","Allcountries":"[\"Taiwan\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":9,"Phase":"PHASE2","lastUpdateDate":"2025-03-28"},{"nctId":"NCT06841978","OrgName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","Titlefull":"Intravenous Thrombosis in Acute Ischemic Stroke Patients with Prior Ischemic Stroke Within 3 Months","BriefSummary":"The primary hypothesis being tested in this trial is that ischemic stroke patients with prior ischemic stroke within 3 months will have improved clinical outcomes when given intravenous thrombolysis compared to standard care.","ExperimentalDrugs":"[\"intravenous thrombolysis\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"mRS at 90 days","total_Score":31,"Phase":"PHASE3","lastUpdateDate":"2025-02-20"},{"nctId":"NCT07141303","OrgName":"Tang-Du Hospital","Titlefull":"Intra-arterial Methylprednisolone After Successful Endovascular Thrombectomy Anterior Circulation Large Vessel Occlusion","BriefSummary":"The purpose of IMPACT-LVO trial is to investigate the efficacy and safety of early adjunctive intra-arterial combined with intravenous administration methylprednisolone sodium succinate after successful endovascular thrombectomy in anterior circulation large vessel occlusion patients.\n\nThis is a multicenter, randomized, double-blind, placebo-controlled trial. Acute ischemia stroke patients with anterior circulation large vessel occlusion within 24 hours from last known well will be screened for this trial. Successful recanalization after mechanical thrombectomy (eTICI 2b-3) patients will be randomized 1:1 to either methylprednisolone sodium succinate group or placebo group. The methylprednisolone sodium succinate group patients will receive intra-arterial methylprednisolone sodium succinate 40mg immediately after the recanalization. Then, intravenous administration with methylprednisolone sodium succinate 2mg/kg in the next 3 days. The placebo group patients will receive intra-arterial and intravenous sterile water for injection.\n\nThe shift on modified Rankin Scale score is designed to detect in the present trial. A sample size of n = 1010 patients (n=505 per group) is required. The intention-to-treat principle will be applied to the primary analysis, therefore, to safeguard against dilution of the treatment effect associated with an approximate 5% non-adherence rate (due to loss to follow-up, consent withdrawal and other reasons), we planned to enrol n=1060 patients (n=530 per group) for this study. The findings of IMPACT-LVO are likely to have a direct impact on clinical practice.","ExperimentalDrugs":"[\"the methylprednisolone sodium succinate\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"PHASE3","lastUpdateDate":"2025-09-12"},{"nctId":"NCT06820411","OrgName":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","Titlefull":"Y-SCOPE Study: A Pilot Study to Assess Optimal Prevention and Outcome Improvement in Young Ischemic Stroke","BriefSummary":"Purpose The Y-SCOPE study aims to improve the health and recovery of young adults aged 18 to 65 who have experienced an ischemic stroke or a high-risk transient ischemic attack (TIA). By focusing on personalized care and lifestyle changes, the study seeks to reduce the chances of another stroke and promote better long-term health.\n\nBackground While strokes are often associated with older adults, recent studies have shown an increase in ischemic strokes among younger individuals. Given that younger patients are typically in their working years and have longer life expectancies, a stroke can lead to significant long-term disability and economic challenges. Addressing the unique needs of this population is crucial for effective care and research.\n\nStudy Design\n\nThis is an open-label pilot study, meaning both participants and researchers know which treatments are being administered. The study will enroll 36 participants who will be randomly assigned in a 2:1 ratio:\n\nIntervention Group (24 participants): Will receive personalized care through a dedicated \"Young Stroke Clinic.\" Control Group (12 participants): Will receive standard post-stroke care.\n\nIntervention Details\n\nParticipants in the intervention group will:\n\n* Attend specialized clinic visits focused on young stroke patients.\n* Receive intensive counseling to manage risk factors such as high blood pressure, cholesterol, and lifestyle habits.\n* Be provided with a wearable device (Whoop 4.0) to monitor health metrics like heart rate, sleep patterns, and physical activity.\n\nDuration The study will last for 12 months, with an 8-month enrollment period and a minimum follow-up of 6 months for each participant.\n\nEligibility Criteria\n\nInclusion:\n\n* Ages 18 to 65.\n* Diagnosed with acute ischemic stroke or high-risk TIA.\n* Moderate to low cardiovascular health status.\n* Able to perform daily activities independently or with minimal assistance.\n\nExclusion:\n\n* Pregnancy.\n* Lack of access to a compatible smartphone for device monitoring.\n* Inability to commit to the follow-up schedule.\n\nObjectives\n\n* Primary Objective: Assess the feasibility of the study by evaluating participant eligibility, consent rates, adherence to interventions, and retention rates.\n* Secondary Objectives: Compare health outcomes between the intervention and control groups, including:\n\nImprovement in cardiovascular health scores. Reduction in major cardiovascular events. Enhancements in physical activity, diet, sleep quality, and smoking cessation. Changes in inflammatory markers in the blood.\n\nPotential Benefits While this is a pilot study and may not provide definitive evidence of effectiveness, it aims to develop a tailored secondary prevention strategy for young stroke patients. The personalized approach could lead to better management of risk factors, improved quality of life, and a reduction in recurrent strokes and other cardiovascular events.\n\nParticipation Participants will be required to attend scheduled clinic visits, engage in counseling sessions, and use the provided wearable device consistently. Regular monitoring and feedback will be integral parts of the program.\n\nConfidentiality All personal health information and data collected during the study will be kept confidential and used solely for research purposes.\n\nThis study is conducted by the Neurology Department and Stroke Unit at the IRCCS Mondino Foundation.","ExperimentalDrugs":"[\"other: standard post-stroke care\"]","Allcountries":"[\"Italy\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"ACTIVE_NOT_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":5,"Phase":"NA","lastUpdateDate":"2026-04-08"},{"nctId":"NCT06297863","OrgName":"University of Milano Bicocca","Titlefull":"Head Down Tilt 15° to Increase Collateral Flow in Acute Ischemic Stroke: a Multicenter, Randomised, Proof of Concept, Phase 2a/b Trial in Patients Treated With Mechanical Thrombectomy","BriefSummary":"The DOWN-SUITE study is multicenter, randomised, controlled, open-label clinical trial with blinded outcome assessment comparing collateral status in patients with acute ischemic stroke treated with an in-hospital application of head down tilt -10° to -15° (HDT15) versus usual positioning (0° to +30°) before endovascular mechanical thrombectomy.\n\nThis study will involve adult patients who are eligible for mechanical thrombectomy and who have acute ischemic stroke due to left or right middle cerebral artery occlusion (M1 segment).\n\nThe investigators hypothesise that HDT15, applied in acute ischemic stroke patients with a large vessel occlusion, will improve collateral circulation, prolong the survival of the ischemic penumbra and improve the clinical benefit from mechanical thrombectomy compared with standard of care (usual positioning 0° to +30°).","ExperimentalDrugs":"[\"procedure: head down tilt -10° to -15°\"]","Allcountries":"[\"Italy\"]","FirstAdminInter":"Other","TreatDur":"Day 1 only","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":23,"Phase":"PHASE2","lastUpdateDate":"2026-04-29"},{"nctId":"NCT07232563","OrgName":"Zhujiang Hospital","Titlefull":"Exploratory Study of Intranasal Administration of Small Extracellular Vesicles Derived From Human Umbilical Cord Mesenchymal Stem Cells hUC-MSC-sEV-001 in the Treatment of Ischemic Stroke Patients","BriefSummary":"Evaluation of the Safety and Preliminary Efficacy of Intranasal Administration of Human Umbilical Cord Mesenchymal Stem Cell-Derived Small Extracellular Vesicles (hUC-MSC-sEV-001) in Patients for Ischemic Stroke","ExperimentalDrugs":"[\"biological: intranasal administration of human umbilical cord mesenchymal stem cell-derived small extracellular vesicles (huc-msc-sev-001) therapy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Safety","total_Score":22,"Phase":"PHASE1","lastUpdateDate":"2025-11-14"},{"nctId":"NCT06447116","OrgName":"Jacobs institute","Titlefull":"An EFS to Evaluate the Safety and Preliminary Effectiveness of the CGuard Prime™ Carotid Stent Placement in the Procedure Setting of Acute Ischemic Stroke.","BriefSummary":"The Jacobs Institute is conducting a Sponsor Investigator study of patients ≥ 18 years to establish safety and preliminary effectiveness in treating extracranial stenosis with the CGuard Prime™ Carotid Stent in the setting as an acute ischemic stroke.","ExperimentalDrugs":"[\"device: cguard prime™ carotid stent system\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"ACTIVE_NOT_RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":20,"Phase":"NA","lastUpdateDate":"2026-03-03"},{"nctId":"NCT07575984","OrgName":"Pharmasoft","Titlefull":"A Pilot, Randomized, Multicenter, Comparative, Open-label Study to Evaluate the Clinical, Laboratory, and Instrumental Efficacy and Safety of Mexidol® Solution for Intravenous and Intramuscular Administration, 50 mg/mL (LLC RPC \"PHARMASOFT\", Russia), and Mexidol® FORTE 250 Film-coated Tablets, 250 mg (LLC RPC \"PHARMASOFT\", Russia), in the Treatment of Ischemic Stroke in Hyperacute and Acute Periods","BriefSummary":"The primary objective of this study is to further define the mechanisms of action of Mexidol® (solution for intravenous and intramuscular injection, 50 mg/ml) and Mexidol® FORTE 250 (film-coated tablets, 250 mg) in the hyperacute and acute periods of ischemic stroke, and to evaluate their impact on clinical and neuroimaging outcomes of the disease.","ExperimentalDrugs":"[\"mexidol\",\"glycine\"]","Allcountries":"[\"Russia\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Early efficacy","total_Score":21,"Phase":"PHASE4","lastUpdateDate":"2026-05-08"},{"nctId":"NCT06828679","OrgName":"Chinese University of Hong Kong","Titlefull":"Personalized Rehabilitation Pathways to Maximal Motor Functional Return Through an AI Recovery Prediction System for Diverse Stroke Survivors","BriefSummary":"This project addresses the imminent challenge of providing adequate motor rehabilitation to a growing number of stroke survivors amidst the ageing population, decreasing age of stroke, and shortage of physical/occupational therapists in Hong Kong through AI and precision rehabilitation. To reduce the socioeconomic burden from the stroke survivors' loss of independence and their care (\\>HK$15 billion/year), the efficacy of rehabilitation and efficiency of its delivery must be improved. These goals can be achieved by prescribing them with individually tailored rehabilitations predicted to yield maximal functional return. Defining a predictive model for such personalization remains challenging given the immense heterogeneity of stroke. The investigators aim to build an explainable AI system that predicts a subject's recovery potential and the treatment option that may realize this potential based on multi-modal pre-rehab assessments. Data from clinical, neuroimaging, neurophysiological, and multi-omic evaluations will be collected from stroke survivors (N≥400) before they undergo upper limb rehab with usual care, neuromuscular stimulation, robotic training, or acupuncture. Machine learning-extracted data features will be used to train decision-tree and neural-network AI algorithms for robust predictions. As soon as the model is validated, the investigators will deploy it to implement a personalized rehab program in the community. Our model's ability to predict the optimal intervention from a wide spectrum of input modalities distinguishes ours from previous less-than-accurate models. Our interdisciplinary team of 13 PIs with expertise in neurology, PT/OT, acupuncture, electrical/biomed. engineering, robotics, neuroscience, neuroimaging, multi-omics, data science, and clinical trial management will put us in a world-unique position to execute this project successfully and generate opportunities of interdisciplinary education. In the long run, our prediction system will accelerate marketization of new rehab strategies by facilitating their clinical-trial evaluations in more targeted subjects, thereby leading Hong Kong to be a future global hub of innovative rehabilitation.","ExperimentalDrugs":"[\"other: control group\",\"other: acupuncture\",\"device: robotic training\",\"device: neuromuscular electrical stimulation group\"]","Allcountries":"[\"Hong Kong\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":6,"Phase":"NA","lastUpdateDate":"2025-12-19"},{"nctId":"NCT06712004","OrgName":"Zhujiang Hospital","Titlefull":"Efficacy and Safety of Bevifibatide Citrate Injection in Patients With Acute Ischemic Stroke Without Large or Medium-Sized Vessel Occlusion: A Single-Center, Randomized, Double-Blind, Dose-Response Controlled Clinical Trial","BriefSummary":"BCAIS-I is a single-center, randomized, double-blind, dose-response controlled clinical Trial, to preliminarily explore the efficacy of two different maintenance doses of bevifibatide citrate injection in improving 90-day neurological outcomes and the incidence of symptomatic intracranial hemorrhage in patients with acute ischemic stroke without large or medium-sized vessel occlusion, aiming to identify a dosing regimen that maintains therapeutic efficacy while minimizing the rates of symptomatic intracranial hemorrhage and serious adverse events, thereby providing dosing evidence for future large-scale randomized controlled trials.","ExperimentalDrugs":"[\"bevifibatide citrate injection\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Day 1 only","Status":"RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"PHASE2","lastUpdateDate":"2025-07-15"},{"nctId":"NCT06956521","OrgName":"Baylor College of Medicine","Titlefull":"Intra-Arterial Magnesium Therapy After Mechanical Thrombectomy in Acute Ischemic Stroke","BriefSummary":"The goal of this Phase I unblinded, dose-escalation trial is to evaluate the safety and tolerability of intra-arterial magnesium sulfate injection after mechanical thrombectomy in patients experiencing acute ischemic stroke. This trial is one of the first trials to look at IA administration of magnesium sulfate into at risk brain tissue in a selective and localized fashion.","ExperimentalDrugs":"[\"magnesium sulfate\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Safety","total_Score":22,"Phase":"PHASE1","lastUpdateDate":"2025-05-12"},{"nctId":"NCT07275749","OrgName":"Kafrelsheikh University","Titlefull":"The Safety and Efficacy of Acetyl-leucine in Post-stroke Ataxia: a Randomized Placebo-controlled Trial","BriefSummary":"Along with the current clinical trial, the efficacy and safety of 4 gram of acetyl-leucine daily for three months in patients with post-stroke ataxia following posterior-circulation ischaemic stroke assessed through BBS, SARA, and mRS, and possible adverse effects.","ExperimentalDrugs":"[\"acetyl-leucine\",\"clopidogrel 75 mg oral tablet\",\"aspirin 100mg\"]","Allcountries":"[\"Egypt\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT optional","Endpoint":"Late efficacy","total_Score":28,"Phase":"PHASE3","lastUpdateDate":"2025-12-07"},{"nctId":"NCT07232498","OrgName":"Unidade Local de Saúde de Coimbra, EPE","Titlefull":"Early Doppler-Assisted Mobilization in Adults After Acute Ischemic Stroke - a Randomized Clinical Trial","BriefSummary":"Post-stroke mobilization remains a subject of ongoing debate. While early mobilization-particularly the first out-of-bed mobilization-has been associated with reduced systemic complications and earlier rehabilitation, it also carries potential risks, such as neurological deterioration in the presence of hemodynamic instability.\n\nIn this study, the primary aim is to investigate whether early mobilization, guided by hemodynamic evaluation after acute ischemic stroke offers superior outcomes compared to standard clinical care.","ExperimentalDrugs":"[\"procedure: doppler-guided early mobilization\"]","Allcountries":"[\"Portugal\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":12,"Phase":"NA","lastUpdateDate":"2026-05-20"},{"nctId":"NCT06817512","OrgName":"Harbin Medical University","Titlefull":"Health Effects of Vitamin K2 Supplementation on Skeletal Muscle and Neurological Function After Ischemic Stroke","BriefSummary":"The primary goal of this clinical trial is to assess whether vitamin K2 supplementation can effectively improve skeletal muscle and neurological function in patients with ischemic stroke. The main questions it aims to answer are: 1. Does supplementation with vitamin K2 improve the subjects' muscle strength and muscle mass? 2. Can supplementation with vitamin K2 improve the subjects' neurological function after a stroke? Researchers will compare vitamin K2 supplements with a placebo to observe whether vitamin K2 supplementation can improve skeletal muscle and neurological function in patients with ischemic stroke. Participants will: 1. Take vitamin K2 (MK-7) or a placebo daily for 1 year. 2. Attend face-to-face visits and provide biological samples and relevant data at 0, 3, 6, and 12 months. At 9 months, the visit will be online. After the intervention, follow-up will continue for 1 year to observe the long-term effects.","ExperimentalDrugs":"[\"dietary supplement: vitamin k2\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"ACTIVE_NOT_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":11,"Phase":"NA","lastUpdateDate":"2026-03-02"},{"nctId":"NCT07118345","OrgName":"Xuanwu Hospital, Beijing","Titlefull":"Early Prophylactic Decompressive Hemicraniectomy Following Endovascular Therapy in Large Hemispheric Infarct Trial","BriefSummary":"Early Decompressive Hemicraniectomy for High-Risk Large Ischemic Core Stroke Post-EVTAcute Ischemic Stroke (AIS), particularly Anterior Circulation Large Vessel Occlusion (LVO), is a major cause of global disability and death. While endovascular thrombectomy (EVT) is the standard first-line treatment for LVO, outcomes remain poor in patients with large ischemic cores (ASPECTS ≤5). Despite high recanalization rates (\\>90%), only 14-30% achieve functional independence (mRS 0-2) at 90 days, with 33-50% dead or severely disabled (mRS 5-6). Outcomes worsen dramatically with larger core volumes (e.g., only 4.4% functional independence with cores ≥150mL in SELECT2).A critical complication is Malignant Cerebral Edema (MCE), affecting \\~50% of large-core patients post-EVT. MCE triggers a vicious cycle of rising intracranial pressure, reduced perfusion, and brain herniation. It drastically worsens prognosis: functional independence rates plummet (13.3% vs 51.2% without MCE), mortality significantly increases (OR=7.96, p=0.001), and functional outcomes deteriorate (OR=7.83, p=0.008). Strong predictors include low ASPECTS (\\<7) and large infarct volume.Decompressive Hemicraniectomy (DHC) is a life-saving intervention for MCE. Landmark trials (DESTINY, DECIMAL, HAMLET) and their meta-analysis show DHC within 24 hours in patients aged 18-60 significantly increases 12-month survival (78% vs 29%, ARR 50%) and rates of ambulatory independence (mRS ≤3: 43% vs 21%, ARR 23%). DESTINY II confirmed benefit in patients \\>60, improving functional outcomes (mRS 0-4: 38% vs 16%). Guidelines endorse DHC for large infarcts with deterioration.However, significant challenges persist:\n\nDHC is Underutilized: Despite evidence, clinical adoption remains low.Rescue DHC Fails to Improve Outcomes in Post-EVT MCE: Studies report poor functional outcomes (only 20% mRS 0-2) and high mortality (48.6%) with standard medical therapy (SMT) plus rescue DHC after MCE develops. Retrospective data confirms worse outcomes in these patients (mRS 0-2: 16.4% vs 50%; mortality: 46.5% vs 20%) compared to those without MCE. Crucially, rescue DHC itself fails to improve prognosis once MCE is established (mRS 5-6: 64% vs 57.7%; mortality: 48% vs 46.2%).High-Risk Identification: Patients defined as high-risk for MCE (ASPECTS 3-5 + NIHSS≥30 or ASPECTS≤2) have significantly worse 90-day outcomes (mRS 0-2: 23.2% vs 44.6%; mortality: 44% vs 22.7%).Timing is Critical: Rescue DHC is often performed too late, after irreversible neurological damage occurs. Early/Prophylactic DHC, performed before significant edema and herniation develop, offers a potential pathophysiological advantage. It may:Improve cerebral perfusion pressure earlier. Reduce mass effect and edema progression. Mitigate secondary injury (e.g., reduce oxygen-free radicals, excitatory amino acids).Potentially break the ischemic-edema-herniation cycle sooner.Rationale for the Study: While DHC is effective for established MCE in non-EVT contexts and rescue DHC post-EVT is ineffective, high-quality evidence for early prophylactic DHC in high-risk large-core patients after successful EVT is lacking. Current guidelines do not address this specific, high-risk population where MCE incidence is \\~50% and outcomes are dismal despite recanalization.\n\nStudy Aim: This trial will evaluate the efficacy and safety of early prophylactic decompressive hemicraniectomy compared to standard medical treatment (which includes rescue DHC if MCE develops) in AIS-LVO patients at high risk of MCE (defined by ASPECTS and NIHSS criteria) following successful EVT. The goal is to determine if proactive intervention can improve functional outcomes and reduce mortality in this critically ill population where current strategies fail.","ExperimentalDrugs":"[\"procedure: early prophylactic decompressive hemicraniectomy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"NA","lastUpdateDate":"2026-01-22"},{"nctId":"NCT06937918","OrgName":"Mahidol University","Titlefull":"Effect of Dynamic Arterial Elastance and Assisted Fluid Management Software Guided Adjustment of Vasopressor and Fluid Therapy in Septic Shock Resuscitation; A Pilot Study","BriefSummary":"To investigate the benefit of using the AFM and Eadyn-guided fluid and vasopressor therapy in septic shock resuscitation for mechanically ventilated patients compared with the standard of care. The investigators hypothesize that using the AFM and Eadyn-guided fluid/vasopressor titration in septic shock patients who underwent mechanical ventilation might reduce the time to shock reversal.","ExperimentalDrugs":"[\"other: the standard care for septic shock\",\"device: the afm and eadyn - guided resuscitation group\"]","Allcountries":"[\"Thailand\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":5,"Phase":"NA","lastUpdateDate":"2025-04-22"},{"nctId":"NCT06941753","OrgName":"Peking Union Medical College Hospital","Titlefull":"Effectiveness of Off-script Diagnosis & Differential Diagnosis (D&D) Training in Improving Residents' Competence in Acute Ischemic Stroke Diagnosis and Treatment","BriefSummary":"This study is a single-center, randomized, open-label, controlled, endpoint-blinded study to assess the effect of off-script diagnosis \\& differential diagnosis (D\\&D) training in improving the residents' knowledge of acute ischemic stroke in China. The investigators will enroll 22 residents and assess the score of mASMaQ 30 days after randomization.","ExperimentalDrugs":"[\"other: off-script diagnosis & differential diagnosis (d&d) training\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"3 days or less","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":8,"Phase":"NA","lastUpdateDate":"2025-06-23"},{"nctId":"NCT06760195","OrgName":"Capital Medical University","Titlefull":"Intra-arterial Hypothermic Magnesium Sulfate Infusion in Combination with Endovascular Thrombectomy in Acute Ischemic Stroke: a Safety Study","BriefSummary":"The primary objective of this study is to estimate the safety of intra-arterial hypothermic magnesium sulfate infusion after endovascular thrombectomy in patients with acute ischemic stroke","ExperimentalDrugs":"[\"procedure: intra-arterial hypothermic magnesium sulfate infusion\",\"procedure: endovascular thrombectomy\",\"intravenous thrombolysis\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Late efficacy","total_Score":27,"Phase":"EARLY_PHASE1","lastUpdateDate":"2025-01-03"},{"nctId":"NCT07052045","OrgName":"Paracelsus Medical University","Titlefull":"One-Stop manaGemEnT For A Swift Initiation of Endovascular Therapy - An International, Multicenter, Pragmatic Randomized Controlled Trial (GET-FAST","BriefSummary":"Stroke, especially acute ischemic stroke (AIS) caused by a blocked blood vessel in the brain, is a leading cause of death and long-term disability. When the blockage is in a large blood vessel, a procedure called endovascular therapy (EVT)-where the clot is removed using a catheter-is highly effective. However, the sooner EVT is done, the better the outcome for the patient.\n\nResearch has shown that delays between arriving at the hospital and starting EVT (called door-to-groin time) significantly reduce the chances of recovery. For example, reducing this time by just 15 minutes can mean 20 more patients (out of 1,000 treated) going home instead of to a care facility. Even a 10-minute improvement can result in over 100 extra days of independent living for patients and save more than $10,000 in healthcare costs per patient.\n\nTo reduce these delays, hospitals have improved stroke workflows. In the current standard approach, patients suspected of having a stroke are taken first to a CT scan room to confirm the diagnosis, and then, if a treatable occlusion is found, to a separate room for EVT. This usually takes around 60-70 minutes.\n\nHowever, moving patients between rooms takes time. A new approach called \"One-Stop management\" could solve this. In this method, both the brain scan and the EVT procedure are done in one room-the angiography suite-using special imaging tools called flat panel CT (FDCT) and FDCT angiography (FDCT-A).\n\nA previous study with 230 patients showed that One-Stop management is possible and saves time. But there's a challenge: the decision to follow the One-Stop pathway is made before a clear diagnosis is available. That's important because not all strokes benefit from EVT. Severe stroke symptoms (measured by a score called NIHSS ≥10) can come from:\n\n* A large or medium vessel blockage (which EVT can treat),\n* A small vessel blockage, or\n* A bleed in the brain (hemorrhage). Only the first group benefits from EVT. About 85% of patients with severe symptoms fall into this category. The rest-about 15%-would not benefit, and there are concerns that FDCT might be slightly less accurate than regular CT in diagnosing these types of strokes. So, we need to test whether One-Stop management is safe and effective for all patients, not just those with treatable blockages.\n\nTo do this, the GET-FAST trial will compare the One-Stop approach to the standard two-room process. Patients will be randomly assigned to one of the two strategies. Importantly, this randomization won't affect their actual treatment-everyone will still receive the best care according to current medical guidelines. The main endpoint for the evaluation of the One-Stop approach will be long-term (at 90 days) disability and dependency in daily life as measured with the modified Rankin Scale (mRS).\n\nThis study will include all patients as they were assigned, regardless of what type of stroke they actually had. This is called an \"intention-to-treat\" analysis, and it provides the most reliable measure of the overall impact of One-Stop management.\n\nAnother key aspect of the trial is that any CE-certified imaging system already used in hospitals can be used for the One-Stop process-no specific brand or model is required. This makes the results more applicable to real-world hospital settings.\n\nIf GET-FAST proves that One-Stop management leads to better patient outcomes, this could transform how stroke care is delivered. More patients could return to independent living, and fewer would require long-term care -leading to major reductions in healthcare costs. For example, even a one-point improvement on a common stroke disability scale (mRS) can triple the savings in lifetime care costs.","ExperimentalDrugs":"[\"other: one stop management\",\"other: usual care management\"]","Allcountries":"[\"Germany\",\"Switzerland\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"NA","lastUpdateDate":"2026-01-15"},{"nctId":"NCT07094763","OrgName":"The First Affiliated Hospital of University of Science and Technology of China","Titlefull":"Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset: A Multicenter, Prospective, Randomized, Open-Label, Blinded Endpoint Trial","BriefSummary":"This study aims to evaluate the efficacy and safety of tenecteplase (TNK) intravenous thrombolysis within the extended time window (4.5 to 24 hours) in patients with acute posterior circulation ischemic stroke.","ExperimentalDrugs":"[\"standard medical management\",\"tnk plus standard medical treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":22,"Phase":"NA","lastUpdateDate":"2026-06-05"},{"nctId":"NCT06848894","OrgName":"Beijing Tiantan Hospital","Titlefull":"Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment","BriefSummary":"This study aims to explore the efficacy and safety of Human Urinary Kallidinogenase for acute ischemic stroke patients receiving intravenous thrombolysis and/or endovascular treatment.","ExperimentalDrugs":"[\"human urinary kallidinogenase (huk)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":22,"Phase":"NA","lastUpdateDate":"2025-03-25"},{"nctId":"NCT07139314","OrgName":"Capital Medical University","Titlefull":"Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation: a Randomised Controlled Trial","BriefSummary":"This study evaluates the safety and efficacy of early versus delayed initiation of direct oral anticoagulants (DOACs) in patients with acute ischemic stroke related to atrial fibrillation who develop hemorrhagic transformation after endovascular treatment.","ExperimentalDrugs":"[\"early anticoagulation\",\"delayed anticoagulation\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Late efficacy","total_Score":18,"Phase":"NA","lastUpdateDate":"2026-02-04"},{"nctId":"NCT06525987","OrgName":"University of L'Aquila","Titlefull":"Telecoached Exercise Intervention for Connectivity Enhancement in Small Vessel Disease (TELECONNECT-SVD): a Randomized Clinical Trial","BriefSummary":"The TELECONNECT-SVD study is a prospective, randomized, multicenter trial aimed at testing the efficacy of a remotely delivered exercise protocol on brain functional connectivity in patients with small vessel disease (SVD)-related ischemic stroke. The study will recruit patients aged ≥60 with a history of lacunar stroke, minimal disability (modified Rankin Scale score 0-1), and low physical activity levels.\n\nThe trial will include 60 participants randomized 1:1 to either a 24-week telecoached exercise intervention or usual care. The exercise program consists of multicomponent physical exercises delivered remotely twice a week. Assessments will be conducted at baseline, 12 weeks, 24 weeks, and 48 weeks.\n\nPrimary outcomes include changes in brain functional connectivity assessed by high-density EEG and improvements in physical fitness measured by the Senior Fitness Test. Secondary outcomes encompass changes in physical activity levels, anthropometric measurements, and vital signs.\n\nThe study employs a \"wait list\" design, where the control group receives the intervention after the initial 24-week period. This approach allows for assessment of the intervention's immediate effects and the retention of benefits after cessation.\n\nKey features of the protocol include:\n\n* Use of telecoaching to enhance adherence to the exercise program\n* Comprehensive assessment of brain connectivity using advanced EEG analysis techniques\n* Focus on patients with SVD, who may benefit significantly from exercise interventions\n* Evaluation of both neurophysiological and clinical outcomes\n\nThe study aims to provide evidence for the potential benefits of exercise in enhancing brain connectivity and physical fitness in SVD patients, potentially informing future treatment guidelines and preventive strategies for this population.","ExperimentalDrugs":"[\"behavioral: physical activity\"]","Allcountries":"[\"Italy\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-11-24"},{"nctId":"NCT06316557","OrgName":"Beijing Tiantan Hospital","Titlefull":"HOPE From the Cerebellum: TMS-Induced Cognitive Recovery After Stroke","BriefSummary":"The objective of this clinical trial is to investigate the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) in the cerebellum for individuals with post-stroke cognitive impairment. Participants will undergo rTMS in the cerebellar hemisphere opposite the lesion site, once daily for a total of five days.","ExperimentalDrugs":"[\"device: itbs group\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":14,"Phase":"NA","lastUpdateDate":"2025-06-30"},{"nctId":"NCT07074600","OrgName":"Qinghai University","Titlefull":"Clinical Efficacy of Electroacupuncture Therapy on Limb Dysfunction in Ischemic Stroke Patients at High-Altitude Regions: A Multi-center Randomized Double-blind Controlled Trial","BriefSummary":"The purpose of this clinical trial is to investigate the efficacy of electroacupuncture therapy for limb dysfunction in ischemic stroke patients residing at high-altitude regions. This study aims to address the following research questions: 1. Whether electroacupuncture therapy demonstrates clinical effectiveness in managing limb dysfunction among ischemic stroke patients in high-altitude regions. 2. Whether electroacupuncture therapy maintains an acceptable safety profile in this specific population.\n\nResearchers will conduct a comparative analysis between the active electroacupuncture intervention group and a sham-electroacupuncture control group to evaluate therapeutic efficacy. Participants will: 1. Undergo daily electroacupuncture treatment sessions for a standardized 14-day therapeutic course. 2. Complete comprehensive functional assessments and neurological evaluations at baseline and post-intervention timepoints.","ExperimentalDrugs":"[\"device: electroacupuncture therapy\",\"device: sham electroacupuncture intervention\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2025-07-10"},{"nctId":"NCT07040085","OrgName":"Beijing Tiantan Hospital","Titlefull":"Effects of Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke: a Randomised, Double-blind, Multicenter, Placebo-controlled Phase 3 Trial (FUTURE-2)","BriefSummary":"This study aims to evaluate the efficacy of Y-6 sublingual tablets in improving microcirculation dysfunction and reducing thrombo-inflammation in patients who had AIS caused by LVO and will receive EVT. Moreover, we expect to evaluate the safety of using Y-6 sublingual tablet in such study population.\n\nThis study rationale is based on the following scheme: in patients with acute ischemic stroke caused by LVO, receiving reperfusion therapy may cause futile recanalization and thus lead to microcirculation dysfunction and thrombo-inflammation as consequences. Dexborneol has anti-inflammatory effects and Cilostazol has antiplatelet effects and BBB protection; therefore, the multi-component tablet may exert neuroprotective effects in terms of improving microcirculation dysfunction and reducing thrombo-inflammation in patients with AIS after reperfusion therapy.\n\nThe primary purpose of this study is to investigate the proportion of modified-Rankin scale (mRS) score recovered to 0\\~1 score at 90 days after randomization.\n\nThe follow-up duration is 3 months, and the visit schedule is as follows: Subjects enrolled based on randomization procedures will receive visits at screening/baseline period, 1 day, 7 days, 28 days and 90 days after randomization, and in case of any events.","ExperimentalDrugs":"[\"y-6\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"PHASE3","lastUpdateDate":"2025-06-19"},{"nctId":"NCT06995040","OrgName":"University Hospital, Brest","Titlefull":"Initial Predictors of Long-term Brain Resilience After Minor Ischemic Stroke: a Study Nested in the Brest Stroke Population-based Registry","BriefSummary":"The objective of this clinical trial is to develop, based on patients' initial characteristics (in the first few weeks following the stroke), a predictive model of quality of life more than 4 years after the stroke in patients who have suffered a minor ischemic stroke.\n\nThe main question it aims to answer is:\n\n\\- Is it possible to predict the quality of life of patients who have suffered a minor ischemic stroke based on their initial characteristics?\n\nTo do this, retrospective and prospective data collected as part of the study will be analyzed using a conventional statistical approach and algorithms based on AI approaches in order to create a predictive model.\n\nParticipants will be asked to:\n\n* Complete questionnaires\n* Provide a saliva sample (optional)\n* Undergo an MRI scan (optional)","ExperimentalDrugs":"[]","Allcountries":"[\"France\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":5,"Phase":"NA","lastUpdateDate":"2026-02-20"},{"nctId":"NCT06612710","OrgName":"Tongji Hospital","Titlefull":"An Open-label Exploratory Clinical Trial to Assess the Safety and Efficacy of NouvSoma001 in the Treatment of Ischemic Stroke","BriefSummary":"This is a single-center, randomized, open-label, placebo-controlled, dose-escalation trial. The objective of this research is to evaluate the safety, tolerability, and preliminary efficacy of intravenous administration of human-induced neural stem cell-derived extracellular vesicles (NouvSoma001) in the treatment of ischemic stroke.","ExperimentalDrugs":"[\"extracellular vesicles derived from human induced neural stem cell for intravenous injection\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":15,"Phase":"PHASE1","lastUpdateDate":"2026-01-18"},{"nctId":"NCT07175649","OrgName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","Titlefull":"Methylprednisolone Sodium Succinate With Endovascular ThRombectomy for Large Ischemic STroke: A Randomized, Double-blind, Placebo-controlled Trial","BriefSummary":"It is uncertain whether intravenous methylprednisolone improves outcomes for acute anterior circulation large vessel occlusion (LVO) patients with a large infarct core. In this study, the investigators hypothesize that methylprednisolone plus endovascular thrombectomy (EVT) might be superior to EVT alone in patients with evidence of a large infarct volume. The primary objective of the study is to establish the efficacy of methylprednisolone with EVT in patients with acute anterior circulation LVO and a large infarct core.","ExperimentalDrugs":"[\"methylprednisolone sodium succinate\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":23,"Phase":"NA","lastUpdateDate":"2025-09-09"},{"nctId":"NCT06506279","OrgName":"University of Washington","Titlefull":"Motor Recovery Through Plasticity-Inducing Cortical Stimulation","BriefSummary":"Using the CorTec Brain Interchange (BIC) System, we will examine the effect of a plasticity-inducing therapy regime on the rehabilitation of upper limb impairment post-stroke. This study's main objective is to implement and evaluate neuroplasticity-inducing stimulation. The stimulation methods for inducing neuroplasticity have been selected based on prior preclinical and intraoperative work that has shown promise in providing rehabilitative benefits for stroke patients. We will be structuring this study as an open prospective feasibility study.","ExperimentalDrugs":"[\"device: cortec brain interchange (bic) system\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":14,"Phase":"NA","lastUpdateDate":"2026-04-07"},{"nctId":"NCT07097428","OrgName":"Xuanwu Hospital, Beijing","Titlefull":"Individualized Temperature Health Risk Early Warning for Reducing the Recurrence Risk of Stroke:A Multicenter, Randomized Controlled Trial Study","BriefSummary":"This study applied an application to provide early warnings and advice for stroke patients and explored the impact of this intervention on reducing the risk of stroke recurrence","ExperimentalDrugs":"[\"other: temperature health risk early warning\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":8,"Phase":"NA","lastUpdateDate":"2025-09-02"},{"nctId":"NCT07307989","OrgName":"Chang Gung Memorial Hospital","Titlefull":"Early Statin-Ezetimibe Combination vs. Statin Monotherapy to Achieve LDL-C < 70 mg/dL in Recent Ischemic Stroke Patients With Evidence of Atherosclerosis: A Randomized Controlled Trial","BriefSummary":"This study will be conducted at six medical institutions in Taiwan, recruiting patients who visit neurology outpatient clinics or are hospitalized within 30 days after an ischemic stroke.\n\nParticipants will be randomly assigned to either the experimental group (moderate-intensity statin plus ezetimibe) or the control group (moderate- or high-intensity statin).\n\nResearch assistants will screen patients aged 40 or older who have had an ischemic stroke or transient ischemic attack within 30 days, have atherosclerosis, and have LDL-C levels ≥100 mg/dL. Eligible cases will be reviewed by the attending physician. With physician approval, patients will be invited to join the study, and those who agree and sign informed consent will be enrolled.","ExperimentalDrugs":"[\"statin + ezetimibe\",\"statin monotherapy (rosuvastatin or atorvastatin)\"]","Allcountries":"[\"Taiwan\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":14,"Phase":"PHASE2","lastUpdateDate":"2025-12-28"},{"nctId":"NCT06818513","OrgName":"Ahmadu Bello University Teaching Hospital","Titlefull":"Effects of Gastrostomy and Intermittent Oral Tube Feeding on Patients With Dysphagia After Stroke","BriefSummary":"The goal of this clinical trial is to compare the differences in swallowing function, quality of life and nutritional status between ischemic stroke patients with dysphagia using Intermittent Oro-esophageal Tube and Gastrostomy. Patients will be randomly divided into an oral tube group and a Gastrostomy group, all receiving routine rehabilitation treatment. On this basis, the oral tube group will use Intermittent Oro esophageal Tube for enteral nutrition support, while the Gastrostomy group will use Gastrostomy. Researchers will compare changes in swallowing function, quality of life and nutritional status of two groups of patients before and after the study to see if Intermittent Oro-esophageal Tube can improve the quality of life and nutritional status between ischemic stroke patients compared Gastrostomy.","ExperimentalDrugs":"[\"behavioral: routine rehabilitation therapy\",\"dietary supplement: oral tube feeding\",\"dietary supplement: gastrostomy\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":4,"Phase":"NA","lastUpdateDate":"2025-02-05"},{"nctId":"NCT07172464","OrgName":"Recross Cardio, Inc.","Titlefull":"Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study","BriefSummary":"The goal of this clinical trial is to test a new heart device called P3 Occluder System in patients who have a small opening between the upper chambers of the heart (called a Patent Foramen Ovale or PFO) and have experienced a stroke that may be related to this heart opening. The main question it aims to answer is:\n\n• Is the P3 Occluder System safe and effective for closing a PFO in patients who have had a stroke that could be related to a PFO.\n\nParticipants will:\n\n* Undergo the procedure to implant the P3 Occluder System, if deemed appropriate.\n* Visit their doctor at 1 month, 3 months, 6 months, 1 year, and 5 years after the procedure for follow up exams.\n* Answer a phone call from study staff at 2 years, 3 years, and 4 years after the procedure to answer a survey.","ExperimentalDrugs":"[\"device: recross p3 occluder (p3o) system\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":16,"Phase":"NA","lastUpdateDate":"2026-03-03"},{"nctId":"NCT06871969","OrgName":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","Titlefull":"Clinical Evaluation of Pre-hospital Stroke Triage Devices - Electroencephalography","BriefSummary":"Endovascular thrombectomy (EVT) is the standard treatment for large vessel occlusion (LVO) strokes, but it can only be performed in specialized hospitals. Since ambulance personnel cannot determine if a patient is eligible for EVT, 54% of LVO stroke patients are initially taken to non-EVT-capable hospitals, resulting in an average delay of 1 hour in time-to-EVT in the Netherlands. To reduce this delay, it is crucial for ambulance personnel to identify potential LVO stroke patients and directly transport them to EVT-capable hospitals. Dry electrode electroencephalography (EEG) has shown high diagnostic accuracy for detecting LVO strokes, but in 32% of patients, the EEG signal quality was too poor to analyze.\n\nTo address this issue, TrianecT developed StrokePointer, a portable EEG-based triage device designed to collect and analyze EEG data in patients with suspected acute stroke. The objective of this study is to validate the effectiveness and safety of StrokePointer in detecting LVO stroke among patients with a suspected stroke in the pre-hospital setting.","ExperimentalDrugs":"[\"diagnostic test: dry electrode eeg\"]","Allcountries":"[\"Netherlands\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Other","total_Score":17,"Phase":"NA","lastUpdateDate":"2025-09-30"},{"nctId":"NCT07026331","OrgName":"Beijing Anzhen Hospital","Titlefull":"Effect of Balloon Angioplasty vs Stenting Following Residual Stenosis After Endovascular Treatment of Intracranial Atherosclerotic Acute Ischemic Stroke: A Multicenter, Prospective, Open-label, Endpoint-blinded, Randomized Controlled Study","BriefSummary":"The primary objective of this study is to evaluate whether rescue balloon angioplasty versus stenting for residual stenosis following endovascular therapy improves neurological outcomes in patients with acute large vessel occlusion due to large-artery atherosclerosis. Patients will be randomized into two groups: the balloon angioplasty group receiving balloon treatment alone followed by standard medical therapy, and the stent group receiving stenting treatment with post-procedural standard medical therapy. The primary efficacy endpoint is the proportion of patients achieving functional independence (modified Rankin Scale 0-2) at 90±7 days, while the safety endpoint is the probability of symptomatic intracranial hemorrhage occurring within 48 hours after randomization.","ExperimentalDrugs":"[\"procedure: balloon angioplasty\",\"procedure: stent\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"ACTIVE_NOT_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"NA","lastUpdateDate":"2025-08-12"},{"nctId":"NCT06317194","OrgName":"Magnetic Tides","Titlefull":"A Novel Method of Non-Invasive Brain Stimulation (Kilohertz Transcranial Magnetic Perturbation) to Enhance Motor Function in Chronic Stroke Patients","BriefSummary":"Stroke is a leading cause of disability with many patients suffering chronic motor function impairments that affect their day-to-day activities. The goal of this proposal is to provide a first assessment of the efficacy of an innovative non-invasive brain stimulation system, kTMP, in the treatment of motor impairment following stroke.","ExperimentalDrugs":"[\"device: ktmp\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"ENROLLING_BY_INVITATION","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-05-09"},{"nctId":"NCT05046106","OrgName":"Moleac Pte Ltd.","Titlefull":"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Efficacy and Safety Study of MLC1501 in Patients With Stroke","BriefSummary":"This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a day, MLC1501 high-dose twice a day, or matching placebo for 24 weeks.","ExperimentalDrugs":"[\"mlc1501\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"mRS","total_Score":22,"Phase":"PHASE2","lastUpdateDate":"2023-03-14"},{"nctId":"NCT07084012","OrgName":"Shenzhen Wingor Biotechnology Co., Ltd.","Titlefull":"A Phase IIa Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in the Treatment of Acute Ischemic Stroke (AIS)","BriefSummary":"This is a Phase IIa clinical trial with a three-arm design that utilizes randomization, double-blinding, and placebo control. The primary objective of this study is to evaluate the efficacy of single and multiple intravenous infusions of hUC-MSCs injection in patients with AIS. The secondary objective is to assess the safety and tolerability of single and multiple intravenous infusions of hUC-MSCs injection in patients with AIS. The exploratory objective is to investigate the pharmacokinetic and pharmacodynamic characteristics of hUC-MSCs injection in patients with AIS.","ExperimentalDrugs":"[\"huc-mscs treatment (high dose)\",\"huc-mscs treatment (low dose)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"3 days or less","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS","total_Score":26,"Phase":"PHASE2","lastUpdateDate":"2025-09-23"},{"nctId":"NCT06783049","OrgName":"Beijing Tiantan Hospital","Titlefull":"Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack With an Intelligent System","BriefSummary":"The purpose of this study is to develop a digital health-based intelligent management system for the secondary prevention of ischemic stroke and to evaluate its effectiveness through a multicenter randomized controlled trial, assessing its health economic value.\n\nParticipants will receive usual care after discharge (control group) or be managed with a WeChat-based intelligent management system after discharge (intervention group).\n\nAt one year, all patients will undergo face-to-face follow-up to assess clinical events, medication adherence, and the achievement of target risk factor levels.","ExperimentalDrugs":"[\"behavioral: cerebrovascular disease secondary prevention smart management system\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":9,"Phase":"NA","lastUpdateDate":"2026-01-20"},{"nctId":"NCT06768138","OrgName":"Central Hospital, Nancy, France","Titlefull":"Intra-Arterial Thrombolysis After SUCCESSful Angiographic Recanalization in Acute Large Vessel Occlusion Stroke of the Anterior Circulation: the IA-SUCCESS Multicenter, Randomized Clinical Trial","BriefSummary":"Stroke is a leading cause of disability and mortality worldwide. Despite the clinical benefit of mechanical thrombectomy, 1 out of 2 patients treated are functionally independent at 90 days. Achieving the best possible angiographic reperfusion is a key determinant of clinical outcome in acute ischemic stroke patients with anterior circulation large vessel occlusion. Mechanical thrombectomy is standard treatment for large vessel occlusion stroke patients within 24. In the setting of successful (eTICI ≥2b), adjunct intra-arterial thrombolysis may be a promising therapeutic option allowing recanalization of distal arterial occlusions (not accessible to mechanical devices) and improvement of upstream brain reperfusion by targeting microvascular obstruction.\n\nThe IA-SUCCESS randomized trial aims to assess the clinical and safety of adjunct intra-arterial thrombolysis vs. no adjunct intra-arterial thrombolysis after successful angiographic reperfusion in patients with acute anterior circulation large vessel occlusion stroke.","ExperimentalDrugs":"[\"intra-arterial infusion of alteplase\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":34,"Phase":"PHASE3","lastUpdateDate":"2025-06-03"},{"nctId":"NCT06571149","OrgName":"Insel Gruppe AG, University Hospital Bern","Titlefull":"Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke on Treatment With Direct Oral Anticoagulants: DO-IT - The DOAC Intravenous Thrombolysis Trial","BriefSummary":"DO-IT is an international, multicenter, prospective, two-arm, randomized, open label, blinded endpoint superiority trial determining the safety and efficacy of intravenous thrombolysis (IVT) in participants experiencing an acute ischemic stroke (AIS) with recent (within the last 48 hours) intake of direct oral anticoagulant (DOAC). For this purpose, 906 adult participants experiencing an AIS with recent DOAC intake will be enrolled at several high-volume international stroke centers and randomly assigned in a ratio of 1:1 to one of two treatment arms: (1) IVT and standard of care/best medical treatment or (2) standard of care/best medical treatment. The DO-IT trial is a definitive test of the hypothesis that IVT is superior to standard of care for achieving better outcome at 90 days in AIS participants with recent DOAC intake.","ExperimentalDrugs":"[\"tenecteplase or alteplase\"]","Allcountries":"[\"Belgium\",\"Canada\",\"France\",\"Germany\",\"Greece\",\"Japan\",\"Netherlands\",\"New Zealand\",\"Norway\",\"Portugal\",\"Spain\",\"Switzerland\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT mandatory; EVT optional","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"PHASE4","lastUpdateDate":"2025-03-25"},{"nctId":"NCT07026318","OrgName":"Beijing Anzhen Hospital","Titlefull":"Endovascular Therapy Combined With Tirofiban for Intracranial Atherosclerotic Acute Ischemic Stroke: A Multicenter, Prospective, Double-blind, Vehicle-controlled, Randomized Controlled Trial","BriefSummary":"This randomized controlled trial aims to evaluate whether adjunctive tirofiban therapy combined with endovascular treatment (EVT) improves neurological outcomes in patients with acute large vessel occlusion due to large-artery atherosclerosis. Patients will be randomized to receive either tirofiban or matching placebo after EVT. The primary efficacy endpoint is the proportion of patients achieving functional independence (modified Rankin Scale 0-2) at 90±7 days, while the safety endpoint is the probability of symptomatic intracranial hemorrhagewithin 48 hours after randomization.","ExperimentalDrugs":"[\"tirofiban\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"NA","lastUpdateDate":"2025-09-18"},{"nctId":"NCT06785727","OrgName":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","Titlefull":"StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial","BriefSummary":"Two Dutch guidelines (Stroke and Cardiovascular Risk Management) provide conflicting advice on optimal statin treatment in older patients. In the SAFEST - RCT, the investigators will assess the impact of starting versus not starting a statin in frail individuals aged 70 and above with a recent ischemic stroke or transient ischemic attack (TIA) on their health-related quality of life and Major Adverse Cardiovascular Events (MACE) free survival during a two-year follow-up period.","ExperimentalDrugs":"[\"statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin)\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":11,"Phase":"PHASE4","lastUpdateDate":"2025-01-19"},{"nctId":"NCT07196605","OrgName":"Xuanwu Hospital, Beijing","Titlefull":"Efficacy and Safety of Sodium Sivelestat as an Adjunct to Mechanical Thrombectomy in Acute Large Vessel Occlusion Stroke: A Prospective Single-Arm Exploratory Study","BriefSummary":"Stroke remains a major global health burden, with acute ischemic stroke (AIS) accounting for more than 65% of all cases. Endovascular thrombectomy (EVT) has been established as the standard treatment for large vessel occlusion (LVO) stroke; however, the phenomenon of \"futile recanalization\" remains common, with nearly half of patients failing to achieve favorable outcomes despite successful vessel reperfusion. Increasing evidence indicates that neutrophils and neutrophil extracellular traps (NETs) play pivotal roles in post-reperfusion inflammation, thrombosis, and microcirculatory dysfunction, contributing to thrombolysis resistance and poor prognosis. Neutrophil elastase (NE), a key component of NETs, exacerbates vascular injury and thrombus formation. Sodium sivelestat, a selective NE inhibitor, has demonstrated significant anti-inflammatory and organ-protective effects in patients with acute respiratory distress syndrome and in experimental models of cerebral ischemia. It can preserve blood-brain barrier integrity, attenuate brain edema, and improve neurological outcomes. Based on these findings, we propose a prospective, single-center, single-arm exploratory clinical trial to evaluate the efficacy and safety of sodium sivelestat as an adjunct to EVT in patients with acute LVO stroke within 24 hours of onset. The results of this study are expected to provide new clinical evidence for anti-inflammatory interventions aimed at reducing futile recanalization and improving functional outcomes in AIS.","ExperimentalDrugs":"[\"sodium sivelestat\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":23,"Phase":"NA","lastUpdateDate":"2026-03-23"},{"nctId":"NCT06944834","OrgName":"Shanghai StairMed Technology Co., Ltd.","Titlefull":"A Study on the Safety and Functionality of the Implantable Wireless Brain-Computer Interfaces for Motor Rehabilitation","BriefSummary":"The objective of this study is to evaluate the safety and efficacy of minimally invasive, wireless brain-machine interface system (WRS) in patients with paralysis (resulting from spinal cord injuries, brainstem strokes, amyotrophic lateral sclerosis, or other motor neuron diseases causing complete or incomplete quadriplegia) or bilateral upper limb amputations. By leveraging brain-machine interface alternative technology, participants can use brain signals to control external devices (such as moving cursors, wheelchairs, robotic arms, WeChat Mini Programs, and other physical assistive devices), thereby improving their motor function and quality of life.","ExperimentalDrugs":"[\"device: implant\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":15,"Phase":"NA","lastUpdateDate":"2025-04-17"},{"nctId":"NCT06289985","OrgName":"Medical University of South Carolina","Titlefull":"STEP: StrokeNet Thrombectomy Endovascular Platform","BriefSummary":"STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO).","ExperimentalDrugs":"[]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"NA","lastUpdateDate":"2025-12-03"},{"nctId":"NCT07237308","OrgName":"Yonsei University","Titlefull":"A Multicenter Prospective Randomized Study to Evaluate the Efficacy of Apixaban and Clopidogrel on the Prevention of Recurrent Ischemic Stroke in Patients With Atrial Fibrillation and Cerebral Atherosclerosis","BriefSummary":"This trial aims to compare the safety and efficacy of apixaban alone versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation and concomitant symptomatic intracranial or extracranial atherosclerosis. Participants will be randomly assigned in a 1:1 ratio to receive apixaban monotherapy or dual therapy with clopidogrel for 30 days. The primary outcome is the incidence of symptomatic or asymptomatic recurrent ischemic lesions detected on brain MRI (DWI/FLAIR) at 30 ± 5 days after initiation of study medication.","ExperimentalDrugs":"[\"apixaban\",\"clopidogrel\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":11,"Phase":"PHASE4","lastUpdateDate":"2025-11-14"},{"nctId":"NCT07083986","OrgName":"Pirogov Russian National Research Medical University","Titlefull":"Immediate and Long-term Results of Carotid Endarterectomy and Stenting in the Acute Stage of Ischemic Stroke","BriefSummary":"The objective of this clinical trial is to compare immediate and long-term results of carotid endarterectomy and carotid stenting in acute period of ischemic stroke. Patients who presented with acute stage of ischemic stroke will be treated by carotid artery stenting in 50 cases and by carotid endarterectomy in 50 cases under regional anesthesia.\n\nPatient inclusion criteria:\n\n1. Ischemic stroke in the middle cerebral artery territory\n2. Ipsilateral stenosis of the internal carotid artery more than 50%\n3. Neurological deficit at the time of surgical treatment: the modified Rankin scale (mRs) score of 0-4 and the US National Institutes of Health (NIHSS) stroke scale score no more than 12\n4. The size of the ischemia focus: no more than 1/3 in the territory of the middle cerebral artery brain supply\n5. Terms of operation: from 1 to 28 days from the moment of ischemic stroke\n\nThe primary intra-hospital and/or 30-day study endpoints:\n\n1. Perioperative ipsilateral ischemic stroke.\n2. Any stroke: contralateral ischemic or any hemorrhagic stroke.\n3. Myocardial infarction.\n4. Hemorrhagic complications that required surgical revision of the operating wound or transfusion of blood components.\n5. Surgical site infection\n6. Death\n7. Main adverse cardiovascular events (stroke + myocardial infarction + death).","ExperimentalDrugs":"[\"procedure: carotid artery stent placement\",\"procedure: carotid endarterectomy\"]","Allcountries":"[\"Russia\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"ENROLLING_BY_INVITATION","Add_on":"Other","Endpoint":"Safety","total_Score":18,"Phase":"NA","lastUpdateDate":"2025-07-17"},{"nctId":"NCT07173062","OrgName":"Universidade do Porto","Titlefull":"Algae Effects in Markers of Cardiovascular Risk and Gut Microbiome: a Placebo-controlled Randomized Double-blind Trial","BriefSummary":"The Western diet, rich in fat and sugar, contributes to cardiovascular risk and alters the body metabolism, specifically through the modulation of the microbiome. Microbiome is considered the \"second genome\", functioning as an endocrine-like organ. Gut microbiota-derived metabolites, namely trimethylamine- N-oxide and short-chain fatty acids have been associated with atherosclerosis, vascular and cardiac diseases. Regarding trimethylamine- N-oxide, its association with cardiovascular disease is positive and dose-dependent. In contrast, short-chain fatty acids have been positively associated with the improvement of cardiovascular health.\n\nAlgae probiotics can modulate gut microbiome, stimulating the growth of commensal micro-organisms with health benefits. Previous studies suggested that Spirulina Arthrospira platensis supplementation could improve blood lipid levels and lower blood pressure, revealing anti-inflammatory and antioxidant roles. Other probiotics that could be beneficial to gut microbiota are macroalgae or seaweed. Macroalgae are a rich source of components which may prompt bacterial diversity and abundance.\n\nThe present prospective, randomized, three-armed parallel trial aims to generate good-quality evidence about the potential health effects and impact of Spirulina Arthrospira platensis (microalgae) and Gelidium corneum (macroalgae) supplements in humans. These participants will undergo 3 clinical evaluations: 2 before the beginning of micro- and macro-algae supplementation and the last one after 20 weeks of supplementation. The evaluation includes a vascular, nutritional and physical activity assessment, as well as blood, urine, saliva and stool collection for quantification of plasma biomarkers, oral and gut microbiota analysis, respectively.","ExperimentalDrugs":"[\"dietary supplement: spirulina arthrospira platensis (microalgae)\",\"dietary supplement: gelidium corneum\"]","Allcountries":"[\"Portugal\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":7,"Phase":"NA","lastUpdateDate":"2025-09-12"},{"nctId":"NCT07083362","OrgName":"Beijing Suncadia Pharmaceuticals Co., Ltd","Titlefull":"Safety, Tolerability and Pharmacokinetic Studies of Single and Multiple Administrations of HRS-8829 in Healthy Subjects","BriefSummary":"This study adopted a single-center, randomized, double-blind, placebo-controlled, dose-escalation design and was divided into three parts: single-dose dose-escalation (SAD) 、 multiple-dose dose-escalation (MAD)、drug-drug interaction（DDI）","ExperimentalDrugs":"[\"hrs-8829;placebo\",\"hrs-8829;edaravone injection\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"COMPLETED","Add_on":"Other","Endpoint":"Safety","total_Score":17,"Phase":"PHASE1","lastUpdateDate":"2026-04-23"},{"nctId":"NCT07266662","OrgName":"Lahore University of Biological and Applied Sciences","Titlefull":"Comparative Effects of Sensory Augmentation and Neuromodulation on Enhancing Motor Recovery Among Stroke Survivors","BriefSummary":"This study aims to evaluate the effectiveness of two rehabilitation techniques-Sensory Augmentation (using mirror therapy) and Neuromodulation (using transcranial direct current stimulation, tDCS)-in improving motor recovery among stroke survivors. Stroke often results in long-term impairments, particularly in upper limb motor function, which is critical for daily activities. Although current rehabilitation strategies help, more effective solutions are needed to enhance recovery. Participants, aged 45-65 with chronic stroke and upper extremity impairments, will be randomized into three groups: Group 1 will receive a combination of sensory augmentation (mirror therapy) and neuromodulation (tDCS) with routine physical therapy; Group 2 will receive sensory augmentation (mirror therapy) with routine physical therapy; and Group 3 will receive neuromodulation (tDCS) with routine physical therapy. The interventions will take place four times a week for 8 weeks, and participants will undergo motor function assessments, including the Fugl-Meyer Assessment and Jebsen-Taylor Test, before and after the intervention. The study will compare the effects of each intervention on motor recovery, specifically focusing on upper limb function and motor control. The findings could lead to improved rehabilitation protocols, offering stroke survivors better therapeutic options and enhancing their quality of life.","ExperimentalDrugs":"[\"other: combination of sensory augmentation and neuromodulation\",\"other: sensory augmentation\",\"other: neuromodulation\"]","Allcountries":"[\"Pakistan\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":14,"Phase":"NA","lastUpdateDate":"2025-12-16"},{"nctId":"NCT06040476","OrgName":"StemCyte International, Ltd.","Titlefull":"A Phase II, Randomized, Double-blind, Parallel, Placebo-controlled Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke","BriefSummary":"A Phase II, Randomized, Double-blind, Parallel, Placebo-controlled Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke","ExperimentalDrugs":"[\"biological: hucb\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":23,"Phase":"PHASE2","lastUpdateDate":"2025-02-25"},{"nctId":"NCT06212674","OrgName":"Medical University of Silesia","Titlefull":"Single-stage Pulmonary Vein Isolation Combined With Percutaneous Left Atrial Appendage Occluder Implantation in Patients With Recent Onset Ischemic Stroke and Atrial Fibrillation (PILOS-AF)","BriefSummary":"The project is a multicenter, open-label, randomized medical experiment, which was designed to evaluate the efficacy and safety of single-stage pulmonary vein isolation (PVI) and implantation of left atrial appendage occluder (LAAO) in comparison with either isolated LAAO implantation or chronic therapy with non-vitamin K antagonists anticoagulants (NOAC) in patients with recent-onset ischemic stroke and atrial fibrillation (AF). Based on former randomized controlled trials, percutaneous implantation of LAAO was shown to be non-inferior to vitamin K antagonists (VKA), but according to guidelines the use of LAAO is recommended only in patients with absolute contraindication to chronic anticoagulation therapy. PVI constitutes an acknowledged rhythm control management strategy in patients with paroxysmal and persistent AF, which leads to symptomatic relief in about 60% of treated patients, however, its beneficial effect on long-term outcome was demonstrated only in patients with heart failure with reduced ejection fraction. The feasibility and compatibility of both interventions performed as a combined single-stage procedure are warranted by common vascular access via transseptal puncture, which may lead to reduction of procedural cost and shortened overall duration of both interventions. Taking into consideration the preliminary registry data, the combined single-stage PVI and LAAO implantation are thought to be a safe procedure in patients with a high risk of recurrent ischemic stroke and cardiovascular death.\n\nThe study will comprise 240 patients who were diagnosed with ischemic stroke within preceding 2-12 weeks, with confirmed paroxysmal or persistent AF and low-to-moderate psychomotor dysfunction in the course of cerebral incident, who completed early neurological rehabilitation and are characterized by high risk of ischemic stroke recurrence (CHA2DS2-VA score ≥2 pts) and who received adequate oral anticoagulation therapy (NOAC/VKA) for ≥4 weeks. After exclusion of thrombus and potential anatomical contraindications to the procedure on transesophageal echocardiography, patients will be randomized in 1:1:1 ratio to study group A treated with combined single-stage PVI + LAAO implantation during 3-day hospitalization or to group B treated with LAAO implantation or control group subject to chronic therapy with NOAC.\n\nPatients in Group A and B will be treated with NOAC until 3 months after procedure. At 3-month visit patients in Group A and B will undergo transesophageal echocardiography so as to confirm procedural success and allow for termination of chronic anticoagulation therapy. If device-related thrombus is excluded and not peri-device leak \\>=5 mm is present, the patients will be switched from NOAC to aspirin 1x75 mg daily until the end of the trial.\n\nThe duration of active enrollment phase will be 12 months. Subsequent follow-up phase will include scheduled outpatient visits (at 3, 12, 48 months) and phone call interview (at 6, 18, 24, 36 months) in order to evaluate the occurrence of clinical and safety endpoints, medical symptoms and signs, quality of life reflected by structured questionnaire, the presence of AF on 24, 7-day or 30-day ECG monitoring (at 12 and 48 months).\n\nFollow-up visits will also include blood laboratory tests analysis, including biomarkers of heart failure and left atrial wall stress, as well as transthoracic echocardiography with tissue Doppler imaging and strain imaging.\n\nCo-primary composite endpoint will comprise cardiovascular death, ischemic stroke, transient ischemic attack, systemic arterial embolism and major non-procedural bleeding, including intracranial bleeding (non-inferiority).\n\nThe current project was based on the preliminary results of nonrandomized studies, which delivered evidence for feasibility of combined single-stage PVI and percutaneous left atrial appendage closure and laid ground for future randomized controlled trials. It is expected that the proposed intervention will be non-inferior in terms of composite cerebrovascular events and superior in terms of major nonprocedural bleeding in comparison to chronic NOAC therapy.","ExperimentalDrugs":"[\"procedure: pvi + laao, single stage\",\"procedure: laao\",\"noac\"]","Allcountries":"[\"Poland\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Late efficacy","total_Score":17,"Phase":"PHASE4","lastUpdateDate":"2026-04-07"},{"nctId":"NCT06780891","OrgName":"University of Cadiz","Titlefull":"Telephysical Therapy as a Secondary Stroke Prevention Tool","BriefSummary":"This study investigates the effectiveness of telephysiotherapy as a rehabilitation and secondary prevention tool in patients with minor stroke, TIA, or LACI, comparing an experimental group receiving tele-assisted aerobic and anaerobic exercises to a control group.","ExperimentalDrugs":"[\"behavioral: telephysical therapy\",\"behavioral: educational session\"]","Allcountries":"[\"Spain\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-05-25"},{"nctId":"NCT07113041","OrgName":"Kessler Foundation","Titlefull":"Neuromodulation-Enhanced Use of RObotic BALANCE Training to Improve Balance Function in Individuals With Stroke","BriefSummary":"Our proposed study, \"NEUROBALANCE Stroke,\"; aims to evaluate the effectiveness of a combined intervention involving robotic balance training and noninvasive brain stimulation in improving balance function and postural control in individuals with chronic stroke. The study will recruit 45 participants who have had a stroke at least 6 months before enrolment and experience persistent balance and gait deficits. Participants will be randomized into three groups: (1) robotic balance training with active brain stimulation, (2) robotic balance training with sham brain stimulation, and (3) standard-of-care rehabilitation.\n\nThe study will involve 15 training sessions over 5 weeks, with assessments conducted at baseline, post-training, and two months post-training to evaluate balance recovery and retention. The primary focus is understanding how this intervention affects brain and muscle activity during balance tasks and how these changes translate into functional improvements in clinical outcome measures of balance function. Additionally, participant feedback on brain stimulation and exercise engagement will be collected to inform future studies.\n\nThe findings may guide the development of personalized training protocols and contribute to broader rehabilitation strategies.","ExperimentalDrugs":"[\"device: combined (robotic balance training and high-definition transcranial direct current stimulation)\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":14,"Phase":"NA","lastUpdateDate":"2025-08-01"},{"nctId":"NCT06801054","OrgName":"Memorial Hermann Health System","Titlefull":"Safety Of A Second Dose Of Tenecteplase In Selected Acute Ischemic Stroke Patients Not Responding To The First Dose","BriefSummary":"In this pilot safety study, the investigators will give a second dose of Intravenous Tenecteplase (IV TNK) to patients receiving the initial TNK dose within 3 hrs of last known normal (LKN), have a baseline National Institutes of Health Stroke Scale (NIHSS) \\> 6, and who do not clinically improve within 45 minutes of the first dose, or who improve but then deteriorate, and can still be treated within 4.5 hours from LKN. Patients will require a second computed tomography (CT) scan to rule out any bleeding, and meet the usual inclusion and exclusion criteria for TNK treatment, before the second dose which must be given within 4.5 hrs of LKN. Both TNK doses will be 0.25 mg/kg. The initial TNK dose may be given on the Mobile Stroke Unit (MSU) or Emergency Department (ED), and the second dose in the ED. Informed consent will be obtained before the second dose is given.\n\nThe primary outcome will be symptomatic intracranial hemorrhage (sICH) (SITS-MOST criteria) or serious systemic bleeding within 36 hours. Secondary outcomes will be any intracranial hemorrhage, any bleeding, discharge NIHSS and modified Rankin Score (mRS), and mRS at 90 days (sliding dichotomy).\n\n20 patients will be enrolled. Enrollment will be stopped if more than 3 sICH occur (\\> 80% confidence that sICH rate is \\> 5%. If successful, this study will be followed by a larger phase 2b controlled safety confirmation and pilot efficacy study,","ExperimentalDrugs":"[\"tenecteplase (tnk) (0.25 mg/kg, to maximum of 25mg)\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Day 1 only","Status":"NOT_YET_RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"Safety","total_Score":24,"Phase":"PHASE1","lastUpdateDate":"2025-06-03"},{"nctId":"NCT07151430","OrgName":"Xuanwu Hospital, Beijing","Titlefull":"Development and Validation of a Comprehensive Management Service Package for Older Adults With Multimorbidity: A Randomized Controlled Trial","BriefSummary":"This study aims to test a new comprehensive management service package for older adults with two or more chronic conditions (multimorbidity). The package includes digital health tools, personalized guidance, and long-term management support. Researchers will compare the service package with usual care to see whether it reduces hospital readmissions, improves quality of life, and supports daily functioning. About 394 participants will be randomly assigned to either the service package group or the usual care group. Participants will be followed for 6 months to measure health outcomes, treatment adherence, and safety.","ExperimentalDrugs":"[\"device: service package group\"]","Allcountries":"[]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":7,"Phase":"NA","lastUpdateDate":"2025-08-28"},{"nctId":"NCT06857487","OrgName":"Dongzhimen Hospital, Beijing","Titlefull":"Efficacy and Safety of Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Patients With Acute Ischemic Stroke : A Randomized Double-blind Placebo-controlled Pilot Trial","BriefSummary":"The purpose of this study is to assess the effectiveness and safety of Qingre Huatan formula versus placebo on preventing early neurological deterioration in patients with acute ischemic stroke within 48 hours after onset.","ExperimentalDrugs":"[\"qingre huatan formula\",\"other: guidelines-based standard care\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Early efficacy","total_Score":20,"Phase":"PHASE1","lastUpdateDate":"2025-11-24"},{"nctId":"NCT06709898","OrgName":"Finnish Institute of Occupational Health","Titlefull":"Stroke in Working Age and Job Accommodation in Facilitating Transition Back to Work","BriefSummary":"The aim of this randomized controlled trial (RCT) is to investigate whether cognitive job accommodation intervention enhances return to work, work ability and performance after ischemic stroke in working-age population. The main questions are:\n\n* Does the cognitive job accommodation intervention affect absenteeism and presenteeism after stroke?\n* Does the intervention affect work ability and perceived cognitive and emotional difficulties at work?\n* Does the intervention decrease mental strain, fatigue and negative mood symptoms after return to work?\n* Does the intervention affect life satisfaction among the stroke patients returning to work?\n\nResearchers will compare the intervention group to a control group returning to work after stroke with current healthcare practices and work procedures.\n\nParticipants:\n\n* At baseline, 6 and 12 month follow-up web-based questionnaires and cognitive tests are administered.\n* At 3 month follow-up participants fill in Brain Work Questionnaire (BWQ) that measures cognitive demands and difficulties at work.","ExperimentalDrugs":"[\"other: cognitive job accommodation\"]","Allcountries":"[\"Finland\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":6,"Phase":"NA","lastUpdateDate":"2025-03-11"},{"nctId":"NCT07252544","OrgName":"Beijing Tiantan Hospital","Titlefull":"Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke: a 2×2 Factorial Randomized Controlled Trial (IMPACT)","BriefSummary":"The goal of this multicenter, double-blind, 2×2 factorial randomized controlled trial is to evaluate the efficacy and safety of isosorbide mononitrate, butylphthalide, and their combination in reducing disability in patients with acute lacunar stroke.","ExperimentalDrugs":"[\"isosorbide mononitrate\",\"butylphthalide\",\"butylphthalide placebo\",\"isosorbide mononitrate placebo\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":15,"Phase":"PHASE3","lastUpdateDate":"2025-11-24"},{"nctId":"NCT07197606","OrgName":"Shanghai IxCell Biotechnology Co., LTD","Titlefull":"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of IxCell hUC-MSC-S in Patients With Ischemic Stroke in the Recovery Phase","BriefSummary":"The goal of this clinical trial is to evaluate the efficacy, safety, and pharmacodynamic characteristics of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in adults with ischemic stroke in the anterior circulation during the recovery phase. Researchers will compare hUC-MSCs to a placebo to determine whether hUC-MSCs treatment is effective in treating recovery-phase anterior circulation ischemic stroke.","ExperimentalDrugs":"[\"ixcell huc-msc-s (human umbilical cord mesenchymal stem cells)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":21,"Phase":"PHASE2","lastUpdateDate":"2025-09-22"},{"nctId":"NCT07111806","OrgName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","Titlefull":"Intravenous Tirofiban Versus Placebo After Delayed Thrombolysis (4.5-24h) in Acute Ischemic Stroke (PEARL-TIRO): A Multicenter, Double-Blind, Double-Dummy, Randomized Controlled Trial","BriefSummary":"A multicenter, double-blind, double-dummy, randomized trial evaluating the efficacy and safety of intravenous tirofiban in acute ischemic stroke (AIS) patients without large/medium vessel occlusion, who presented 4.5-24 hours after onset and received intravenous thrombolysis (IVT).","ExperimentalDrugs":"[\"tirofiban\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT mandatory; EVT optional","Endpoint":"mRS at 90 days","total_Score":22,"Phase":"PHASE3","lastUpdateDate":"2025-08-01"},{"nctId":"NCT07243314","OrgName":"King Saud University","Titlefull":"Evaluating Functional Outcomes of 3D-Printed Splints in Post-Stroke Upper Limb Recovery","BriefSummary":"This study aims to evaluate the upper limb motor recovery using a 3D-printed dynamic orthosis compared to a conventional one as part of a rehabilitation program in individuals with chronic stroke.\n\nThe main question it seeks to answer:\n\nWhich type of dynamic splint (3D-printed or traditional), combined with the task-oriented therapy program, leads to greater improvement in affected upper-limb function, patient satisfaction, and usability in stroke patients? Researchers will compare these two types of dynamic splints.\n\nParticipants will:\n\nReceive 20 sessions of task-oriented therapy combined with either a 3D-printed dynamic splint or a traditional dynamic splint.\n\nVisit the clinic five times a week for a period of four weeks. Undergo assessments before and after the 4-week program.","ExperimentalDrugs":"[\"device: 3d printed splint\",\"device: conventional splint\"]","Allcountries":"[\"Saudi Arabia\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2025-11-17"},{"nctId":"NCT07203521","OrgName":"Fuzhou Neurodawn Rongkang Pharmaceutical Co., Ltd","Titlefull":"An Open-label, Blinded Phase II Study Investigating the Treatment of Acute Large Hemispheric Infarction by Transcranial Bone Marrow Injection of RK-4 Injection","BriefSummary":"An open-label, blinded phase II study investigating the treatment of acute large hemispheric infarction by transcranial bone marrow injection of RK-4 injection For subjects with acute large hemispheric infarction who are contraindicated to vascular recanalization or have poor response to vascular recanalization therapy, the safety, tolerability, and PK characteristics of RK-4 injection injected into the brain cell marrow through the cranial bone marrow will be preliminarily evaluated, and the efficacy will be preliminarily explored. The main questions it aims to answer are:\n\n* The efficacy of RK-4 injection injected into the brain cell marrow through the cranial bone marrow.\n* If drug RK-4 is safe and tolerate in the patients with LHI? Researchers will analyze data from different groups, includes cranial administration group and conventional treatment group , to see efficacy of RK-4 injection injected into the brain cell marrow through the cranial bone marrow and If drug RK-4 is safe and tolerate in the patients with LHI .\n\nParticipants will:\n\n* Take drug RK-4 (2mg/mL, 1mL) by transcranial bone marrow injection once daily for consecutive 3 days or just receive conventional treatments.\n* Truthfully provide medical history and \"previous participation in clinical trials\" and a statement of no history of mental disorders.\n* Take the drug at the specified time every day according to the dosage prescribed by the doctor\n* Receive the investigational drug as instructed by the doctor and visiting as required\n* Tell the investigators about any medications (including chemicals, biological drugs, proprietary Chinese medicines, etc.) and related treatments you take during the study\n* unpermitted stop the investigational drug yourself at the end of the study or when you decide to withdraw from the study, you need to stop the investigational drug as directed by your doctor to ensure your safety\n* take reasonable contraception actions\n* unallowed to use unmarketed drugs or other clinical trial drugs during the study","ExperimentalDrugs":"[\"rk-4 injection\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"3 days or less","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"PHASE2","lastUpdateDate":"2025-09-24"},{"nctId":"NCT06819657","OrgName":"Beijing Tiantan Hospital","Titlefull":"Remote Ischemic Conditioning for Safety, Feasibility, and Preliminary Efficacy in Patients With Aneurysmal Subarachnoid Hemorrhage After Aneurysm Clipping: An Open-Label, Evaluator-Blinded Randomized Controlled Trial","BriefSummary":"This study was designed to evaluate the safety and efficacy of remote ischemic conditioning (RIC) in patients with aneurysmal subarachnoid hemorrhage (aSAH) following surgical clipping.\n\nAneurysmal subarachnoid hemorrhage is a life-threatening condition that occurs when a cerebral aneurysm ruptures, causing bleeding into the subarachnoid space. Surgical clipping of the aneurysm is a standard procedure used to stop the bleeding and prevent re-rupture, thereby stabilizing the patient's condition.\n\nRemote ischemic conditioning (RIC) is a non-invasive treatment that involves using a blood pressure cuff to induce brief, temporary cycles of ischemia and reperfusion in a limb. Research suggests that this process may confer systemic protective effects, potentially improving recovery from brain injury or surgery. Although RIC has shown potential to improve outcomes in patients with other neurological conditions, its effect on patients with aSAH who undergo surgical clipping remains unclear.\n\nThis study will evaluate whether RIC can reduce complications, improve neurological function, and enhance overall recovery in these patients. The findings will help determine whether RIC should be incorporated into the standard treatment regimen for aSAH.","ExperimentalDrugs":"[\"device: remote ischemic conditioning treatment instrument\",\"other: guideline-based therapy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":15,"Phase":"NA","lastUpdateDate":"2025-09-08"},{"nctId":"NCT06767657","OrgName":"Italian Society of Vascular and Endovascular Surgery","Titlefull":"Multicenter, Open-label Randomized Study Comparing Urgent Carotid Endarterectomy (CEA) (Within 72 Hours) Versus Delayed CEA (After 72 Hours) in Patients With Symptomatic Carotid Stenosis (SPREAD-STACI II)","BriefSummary":"In patients with internal carotid artery (ICA) stenosis of 50% or greater (measured according to the criteria of the North American Symptomatic Carotid Endarterectomy Trial (NASCET)) who have experienced a transient ischemic attack (TIA) or minor ipsilateral stroke, carotid endarterectomy (CEA) offers maximum benefit if performed within 15 days of the initial ischemic symptom. National and international guidelines recommend surgical treatment (CEA) within this timeframe; however, no studies have specifically evaluated the optimal timing for CEA after a TIA or minor stroke.\n\nIt is well established that the risk of a major stroke is highest in the first few days following a transient ischemic attack or minor stroke and then decreases over the subsequent days and weeks.\n\nThis raises the hypothesis that performing an urgent carotid endarterectomy (within 3 days) may provide greater benefit compared to a delayed procedure (between 4 and 15 days).","ExperimentalDrugs":"[\"procedure: cea (carotid endarterectomy)\"]","Allcountries":"[\"Italy\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Late efficacy","total_Score":25,"Phase":"NA","lastUpdateDate":"2026-03-02"},{"nctId":"NCT07145294","OrgName":"Shanghai 6th People's Hospital","Titlefull":"Induced Pluripotent Stem Cells-derived Small Extracellular Vesicles May Promote Neurological Function and Improve Cognitive Impairment in Acute Ischemic Stroke Patients","BriefSummary":"This study primarily evaluates whether iEV nasal administration can improve neurological impairment and cognitive dysfunction in patients with acute cerebral infarction and cognitive impairment, and preliminarily explores its clinical efficacy.","ExperimentalDrugs":"[\"biological: iev\",\"other: basic treatments\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":18,"Phase":"PHASE1","lastUpdateDate":"2025-08-20"},{"nctId":"NCT06447701","OrgName":"Zhujiang Hospital","Titlefull":"Effect of Interleukin-6 Receptor Inhibition for Avoiding Recurrence of Ischemic Stroke in Patients With Symptomatic Intracranial Atherosclerosis: a Double-blind, Randomized, Placebo-controlled Trial","BriefSummary":"IRIS-sICAS is a multicenter, randomized, double-blind, placebo-controlled clinical trialis a multicenter, randomized, double-blind, placebo-controlled clinical trial, to assess the safety and efficacy of tocilizumab injection in lowering the incidence of newly diagnosis ischemic stroke and improving prognosis in symptomatic intracranial atherosclerosis patients.","ExperimentalDrugs":"[\"tocilizumab\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Late efficacy","total_Score":26,"Phase":"PHASE3","lastUpdateDate":"2025-07-24"},{"nctId":"NCT06791551","OrgName":"China National Center for Cardiovascular Diseases","Titlefull":"Non-pharmacologial, Non-invassive Intervention Before Cardiac Surgry: a Randomized Controlled Trial","BriefSummary":"Perioperative neurological complications in cardiovascular surgical procedures are associated with a significant risk of mortality and disability. The goal of this clinical trial is to learn if ischemic preconditioning and transcranial electrical stimulation to reduce perioperative neurological complications. It will also learn about the safety of remote ischemic preconditioning and transcranial electrical stimulation before cardiac surgery. The main questions it aims to answer are \"Do remote ischemic preconditioning and transcranial electrical stimulation make good effect on perioperative neurological complications?\" \"Are remote ischemic preconditioning and transcranial electrical stimulation safe?\" Researchers will compare remote ischemic preconditioning and transcranial electrical stimulation to traditional treatment to see if remote ischemic preconditioning and transcranial electrical stimulation work to reduce perioperative neurological complications.\n\nParticipants will:Undergo remote ischemic preconditioning and transcranial electrical stimulation or sham treatment twice every day for 3 days before surgery.\n\nUndertake psychological assessment and clinical symptom follow-up after cardiac surgery.","ExperimentalDrugs":"[]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"3 days or less","Status":"RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-06-04"},{"nctId":"NCT06941961","OrgName":"The First Hospital of Jilin University","Titlefull":"Efficacy and Safety of Intermittent Theta Burst Stimulation in Acute Anterior Circulation Ischemic Stroke Patients Undergoing Mechanical Thrombectomy","BriefSummary":"The goal of this randomized, single-blind, parallel-controlled clinical trial is to evaluate the efficacy and safety of intermittent theta burst stimulation (iTBS) as an adjunctive therapy for acute anterior circulation ischemic stroke patients who have undergone successful mechanical thrombectomy (MT). The study population includes adults aged 18-85 with NIHSS scores 5-25 post-MT and eTICI≥2b reperfusion.","ExperimentalDrugs":"[\"device: intermittent theta burst stimulation\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"NA","lastUpdateDate":"2025-04-28"},{"nctId":"NCT07003386","OrgName":"Shanghai Yueyang Integrated Medicine Hospital","Titlefull":"Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke Based on the Neurovascular Unit","BriefSummary":"Although mechanical thrombectomy or thrombolytic therapy for large vessels can achieve a revascularization rate (TICI ≥2b) of over 90%, 30-50% of patients still exhibit poor functional outcomes. This phenomenon of \"ineffective reperfusion\" suggests that microcirculatory dysfunction plays a decisive role in post-stroke neural injury. Therefore, it is necessary to combine brain protection strategies with microcirculatory reperfusion therapy to improve the functional prognosis of stroke patients.Increasing cerebral blood flow (CBF) and neurovascular unit (NVU)-based cerebral protection are current hotspots in the emergency treatment of stroke.\n\nGalantamine, extracted from Lycoris aurea (a traditional Chinese medicinal herb), is an acetylcholinesterase inhibitor (AChEI) that has been widely recognized for improving cerebral blood flow and modulating inflammatory responses in ischemic stroke (IS).\n\nTherefore, the applicant will conduct an internationally compliant, randomized controlled clinical study with routine treatment to evaluate the efficacy of galantamine in the treatment of acute cerebral infarction. This project will conduct a comprehensive assessment of the drug's efficacy from multiple aspects, including improvements in stroke-related outcomes, Traditional Chinese Medicine (TCM) syndrome manifestations, cognitive function, cerebral blood flow, and inflammatory factors.","ExperimentalDrugs":"[\"galantamine\",\"standard treatment for acute ischemic stroke\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"NIHSS","total_Score":17,"Phase":"PHASE2","lastUpdateDate":"2025-09-15"},{"nctId":"NCT07294391","OrgName":"Tianjin Huanhu Hospital","Titlefull":"The Preliminary Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke：Dual-Center, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial","BriefSummary":"Albumin-assisted therapy has demonstrated good safety and potential neuroprotective effects following mechanical thrombectomy. To further systematically evaluate its efficacy and safety, we are conducting a Phase IIa clinical trial of intra-arterial albumin administration combined with mechanical thrombectomy in patients with acute ischemic stroke. This is a double-center, prospective, open-label, endpoint-blinded, randomized controlled trial designed to preliminarily assess the efficacy and safety of intra-arterial infusion of 20% human albumin after successful recanalization in patients with acute ischemic stroke caused by anterior circulation large-vessel occlusion who undergo mechanical thrombectomy. A total of 60 patients will be enrolled and randomized in a 1:1 ratio by dynamic minimization into two groups: the albumin group (0.6 g/kg of 20% human albumin solution plus mechanical thrombectomy) and the control group (mechanical thrombectomy alone).\n\nThe primary objective of this study is to preliminarily evaluate whether intra-arterial infusion of 0.6 g/kg of 20% human albumin via the internal carotid artery immediately after achieving successful recanalization (eTICI ≥ 2b) can reduce infarct volume compared with mechanical thrombectomy alone in patients with anterior circulation large-vessel occlusion who undergo standard mechanical thrombectomy. The secondary objective is to assess the safety and feasibility of intra-arterial infusion of 0.6 g/kg of 20% human albumin immediately after successful recanalization in this patient population.","ExperimentalDrugs":"[\"human serum albumin infusion 20%\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":28,"Phase":"PHASE2","lastUpdateDate":"2025-12-07"},{"nctId":"NCT07271082","OrgName":"Capital Medical University","Titlefull":"Efficacy and Safety of Home-based Structured Physical Exercise in Patients With Acute Ischemic Stroke: a Randomized Controlled, Open-label, Blinded Endpoint Trial-2 (HOPE-STROKE 2)","BriefSummary":"This study is a randomized controlled, open-label, blinded endpoint trial. The investigators aim to assess the efficacy and safety of home-based structured physical exercise in participants with acute ischemic stroke.","ExperimentalDrugs":"[\"behavioral: exercise intervention\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"ACTIVE_NOT_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":14,"Phase":"NA","lastUpdateDate":"2026-05-16"},{"nctId":"NCT06029491","OrgName":"RapidPulse, Inc","Titlefull":"The Pivotal Study of RapidPulseTM Aspiration System as Frontline Approach for Patient With Acute Ischemic Stroke Due to Large Vessel Occlusions","BriefSummary":"The goal of this clinical trials is to demonstrate the safety and effectiveness for the RapidPulseTM Aspiration System in patients experiencing acute ischemic stroke within 8 hours of symptom onset or last seen normal. Subjects will undergo mechanical thrombectomy (a procedure to remove a clot in the brain which is preventing blood flow), with the RapidPulseTM Aspiration System. Participation in the trial is for 90 days.","ExperimentalDrugs":"[\"device: rapidpulsetm aspiration system\"]","Allcountries":"[\"France\",\"Spain\",\"Turkey (Türkiye)\",\"United States\"]","FirstAdminInter":"Within 12 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":28,"Phase":"NA","lastUpdateDate":"2025-12-19"},{"nctId":"NCT05293080","OrgName":"Universitätsklinikum Hamburg-Eppendorf","Titlefull":"Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE","BriefSummary":"This study will determine whether early, comprehensive, rhythm control therapy prevents adverse cardiovascular outcome in patients with acute ischemic stroke and atrial fibrillation compared to usual care.","ExperimentalDrugs":"[\"other: medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version)\",\"other: usual care for atrial fibrillation\"]","Allcountries":"[\"Germany\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":16,"Phase":"PHASE3","lastUpdateDate":"2026-05-14"},{"nctId":"NCT06823128","OrgName":"The First Affiliated Hospital of University of Science and Technology of China","Titlefull":"Safety and Efficacy of Remote Ischemic Conditioning in Patients With Severe Stenosis or Occlusion of Anterior Intracranial Circulation Vessels","BriefSummary":"The primary purpose of this study is to examine whether remote ischemic treatment can better the 90 - day neurological outcomes in acute ischemic stroke patients having severe stenosis or occlusion of anterior intracranial circulation vessels.","ExperimentalDrugs":"[\"device: ric\",\"other: guideline-based therapy\",\"device: sham\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"TERMINATED","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-06-08"},{"nctId":"NCT06757764","OrgName":"Asan Medical Center","Titlefull":"The Effect and Safety of Therapy Adding Cilostazol in Acute Ischemic Stroke Due to Large Artery Atherosclerosis: CHANGE Trial","BriefSummary":"Currently, aspirin plus clopidogrel is considered as a standard acute treatment of ischemic stroke, based on results of CHANCE and POINT trial. However, still a considerable portion of patients showed early stroke recurrence, especially in those with stroke due to large artery atherosclerosis. Cilostazol may have benefit in reducing early stroke recurrence of neurologic deterioriation. The post-hoc analysis of CSPS.com showed that use of cilostazol after 15 days of stroke was effective for preventing subsequent stroke. The effect of adding cilostazol was more effective in those with large artery atherosclerosis and those receiving clopidogrel than aspirin.","ExperimentalDrugs":"[\"aspirin\",\"clopidogrel\",\"cilostazol\"]","Allcountries":"[\"South Korea\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":15,"Phase":"PHASE4","lastUpdateDate":"2026-03-25"},{"nctId":"NCT06943586","OrgName":"University of Alabama at Birmingham","Titlefull":"Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing in Patients With Minor Stroke or High Risk TIA (CYP2C19 and Stroke)","BriefSummary":"The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.","ExperimentalDrugs":"[\"genetic: cyp2c19 genotype guided dapt (dual antiplatelet therapy)\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Other","total_Score":9,"Phase":"NA","lastUpdateDate":"2026-04-20"},{"nctId":"NCT06813651","OrgName":"ThromBio Pty. Ltd.","Titlefull":"Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem Occlusion","BriefSummary":"Co-STAR is a multicenter, prospective, open-label, Bayesian Optimal Phase 2 (BOP2) trial that aims to assess the safety and efficacy of adjunctive intravenous TBO-309 in Acute Ischaemic Stroke (AIS) patients with tandem occlusion receiving intra-cranial endovascular thrombectomy (EVT) and acute extracranial carotid artery stenting.\n\nCo-STARS study will test the hypothesis that patients with tandem occlusion treated with EVT and acute stenting in conjunction with TBO-309 will:\n\n* have persistent stent patency without requiring rescue therapy with GPIIb/IIIa inhibitors and\n* not experience high rates of symptomatic intra-cranial haemorrhage (sICH).\n\nPatients with tandem occlusion undergoing EVT and acute stenting will receive intravenous TBO-309 bolus and infusion. TBO-309 is a potent, selective and ATP competitive PI3K\\[beta\\] inhibitor which reduces platelet activation adhesion/aggregation particularly under conditions of disturbed blood flow and promotes platelet disaggregation. By targeting PI3K\\[beta\\], TBO-309 specifically inhibits thrombosis whilst minimizing the impact on normal hemostasis.","ExperimentalDrugs":"[\"tbo-309: 60 mg\",\"tbo-309: 120 mg\",\"tbo-309: 30 mg\"]","Allcountries":"[\"Australia\"]","FirstAdminInter":"Other","TreatDur":"Day 1 only","Status":"RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":23,"Phase":"PHASE2","lastUpdateDate":"2025-11-19"},{"nctId":"NCT07098572","OrgName":"MED-EL Elektromedizinische Geräte GesmbH","Titlefull":"Efficacy of EMG-triggered Four-Channel Functional Electrical Stimulation vs. Cyclic One-Channel Electrical Stimulation on Moderate Arm/Hand Paresis in Subacute Stroke Patients. A Randomized Controlled Single Blinded Multicenter Study","BriefSummary":"This study will compare two treatments that may help participants recover after having suffered from stroke. Persons who experience weakness or paralysis of their arms/hands will be randomly placed in one of two groups. Each receives treatment five times a week for three weeks. One group will be treated with electrostimulation following a cyclic pattern (control treatment), the other group will be treated with electrostimulation triggered by nerve signals (i.e. stimulation starts when they deliberately try to move their arm (investigational treatment). Before and after the three weeks and additionally 12 weeks later, the ability to move the arm and hand will be documented with standardized tests.","ExperimentalDrugs":"[\"device: cyclic single channel neuromuscular stimulation\",\"device: electromyogram-triggered 4 channel neuromuscular stimulation\"]","Allcountries":"[\"Austria\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":18,"Phase":"NA","lastUpdateDate":"2025-08-25"},{"nctId":"NCT07237542","OrgName":"Jinling Hospital, China","Titlefull":"Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction (RIC-END): A Randomised Multicentre Trial","BriefSummary":"This study aims to conduct a prospective, randomized, double-blind, multicenter, parallel-controlled, group-sequential trialto scientifically evaluate the safety and efficacy of remote ischemic preconditioning (RIC) in preventing early neurological deterioration (END) in patients with acute perforating artery infarction (PAI).","ExperimentalDrugs":"[\"device: remote ischemic preconditioning\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Early efficacy","total_Score":18,"Phase":"NA","lastUpdateDate":"2026-01-30"},{"nctId":"NCT06601127","OrgName":"Tianjin Institute of Pharmaceutical Research Co., Ltd","Titlefull":"A Phase 2, Randomised, Double-blind, Positive-controlled, Multicentre Study of Tiprogrel in the Treatment of Patients with Acute Minor Ischaemic Stroke or High-risk Transient Ischaemic Attack.","BriefSummary":"This study is designed to evaluate efficacy and safety of tiprogrel in the treatment of patients with acute ischemic cerebrovascular events.","ExperimentalDrugs":"[\"tiprogrel\",\"clopidogrel\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Other","total_Score":20,"Phase":"PHASE2","lastUpdateDate":"2025-03-05"},{"nctId":"NCT06761183","OrgName":"Beijing Tiantan Hospital","Titlefull":"Safety and Preliminary Efficacy of NXL-001 in Patients with Ischemic Stroke","BriefSummary":"This is a single-arm, open-label, single center, dose-escalation exploratory clinical study to evaluate the safety and tolerability of a single intracerebral injection of NXL-001, a NeuroD1 base gene therapy, in patients with chronic neuronal deficits from ischemic stroke.","ExperimentalDrugs":"[\"genetic: intracerebral stereotactic injection of nxl-001\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":18,"Phase":"EARLY_PHASE1","lastUpdateDate":"2024-12-30"},{"nctId":"NCT06634303","OrgName":"Hybernia Medical","Titlefull":"Hybernia Delta H (ΔH) Brain Cooling System for: Post-Mechanical Endovascular Cerebral Cooling","BriefSummary":"Reducing the temperature of tissue or organs (hypothermia) produces a protective state, through multiple molecular mechanisms, against adverse effects that arise from disrupted organ blood flow, e.g. in acute ischemic stroke (AIS). AIS is often caused by a blood clot that occludes a brain artery which, in turn disrupts brain blood flow. In large vessel occlusions, the current standard includes mechanical thrombectomy (MT), a minimally-invasive procedure that aims at removing the clot via endovascular means. In this case, brain cooling can lead to protection (neuroprotection) not only from the adverse effects of stroke/ischemia itself, but also from complications arising from sudden re-opening of the blocked artery through primary treatment, MT. This potential complication of MT is called reperfusion injury.\n\nIn this first-in-human investigational deivce study, Hybernia Medical's endovascular brain cooling system will be applied in acute ischemic stroke patients undergoing MT. Post-MT, selective brain hypothermia will be induced and maintained over 30 minutes. Endpoints of this study include, clinical safety, device performance/usability, and clinical outcome.","ExperimentalDrugs":"[\"device: brain cooling\"]","Allcountries":"[\"Spain\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"COMPLETED","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":17,"Phase":"NA","lastUpdateDate":"2026-03-14"},{"nctId":"NCT07166380","OrgName":"Neurodawn Pharmaceutical Co., Ltd.","Titlefull":"An Open-label, Blinded Ib/IIa Study Investigating the Treatment of Acute Large Hemispheric Infarction by Transcranial Bone Marrow Injection of RK-4 Injection","BriefSummary":"An open-label, blinded Ib/IIa study investigating the treatment of acute large hemispheric infarction by transcranial bone marrow injection of RK-4 injection\n\nFor subjects with acute large hemispheric infarction who are contraindicated to vascular recanalization or have poor response to vascular recanalization therapy, the safety, tolerability, and PK characteristics of RK-4 injection injected into the brain cell marrow through the cranial bone marrow will be preliminarily evaluated, and the efficacy will be preliminarily explored. The main questions it aims to answer are:\n\n* If drug RK-4 is safe and tolerate in the patients with LHI?\n* What the pharmacokinetic profiles of RK-4 injection injected into the brain cell marrow through the cranial bone marrow?\n* The efficacy of RK-4 injection injected into the brain cell marrow through the cranial bone marrow Researchers will analyze data from different groups, includes low dose group (1mg，QD), medium dose group(2mg，QD), high dose group(4mg，QD), to see If drug RK-4 is safe and tolerate in the patients with LHI and the pharmacokinetic profiles and efficacy of RK-4 injection injected into the brain cell marrow through the cranial bone marrow.\n\nParticipants will:\n\n* Take drug RK-4 (1 mg or 2 mg or 4 mg) by transcranial bone marrow injection once daily for consecutive 3 days.\n* Truthfully provide medical history and \"previous participation in clinical trials\" and a statement of no history of mental disorders.\n* Take the drug at the specified time every day according to the dosage prescribed by the doctor\n* Receive the investigational drug as instructed by the doctor and visiting as required\n* Tell the investigators about any medications (including chemicals, biological drugs, proprietary Chinese medicines, etc.) and related treatments you take during the study\n* unpermitted stop the investigational drug yourself at the end of the study or when you decide to withdraw from the study, you need to stop the investigational drug as directed by your doctor to ensure your safety\n* take reasonable contraception actions\n* unallowed to use unmarketed drugs or other clinical trial drugs during the study","ExperimentalDrugs":"[\"rk-4 injection\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"3 days or less","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Safety","total_Score":26,"Phase":"PHASE1","lastUpdateDate":"2025-09-24"},{"nctId":"NCT04696523","OrgName":"Turku University Hospital","Titlefull":"Effect of Xenon on Brain Injury, Neurological Outcome and Survival in Patients After Aneurysmal Subarachnoid Hemorrhage","BriefSummary":"An investigator-initiated clinical drug study\n\nMain Objective:\n\nTo explore neuroprotective properties of xenon in patients after aneurysmal subarachnoid hemorrhage (SAH).\n\nPrimary endpoint: Global fractional anisotropy of white matter of diffusion tensor imaging (DTI). Hypothesis: White matter damage is less severe in xenon treated patients, i.e. global fractional anisotropy is significantly higher in the xenon group than in the control group as assessed with the 1st magnetic resonance imaging (MRI).\n\nAfter confirmation of aSAH and obtaining a signed assent subjects will be randomized to the following groups:\n\nControl group: Standard of Care (SOC) group: Air/oxygen and Normothermia 36.5-37.5°C; Xenon group: Normothermia 36.5-37.5°C +Xenon inhalation in air/oxygen for 24 hours. Brain magnetic resonance imaging techniques will be undertaken to evaluate the effects of the intervention on white and grey matter damage and neuronal loss. Neurological outcome will be evaluated at 3, 12 and 24 months after onset of aSAH symptoms Investigational drug/treatment, dose and mode of administration: 50±2 % end tidal concentration of inhaled xenon in oxygen/air.\n\nComparative drug(s)/placebo/treatment, dose and mode of administration: Standard of care treatment according to local and international consensus reports.\n\nDuration of treatment: 24 hours\n\nAssessments:\n\nBaseline data Information that characterizes the participant's condition prior to initiation of experimental treatment is obtained as soon as is clinically reasonable. These include participant demographics, medical history, vital signs, oxygen saturation, and concentration of oxygen administered.\n\nAcute data The collected information will contain quantitative and qualitative data of aSAH patients, as recommended by recent recommendations of the working group on subject characteristics, and including all relevant Common Data Elements (CDE) can be applied. Specific definitions, measurements tools, and references regarding each SAH CDE can be found on the weblink here: https://www.commondataelements.ninds.nih.gov/SAH.aspx#tab=Data\\_Standards.","ExperimentalDrugs":"[\"air/oxygen\",\"xenon\"]","Allcountries":"[\"Finland\",\"Sweden\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":12,"Phase":"PHASE2","lastUpdateDate":"2025-04-28"},{"nctId":"NCT07263308","OrgName":"Capital Medical University","Titlefull":"Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2","BriefSummary":"This study is a prospective, multicenter, open-label, randomized controlled clinical trial. The investigators will apply albumin to the reperfusion treatment of patients with acute ischemic stroke in the anterior circulation. This study aims to verify the efficacy and safety of albumin combined with endovascular treatment in patients with anterior circulation acute ischemic stroke.","ExperimentalDrugs":"[\"albumin\",\"procedure: endovascular treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"PHASE3","lastUpdateDate":"2026-04-12"},{"nctId":"NCT06767969","OrgName":"Beijing Tiantan Hospital","Titlefull":"Effect of Acetaminophen on Neurological Outcome in Acute Ischemic Stroke Patients Undergoing Endovascular Treatment","BriefSummary":"Neuro-inflammation response plays an important role in the development of acute ischemic stroke(AIS). The aim of this study was to conduct a prospective randomized controlled study on the effect of acetaminophen on long-term neurological prognosis in AIS patients undergoing endovascular treatment(EVT). The primary outcome was the incidence of neurological independence (mRS 0-2, modified Rankin scale) at 90 days after surgery. The secondary outcome measures were early neurological outcome (NIHSS score at 7 days after surgery or at discharge) and the incidence of symptomatic intracerebral hemorrhage during hospitalization. This study explored the effect of acetaminophen on the prognosis of neurological function of patients, and the expected results provide evidence of safety and effectiveness for acetaminophen to improve the prognosis of neurological function of patients, and provide theoretical and practical basis for the subsequent \"new use of old drugs\" of acetaminophen and large sample and multi-center clinical research or clinical application.","ExperimentalDrugs":"[\"acetaminophen\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":23,"Phase":"NA","lastUpdateDate":"2025-05-03"},{"nctId":"NCT07353424","OrgName":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","Titlefull":"A Multicenter Randomized Clinical Trial Compared With Standard Clinical Practice to Evaluate the Efficacy of a Polyphenol-rich Salicornia Extract in the Progression of Cognitive Decline in a Cohort of Patients With Lacunar Infarcts","BriefSummary":"SALACUNAR (LACI-2-polyphenols) is a multi-center randomized controlled trial (RCT) to evaluate the effect of a polyphenol-rich supplement on small vessel neurovascular disease. Specifically, the compound to be tested is a dietary supplement based on Salicornia extract and B vitamins (B-salicornia), which in previous studies has demonstrated a good safety profile and consistent effects in reducing homocysteine levels and improving cognitive outcomes (MOCA) in patients with lacunar infarcts. This has been used to calculate the sample size based on these endpoints. Considering an intragroup variability of the treatment groups (sigma) of 6.07, and accepting an alpha risk of 0.05, a sample of 150 patients per group would achieve a 1-beta statistical power greater than 0.8 in a two-tailed test for differences between means of at least two points on the MOCA scale.\n\nThree hundred patients with lacunar infarcts diagnosed within the last year and confirmed by MRI performed as part of routine clinical practice will be included.\n\nWe will administer 500 mg/24 h of the dietary supplement B-Salicornia for six months (or the control group will be managed according to routine clinical practice) following a PROBE design.\n\nRoutine blood tests will be performed pre- and post-treatment, with routine vascular parameters such as lipids and homocysteine, as well as baseline and six-month assessments of neuropsychological and gait scales.","ExperimentalDrugs":"[\"dietary supplement: b-salicornia\"]","Allcountries":"[\"Spain\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":8,"Phase":"NA","lastUpdateDate":"2026-01-19"},{"nctId":"NCT07133932","OrgName":"Xuanwu Hospital, Beijing","Titlefull":"Transcutaneous Electrical Phrenic Nerve Stimulation for Reducing Mechanical Ventilation Duration in Acute Cerebral Infarction: A Multicenter Randomized Controlled Trial","BriefSummary":"The goal of this clinical trial is to learn if non-invasive phrenic nerve stimulation works in adult acute cerebral infarction participants undergoing mechanical ventilation. It will also learn about the safety of non-invasive phrenic nerve stimulation. The main questions it aims to answer are：\n\n1. Can non-invasive phrenic nerve stimulation shorten the duration of ventilator use and improve long-term prognosis?\n2. What medical problems do participants have when taking non-invasive phrenic nerve stimulation? Researchers will compare non-invasive phrenic nerve stimulation to a sham stimulation to see if non-invasive phrenic nerve stimulation works.\n\nParticipants will:\n\n1. Receive 14 days of non-invasive phrenic nerve stimulation or sham stimulation\n2. Visit the clinic or call for follow-up at 90 days of onset","ExperimentalDrugs":"[\"device: transcutaneous electrical phrenic nerve stimulation\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":10,"Phase":"NA","lastUpdateDate":"2025-08-13"},{"nctId":"NCT06042335","OrgName":"MIVI Neuroscience, Inc.","Titlefull":"A Feasibility Study for the DAISe EZ Thrombectomy Device - Pacific","BriefSummary":"The study is a prospective, multi-center, single arm, feasibility study that will enroll a maximum of 20 subjects. A maximum of 5 investigational centers in Australia will participate. Enrollment is expected to take about 4 months, subject participation will last about 3 months.","ExperimentalDrugs":"[\"device: daise ez\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Safety","total_Score":29,"Phase":"NA","lastUpdateDate":"2024-08-07"},{"nctId":"NCT07002476","OrgName":"Shanghai East Hospital","Titlefull":"A Prospective, Multicenter, Open-Label, Randomized Controlled Study of Early Intensive Lipid-Lowering in Endovascular Treatment for Acute Ischemic Stroke","BriefSummary":"A prospective, multicenter, open-label, randomized controlled study to assess the effects of early intensive lipid-lowering initiated before endovascular treatment setting on (i) functional outcome in patients with acute ischemic stroke between preoperative intensive lipid-lowering therapy with PCSK9 inhibitor (PCSK9i) and guideline-recommended standard of care (SoC)(ii) safety in these patients.","ExperimentalDrugs":"[\"guideline-recommended soc\",\"recaticimab (intensive)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"PHASE3","lastUpdateDate":"2026-01-18"},{"nctId":"NCT07357285","OrgName":"iVascular S.L.U.","Titlefull":"Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO).","BriefSummary":"Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the iNstroke 4F Thromboaspiration Catheter in Patients with Acute Ischaemic Stroke due to Primary Distal Medium Vessel Occlusions.","ExperimentalDrugs":"[]","Allcountries":"[\"Germany\",\"Hungary\",\"Spain\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":28,"Phase":"NA","lastUpdateDate":"2026-01-22"},{"nctId":"NCT06995625","OrgName":"S&Ebio Co. Ltd.","Titlefull":"An Open-Label, Single-Arm, Dose Escalation Phase I Clinical Trial to Evaluate the Safety and Tolerability of SNE-101 in Patients With Acute Ischemic Stroke","BriefSummary":"This is a multicenter open-label, single-arm, dose escalation phase I clinical trial to evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke","ExperimentalDrugs":"[\"sne-101\"]","Allcountries":"[\"South Korea\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Safety","total_Score":20,"Phase":"PHASE1","lastUpdateDate":"2025-07-31"},{"nctId":"NCT06821347","OrgName":"NHS Greater Glasgow and Clyde","Titlefull":"NanO2 in Large VessEL Occlusion Stroke (NOVEL): a Multicentre Single-blind, Randomised, Placebo-controlled Blinded Biomarker End-point Clinical Trial of Perfluorocarbon in Acute Ischaemic Stroke Due to Large Vessel Occlusion","BriefSummary":"This is a National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation (EME) clinical trial aiming to investigate a possible new treatment to limit damage to the brain caused by a stroke. Strokes that are caused by a clot blocking an artery in the brain ('ischaemic' strokes) starve brain tissue of oxygen and nutrients. Over a short period of time without oxygen, this tissue becomes permanently damaged. The trial aims to investigate the effects of a drug that carries extra oxygen, called NanO2, on the amount of brain tissue damage. By carrying extra oxygen to brain tissue NanO2 may allow the tissue to survive for longer. It might be especially useful to prevent further damage happening while treatments to try and open the blocked blood vessel are given. Treatments may include 'clot-busting' drugs, or procedures to physically open a blocked artery. These treatments are very effective, but take time to successfully open the blockage. The study will involve treating people as early as possible after the stroke, and comparing brain scans before and after treatment. Patients diagnosed with a stroke that has occurred within the past 9 hours will be eligible to participate. The study will involve 8-15 hospitals across the UK. Participation in the study will last approximately 90 days. The majority of the study assessments will be during the first 5 days during inpatient hospital stay. There will be a telephone follow-up at 30 days and 90 days post-discharge.","ExperimentalDrugs":"[\"nano2tm\"]","Allcountries":"[\"United Kingdom\"]","FirstAdminInter":"Within 12 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Early efficacy","total_Score":21,"Phase":"PHASE2","lastUpdateDate":"2025-04-01"},{"nctId":"NCT06959199","OrgName":"The Second Hospital of Anhui Medical University","Titlefull":"EndoVascular Treatment Beyond 24 Hours for AcutE Ischemic Stroke Caused by Anterior Circulation LArge Vessel STEnosis: A Multicenter RandomizeD Controlled Trial(EVT-BELATED)","BriefSummary":"Endovascular therapy (EVT) is currently recommended as the first-line treatment for patients with acute large vessel occlusion (LVO) in the anterior circulation within 24 hours of symptom onset. However, the therapeutic benefit of EVT beyond 24-hour window remains uncertain due to limited evidence. The EVT-BELATED trial is a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study designed to assess the safety and efficacy of EVT in patients with acute ischemic stroke (AIS) caused by anterior circulation LVO presenting beyond 24 hours after symptom onset.","ExperimentalDrugs":"[\"procedure: endovascular treatment\",\"best medical treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"NA","lastUpdateDate":"2025-05-08"},{"nctId":"NCT06997939","OrgName":"Affiliated Hospital of Nantong University","Titlefull":"A Clinical Trial of Autologous Bone Marrow-Derived Mesenchymal Stem Cell Transplantation for Precision Therapy in Ischemic Stroke","BriefSummary":"Stroke is a group of diseases mainly characterized by cerebral ischemia or hemorrhage, with a high fatality rate and disability rate. It has now become a major obstacle to social and economic development. Stem cells are a type of primitive cells with self-renewal, proliferation and differentiation potential. Under certain conditions, they can differentiate into cells of various tissues and organs. They have now become one of the key research directions for the repair of functional disorders after ischemic stroke. Compared with other types of stem cells, bone marrow mesenchymal stem cells (BMSCs) have the advantages of being relatively easy to obtain with less tissue damage, convenient and rapid in vitro expansion and culture, and the ability to actively migrate to the lesion area after injection without the risk of canceration.\n\nThis study plans to recruit and screen 12 subjects with ischemic stroke, divided into three groups (Ommaya drug reservoir group, low-dose internal carotid artery transplantation group, and high-dose internal carotid artery transplantation group), with 4 subjects in each group, for a clinical study of ABMSCs treatment for functional disorders after ischemic stroke. In accordance with the established treatment protocol, bone marrow will be collected from subjects during the stable phase of their condition, and ABMSCs will be infused three times via Ommaya drug reservoir/internal carotid artery within 1-6 months after collection. The study will assess the improvement of motor function in patients and analyze the feasibility and effectiveness of this therapy, laying a solid foundation for future clinical applications.","ExperimentalDrugs":"[\"biological: abmsc\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":19,"Phase":"PHASE1","lastUpdateDate":"2025-05-22"},{"nctId":"NCT06899711","OrgName":"Johns Hopkins University","Titlefull":"A Prospective Study to Evaluate the Protective Effects of External Cranial Prosthesis on Incidence of Sunken Flap Syndrome in Decompressive Craniectomy Patients","BriefSummary":"Patients that undergo decompressive craniectomy are at risk of delayed changes in brain function known as \"Sunken Flap Syndrome\" or \"Syndrome of the Trephined.\" The goal of this clinical trial is to see if placing a prosthetic over patients' skull defects can prevent \"Sunken Flap Syndrome.\"\n\nThe main questions are:\n\n1. Can placing a prosthetic device over patients' skull defects prevent Sunken Flap Syndrome?\n2. Can placing a prosthetic device over patients' skull defects decrease healthcare costs?\n3. Can placing a prosthetic device over patients' skull defects improve recovery and return of brain function after decompressive craniectomy?\n\nPatients that experience traumatic brain injuries, brain bleeds, and large strokes can build up high levels of pressure in the skull. When this pressure can't be controlled with medications, a life-saving surgery called a decompressive hemicraniectomy (DC) is often performed. In this surgery, a large portion of the patient's skull is removed to decrease pressure on the brain and decrease permanent damage.\n\nAfter this surgery, many patients experience sinking of the brain in the skull as the pressure inside the head improves. The skull normally protects the brain from the outside environment. When large parts of the skull are removed, the brain is not able to regulate itself normally. This can lead to a number of problems, such as headaches, weakness, seizures, and even coma and permanent brain damage. This is referred to as \"Sunken Flap Syndrome\" (SFS) or \"Syndrome of the Trephined\" (SoT). After 3-6 months, patients can have the missing skull surgically repaired, which improves and sometimes fixes SFS, but the damage is sometimes too severe to be reversed.\n\nThere are reports of patients with SFS treated with custom-made prosthetics that cover the missing piece of skull. In this study, the researchers want to see if wearing a custom-made prosthetic can prevent patients from experiencing SFS. Patients will also receive additional non-invasive measurement to see if the prosthetic can improve brain function and recovery. Finally, the researchers want to know if the prosthetic is cost-effective by decreasing the frequency that patients see doctors or receive care to treat SFS.\n\nPatients or the patient's medical decision makers will be asked if the patient wants to participate in the study after DC. If the patient or decision maker agrees to participate, the patient will be also asked if the patient wants to wear the prosthetic. The prosthetic is made of a common material used in other facial prosthetics. Patients that agree to wear the prosthetic will have a custom plate made for the participant.\n\nAll patients will receive the same post-operative care and appointments whether or not the prosthetic is worn. The participant will go to the normally scheduled post-operative doctor's appointments at 2 and 4 weeks after initial DC surgery. Patient's that agree to wear the prosthetic will receive it at the 4-week post-DC appointment. The participant will then be asked to wear it as much as possible, but to let the researchers know if the participant experiences any pain, itching, discomfort or other problems.\n\nAll patients will also be seen by the patient's physician before and after and after skull repair. At all appointments, patients will receive non-invasive testing of brain function. Recovery and rate of SFS will be compared between patients that do and do not wear the prosthetic.\n\nParticipants will:\n\n* Go to the normally scheduled 2 and 4 week post-DC appointments\n* Go to the normally scheduled pre- and post-skull repair appointments\n* Receive additional non-invasive brain health testing at each appointment\n\nParticipants that agree to wear a prosthetic will:\n\n* Receive the custom prosthetic at the 4-week post-DC appointment\n* Wear the prosthetic as much as possible, including at night\n* Take a brief survey about the prosthetic at the post-skull repair appointment","ExperimentalDrugs":"[\"device: external cranial prosthesis\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":7,"Phase":"NA","lastUpdateDate":"2026-05-08"},{"nctId":"NCT07046299","OrgName":"Capital Medical University","Titlefull":"Safety and Efficacy of Endovascular Therapy for Acute Basilar Artery Occlusion With Large Core Infarct: A Prospective, Multicenter, Randomized, Open-Label Controlled Trial","BriefSummary":"This study evaluates the safety and efficacy of endovascular therapy for acute basilar artery occlusion with large core infarcts in a multicenter randomized trial.","ExperimentalDrugs":"[\"procedure: endovascular therapy plus best medical treatment\",\"best medical treatment alone\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"NA","lastUpdateDate":"2025-06-29"},{"nctId":"NCT07500116","OrgName":"Hospital Universitari Vall d'Hebron Research Institute","Titlefull":"NORA-HOME. Efficiency And Safety An Ambulatory Multimodal Monitoring Model In Patients With Minor Stroke And Transient Ischemic Attacks","BriefSummary":"In this project, we aim to validate a Home Hospitalization plan for patients with TIA or minor stroke. Our hypothesis is that our Multimodal Home Hospitalization program (NORAHOME) for patients with TIA and minor stroke is safe, reduces the complications associated with conventional hospitalization, and is more efficient than Standard Clinical Practice. To conduct the study, we require the voluntary participation of patients with TIA and minor strokes.","ExperimentalDrugs":"[\"other: home hospitalization\"]","Allcountries":"[\"Spain\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Late efficacy","total_Score":11,"Phase":"NA","lastUpdateDate":"2026-03-25"},{"nctId":"NCT07240467","OrgName":"Tongji Hospital","Titlefull":"Safety and Efficacy of Bovis Calculus Stativus in the Treatment of Acute Cerebral Ischemic Stroke With Impaired Consciousness- A Multicenter, Prospective, Double-blind, Randomized Trial","BriefSummary":"Acute ischemic stroke (AIS) is a severe and life-threatening condition, with 35% of AIS patients experiencing impaired consciousness upon admission within 24 hours of onset. Previous studies indicated that patients with impaired consciousness at the onset of stroke have a higher incidence of stroke-related complications, particularly cerebral edema and pneumonia, as well as higher in-hospital and three-month mortality rates. The etiology of impaired consciousness in AIS is complex: ischemic damage to reticular activating system of the brainstem can directly lead to cell necrosis and result in impaired consciousness. Furthermore, secondary pathological changes following AIS, such as excitatory amino acid toxicity, oxidative stress, free radical production, and cascading inflammatory responses, can indirectly worsen impaired consciousness. Therefore, impaired consciousness at the onset of AIS is the result of cellular damage under multiple pathophysiological mechanisms. Developing neuroprotective drugs with multiple targets is key to effectively improving adverse outcomes related to impaired consciousness in AIS. However, there is currently a lack of treatment specifically aimed at improving impaired consciousness at the onset of AIS.\n\nCultivated Bovine Bezoar (Bovis Calculus Stativus, BCS) combines the advantages of pharmacological similarity to natural bovine by adding components such as deoxycholic acid, cholic acid, and composite calcium bilirubin to fresh bovine bile. It is rich in various trace elements and amino acids and is a compound medication that can exert neuroprotective effects through multiple pathways and targets. In traditional Chinese medicine, it has long been used to treat various consciousness disorder-related diseases, including stroke. The various components of in vitro cultivated bezoar are also widely used in clinical research for various neurological diseases.The above evidence fully demonstrates that BCS is an optimal treatment for impaired consciousness in stroke.\n\nThe goal of this clinical trial is to learn if Bovis Calculus Stativus works to treat acute cerebral ischemic stroke with impaired consciousness. It will also learn about the safety of Bovis Calculus Stativus. The main questions it aims to answer are:\n\n1. Does Bovis Calculus Stativus treat and alleviate consciousness disorders in patients with acute cerebral infarction accompanied by impaired consciousness ？\n2. What medical problems do participants have when taking Bovis Calculus Stativus?\n\nResearchers will compare Bovis Calculus Stativus to a placebo (a look-alike substance that contains no drug) to see if Bovis Calculus Stativus works to treat acute cerebral ischemic stroke with impaired consciousness.\n\nParticipants will:\n\n1. receive treatment with Bovis Calculus Stativus (or placebo) for 5 days.\n2. Take an in-person or telephone follow-up within 90 days after the acute stroke.","ExperimentalDrugs":"[\"bovis calculus stativus (bcs)\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":19,"Phase":"PHASE2","lastUpdateDate":"2025-12-10"},{"nctId":"NCT07107958","OrgName":"University of Science Ho Chi Minh City","Titlefull":"Assessment of Tongue Diagnosis Changes Before and After Electroacupuncture in Early Rehabilitation of Ischemic Stroke Patients Using ZMT-1A Tongue Analysis System","BriefSummary":"This prospective clinical study aims to evaluate changes in tongue characteristics before and after a four-week course of electroacupuncture in patients undergoing early rehabilitation following ischemic stroke. Electroacupuncture is widely used in Vietnam as part of traditional medicine-based stroke rehabilitation, yet few studies have objectively quantified its effects on tongue diagnosis.\n\nThe study uses the ZMT-1A Tongue Imaging System, an automated diagnostic tool developed in China and currently used at the University of Medicine and Pharmacy at Ho Chi Minh City. The system enables standardized tongue image acquisition and analysis of key features such as tongue body color, tongue shape, coating color, and coating texture.\n\nA total of 385 participants with confirmed ischemic stroke in the early recovery stage (from day 2 to 3 months post-stroke) will be recruited from three hospitals. Each participant will receive electroacupuncture treatment according to standardized protocols for 4 weeks. Tongue images will be collected before and after the intervention. The primary outcome is the change in tongue characteristics. Secondary outcomes include changes in functional status as measured by the Barthel Index and the correlation between tongue changes and functional improvement.\n\nThis study aims to provide evidence for the clinical relevance of tongue diagnosis in stroke rehabilitation and to explore its role in monitoring treatment response to electroacupuncture.","ExperimentalDrugs":"[\"procedure: electroacupuncture\"]","Allcountries":"[\"Vietnam\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"ACTIVE_NOT_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":11,"Phase":"NA","lastUpdateDate":"2025-08-03"},{"nctId":"NCT07168278","OrgName":"The First Affiliated Hospital of University of Science and Technology of China","Titlefull":"Tenecteplase vs Medical Management in 4.5-24h Anterior Circulation Large Vessel Occlusion With no Access to EVT","BriefSummary":"The goal of this clinical trial is to learn if tenectplase works to acute ischemic stroke (AIS) with onset 4.5-9 hours. It will also learn about the safety of tenectplase in AIS with onset 4.5-9 hours. The main question it aims to answer is: Does tenectplase improve the 90-days functional outcome in participants with acute large vessel occlusion? Researchers will compare tenectplase thrombolysis to non-use to see if tenectplase works to improve the functional outcome in participants with onset 4.5-9 hours. Participants will:\\* Receive 0.25mg/kg (max 25mg) tenectplase at admission (after randomization) .\\* Receive neurological assessment at admission, Day 5-7 or on hospital discharge (whichever earlier). Audio or video of the assessment may be recorded if possible.\\* Receive brain CT + CT angiogram + CT perfusion and MRI after randomization, where the CT scan may be repetitive.","ExperimentalDrugs":"[\"tnk\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":27,"Phase":"PHASE3","lastUpdateDate":"2025-09-05"},{"nctId":"NCT07163299","OrgName":"Capital Medical University","Titlefull":"Selective Intra-arterial Hypothermic Magnesium Sulfate Infusion in Combination With Endovascular Thrombectomy in Acute Ischemic Stroke: A Phase 1/2 Randomized Clinical Trial","BriefSummary":"The primary objective of this study is to estimate the safety and effectiveness of selective intra-arterial hypothermic magnesium sulfate infusion after endovascular thrombectomy in patients with acute ischemic stroke","ExperimentalDrugs":"[\"procedure: endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (350 ml).\",\"procedure: endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (500 ml).\",\"procedure: endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (650 ml).\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"ENROLLING_BY_INVITATION","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":31,"Phase":"PHASE1","lastUpdateDate":"2026-05-24"},{"nctId":"NCT06115070","OrgName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","Titlefull":"Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits","BriefSummary":"Minor stroke is considered an acute ischemic stroke (AIS) that has a National Institute of Health Stroke Scale (NIHSS) score ≤ 5 points. About 1/3 patients with mild stroke have poor prognosis, whether patients with this type undergo thrombolysis has been a controversial issue. A pooled analysis published in the Lancet in 2014 included 9 high-quality RCT studies of intravenous thrombolysis such as NINDS and IST3, and a total of 666 (10%) patients with mild stroke were included in the analysis. For mild stroke, the proportion of good prognosis in the control group and the alteplase group was 58.9% and 68.7% (OR 1.48, 95%Cl 1.07-2.06), respectively. Therefore, guidelines recommended alteplase thrombolytic therapy for patients with mild stroke. However, PRISMS, a randomized controlled trial of intravenous thrombolytic therapy for mild stroke published in 2018, found that alteplase intravenous thrombolytic therapy did not improve clinical outcomes compared with aspirin in patients with mild non-disabled stroke (90-day mRS 0-1 ratio 78.2% vs 81.5%), and the incidence of symptomatic intracranial hemorrhage was higher. However, a major limitation of the PRISMS study was that more than 85% of patients had numbness and dysarticulation, so this conclusion cannot be extrapolated to patients with other mild stroke symptoms. Moreover, due to the early termination of the sponsorship of this trial, the number of enrolled cases did not reach the pre-designed number, resulting in a serious decline in the authenticity of the study results. Symptoms and outcomes of minor stroke are important criteria for assessment. However, there is currently no uniform standard for the assessment of disability.\n\nBoth international and domestic guidelines recommend IVT with alteplase for minor disabling stroke within 4.5h, but not routinely recommend intravenous thrombolysis for minor nondisabling stroke within 4.5h. It is important to underline that strokes with low NIHSS scores are not necessarily nondisabling. Despite, patients with mild stroke symptoms are often excluded from IVT due to safety concerns potentially outweighing the putative benefits of recanalization therapy.\n\nTherefore, the investigators developed a new definition to refine the disability assessment of stroke symptoms. The purpose of this study was to investigate whether AIS patients with NIHSS ≤ 5, a limb-related NIHSS item score of 0, and with any of the following NIHSS item ≥2: Best Gaze, Visual, Facial palsy, Limb ataxia, Sensory, Best language, Dysarthria, Extinction and Inattention, could benefit from intravenous thrombolysis.","ExperimentalDrugs":"[\"intravenous thrombolysis (alteplase and other guideline-recommended thrombolytic agents)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Day 1 only","Status":"NOT_YET_RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":26,"Phase":"PHASE4","lastUpdateDate":"2025-03-05"},{"nctId":"NCT06674460","OrgName":"Peking Union Medical College Hospital","Titlefull":"Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease: A Randomized, Double-Blind, Placebo-Controlled Study","BriefSummary":"This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of Edaravone Dexborneol Sublingual Tablets in patients with acute ischemic stroke due to small vessel disease (TASTE-SVD).\n\nThe study will enroll approximately 600 participants aged 30 to 80 years who have experienced a recent small subcortical infarct (RSSI) confirmed by MRI. Participants will be randomized in a 1:1 ratio into either the Edaravone Dexborneol Sublingual Tablets group or the placebo group, with a 24-week treatment period followed by a 28-week follow-up.\n\nThe primary endpoint is a hierarchical composite endpoint at week 24, including all-cause mortality, modified Rankin Scale (mRS) score ≥2, recurrent stroke, changes in MoCA score, and changes in VaDAS-Cog score.\n\nSecondary endpoints include additional functional and cognitive assessments at 24 and 52 weeks, as well as MRI markers of white matter hyperintensities, new infarctions, microbleeds, and brain atrophy. Safety assessments will include adverse events (AEs), treatment-related adverse events (TRAEs), and serious adverse events (SAEs).\n\nThe study aims to determine whether Edaravone Dexborneol Sublingual Tablets improve functional outcomes and cognitive performance in patients with small vessel disease-related stroke.","ExperimentalDrugs":"[\"edaravone dexborneol sublingual tablets\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":19,"Phase":"PHASE3","lastUpdateDate":"2025-09-22"},{"nctId":"NCT06996769","OrgName":"Al-Zaytoonah University of Jordan","Titlefull":"Constrain Induced Therapy to Improve Motor Function and Body Balance in Patients With Stroke","BriefSummary":"Constraint-induced movement therapy (CIMT) is a neurological rehabilitation treatment designed to improve upper and lower extremities motor functions after stroke. The basis of CIMT is improving the function of the affected limb after a stroke by restricting the use of the healthy limb and forcing the use of the affected side. The core strategy of CIMT is the application of movement techniques, behavioral techniques and restriction methods to increase the frequency of use of the affected limb in stroke patients, improve the quality of movement of the affected limb in real-life scenarios, prevent or correct the learned non-use of the affected limb, and promote the recovery of motor function in the affected limb. This method induces the use of the affected limb, corrects or reverses habitual disuse and neglect of the affected limb, and provides structural and functional training and repeated practice opportunities for the affected limb.","ExperimentalDrugs":"[\"other: conventional therapy for stroke patient\",\"other: constraint induced therapy\"]","Allcountries":"[\"Jordan\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"COMPLETED","Add_on":"Other","Endpoint":"Late efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2025-08-21"},{"nctId":"NCT04157231","OrgName":"The George Institute","Titlefull":"Essential Acute Stroke Care in Low Resource Settings: a Pilot Study","BriefSummary":"An investigator-initiated, evaluator-blinded, prospective, multi centre, before-and-after, effectiveness-implementation hybrid design study to assess the feasibility of essential acute stroke care in a low resource setting","ExperimentalDrugs":"[]","Allcountries":"[\"Nigeria\",\"Peru\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Other","total_Score":8,"Phase":"NA","lastUpdateDate":"2026-06-09"},{"nctId":"NCT07301372","OrgName":"The Affiliated Hospital of Xuzhou Medical University","Titlefull":"A Randomized, Open-label, Blinded Endpoint Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemic Stroke","BriefSummary":"This study is a Phase IIa clinical trial initiated by the researchers, which is prospective, single-center, randomized, open-label, with blinded endpoint evaluation (PROBE design). Patients were screened through the emergency stroke green channel and included if they had an onset within 9 hours, met the criteria for large artery atherosclerosis (LAA) after multimodal imaging screening, received intravenous thrombolysis, and signed informed consent to participate. The study used block randomization (block size of 4), stratified by baseline National Institutes of Health Stroke Scale (NIHSS) score (5-10 vs \\>10-20) and onset-to-thrombolysis time (\\<4.5 hours vs 4.5-9 hours).\n\nIntervention group: received subcutaneous injections of Ilyumumab 420 mg (three syringes) within 24 hours after thrombolysis plus standard drug therapy (including statins). Control group: received conventional statin therapy (atorvastatin 20 mg/day) after thrombolysis. All patients received standardized stroke treatment (initiating antiplatelet therapy 24 hours after thrombolysis) and standardized management of blood pressure and blood glucose.\n\nNIHSS scores were assessed every 12 hours within 72 hours post-thrombolysis, and then daily thereafter, to evaluate the effectiveness of combined therapy in reducing early neurological deterioration (END).\n\nBlinding: The study is open-label. An independent Clinical Endpoint Committee (CEC) was established, and all clinical endpoint events (END assessment, 90-day mRS scores) were evaluated in a blinded manner by experts who were completely unaware of group assignments.","ExperimentalDrugs":"[\"ivolumab 420mg (three vials)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 12 hours","TreatDur":"Only once","Status":"COMPLETED","Add_on":"IVT mandatory; EVT optional","Endpoint":"Early efficacy","total_Score":25,"Phase":"PHASE4","lastUpdateDate":"2026-04-29"},{"nctId":"NCT07143149","OrgName":"Beijing Tiantan Hospital","Titlefull":"Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China","BriefSummary":"This study will conduct a cluster randomized controlled trial to Evaluate whether the Intelligent Lipid Management Decision-support System can increase the proportion of patients 1-year target achievement (\\<1.8 mmol/L) in acute ischemic stroke or TIA patients under Evolocumab treatment within 12 months post-intervention.","ExperimentalDrugs":"[\"device: the intelligent lipid management decision-support system\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":8,"Phase":"NA","lastUpdateDate":"2025-12-29"},{"nctId":"NCT07001852","OrgName":"University of Iowa","Titlefull":"EnDOvascular Therapy for Late WiNdow IschEmic Stroke Patients Selected bY AutoMatic Plain ComputErized Tomography","BriefSummary":"The DONE SYMPLE Investigator-initiated phase III prospective, randomized, open-label, blinded endpoint-controlled clinical trial.\n\nThis clinical trial is a global clinical study testing whether a procedure called endovascular therapy, which removes blood clots from blocked brain arteries, can safely benefit more stroke patients when used up to 72 hours after symptoms begin. Endovacular Therapy is already proven to improve recovery in patients treated within 6 hours, but only when advanced imaging like Computed Tomography (CT) perfusion or Magnetic Resonance Imaging (MRI) is available to guide treatment. Unfortunately, many hospitals, specially in underserved areas, do not have access to this type of imaging.\n\nThis trial will investigate whether a basic brain scan called non-contrast CT, which is widely available in hospitals around the world, can be used instead. Special software will automatically analyze the CT scan to help doctors decide if a patient has enough brain tissue left to save with Endovascular Therapy. If this simpler approach works, it could expand access to lifesaving stroke care for more people globally.\n\nThe study will enroll 500 adult stroke patients, ages 18 to 80, with a large vessel blockage in the brain's anterior circulation, moderate to severe stroke symptoms, and who are between 6 and 72 hours from when they were last known to be well. All participants will undergo CT imaging analyzed by the automated software. If the scan shows a small core of already damaged brain tissue and a larger area of threatened but still viable brain, the patient will qualify.\n\nParticipants will be randomly assigned to receive either standard medical therapy alone or medical therapy plus Endovasculat Therapy which involves inserting a catheter through a blood vessel to reach the brain and using a device to remove the clot. This procedure is performed by trained stroke or neurointerventional specialists. The study is \"open-label,\" meaning patients and doctors know which treatment is given, but the assessment of patient recovery will be done by independent reviewers who do not know the group assignments.\n\nThe primary goal is to determine if patients who receive Endovascular Therapy have better recovery at 90 days, measured by a scale called the modified Rankin Scale, which assesses how much disability a patient has after a stroke. The trial will also look at safety (especially brain bleeding after treatment), size and growth of brain injury on follow-up scans, recovery of strength and language, and overall quality of life and survival. Imaging will be reviewed centrally by a specialized team, and results will be analyzed to see how well Endovascular Therapy performs using this new patient selection method.\n\nThe DONE SYMPLE Trial is sponsored by Foundacio Ictus in Barcelona Spain and the University of Iowa is the Central Coordinating Center for the Study. It will take place at up to 20 hospitals worldwide. All patients will be followed closely with exams and imaging at specific time points up to 90 days after treatment.\n\nIf successful, this trial could change stroke care around the world by proving that Endovascular Therapy can be used safely and effectively even without advanced imaging, using tools available in most hospitals. This could help more stroke patients, especially in rural or resource-limited areas, access treatments that may improve their chances of recovery and reduce long-term disability.","ExperimentalDrugs":"[\"other: endovascular therapy (mechanical thrombectomy)\",\"other: standard medical management\"]","Allcountries":"[\"Armenia\",\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"NA","lastUpdateDate":"2025-10-14"},{"nctId":"NCT07241520","OrgName":"Shanghai Hutchison Pharmaceuticals Limited","Titlefull":"Phase III Clinical Trial to Evaluate the Efficacy and Safety of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke（SAIL）- a Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial","BriefSummary":"This study is designed to determine the efficacy and safety of SHPL-49 intravenous infusion in acute ischemic stroke patients.","ExperimentalDrugs":"[\"shpl-49 injection\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":26,"Phase":"PHASE3","lastUpdateDate":"2026-01-03"},{"nctId":"NCT07295366","OrgName":"The Affiliated Hospital of Xuzhou Medical University","Titlefull":"Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Controlled Trial","BriefSummary":"This study (EPOCH-TECT) was a single-center, randomized, open-label, blinded, endpoint-assessing controlled trial conducted at the Affiliated Hospital of Xuzhou Medical University. It aimed to investigate the efficacy and safety of administering the PCSK9 inhibitor evolocumab early (within 6 hours) after successful thrombectomy in patients with atherosclerotic large vessel occlusive stroke. The study planned to enroll 60 patients, who were randomly assigned 1:1 to either the \"thrombectomy + evolocumab\" group or the \"thrombectomy alone\" group. The primary endpoint was the incidence of early neurological deterioration within 7 days post-procedure (NIHSS score increase ≥2 points from post-operative best or death from any cause); secondary endpoints included 24-hour recanalization failure rate, 90-day functional recovery (mRS score 0-2), changes in serum biomarkers, and safety indicators such as symptomatic intracranial hemorrhage. This study aimed to provide prospective evidence for early intensive lipid-lowering and neuroprotective strategies after thrombectomy.","ExperimentalDrugs":"[\"elavolocumab(420 mg injections)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Day 1 only","Status":"COMPLETED","Add_on":"IVT optional; EVT mandatory","Endpoint":"Safety","total_Score":25,"Phase":"PHASE4","lastUpdateDate":"2026-05-01"},{"nctId":"NCT07581210","OrgName":"Shanghai QuietD Biotechnology Co., Ltd.","Titlefull":"A Multicentre, Randomized, Double-blinded, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety, Pharmacokinetic Profile, and Efficacy of QD202 Injection in Patients With Acute Ischemic Stroke Undergoing Thrombolysis","BriefSummary":"This is a randomized, double-blinded, placebo-controlled study investigating the safety and efficacy of QD202 injection in patients with acute ischemic stroke undergoing thrombolysis excluding endovascular thrombectomy. Up to 120 male and female patients with acute ischemic stroke undergoing thrombolysis excluding endovascular thrombectomy will be dosed with QD202 injection or placebo as a 60 minute intravenous infusion after completion of the thrombolysis procedure on Day 1-5 of the study period. Subjects will undergo interim procedures at Day 7 or the day of discharge, Day 30, and end-of-study procedures on Day 90.","ExperimentalDrugs":"[\"qd202\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"Safety","total_Score":26,"Phase":"PHASE2","lastUpdateDate":"2026-05-06"},{"nctId":"NCT06931535","OrgName":"General Hospital of Shenyang Military Region","Titlefull":"Remote Ischemic Conditioning for Acute Moderate Posterior Ischemic Stroke (RICAMIS2): a Prospective, Random, Open Label, Blinded End Point, Multi-center Study","BriefSummary":"A substantial body of basic and clinical research has demonstrated the protective effects of remote ischemic conditioning (RIC) in ischemic stroke. While these clinical studies support the safety of RIC, the neuroprotective benefits of RIC in acute ischemic stroke (AIS) patients lack robust evidence due to small sample sizes, heterogeneous RIC protocols, and variability in the severity of neurological deficits among study populations. Our recent multicenter randomized clinical trial, the RICAMIS study, investigated the efficacy of RIC in patients with acute moderate ischemic stroke. The results showed that RIC administered within 48 hours of onset significantly improved 90-day neurological outcomes in patients with moderate stroke severity. It is well established that anterior circulation stroke (ACS) and posterior circulation stroke (PCS) differ in multiple aspects, including anatomical structure, collateral circulation, blood supply, clinical manifestations, prognosis, ischemic tolerance time, and treatment response. For instance, compared to the anterior circulation, the posterior circulation has poorer collateral circulation, a higher proportion of stroke etiologies attributed to atherosclerosis, and longer ischemic tolerance time. Consequently, intravenous thrombolysis and endovascular therapy may offer a more extended therapeutic time window for PCS patients. A prespecified subgroup analysis of the RICAMIS study revealed that patients with PCS derived greater benefit from RIC than those with ACS. However, this finding requires further validation through prospective studies, as prior research has never specifically examined the efficacy of RIC in PCS patients.\n\nBased on the above discussion, this study aims to investigate the efficacy and safety of RIC in patients with acute moderate PCS.","ExperimentalDrugs":"[\"device: remote ischemic conditioning\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":20,"Phase":"NA","lastUpdateDate":"2026-04-22"},{"nctId":"NCT06679803","OrgName":"University of Minnesota","Titlefull":"PA-ChatS: Feasibility of Delivering a First-Line Physical Activity Intervention After Stroke","BriefSummary":"The goal of this study is to explore a new intervention that supports physical activity within the first 6 weeks after stroke. All participants will complete assessments at weeks 0 and 7. During weeks 1 through 6, participants will use a Fitbit Inspire to track their step counts and meet with an occupational therapist one time per week. They will also complete weekly surveys. Physical activity levels will be measured using surveys and a wearable activPAL monitor 6 times during the study: Weeks 1, 3, 5, 7, 12, and 24.","ExperimentalDrugs":"[\"behavioral: physical activity chats after stroke (pa-chats)\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"ENROLLING_BY_INVITATION","Add_on":"Other","Endpoint":"Other","total_Score":11,"Phase":"NA","lastUpdateDate":"2026-02-10"},{"nctId":"NCT07209982","OrgName":"University of Lahore","Titlefull":"Dual Task Training Versus Single Task Training in Chronic Hemiplegic Stroke Patients","BriefSummary":"What is this study about? This study compares two common ways of practicing walking and balance after a stroke: (1) dual-task training, where a person walks or balances while doing a second task (such as counting backward or carrying a light object), and (2) single-task training, where a person practices walking and balance without any extra task. The goal is to learn whether practicing with or without an added task is more practical and acceptable for people living with long-standing weakness on one side of the body (hemiplegia) after stroke.\n\nWhy is this important? Many everyday activities-walking while talking, looking for a bus, or carrying a bag-require attention to more than one thing at a time. Some stroke survivors find this difficult. Training that safely mimics real-life multitasking may help therapists design better rehabilitation plans.\n\nWho can take part? Adults aged 45-65 years with a diagnosis of hemiplegic stroke who can walk without hands-on help may be eligible. People with other neurological conditions that affect walking, severe problems with understanding or communication, or recent serious medical/surgical issues will not be included. Additional screening will check safety for exercise.\n\nWhat will happen if I join?\n\nParticipants are randomly assigned (like a coin toss) to one of two groups:\n\nDual-task training group: walking/balance activities plus a simple cognitive or motor task.\n\nSingle-task training group: the same walking/balance activities without any extra task.\n\nBoth groups attend 60-minute sessions, three times per week, for six weeks at The University of Lahore Teaching Hospital or Sehat Medical Complex. A trained therapist supervises all sessions and adjusts difficulty gradually. Short rest breaks are provided.\n\nWhat will be measured? At baseline, 2 weeks, 4 weeks, and 6 weeks, an assessor who does not know the assigned group will record walking and balance using the Tinetti Performance-Oriented Mobility Assessment (POMA). Safety (such as any falls, dizziness, or discomfort) and attendance will also be recorded.\n\nWhat are the possible risks and benefits? Risks are similar to supervised physiotherapy: temporary muscle soreness, fatigue, or loss of balance. Therapists use safety measures (close supervision, stable equipment, and rest periods). Participants may experience the general benefits of structured rehabilitation (practice, education, and monitored activity). Taking part is voluntary, and usual care remains available.\n\nPrivacy and cost Personal information is kept confidential and stored securely. There is no payment for participation. There are no charges for study-related therapy sessions.\n\nTime commitment About 18 sessions over 6 weeks, plus four short assessment visits.\n\nContacts Study team members can answer questions at any time and will obtain written informed consent before any study procedures begin.","ExperimentalDrugs":"[\"behavioral: dual-task training (dtt)\",\"behavioral: single-task training (stt)\"]","Allcountries":"[\"Pakistan\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-09-29"},{"nctId":"NCT07011888","OrgName":"Medipol University","Titlefull":"Current and Innovative Physiotherapy Practices in Stroke Rehabilitation: A Clinical Case Report","BriefSummary":"This study reports a single-case rehabilitation program for a chronic stroke patient focusing on innovative physiotherapy techniques. Over six weeks, the patient will undergo combined treatments including vestibular rehabilitation therapy, ultrasound therapy, and functional hand therapy using Saebo devices. The goal is to improve motor functions and daily living independence. This report aims to share clinical insights and outcomes to support stroke rehabilitation practices.","ExperimentalDrugs":"[\"device: saebostim go with saebo glove rehabilitation program\"]","Allcountries":"[\"Turkey (Türkiye)\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2025-09-26"},{"nctId":"NCT06775782","OrgName":"First Affiliated Hospital Xi'an Jiaotong University","Titlefull":"Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis: A Multi-centered, Open-label, Blind Endpoint, Randomized Controlled Trial","BriefSummary":"Large Artery Atherosclerosis is one of the most prevalent causes of stroke worldwide and is associated with a high risk of disability and recurrent strokes. Remote Ischemic Conditioning (RIC) is a promising therapy, and it has been recommended for further investigation in patients with acute ischemic stroke resulting from large artery atherosclerosis. The primary objective of this study is to assess the efficacy of RIC in patients suffering from acute moderate ischemic stroke due to large artery atherosclerosis.","ExperimentalDrugs":"[\"device: remote ischemic conditioning (ric) treatment\",\"medical management\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":21,"Phase":"NA","lastUpdateDate":"2025-08-11"},{"nctId":"NCT07174505","OrgName":"Anaconda Biomed S.L.","Titlefull":"A Prospective, Single-Arm, Multi-Center Study to Assess the Safety, Performance, and Preliminary Efficacy of Mechanical Thrombectomy Using the CONDA Stent Retriever in Subjects With Acute Ischemic Stroke","BriefSummary":"The goal of this study is to evaluate the safety and performance of the CONDA stent retriever in patients with acute ischemic stroke due to large vessel occlusion, treated within 24 hours of symptom onset.\n\nThe main objectives are:\n\n* To determine the rate of device success, defined as the ability of the CONDA retriever to reach the blocked vessel, be deployed and retrieved successfully, and facilitate reperfusion.\n* To evaluate safety, measured as the rate of symptomatic intracranial hemorrhage within 24 hours of the procedure.\n\nThe use of CONDA in this study follows the same approach as other CE-marked stent retrievers. Supportive devices (such as long sheaths, guide catheters, balloon catheters, distal access catheters, the ANA funnel catheter, microcatheters, and microwires) may be used according to investigator preference and local practice, in line with their labeling and instructions for use.\n\nParticipants will:\n\n* Be evaluated using standard clinical and imaging assessments to confirm eligibility.\n* Undergo mechanical thrombectomy with the CONDA device, with or without supportive devices as selected by the treating physician.\n* Have standard follow-up evaluations to assess treatment safety and effectiveness.","ExperimentalDrugs":"[\"device: mechanical thrombectomy using the conda stent retriever\"]","Allcountries":"[\"Hungary\",\"Spain\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":28,"Phase":"NA","lastUpdateDate":"2025-09-11"},{"nctId":"NCT07016854","OrgName":"Sir Run Run Shaw Hospital","Titlefull":"Evaluation of Early Endovascular Treatment in Acute Ischemic Stroke With Isolated Internal Carotid Artery Occlusion (EVT-iICAO)","BriefSummary":"The primary hypothesis being tested in this trial is that acute ischemic stroke with isolated internal carotid artery occlusion will have improved clinical outcomes when given early endovascular treatment compared with that of given best medical treatment.","ExperimentalDrugs":"[\"procedure: endovascular treatment\",\"the best medical treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"NA","lastUpdateDate":"2025-06-10"},{"nctId":"NCT06901466","OrgName":"Chinese Academy of Medical Sciences, Fuwai Hospital","Titlefull":"STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-edge Repair in Patients With an Indication for Oral Anticoagulant: a Multicenter Randomized Controlled Trial","BriefSummary":"Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups). Transcatheter edge-to-edge repair (TEER) is now a well-established strategy in high-risk patients with MR. Globally, over 250,000 patients have benefited from the TEER technique.Studies have shown that patients with severe mitral regurgitation exhibit a high prevalence of atrial fibrillation (AF), reaching up to 63%, which is an indication for long-term oral anticoagulation (OAC) therapy. However, no dedicated study has prospectively evaluated different antithrombotic strategies following TEER in patients with an indication for OAC. Current guidelines do not provide any recommendations for the antithrombotic management of TEER. Consequently, considerable treatment variation exists in clinical studies and practice. The investigators will conduct a multicenter, open-label randomized trial to compare different antithrombotic strategies following TEER in patients who have an indication for OAC.","ExperimentalDrugs":"[\"experimental: rivaroxaban monotherapy\",\"active comparator: rivaroxaban+clopidogrel\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":13,"Phase":"PHASE4","lastUpdateDate":"2026-03-05"},{"nctId":"NCT07282041","OrgName":"National University of Singapore","Titlefull":"Role of Glucagon-like Peptide 1 Receptor Agonist (GLP1 RA) Dulaglutide on Cerebral Hemodynamics In Patients With Severe and symptomAtic steNosis of inTracranial Internal Carotid Artery or Middle Cerebral Artery With Impaired Cerebral Vasodilatory Reserve- an Open-label Randomised Clinical Trial (RADIANT)","BriefSummary":"One important mechanism of action of GLP1 RA is the improvement in endothelial function, which may be evaluated by the assessment of cerebral vasodilatory reserve (CVR) in patients with severe ICAD. The investigators believe that GLP1 RA would be beneficial for patients with severe ICAD and lead to an improvement in cerebral vasodilatory reserve (CVR) in patients with severe and recently symptomatic stenosis of intracranial carotid artery (ICA) or middle cerebral artery (MCA).\n\nIn this open label randomised clinical trial, patients with recently symptomatic and severe stenosis of intracranial carotid artery (ICA) or middle cerebral artery (MCA) with impaired cerebral vasodilatory reserve (CVR) will be included. CVR will be measured with transcranial Doppler (TCD) breath holding index and acetazolamide-challenged single photon emission computed tomography (SPECT). Patients meeting the eligibility criteria would be randomised to receive best medical therapy (according to the international guidelines and institutional practices) or Dulaglutide subcutaneous injection (0.75mg and titrating to 1.5mg, if indicated) once a week, in addition to the best medical therapy. CVR will be measured again at the completion of 1 year. MRI of the brain will be repeated to evaluate any new ischaemic brain lesions. All patients would be followed up for two years for cerebral ischaemic events.\n\nThe investigators hypothesize that addition of GLP1 RA therapy would lead to a reduction of at least 4 units in CVR on SPECT as compared to best medical therapy.","ExperimentalDrugs":"[\"dulaglutide\"]","Allcountries":"[\"Singapore\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":11,"Phase":"PHASE2","lastUpdateDate":"2025-12-16"},{"nctId":"NCT07208422","OrgName":"National Assembly Clinic","Titlefull":"Study Protocol for a Pilot Randomized Controlled Trial of Task-Specific Self-Rehabilitation Training (TASSRET) for Improving Functional Mobility in Community-Dwelling Stroke Survivors in a Low-Resource Setting","BriefSummary":"The goal of this pilot RCT is to evaluate the effectiveness of a Task-specific Self-rehabilitation Training (TASSRET) program and compare the effect of the two formats of the TASSRET (video vs manual) on functional ability (upper extremity fine and gross motor skills, upper extremity manual dexterity and speed, voluntary movement and basic mobility, gait velocity, balance) and health-related quality of life among Hausa-native stroke survivors.\n\nThe main questions it aims to answer are:\n\n1. What is the immediate effect and durability of TASSRET on functional ability (upper extremity fine and gross motor skills, upper extremity manual dexterity and speed, voluntary movement and basic mobility, gait velocity, balance) and health-related quality of life among the Hausa-native stroke survivors?\n2. Which of the self-rehabilitation formats (TASSRET-manual or TASSRET-video) is more effective (immediate and durable) at improving functional ability (upper extremity fine and gross motor skills, upper extremity manual dexterity and speed, voluntary movement and basic mobility, gait velocity, balance) and health-related quality of life among the Hausa-native stroke survivors?","ExperimentalDrugs":"[\"behavioral: video-based task-specific training\",\"behavioral: manual-based task-specific training\"]","Allcountries":"[\"Nigeria\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":9,"Phase":"NA","lastUpdateDate":"2025-12-13"},{"nctId":"NCT06801457","OrgName":"Capital Medical University","Titlefull":"Adjuvant Cerebroprotection Using Normobaric Hyperoxia in Pre-hospital Patients with Suspected Stroke","BriefSummary":"The primary objective of this study is to determine the efficacy and safety of inhaled normobaric hyperoxia therapy (NBO) beginning in the pre-hospital setting in patients with suspected acute cerebral ischemia (ACI) due to large vessel occlusion presenting within 6 hours of symptom onset.","ExperimentalDrugs":"[\"other: nbo\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 6 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"PHASE3","lastUpdateDate":"2025-01-24"},{"nctId":"NCT07302594","OrgName":"People's Hospital of Zhengzhou University","Titlefull":"Effects of Oro-esophageal Versus Nasogastric Tubes on Swallowing Function in Ischemic Stroke Survivors: A Randomized Controlled Trial","BriefSummary":"This is an open-label randomized controlled trial. The participants are ischemic stroke patients requiring enteral nutrition. The study is conducted in the Department of Rehabilitation Medicine and Department of Neurology.\n\nThe purpose of this study is to explore the effects of Intermittent Oro-esophageal Tube Feeding versus Nasogastric Tube Feeding on participants' swallowing function and airway protection.\n\nSpecifically, the study aims to answer the following two key questions:\n\nIs there any difference between the two feeding methods in terms of their effects on swallowing function? Are the safety profiles of the two feeding methods consistent? Compared to Nasogastric Tube Feeding, can the Intermittent Oro-esophageal Tube Feeding better improve the nutritional status, extubation of tracheostomy tube, pulmonary infection, neurological deficit of Patients with Intracerebral Hemorrhage Compared to Nasogastric Tube Feeding, is the Intermittent Oro-esophageal Tube Feeding safer.\n\nParticipants will be divided into two groups randomly, with different nutritional support respectively.","ExperimentalDrugs":"[\"behavioral: standard rehabilitation therapy\",\"dietary supplement: oro-esophageal feeding\",\"dietary supplement: nasogastric feeding\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":6,"Phase":"NA","lastUpdateDate":"2025-12-11"},{"nctId":"NCT07043686","OrgName":"University Medical Centre Ljubljana","Titlefull":"Effect of Cerebrolysin on Early Rehabilitation After Ischemic Stroke at the Department of Vascular Neurology and Intensive Neurological Therapy (KOVNINT), University Medical Centre Ljubljana","BriefSummary":"The study evaluates the effect and safety of Cerebrolysin administered during early rehabilitation in patients with moderate neurological impairment after acute ischemic stroke, conducted at the Department of Vascular Neurology and Intensive Neurological Therapy, UMC Ljubljana.","ExperimentalDrugs":"[\"cerebrolysin treatment\",\"other: standard treatment (including neurorehabilitation) of acute ischemic stroke\"]","Allcountries":"[\"Slovenia\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-07-03"},{"nctId":"NCT07007143","OrgName":"Chinese Academy of Medical Sciences, Fuwai Hospital","Titlefull":"STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-edge Repair in Patients Without an Indication for Oral Anticoagulant: a Multicenter Randomized Controlled Trial","BriefSummary":"Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups). Transcatheter edge-to-edge repair (TEER) is now a well-established strategy in high-risk patients with MR. Globally, over 250,000 patients have benefited from the TEER technique. However, no dedicated study has prospectively evaluated different antithrombotic strategies following TEER in patients undergone TEER procedure. Current guidelines do not provide any recommendations for the antithrombotic management of TEER. Consequently, considerable treatment variation exists in clinical studies and practice. The investigators will conduct a multicenter, open-label randomized trial to compare different antithrombotic strategies following TEER in patients without an indication for OAC.","ExperimentalDrugs":"[\"experimental: aspirin monotherapy\",\"active comparator: aspirin+clopidogrel\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":13,"Phase":"PHASE4","lastUpdateDate":"2026-03-05"},{"nctId":"NCT06763458","OrgName":"General Hospital of Shenyang Military Region","Titlefull":"Balloon Angioplasty for Minor Unstable Stroke With IntraCranial Atherosclerosis Stenosis (BAMUS-ICAS): a Prospective, Randomized, Multi-center Study","BriefSummary":"Intracranial atherosclerotic stenosis (ICAS) is a common cause of stroke, especially in East and South Asia, and is significantly associated with stroke recurrence and early neurological deterioration (END) despite aggressive medical management. Minor stroke (National Institutes of Health Stroke, NIHSS score ≤ 5) patients with ICAS often has higher risk of END. The early realization of blood flow patency is closely related to the improvement of patient outcomes. Submaximal balloon angioplasty (SBA) as a safer and simpler intervention which can improve cerebral blood flow. Thus, SBA may be an effective strategy for preventing END in acute ischemic stroke patients with ICAS.","ExperimentalDrugs":"[\"procedure: submaximal balloon angioplasty\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":18,"Phase":"NA","lastUpdateDate":"2026-04-22"},{"nctId":"NCT07199920","OrgName":"University Hospital, Grenoble","Titlefull":"Implementation of New Multimodal MRI Sequences by Fingerprint to Improve Ischemic Stroke Examination, a Pilot Study and Proof of Concept","BriefSummary":"Currently, standard brain MRI takes 20 to 25 minutes, but in the case of ischemic stroke, every minute counts to limit the extension of the necrotic core, with the possibility of recanalizing the occluded artery (intravenous thrombolysis and/or mechanical thrombectomy).\n\nThe recent concept of MRI \"Fingerprint\" (Magnetic Resonance Fingerprinting, MRF) allows the production of a rapid single sequence and the extraction of numerous parameters.\n\nDemonstrating the feasibility and interpretability of multimodal MRI images acquired in MRF would make it possible to consider implementing and, ultimately, replacing conventional sequences, with the aim of shortening acute stroke management times, increasing the number of sequences acquired within a short timeframe (by increasing informativeness), and thus improving patients\\&#39; short and long-term vital and functional prognosis.","ExperimentalDrugs":"[\"device: achieva 3.0t dstream philips\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":10,"Phase":"NA","lastUpdateDate":"2025-09-22"},{"nctId":"NCT06940128","OrgName":"General Hospital of Shenyang Military Region","Titlefull":"Direct Ischemic Conditioning for Endovascular Recanalization for Anterior Large Vessel Occlusion (DICER-aLVO): a Prospective, Randomized, Open Label, Blinded-end Point, Phase 2, Multi-centre Study","BriefSummary":"Acute ischemic stroke (AIS) is the most common type of stroke, with high incidence rate and mortality. Endovascular therapy is currently the most effective treatment for AIS with large vessel occlusion, but only about 50% of patients achieve good outcome after endovascular therapy, while 50% of patients have poor prognosis, commonly referred to as ineffective perfusion. Therefore, how to improve ineffective perfusion is currently a hot topic.\n\nNumerous studies have shown that Remote Ischemic Therapy (RIC) has a protective effect on ischemic stroke. Our recent RICAMIS study has demonstrated that RIC can significantly improve the functional prognosis of moderate acute ischemic stroke. Furthermore, direct ischemic conditioning has also showed neuroprotective effect. For example, in a rat model, within 2 minutes after reperfusion, using three cycles of 30 s reperfusion and 10 s occlusion for direct ischemic conditioning can effectively alleviate hyperperfusion and reduce cerebral infarction volume. Meanwhile, in previous clinical exploration studies, it was found that even induction by 5-minute ischemia and 5-minute reperfusion for up to 4 cycles is safe, feasible, and well tolerated for AIS patients receiving endovascular treatment. Immediate control of bilateral carotid artery blood flow after ischemia-reperfusion can significantly reduce cerebral infarction area and brain edema, and improve neurological function recovery in rats. Subsequent molecular mechanism studies have shown that direct ischemic conditioning can reduce the production of free radicals after cerebral ischemia-reperfusion, inhibit inflammatory reactions and cell apoptosis, downregulate the expression of signaling molecules mediating brain edema, promote Akt survival pathway, and improve the integrity of the blood-brain barrier, thereby exerting neuroprotective effects. Recent studies have also confirmed the safety and feasibility of direct ischemic conditioning for stroke patients achieving successful recanalization. More importantly, a recent cohort study has shown that direct ischemic conditioning can reduce infarct growth and brain edema after reperfusion in patients with AIS who have undergone thrombectomy for occlusion of large blood vessels in the anterior circulation, and improve prognosis after 90 days.\n\nBased on the above discussion, this trial aims to evaluate the effectiveness and safety of direct ischemic conditioning for patients with AIS who have undergone thrombectomy for occlusion of large blood vessels in the anterior circulation.","ExperimentalDrugs":"[\"procedure: direct ischemic conditioning a\",\"procedure: direct ischemic conditioning b\",\"procedure: direct ischemic conditioning c\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"NA","lastUpdateDate":"2026-04-22"},{"nctId":"NCT07230587","OrgName":"Peking Union Medical College Hospital","Titlefull":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long-Term Efficacy of Butylphthalide in Patients With Minor Acute Ischemic Stroke (BLESS)","BriefSummary":"This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the long-term efficacy and safety of butylphthalide in patients with minor acute ischemic stroke (BLESS Trial).\n\nA total of 1200 participants aged 40 to 80 years with a minor acute ischemic stroke confirmed by MRI will be enrolled. Participants will be randomly assigned in a 1:1 ratio to receive butylphthalide or placebo for 12 months.\n\nThe primary outcome is a hierarchical composite endpoint assessed at 12 months, including:\n\n1. All-cause mortality\n2. Stroke recurrence\n3. Modified Rankin Scale (mRS) score ≥2\n4. New MRI-confirmed infarcts\n5. Change in Montreal Cognitive Assessment (MoCA) score from baseline\n\nSecondary outcomes include additional functional, cognitive, and imaging-based assessments at 12 months.\n\nThis study aims to determine whether butylphthalide can improve long-term functional and cognitive outcomes in patients with minor ischemic stroke, contributing to better secondary stroke prevention strategies.","ExperimentalDrugs":"[\"butylphthalide\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"mRS","total_Score":18,"Phase":"PHASE3","lastUpdateDate":"2025-11-13"},{"nctId":"NCT06486792","OrgName":"Assistance Publique - Hôpitaux de Paris","Titlefull":"Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation","BriefSummary":"Patients who have recently had an ischemic stroke with no clear cause might have undetected atrial fibrillation (AF) that isn't caught during their initial hospital stay. After discharge, these patients are typically monitored for AF using devices like Holter monitors or implantable loop recorders. Treatment options during this period include anticoagulants or aspirin. Anticoagulants are more effective in preventing recurrent strokes if AF is present, offering an 80% risk reduction compared to aspirin's 20%. If AF is detected, anticoagulant treatment continues; if not, patients may switch to aspirin after 6-12 months. Despite the clinical rationale for using anticoagulants during this search period, their benefit-risk ratio compared to aspirin has not been fully evaluated.","ExperimentalDrugs":"[\"apixaban\",\"aspirin\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":15,"Phase":"PHASE4","lastUpdateDate":"2026-06-03"},{"nctId":"NCT07205263","OrgName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","Titlefull":"A Multicenter, Randomized, Controlled, Umbrella Trial for Minimally Invasive Neurosurgery With Al-assisted Robotic Guidance for Hemorrhagic Stroke (RAINBOW-ICH)","BriefSummary":"Intracerebral hemorrhage (ICH) is one of the most devastating forms of stroke, with high rates of death and disability worldwide. Despite advances in medical and surgical care, effective therapeutic options remain limited. To address this gap, the RAINBOW-ICH trial has been designed as a nationwide, multicenter, randomized umbrella trial evaluating the efficacy and safety of AI-assisted, robotic-guided minimally invasive neurosurgery compared with conventional strategies across major ICH subtypes.\n\nUnder a single master protocol, RAINBOW-ICH incorporates multiple parallel randomized controlled substudies, each targeting a distinct ICH population-large basal ganglia hemorrhage, moderate basal ganglia hemorrhage, intraventricular hemorrhage, and brainstem hemorrhage. This umbrella design allows efficient use of resources while generating high-quality evidence tailored to the specific needs of different ICH subgroups, thereby supporting a more patient-centered approach to care.","ExperimentalDrugs":"[\"procedure: ai-assisted robotic-guided endoscopic hematoma evacuation\",\"procedure: conventional craniotomy\",\"procedure: ai-assisted robotic-guided puncture and hematoma evacuation\",\"other: standard medical management\",\"procedure: ai-assisted robotic-guided endoscopic ventricular hematoma evacuation plus external ventricular drainage\",\"procedure: external ventricular drainage (evd)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS","total_Score":18,"Phase":"NA","lastUpdateDate":"2026-01-06"},{"nctId":"NCT07347665","OrgName":"Hyogo Medical University","Titlefull":"Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral Artery (the Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism-M2 Occlusion Trial: RESCUE-M2O Trial)","BriefSummary":"RESCUE-M2O trial is a prospective, open label, blinded endpoint (PROBE), two-arm, randomized, controlled, post-market study to assess the efficacy and safety of endovascular therapy for acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery.","ExperimentalDrugs":"[\"procedure: endovascular therapy\"]","Allcountries":"[\"Japan\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"NA","lastUpdateDate":"2026-02-22"},{"nctId":"NCT04038424","OrgName":"Cairo University","Titlefull":"The Effect of Art Therapy on Cognitive Ability, Arm Activity and Mental Health Status in Patients With Stroke","BriefSummary":"Stroke can affect the physical, emotional and social aspects of the patient and their family members. It is the main cause of complex disability, with a high number of people living with its effects. Stroke can result in impairments in motor function, language, cognition, sensory processing, cognition, and emotional disturbances, which can affect the performance of functional activities and mental health status. Getting patients involved in art therapy (AT) class has shown to alleviate stress and promote a sense of wellbeing, which can aid their recovery and rehabilitation. The benefits of art therapy for people living with different health conditions worldwide have been reported, however, its effect on Egyptian patients with stroke has been neglected.","ExperimentalDrugs":"[\"other: art therapy\"]","Allcountries":"[\"Egypt\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":7,"Phase":"NA","lastUpdateDate":"2025-08-11"},{"nctId":"NCT07156955","OrgName":"Sungkyunkwan University","Titlefull":"Proprioceptive Error Correction Technique Development to Promote Post-stroke Upper Limbs Motor Rehabilitation","BriefSummary":"The investigators aim to develop sensory transformation and augmentation technologies that minimize the impact of proprioceptive errors, thereby significantly enhancing motor learning and rehabilitation of the upper limbs. This study is designed to test proprioceptive error compensation techniques in stroke patients.\n\nThe human nervous system often receives mismatched information from vision and proprioception during upper limb control, resulting in conflicting sensory inputs that limit the effectiveness of motor learning. In other words, real-time sensory feedback - a critical component of motor learning in the nervous system - is not reliably delivered. Therefore, this study seeks to resolve sensory conflicts by providing additional sensory information through electrical stimulation, with the goal of dramatically improving the effectiveness of motor learning.","ExperimentalDrugs":"[\"behavioral: electrical stimulation cue\",\"behavioral: visual stimulation cue\",\"behavioral: no cue\"]","Allcountries":"[\"South Korea\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":14,"Phase":"NA","lastUpdateDate":"2026-06-10"},{"nctId":"NCT07263776","OrgName":"Capital Medical University","Titlefull":"Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial-2 (IRIS-2)","BriefSummary":"This study is a randomized, double-blind, placebo-controlled clinical trial. Investigators aim to assess the efficacy and safety of interleukin-6 receptor inhibitor combined with endovascular treatment in patients with acute anterior circulation large vessel occlusion stroke.","ExperimentalDrugs":"[\"tocilizumab\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"ACTIVE_NOT_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":34,"Phase":"PHASE3","lastUpdateDate":"2026-06-11"},{"nctId":"NCT07331714","OrgName":"Riphah International University","Titlefull":"Comparative Effects of Proprioceptive Neuromuscular Facilitation and Modified Constraint Induced Movement Therapy on Lower Limb Function in Patient With Stroke","BriefSummary":"Stroke, which is frequently characterized by weakness, poor balance, and decreased mobility that impede independence in everyday activities, has been identified as a major cause of long-term impairment globally. There have been reports of an increasing number of stroke survivors in Pakistan, however access to proper rehabilitation is sometimes hampered by a lack of resources and awareness. It is thought that improving walking ability, balance, and day-to-day functioning requires the restoration of lower limb function. Modified Constraint-Induced Movement Therapy (mCIMT) and Proprioceptive Neuromuscular Facilitation (PNF) have been found to be successful physiotherapy interventions for improving motor recovery, but there is little comparative data on their impact on lower limb function.\n\nThe purpose of this study is to examine the effects of PNF and mCIMT in order to identify whether strategy is better for lower limb rehabilitation after stroke. The findings are expected to give physiotherapists evidence-based recommendations for treatment choices, enabling stroke patients to recover more quickly and become more independent. In the end, community-level advantages are anticipated in the form of less impairment, less caregiver stress, and an overall improvement in the quality of life for stroke victims.","ExperimentalDrugs":"[\"other: pnf\",\"other: mcimt\"]","Allcountries":"[\"Pakistan\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-12-29"},{"nctId":"NCT07080567","OrgName":"University Hospital, Geneva","Titlefull":"Maraviroc for Stroke Recovery (MASTER): A Phase 2 Double-Blind Placebo-Controlled Randomized Clinical Trial","BriefSummary":"MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.","ExperimentalDrugs":"[\"maraviroc\"]","Allcountries":"[\"Switzerland\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":17,"Phase":"PHASE2","lastUpdateDate":"2025-08-07"},{"nctId":"NCT07198048","OrgName":"Purdue University","Titlefull":"Treating Attention and Language in Post-stroke Aphasia Using a Music-based Intervention.","BriefSummary":"The goal of this clinical trial is to learn if a music-based intervention can acutely improve three types of attention (alerting, orientating, executive control) in people with aphasia following a stroke.\n\nThe main questions it aims to answer are:\n\n1. Is a music based intervention effective at improving attention with someone who has aphasia?\n2. Does music-induced changes in attention improve language abilities and quality of life with someone who has aphasia? Researchers will compare a group that listening to music, to listing to an audiobook group, to a group that serves as a control to see if there are changes in attention over time.\n\nParticipants will:\n\n1. Listen to music or an audiobook for 30 minutes a day for 8 weeks\n2. Complete a daily journal about each day's listening experience\n3. Complete three testing sessions where attention, language, and quality of life are assessed.","ExperimentalDrugs":"[\"behavioral: music-based therapy for post stroke aphasia\",\"behavioral: audiobook intervention for post stroke aphasia\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-09-25"},{"nctId":"NCT06749834","OrgName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","Titlefull":"Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on New Oral Anticoagulants","BriefSummary":"New oral anticoagulants (NOACs), including rivaroxaban, apixaban, dabigatran, and edoxaban, have become the first-line therapy for preventing ischemic stroke associated with non-valvular atrial fibrillation (NVAF). Despite the effectiveness of NOACs in preventing thromboembolic events, approximately 1% to 2% of patients taking NOACs experience an ischemic stroke annually. Intravenous thrombolysis is an important means of treating acute ischemic stroke (AIS). However, due to concerns about the risk of symptomatic intracranial hemorrhage (sICH) or other severe bleeding complications, current guidelines still consider the use of NOACs within 48 hours before symptom onset as a contraindication to intravenous thrombolysis. Epidemiological data suggest that this may result in up to 18% of AF patients being unable to receive intravenous thrombolysis when they have an AIS episode.\n\nPrevious animal experiments have shown that NOACs do not increase the risk of hemorrhagic transformation after intravenous thrombolysis. Pharmacokinetic studies have demonstrated that 24 to 48 hours after taking NOACs, the anti-Xa level in patients is relatively low (\\<0.5 U/mL). In recent years, multiple retrospective studies and meta-analyses have shown that prior use of NOACs does not increase the risk of sICH in AIS patients receiving intravenous thrombolysis, and there are no significant differences in functional outcomes at 3 months. With solid pharmacokinetic and retrospective clinical evidence to support, it is hypothesized that IVT are safe in IS-NOAC patient. The investigators hereby propose a prospective multicenter study to determine the efficacy and safety of IVT in acute IS-NOAC.","ExperimentalDrugs":"[\"intravenous thrombolysis\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"mRS at 90 days","total_Score":32,"Phase":"PHASE3","lastUpdateDate":"2025-02-20"},{"nctId":"NCT07139301","OrgName":"Capital Medical University","Titlefull":"Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation：a Randomised Controlled Trial","BriefSummary":"This study evaluates the safety and efficacy of early versus delayed initiation of direct oral anticoagulants (DOACs) in patients with acute ischemic stroke related to atrial fibrillation after emergency endovascular therapy (EVT).","ExperimentalDrugs":"[\"early anticoagulation\",\"delayed anticoagulation\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Late efficacy","total_Score":18,"Phase":"NA","lastUpdateDate":"2026-02-04"},{"nctId":"NCT07371624","OrgName":"Tasly Pharmaceutical Group Co., Ltd","Titlefull":"A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Allogeneic Adipose-Derived Mesenchymal Stromal Cell Injection (B2065) in Participants With Acute Ischemic Stroke.","BriefSummary":"This Phase I/IIa, randomized, double-blind, placebo-controlled study evaluates the safety, tolerability, and preliminary efficacy of B2065, an allogeneic adipose-derived mesenchymal stromal cell (AD-MSC) injection, in patients with acute ischemic stroke. Participants receive a single intravenous infusion of B2065 or placebo within 36 hours of stroke symptom onset. Phase I uses dose escalation with sentinel dosing to assess dose-limiting toxicities within 28 days and to inform dose selection. Phase IIa expands 1-2 selected dose level(s) and randomizes participants 2:1 (B2065:placebo). Safety and functional outcomes are assessed through 24 months.","ExperimentalDrugs":"[\"b2065\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Safety","total_Score":27,"Phase":"PHASE1","lastUpdateDate":"2026-01-19"},{"nctId":"NCT06638151","OrgName":"University of Alberta","Titlefull":"Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime): A Randomized Pilot Study","BriefSummary":"Stroke is a common cause of disability. The most common type of stroke, an ischemic stroke, is caused by a blood vessel in the brain getting blocked by a clot. When this happens, part of the brain is damaged because it is not getting the blood supply it needs. To treat this type of stroke, doctors give medication and/or do a procedure to remove the blockage and restore blood supply to the brain.\n\nUnfortunately, patients who have had an ischemic stroke are at higher risk of having another ischemic stroke. This risk is highest in the first 21 days after a stroke. Currently, doctors give patients the medication aspirin every day, starting 24 hours after stroke treatment, to prevent recurrent strokes. However, some studies have shown that giving another medication, clopidogrel, in addition to aspirin, is safe and may work better than aspirin alone at preventing repeat strokes. Both aspirin and clopidogrel are a type of medication called an antiplatelet that prevents clots from forming in the blood. When both medications are given together, it is called dual antiplatelet treatment. The main risk of antiplatelet medications is bleeding.\n\nThis research aims to study the safety and feasibility of using dual antiplatelet treatment to prevent recurrent strokes. Patients who have received treatment for an ischemic stroke will first be screened to rule out patients at high risk of bleeding. Following informed consent, patients at low risk of bleeding will be enrolled in the study 24 hours after their initial stroke treatment. Patients will be randomly assigned to either take aspirin alone or aspirin and clopidogrel for 21 days for recurrent stroke prevention. The study team will then follow patients for three months after treatment to collect information about their recovery and assess differences between the two groups.","ExperimentalDrugs":"[\"aspirin\",\"aspirin + clopidogrel\"]","Allcountries":"[\"Canada\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Safety","total_Score":22,"Phase":"PHASE2","lastUpdateDate":"2025-09-02"},{"nctId":"NCT07098143","OrgName":"Xuanwu Hospital, Beijing","Titlefull":"Individualized Risk Factor Management Application for Reducing the Recurrence Risk of Stroke: A Multicenter, Randomized Controlled Trial Study","BriefSummary":"This study applied an application that provides personalized suggestions and explore the effect of this actual intervention on reducing the risk of stroke recurrence","ExperimentalDrugs":"[\"other: risk factor management\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":8,"Phase":"NA","lastUpdateDate":"2025-09-02"},{"nctId":"NCT06911671","OrgName":"I.R.C.C.S. Fondazione Santa Lucia","Titlefull":"Innovative Upper Limb Stroke Rehabilitation Approach Combining Myoelectric Control Assistance in Virtual Reality and Cerebellar TBS Plasticity Enhancement","BriefSummary":"The investigators hypothesize that a myoelectric (EMG) controlled virtual reality (VR) interface allows for effective upper limb motor recovery of stroke patients. EMG control offers the possibility to alter visual feedback according to the recorded muscle activity in real-time. By manipulating the motion of a virtual hand associated with the recorded muscle patterns, assistance can be provided to stroke patients by correcting the error between the actual (dysfunctional) and a reference (functional) muscle pattern. Thus, through such an assistive EMG control algorithm, patients will be able to perform reaching movements with the virtual hand despite their motor impairment. By gradually reducing assistance, it is hypothesized that the salient error in the task space provided as visual feedback will systematically change the muscle patterns, thereby driving adaptation of the dysfunctional muscle patterns, enhancing motor recovery. Moreover, due to its relevant role in motor learning, it is expected that cerebellar stimulation will favor the underlying processes of adapting cerebello-cortical plasticity involved in motor learning. Therefore, it is hypothesized that an assistive EMG control algorithm in combination with cerebellar transcranial magnetic stimulation will further enhance upper limb recovery.","ExperimentalDrugs":"[\"device: virtual reality interface + cerebellar itbs (c-itbs)\",\"other: physical therapy\"]","Allcountries":"[\"Italy\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-01-30"},{"nctId":"NCT07113067","OrgName":"Medical University of South Carolina","Titlefull":"Accelerated rTMS for Post-stroke Apathy: A Double-blind Randomized Controlled Trial","BriefSummary":"Apathy is a common set of symptoms seen in many people following a stroke. Apathy occurs when a person has lost motivation, becomes withdrawn, and stops doing things that used to be important to them. Apathy has a large negative impact on a person's quality of life, and can also have a large impact the people who take care of them. There are currently no FDA-approved treatments to help with apathy, and other services like therapy may be difficult to access for people who have had a stroke. To address this problem, investigators are conducting a study to find out if a form of treatment called repetitive transcranial magnetic stimulation (rTMS) can be safe and helpful for people struggling with apathy after a stroke. This study will apply a new form of rTMS which can be delivered quickly to a part of the brain called the medial prefrontal cortex (mPFC). This study will help establish whether this treatment is safe, comfortable, and effective for people with apathy after a stroke, and will help researchers develop new forms of treatment.","ExperimentalDrugs":"[\"device: magventure magpro transcranial magnetic stimulation (tms) system (active)\",\"other: brainsight neuronavigation system\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":15,"Phase":"PHASE1","lastUpdateDate":"2025-10-21"},{"nctId":"NCT07483580","OrgName":"Jose R. Reyes Memorial Medical Center","Titlefull":"Elevated Leg Positioning For Acute Moderate Ischemic Stroke: The LEG-UP Randomized Feasibility Study","BriefSummary":"Augmentation of penumbral perfusion through nonpharmacological hemodynamic interventions such as patient positioning may offer a pragmatic approach to improve outcomes in acute ischemic stroke (AIS). This study aimed to assess the feasibility and safety of elevated leg positioning (ELP) in AIS, and to generate preliminary estimates of effect sizes to inform the design of a future definitive randomized trial.","ExperimentalDrugs":"[\"other: elevated leg positioning\"]","Allcountries":"[\"Philippines\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Other","total_Score":16,"Phase":"NA","lastUpdateDate":"2026-03-19"},{"nctId":"NCT06437600","OrgName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","Titlefull":"Immediate Angioplasty For Acute Ischemic Stroke With Severe Intracranial Atherosclerotic Stenosis (MAGIC): A Multicenter, Prospective, Open-label, Blinded Endpoint, Randomized Controlled Trial","BriefSummary":"A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial that aims to evaluate the effect of immediate angioplasty (with or without stenting) for acute ischemic stroke (AIS) with severe intracranial atherosclerotic stenosis (ICAS) in improving the 90-day functional outcome.","ExperimentalDrugs":"[\"procedure: immediate angioplasty\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"NA","lastUpdateDate":"2025-05-20"},{"nctId":"NCT06759753","OrgName":"Beijing Tiantan Hospital","Titlefull":"Aleeto in Acute ISchemic Stroke：A RandomISed Controlled Clinical Trial","BriefSummary":"This study is a prospective, double-blind, 1:1:1 randomized controlled study aimed at evaluating the efficacy and safety of Aleeto treatment compared to placebo in improving the NIHSS score at 14 days in patients with moderate to severe acute ischemic stroke. It also aims to explore the neuroprotective effects of Aleeto in moderate to severe acute ischemic stroke and provide data support and evidence for future clinical trials and evidence-based medicine.","ExperimentalDrugs":"[\"aleeto\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"NIHSS","total_Score":17,"Phase":"PHASE2","lastUpdateDate":"2025-09-01"},{"nctId":"NCT05930145","OrgName":"Fundación EPIC","Titlefull":"A Randomized Study Comparing the Effectiveness and Security of the Use of Two Stentrievers Simultaneously Versus One Stentriever as a Primary Treatment in Acute Ischemic Stroke Patients.","BriefSummary":"Several studies have demonstrated that simultaneous treatment with two stentrievers (STs) as rescue treatment is very effective, with high recanalization rates even in this group of patients where other revascularization techniques have failed. There has been no observed increase in hemorrhagic complications. Recently, a prospective study has been published where treatment with two ST has been shown to be effective and safe if used as a first-choice treatment (not as rescue) with a successful recanalization rate (eTICI 2c/3) after the first pass of 69%. These results have been reinforced after the publication of a randomized study that confirms, in vitro, the superiority of using two ST over one.","ExperimentalDrugs":"[\"device: double stentriever\",\"device: single stentriever\"]","Allcountries":"[\"Germany\",\"Spain\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":24,"Phase":"NA","lastUpdateDate":"2025-07-24"},{"nctId":"NCT07295301","OrgName":"Wenshan City People's Hospital","Titlefull":"A Clinical Applied Study on the Impact of Different Early Protein Supplementation Levels on the Prognosis of Neurocritical Patients","BriefSummary":"This study investigates the effect of different early protein supplementation levels (1.0-2.0g/kg/d, divided into three groups) on the prognosis of neurocritical patients, focusing on the 28-day Glasgow Coma Scale (GCS) score improvement rate. Participants will be randomly assigned to receive varying protein doses, and their short-term (28-day mortality, ICU stay, complications) and long-term (90-day mortality, readmission rate) clinical outcomes will also be compared.","ExperimentalDrugs":"[\"dietary supplement: low-dose enteral protein supplementation (enteral nutrition formulas + whey protein powder)\",\"dietary supplement: moderate-dose enteral protein supplementation (enteral nutrition formulas + whey protein powder)\",\"dietary supplement: high-dose enteral protein supplementation (enteral nutrition formulas + whey protein powder)\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2025-12-07"},{"nctId":"NCT07001267","OrgName":"University of Kansas Medical Center","Titlefull":"Prospective Randomized Observer Blinded Single Center Study Comparing 90-day Functional Outcome in Patients Who Received Intravenous Propofol Infusion Versus Inhalational Sevoflurane for General Anesthesia During Mechanical Thrombectomy in Patients Who Suffered From Acute Ischemic Stroke","BriefSummary":"This study is being done to compare outcomes after surgery for individuals who receive anesthesia through by inhaling medication and individuals who receive anesthesia intravenously by needle when experiencing treatment for their stroke. Currently very little is known about the outcomes for patients when comparing these two techniques of providing anesthesia during surgery. This study will provide information regarding outcomes that will help health care providers decide which technique will be better for patients","ExperimentalDrugs":"[\"procedure: anesthesia drugs during the surgery\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Other","TreatDur":"Day 1 only","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":23,"Phase":"NA","lastUpdateDate":"2026-03-10"},{"nctId":"NCT07084051","OrgName":"University of Kentucky","Titlefull":"Intervention to Improve Medication Adherence Among Stroke Survivors in Rural Kentucky","BriefSummary":"To test the feasibility and promise of a combined intervention provided by community health worker (CHW) in collaboration with pharmacy technician and pharmacist to improve hypertension and long-term stroke outcomes by identifying and reducing barriers to medication adherence among ischemic stroke survivors. This collaborative intervention involves a self-management program including an educational session on practical strategies to improve hypertension control (i.e., appropriately taking medications, necessity of treatment, and consequences of not taking medicine, etc.), complemented by individually-tailored sessions to identify and address barriers to medication adherence.","ExperimentalDrugs":"[\"behavioral: i-mas\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"COMPLETED","Add_on":"Other","Endpoint":"Other","total_Score":9,"Phase":"NA","lastUpdateDate":"2026-01-22"},{"nctId":"NCT06878066","OrgName":"Oslo University Hospital","Titlefull":"The Efficacy and Safety of Intravenous Thrombolysis in Acute Ischemic Stroke Patients With Recent Ingestion of Factor Xa-inhibitors Trial (SIFT)","BriefSummary":"This study looks at whether stroke patients who take FXa inhibitors (a type of blood thinner) can safely receive clot-busting treatment (IVT). IVT is a common emergency treatment for stroke, but current guidelines say it should not be given to people who have taken FXa inhibitors in the last 48 hours. This is because doctors worry that IVT might cause dangerous bleeding in the brain.\n\nHowever, new research suggests that IVT might be safe for these patients. Some studies even show that stroke patients on FXa inhibitors who receive IVT do not have a higher risk of brain bleeding than other stroke patients. But because these studies were not designed as full medical trials, doctors still avoid IVT for this group.\n\nThe SIFT trial will compare two groups of stroke patients who take FXa inhibitors:\n\nOne group will receive IVT to see if it helps them recover better. One group will not receive IVT, which is the current standard. Doctors will check if IVT helps with recovery and if it causes any serious bleeding. If IVT is found to be safe and effective, this study could change stroke treatment guidelines and help more patients get life-saving care.\n\nRight now, some guidelines say that stroke patients on FXa inhibitors should have a blood test before getting IVT, to measure how much of the drug is in their system. But these tests are not available in most hospitals, and waiting for results could delay important treatment. The SIFT trial will not require this test before giving IVT.\n\nMore and more people use FXa inhibitors to prevent strokes, but right now, they are being denied IVT based on old rules. If this study proves that IVT is safe for them, it could help doctors give better care to thousands of stroke patients.","ExperimentalDrugs":"[\"thrombolysis therapy\"]","Allcountries":"[\"Norway\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Early efficacy","total_Score":29,"Phase":"PHASE3","lastUpdateDate":"2025-08-29"},{"nctId":"NCT07073469","OrgName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","Titlefull":"Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial","BriefSummary":"The primary hypothesis being tested in this trial is that ischemic stroke patients in posterior circulation at 4.5 - 24 hours post onset of stroke will have improved clinical outcomes when given intravenous TNK compared to standard care.","ExperimentalDrugs":"[\"tenecteplase (tnk) (0.25 mg/kg, to maximum of 25mg)\",\"other: standard medical treatment\"]","Allcountries":"[]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":26,"Phase":"PHASE3","lastUpdateDate":"2025-08-14"},{"nctId":"NCT06829212","OrgName":"Shanghai StairMed Technology Co., Ltd.","Titlefull":"A Prospective Clinical Trial to Evaluate the Safety and Efficacy of Implantable Wireless Recording System (WRS) for General Control of External Devices in Paralyzed/Amputee Patients","BriefSummary":"The clinical trial aims to evaluate the safety and efficacy of the minimally invasive, wireless brain-machine interface system (WRS) in enabling general brain control of external devices, such as a cursor and other assistive technologies, for paralyzed and amputee patients.\n\nWRS integrates a high-throughput, ultra-flexible neural electrode with an extremely small cross-sectional size-approximately one-hundredth the diameter of a human hair. Moreover, the implantable component is fully embedded within the body, leaving no visible external traces.","ExperimentalDrugs":"[\"device: wrs\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":16,"Phase":"NA","lastUpdateDate":"2025-03-10"},{"nctId":"NCT07291024","OrgName":"Mayo Clinic","Titlefull":"Vagus Nerve Stimulation (VNS) Paired With Mobility Training For Gait Recovery After Chronic Ischemic Stroke With Integration Of Biomarker Assessment","BriefSummary":"The purpose of this study is to evaluate the safety, feasibility, and efficacy of vagus nerve stimulation (VNS) paired with mobility training to improve lower extremity function and gait in individuals with chronic ischemic stroke.","ExperimentalDrugs":"[\"other: vagus nerve stimulation (vns) paired with mobility training\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-02-12"},{"nctId":"NCT06781385","OrgName":"Wake Forest University Health Sciences","Titlefull":"Intra-Arterial Tenecteplase Following Endovascular Thrombectomy for Large Vessel Occlusion Stroke","BriefSummary":"The purpose of this study is to determine the safety and feasibility of using intra-arterial Tenecteplase in patients undergoing blood clot extraction for treatment of acute ischemic (non-bleeding) stroke. Intravenous Tenecteplase is FDA-approved to treat patients with an ischemic stroke presenting within the 0-3-hour time window.","ExperimentalDrugs":"[\"intra-arterial tenecteplase\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"ENROLLING_BY_INVITATION","Add_on":"IVT optional; EVT mandatory","Endpoint":"Safety","total_Score":24,"Phase":"PHASE2","lastUpdateDate":"2026-05-29"},{"nctId":"NCT07235514","OrgName":"University Hospital, Clermont-Ferrand","Titlefull":"General Anesthesia Versus Procedural Sedation in Endovascular Therapy for Anterior Circulation Large Vessel Occlusion Stroke: A Multicenter Prospective Randomized Trial","BriefSummary":"The goal of this clinical trial is to learn what is the best anesthetic management in participants with severe stroke that require a medical intervention called mechanical thrombectomy (MT) done to open the occluded brain vessel.\n\nThe main question it aims to answer is:\n\n• Is general anesthesia (GA) better than procedural sedation (PS) for improving functional performance and decrease dependance in daily life 3 months after stroke?\n\nGA (a non-arousable state induced by anesthetic medications that require respiratory assistance) or PS (a state of reduced arousal induced by lesser dose of anesthetic medications that do not require respiratory assistance) are both used for MT. GA enables strict immobility that could facilitate the conduct of MT but lessen blood pressure and blood flow in the brain. PS provides less drop in blood pressure but MT could be more difficult due to possible movement and breathing may be decreased.\n\nResearchers will compare GA with PS to see which one is better for MT success and for the functional consequences of stroke.\n\nParticipants will be treated with GA or PS for the intervention of MT and will be followed by researchers during their hospital stay and asked by a telephone interview how is their functional status 3 months after stroke.","ExperimentalDrugs":"[\"procedure: general anesthesia\",\"procedure: procedural sedation\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Other","TreatDur":"Day 1 only","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":22,"Phase":"NA","lastUpdateDate":"2025-11-17"},{"nctId":"NCT06440707","OrgName":"University of California, Los Angeles","Titlefull":"Transcranial Electrical Stimulation in Stroke EaRly After Onset Clinical Trial 2","BriefSummary":"Many patients with acute ischemic stroke are ineligible for currently available standard treatments (clot-busting medication, also known as intravenous thrombolytic or mechanical removal of a clot), and many are non-responders, resulting in a low rate of excellent outcomes, which necessitates the development of novel therapies.\n\nIn this study, investigators are testing a new treatment in which a weak electrical current will be applied via scalp electrodes to increase collateral blood flow to the brain and rescue the brain tissue at risk of injury. The primary aim is to find an optimal dose of this therapy that is both adequately safe and effective on imaging markers of brain tissue rescue.","ExperimentalDrugs":"[\"device: high-definition cathodal transcranial direct current stimulation (hd c-tdcs)\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"Safety","total_Score":27,"Phase":"PHASE2","lastUpdateDate":"2026-04-27"},{"nctId":"NCT07113184","OrgName":"Instituto de Investigación Marqués de Valdecilla","Titlefull":"DUAL VERSUS SINGLE STENTRIEVER FOR RECANALIZATION IN ACUTE ISCHEMIC STROKE: THE RANDOMIZED DOUBLE UP TRIAL","BriefSummary":"This study seeks to provide high-quality evidence on the potential benefits of the dual stentriever approach, potentially informing future clinical guidelines and improving outcomes in patients with anterior circulation large vessel occlusion strokes.","ExperimentalDrugs":"[\"device: dual sr\",\"device: single sr\"]","Allcountries":"[\"Spain\"]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":16,"Phase":"NA","lastUpdateDate":"2025-08-04"},{"nctId":"NCT06905314","OrgName":"Beijing Suncadia Pharmaceuticals Co., Ltd","Titlefull":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HRS-4029 Following a Single Dose in Healthy Subjects","BriefSummary":"The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-4029 following a single intravenous dose administration in healthy subjects.","ExperimentalDrugs":"[\"hrs-4029\",\"placebo\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":22,"Phase":"PHASE1","lastUpdateDate":"2025-03-25"},{"nctId":"NCT07163338","OrgName":"CHU de Reims","Titlefull":"A Prospective, Single-center Cohort Study to Determine the Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS)","BriefSummary":"Stroke represents a major cause of morbidity and mortality despite significant progress in recent decades. In individuals under the age of 65, the etiologies of ischemic stroke (IS) are diverse, and management is well-established. Antiphospholipid syndrome (APS) accounts for 10 to 20% of the causes of stroke in this population. In elderly individuals, APS is not systematically investigated due to the predominance of embolic, atherosclerotic, and small vessel disease causes. However, delayed discovery of APS is not uncommon and is more frequently associated with the occurrence of arterial thrombosis. Moreover, the management of APS involves several challenges given the risk of recurrence of thrombosis and the potential association with conventional cardiovascular risk factors. The antithrombotic treatment consists of lifelong anticoagulation, excluding direct oral anticoagulants (DOACs) due to the risk of thrombotic recurrence. The main objective of the study will be to assess the prevalence of antibodies useful for the diagnosis of APS (Sapporo criteria) in individuals aged 65 or older hospitalized for an ischemic stroke (IS) or transient ischemic attack (TIA).\n\nFurthermore, the classification of APS is likely to evolve in the coming years with the inclusion of new clinically relevant antibodies (anti-phosphatidylserine and anti-phosphatidylethanolamine) because of their strong association with the occurrence of thrombosis. Even though they are often associated with circulating anticoagulants, they are also found in 10% of APS cases negative for other antibodies.\n\nPatient inclusion in the study should occur during the acute phase of the stroke, before the initiation of anticoagulant treatment.\n\nThus, after verifying the inclusion and exclusion criteria, patients will be informed and must sign the informed consent form if they agree to participate.\n\nAfter inclusion, the research procedure will be as follows:\n\n* Conduct a unique immunological biological assessment with:\n\n  * Part performed as part of standard care: circulating anticoagulants, anti-cardiolipin antibodies, and anti-β2-glycoprotein type 1.\n  * Part performed specifically for the study (3.5 mL of additional blood): anti-phosphatidylserine and anti-phosphatidylethanolamine antibodies. The search for these antibodies will be performed using the 7mL dry tube collected for anti-cardiolipin and anti-β2-glycoprotein type 1 antibody testing.\n  * If the diagnostic sample is positive for any of these antibodies, a follow-up at 3 months is recommended and will be performed as part of standard care to confirm the APS diagnosis.\n* Data collection will include patient details, stroke/TIA details, biological data, and follow-up. As part of routine follow-up, patients will be seen in a neurological consultation at 6 months.\n\nClinical and biological data will be reviewed at the end of the study by two doctors (a neurologist and an internist) to confirm or exclude the APS diagnosis and its contribution to the neurological condition.\n\nAn internal medicine follow-up will be initiated for patients with confirmed APS, and an appropriate treatment will be proposed.","ExperimentalDrugs":"[\"other: collectio nof blood\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":5,"Phase":"NA","lastUpdateDate":"2025-11-24"},{"nctId":"NCT06987643","OrgName":"EIP Pharma Inc","Titlefull":"A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic Stroke","BriefSummary":"The purpose of this interventional study is to determine whether neflamapimod can improve residual physical disability and/or cognitive dysfunction after Moderate to Severe Acute Ischaemic Stroke.","ExperimentalDrugs":"[\"neflamapimod\"]","Allcountries":"[\"Australia\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":21,"Phase":"PHASE2","lastUpdateDate":"2026-02-05"},{"nctId":"NCT06920706","OrgName":"Xuanwu Hospital, Beijing","Titlefull":"Efficacy of Remote Ischemic Conditioning in Preventing Post-Stroke Depression: A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial","BriefSummary":"Post-stroke depression (PSD) is characterized primarily by low mood and loss of interest following a stroke. It is one of the most common and serious complications of stroke, with an incidence of 11% to 41% within two years post-stroke. PSD significantly impacts stroke prognosis, not only hindering neurological recovery but also increasing clinical disability and mortality rates, thereby imposing substantial economic and psychological burdens on families and society. Therefore, preventing PSD is crucial for stroke rehabilitation.\n\nClinical trials have demonstrated that preventive antidepressant treatment can reduce PSD incidence and improve clinical outcomes; however, controversies remain regarding the timing, methods, and safety. Meanwhile, preventive psychological therapy faces challenges in implementation due to effectiveness, accessibility, and cost-effectiveness.\n\nRemote ischemic preconditioning (RIC) is a non-invasive, cost-effective, and non-pharmacological intervention. By modulating small molecules in the peripheral and central nervous systems through transient, periodic limb blood flow restriction and reperfusion, RIC reverses neurobiological changes and demonstrates neuroprotective potential in various neurological diseases. Recently, a study showed that RIC is safe and effective in preventing PSD; however, the sample size is small and the specific mechanisms remain unclear. Therefore, this study aims to further explore the role and mechanisms of RIC in PSD prevention.","ExperimentalDrugs":"[\"device: ric\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":11,"Phase":"NA","lastUpdateDate":"2025-04-02"},{"nctId":"NCT06853535","OrgName":"Sichuan Provincial People's Hospital","Titlefull":"Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE","BriefSummary":"The objective of this clinical trial is to evaluate the efficacy and safety of platelet aggregation function - guided precision anti - platelet therapy in patients with acute cerebral infarction. The main question it aims to answer is: among the cerebral infarction patients with possible clopidogrel resistance detected by platelet aggregation function tests, what is the efficacy and safety of using ticagrelor to replace the clopidogrel treatment regimen.","ExperimentalDrugs":"[\"the ticagrelor\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Late efficacy","total_Score":21,"Phase":"PHASE3","lastUpdateDate":"2026-05-11"},{"nctId":"NCT07063810","OrgName":"Slb Pharma","Titlefull":"NEO-REEDUC - Mixed Reality for Motor Rehabilitation: a Prospective, Multicenter, Controlled, Randomized, Open Study.","BriefSummary":"This study aims to assess the effectiveness of a motor rehabilitation protocol that includes mixed reality activities, compared to conventional rehabilitation, on postural stability in children and adult patients with neurological impairments.","ExperimentalDrugs":"[\"device: mixed reality rehabilitation\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-07-02"},{"nctId":"NCT07244952","OrgName":"University of Lahore","Titlefull":"Effects of Vojta Therapy on Posture and Trunk Control in Patients With Sub-acute Stroke","BriefSummary":"Vojta therapy that is reflex locomotion therapy is a neurophysiological rehabilitation approach that stimulates specific \"reflex zones\" on the body to activate global, innate movement patterns. In stroke rehabilitation, it is used to improve postural control, trunk stability, and functional movement by engaging automatic motor responses. Vojta stimulation can activate motor cortical and subcortical areas as well as postural muscles. Pose estimation will be used to analyze human motion in stroke patients. The study will identify if there is significant difference in the comparative effects of Vojta therapy in addition to routine physical therapy on posture, trunk control and upper extremity motor function in sub-acute stroke patients","ExperimentalDrugs":"[\"other: vojta therapy\",\"other: routine physical therapy\"]","Allcountries":"[\"Pakistan\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":14,"Phase":"NA","lastUpdateDate":"2025-11-22"},{"nctId":"NCT06386289","OrgName":"Cerenovus, Part of DePuy Synthes Products, Inc.","Titlefull":"Safety, Performance and Lesion Evaluation of Neurothrombectomy Using CEREGLIDE 92 Intermediate Catheter: A Prospective Multi-Center Single-Arm IDE Trial (SPLENDID)","BriefSummary":"The device is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease","ExperimentalDrugs":"[\"device: cereglide 92\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"WITHDRAWN","Add_on":"IVT optional; EVT optional","Endpoint":"Other","total_Score":18,"Phase":"NA","lastUpdateDate":"2025-08-25"},{"nctId":"NCT06472336","OrgName":"University Hospital, Basel, Switzerland","Titlefull":"IntraCranial Atherosclerosis Related Large-vessel Occlusion Treated With Urgent Stenting - a Pragmatic, International, Multicentre, Randomized Trial","BriefSummary":"The goal of this international, multi-center, randomized clinical trial is to compare two treatment options, early intracranial stenting and continued stent-retriever or aspiration based endovascular treatment, for stroke patients with a large vessel occlusion, who experienced failure of recanalisation after initial treatment due to intracranial atherosclerosis.","ExperimentalDrugs":"[\"procedure: intracranial stenting\",\"procedure: continuation of conventional endovascular therapy (evt)\"]","Allcountries":"[\"Switzerland\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"NA","lastUpdateDate":"2025-12-09"},{"nctId":"NCT07096687","OrgName":"Azienda Usl di Bologna","Titlefull":"Targeted Temperature Management for Neuroprotection in Acute Ischemic Stroke: A Randomized Controlled Pilot Trial","BriefSummary":"The goal of this interventional trial is to evaluate whether the CB240\\_Aurora medical device is effective for targeted temperature management in adult patients with acute ischemic stroke. The main questions it aims to answer are: Is the CB240\\_Aurora effective in maintaining normothermia in patients with acute ischemic stroke? Does the medical device improve clinical and radiological outcomes? Is the medical device well tolerated by patients? Researchers will compare an interventional arm, in which the CB240\\_Aurora measures and treats body temperature to maintain normothermia, with a control arm, in which the CB240\\_Aurora only measures but does not treat body temperature. Participants will wear the medical device for 72 consecutive hours in the Stroke Unit. Outcome assessments will be performed at 72 hours, 7 days, and 3 months.","ExperimentalDrugs":"[\"device: targeted temperature management with cb240_aurora\",\"device: standard of care temperature treatment\"]","Allcountries":"[\"Italy\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Other","total_Score":14,"Phase":"NA","lastUpdateDate":"2025-09-11"},{"nctId":"NCT07302854","OrgName":"Tongji Hospital","Titlefull":"Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion -- A Multicenter, Prospective, Randomized, Open-label, Blinded End-point Trial","BriefSummary":"Medium vessel occlusion (MeVO) accounts for 20-45% of acute ischemic stroke (AIS). Although patients with MeVO often present with relatively low NIHSS scores, up to one-third remain functionally dependent at follow-up despite receiving standard medical therapy, including intravenous thrombolysis. Recent randomized trials (DISTAL, ESCAPE-MeVO, DISCOUNT) have not demonstrated clinical benefit of endovascular treatment (EVT) for MeVO and have suggested higher risks of symptomatic intracranial hemorrhage and mortality, underscoring the need for safer and more targeted reperfusion strategies.\n\nIntra-arterial thrombolysis (IAT) enables localized, high-concentration thrombolytic delivery with minimal mechanical manipulation, which may be advantageous for medium and distal vessels. Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA), a genetically engineered third-generation thrombolytic agent, has shown favorable pharmacologic properties and clinical safety in AIS, including in intra-arterial use following EVT. However, prospective evidence supporting its direct therapeutic role in MeVO-related AIS remains lacking.\n\nThis multicenter, prospective, open-label randomized controlled trial with blinded endpoint assessment is designed to evaluate the efficacy and safety of intra-arterial rhTNK-tPA thrombolysis in improving functional outcome in MeVO within 24 hours of symptom onset.","ExperimentalDrugs":"[\"procedure: intra-arterial thrombolysis\",\"standard medical treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":32,"Phase":"PHASE2","lastUpdateDate":"2026-01-19"},{"nctId":"NCT07174375","OrgName":"Nanfang Hospital, Southern Medical University","Titlefull":"Efficacy and Safety of PCSK9 Inhibitors in Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy: A Prospective, Multicenter, Open-Label, Parallel, Randomized Controlled Clinical Trial","BriefSummary":"This is a prospective, multicenter, randomized controlled clinical study to evaluate the efficacy of PCSK9 inhibitor in addition to standard therapy in patients with acute ischemic stroke undergoing endovascular therapy.","ExperimentalDrugs":"[\"pcsk9 inhibitor\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":21,"Phase":"PHASE2","lastUpdateDate":"2025-09-12"},{"nctId":"NCT06826144","OrgName":"The First Affiliated Hospital with Nanjing Medical University","Titlefull":"Chronic Remote Ischemic Conditioning in Small Infarctions Associated with Stent-assisted Coiling of Unruptured Intracranial Aneurysms: a Single-center Randomized Controlled Trial.","BriefSummary":"1. Disease Description Stent-assisted coiling has become an effective treatment modality for intracranial aneurysms. With continuous advancements in periprocedural antiplatelet regimens, the incidence of symptomatic thromboembolic events has significantly decreased. However, the rate of procedure-related microembolic infarctions, which are characterized by punctate hyperintense signals on DWI, remains high (10%-76.5%). The underlying causes of these microembolic infarctions remain controversial and may be associated with factors such as different stent types, sheath types, antiplatelet regimens, intraoperative adverse events (e.g., vascular dissection or spasm), patient age, and procedure duration. While most patients with microembolic infarctions exhibit no overt clinical symptoms, the presence of these infarctions reflects underlying tissue damage, posing potential risks that cannot be ignored. Furthermore, their occurrence highlights insufficient preoperative preparation or intraoperative technical issues, which may increase the likelihood of symptomatic embolism. Therefore, investigating the causes of microembolic infarctions and exploring preventive strategies is of great clinical significance.\n2. Intervention Description Remote ischemic conditioning (RIC) involves inducing temporary ischemia in distal vessels to protect target vessels from ischemic and reperfusion injuries. RIC can be performed before, during, or after ischemic events and is widely used in the context of coronary artery ischemia. Some studies have shown that RIC can mitigate ischemia-related injuries in the myocardium, kidneys, and lower limbs following cardiovascular surgeries. Previous research has also demonstrated the neuroprotective effects of RIC in ischemia-reperfusion injuries of the nervous system. For instance, RIC significantly improves outcomes in cerebral small vessel disease (CSVD)-related acute stroke events and ameliorates cognitive impairments associated with CSVD. Moreover, the safety and efficacy of RIC have been validated in other conditions or procedures, such as aneurysmal subarachnoid hemorrhage (aSAH), intracranial atherosclerotic stenosis, and carotid artery stenting.\n3. Research Hypothesis Current clinical studies on RIC have primarily focused on acute ischemic stroke (including large artery atherosclerosis and CSVD), spontaneous intracerebral hemorrhage, and subarachnoid hemorrhage. The Remote Ischemic Conditioning for Acute Stroke Trial (RESIST) indicated that RIC effectively improves outcomes in acute strokes related to CSVD, including reducing white matter hyperintensities, infarct volume, and modified Rankin Scale (mRS) scores. A clinical study conducted at the Mayo Clinic demonstrated the safety of remote ischemic preconditioning (RIPC) during intracranial aneurysm coiling. Our center's previous study on \"Tirofiban and Procedure-Related Microemboli in Stent-Assisted Aneurysm Coiling\" revealed that the incidence of procedure-related microembolic infarctions was 61.1% in the non-tirofiban group and 19.4% in the tirofiban-treated group. However, there is currently a lack of research on the use of RIC for procedure-related microembolic infarctions in stent-assisted aneurysm coiling.\n\nThis study aims to explore the efficacy of ischemic conditioning treatment, performed preoperatively and postoperatively, in reducing procedure-related microembolic infarctions during standard stent-assisted aneurysm coiling. The primary outcomes include the incidence of acute microembolic infarctions postoperatively and the incidence of symptomatic microembolic infarctions at one month following RIC.","ExperimentalDrugs":"[\"procedure: remote ischemic conditioning\"]","Allcountries":"[]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":8,"Phase":"NA","lastUpdateDate":"2025-02-10"},{"nctId":"NCT07279493","OrgName":"Kunming Pharmaceuticals, Inc.","Titlefull":"A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase Ⅱb Clinical Trial to Evaluate the Efficacy and Safety of the KPCXM18 Injection at Different Doses in The Treatment of Acute Ischemic Stroke","BriefSummary":"This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke.","ExperimentalDrugs":"[\"the kpcxm18 injection\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 12 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"PHASE2","lastUpdateDate":"2025-12-09"},{"nctId":"NCT07127172","OrgName":"Neuralink Corp","Titlefull":"GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices","BriefSummary":"The GB-PRIME Study is an early feasibility study designed to assess the clinical safety and functionality of the Neuralink N1 Implant and R1 Robot. This study involves participants who have tetraparesis, tetraplegia, or a diagnosis that may lead to these conditions.\n\nThe N1 Implant is a wireless, rechargeable device mounted on the skull, connected to electrode threads that are inserted into the brain by the R1 Robot, which is a robotic device specifically designed for this procedure.","ExperimentalDrugs":"[]","Allcountries":"[\"United Kingdom\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":11,"Phase":"NA","lastUpdateDate":"2025-08-11"},{"nctId":"NCT07026344","OrgName":"Beijing Anzhen Hospital","Titlefull":"Efficacy of Rescue Stenting/Angioplasty After Failed Thrombectomy for Acute Large Intracranial Vascular Occlusion: A Multicenter, Prospective, Open-label, Endpoint-blinded, Randomized Controlled Trial","BriefSummary":"The primary objective of this study is to evaluate whether rescue stenting therapy can improve neurological functional outcomes after failed endovascular treatment for acute ischemic stroke caused by large vessel occlusion. The study population is divided into two groups:\n\nStent Placement Group: If recanalization is not achieved after 3-5 attempts of thrombectomy, direct stent placement or balloon angioplasty is performed.\n\nContinued Thrombectomy Group: If recanalization is not achieved after 3-5 attempts of thrombectomy, at least one additional thrombectomy attempt is performed.\n\nThe primary efficacy endpoint is the proportion of patients achieving a modified Rankin Scale (mRS) score of 0-2 at 90±7 days.\n\nThe safety endpoint is the incidence of symptomatic intracranial hemorrhage within 48 hours after randomization.","ExperimentalDrugs":"[\"procedure: stent placement\",\"procedure: balloon angioplasty\",\"procedure: continued thrombectomy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"ACTIVE_NOT_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"NA","lastUpdateDate":"2025-08-12"},{"nctId":"NCT06777680","OrgName":"Ospedali Riuniti Trieste","Titlefull":"Efficacy of Palmitoylethanolamide and Luteolin on Early Functional Recovery in Acute Stroke Patients Treated with Thrombectomy: a Pilot Randomized Placebo-controlled Prospective Study","BriefSummary":"Acute ischemic stroke is caused by reduced blood supply to the brain associated with neuroinflammation. This mechanism contributes to acute neuronal death and persists even after reopening of the closed vessel, with consequent limitation of clinical and functional improvement.\n\nExperimental and clinical evidence demonstrated the anti-inflammatory and neuroprotective effect of micronized and ultramicronized Palmitoylethanolamide (PEA).\n\nThe aim of this study is to evaluate the effect of co-ultramicronized PEA and luteolin (700 mg + 70 mg in 10 ml) on the clinical outcomes of patients with acute ischemic stroke undergoing mechanical thrombectomy.","ExperimentalDrugs":"[\"dietary supplement: co-ultramicronized palmitoylethanolamide + luteolin (770 mg)\",\"procedure: thrombectomy\"]","Allcountries":"[\"Italy\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"NIHSS","total_Score":11,"Phase":"NA","lastUpdateDate":"2025-01-10"},{"nctId":"NCT07201688","OrgName":"CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.","Titlefull":"Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Recombinant Human TNK Tissue-Type Plasminogen Activator for Injection (rhTNK-tPA, Mingfule) in Intravenous Thrombolysis for Acute Ischemic Stroke With Extended Time Window (4.5-24 Hours After Onset).","BriefSummary":"This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy of recombinant human tissue-type plasminogen activator variant (rhTNK-tPA) (0.25 mg/kg, maximum dose 25 mg) compared with placebo in patients with acute large vessel occlusive stroke who present within 4.5 to 24 hours of symptom onset. The study plans to enroll patients with acute large vessel occlusive stroke who present within 4.5 to 24 hours of symptom onset (including wake-up strokes and strokes without witnesses). A centralized 1:1 randomization will be adopted, and eligible participants will be randomly assigned to two groups: the experimental group will receive rhTNK-tPA at a dose of 0.25 mg/kg, while the placebo group will receive rhTNK-tPA placebo.","ExperimentalDrugs":"[\"rhtnk-tpa\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"PHASE3","lastUpdateDate":"2025-12-08"},{"nctId":"NCT06778525","OrgName":"Istanbul University - Cerrahpasa","Titlefull":"The Effect of Rehabilitative Games With SmartPose Practice on Upper Extremity Recovery in Ischemic Stroke Patients","BriefSummary":"The goal of this clinical trial is to investigate the effects of SmartPose games on upper extremity motor, functional, and sensory recovery in patients with stroke. The main question it aims to answer is:\n\n* Does the use of rehabilitative games with the SmartPose application work to treat upper extremity motor, functional, and sensory recovery in stroke patients?\n\nResearchers will compare the experimental group with the control group, which receives only conventional exercises with proven effectiveness, to determine whether SmartPose has an effect on upper extremity motor, functional, and sensory recovery in stroke patients.\n\nThe experimental group will receive 30 minutes of neuromuscular therapy and 30 minutes of SmartPose, 3 times a week for 8 weeks.\n\nThe control group will receive 60 minutes of neuromuscular therapy, 3 times a week for 8 weeks.","ExperimentalDrugs":"[\"other: exercise\",\"other: smartpose\"]","Allcountries":"[\"Turkey (Türkiye)\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"COMPLETED","Add_on":"Other","Endpoint":"Late efficacy","total_Score":18,"Phase":"NA","lastUpdateDate":"2026-01-20"},{"nctId":"NCT07199322","OrgName":"Fondazione Don Carlo Gnocchi Onlus","Titlefull":"Clinical validatiOn of an AI-based DEcision Support System for Robotic Upper Limb Rehabilitation in Patients With Stroke. A CO-AIDER Study.","BriefSummary":"The goal of this clinical trial is to validate an artificial intelligence-based decision support system (AI-DSS) for robotic rehabilitation in participants with stroke.\n\nThe study aims to answer the following questions:\n\n* Can the AI-DSS support therapists in setting therapy parameters and adapting personalized robotic rehabilitation programs effectively?\n* Can AI-supported robotic rehabilitation improve upper limb function, activities of daily living (ADL), cognitive function, and quality of life compared with standard therapist-guided robotic rehabilitation?\n\nResearchers will compare two groups:\n\n* Robotic rehabilitation supported by the AI-DSS (CO-AIDER);\n* Robotic rehabilitation with parameters set by therapists (control group).\n\nParticipants will:\n\n* Receive robotic rehabilitation for the upper limb, either guided by the AI-DSS or by therapists;\n* Be monitored throughout the program, with therapy parameters adjusted according to their progress;\n* Complete assessments to evaluate changes in upper limb function, activities of daily living, cognitive function, and quality of life.\n\nThe study will also evaluate the usability and acceptability of the AI-supported robotic system as perceived by participants and clinical staff, and will include a cost-effectiveness analysis of the two interventions.","ExperimentalDrugs":"[\"device: robotic upper limb rehabilitation in patients with stroke with ai support\",\"device: robotic upper limb rehabilitation in patients with stroke without ai support\"]","Allcountries":"[\"Italy\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":7,"Phase":"NA","lastUpdateDate":"2025-09-26"},{"nctId":"NCT06930638","OrgName":"Medical College of Wisconsin","Titlefull":"MitoQ and Ischemic Conditioning To Assess Vascular Health Outcomes (MITO Study)","BriefSummary":"Stroke survivors have compromised vascular function which may contribute to secondary stroke risk, cardiovascular disease, and may limit their exercise tolerance. Preliminary data shows a single bout of ischemic conditioning or oral ingestion of an over-the-counter antioxidant supplement called MitoQ may improve vascular function and muscle activity in individuals post-stroke.","ExperimentalDrugs":"[\"device: ischemic conditioning\",\"dietary supplement: antioxidant supplement\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":14,"Phase":"PHASE2","lastUpdateDate":"2025-09-22"},{"nctId":"NCT07202663","OrgName":"Basking Biosciences, Inc.","Titlefull":"A Single Center, Two-part, Double-blind, Randomized, Placebo-controlled, Dose-escalation, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BB-025 or Placebo, Alone and Following a Single Dose of BB-031, in Healthy Volunteers","BriefSummary":"The goal of this 2-part clinical trial is to learn about the safety and pharmacokinetics (PK) of a single dose of BB-025 when given on its own and after being given BB-031. Researchers will compare BB-025 to placebo (a look-alike substance that contains no drug) both on its own and after being given a single dose of BB-031 to assess the use of BB-025 as a reversal agent.\n\nIn the first part of the study, participants will receive a single dose of BB-025 or placebo. They will be followed for 28 days to check if they have any symptoms.\n\nIn the second part of the study, participants will receive a single dose of BB-031 and then be given either BB-025 or placebo. These participants will also be followed for 28 days to check if they have any symptoms.","ExperimentalDrugs":"[\"bb-025\",\"bb-031\"]","Allcountries":"[\"Australia\"]","FirstAdminInter":"Not AIS","TreatDur":"Only once","Status":"COMPLETED","Add_on":"Other","Endpoint":"Safety","total_Score":22,"Phase":"PHASE1","lastUpdateDate":"2026-04-01"},{"nctId":"NCT07300358","OrgName":"Shanghai Lingsi Medical Technology Co., Ltd.","Titlefull":"BIOCLOSE-PFO Study：Evaluation of the Safety and Efficacy of a Biodegradable Patent Foramen Ovale Occluder System: A Prospective, Multicenter, Randomized Controlled, Non-Inferiority Clinical Study","BriefSummary":"To evaluate the Safety and Efficacy of a Novel Biodegradable Occluder for Percutaneous Closure of Patent Foramen Ovale (PFO)","ExperimentalDrugs":"[\"device: active comparator\",\"device: experimental\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":12,"Phase":"NA","lastUpdateDate":"2025-12-09"},{"nctId":"NCT07137832","OrgName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","Titlefull":"OPtimizing REperfusion by Intra-Arterial ThRomboLysis as Adjunct to Endovascular Treatment for Medium Vessel Occlusion (PEARL-MeVO): A Multicenter, Prospective, Randomized Controlled, Open-label, Blinded-Endpoint Clinical Trial","BriefSummary":"PEARL-MeVO is an investigator-initiated, multicenter, prospective, randomized controlled, open-label, blinded endpoint (PROBE) clinical trial aiming at evaluating the efficacy and safety of intra-arterial thrombolysis as adjunct to endovascular treatment in improving 90-day functional outcome in acute ischemic stroke patients due to medium vessel occlusion (MeVO) within 24 hours of symptom onset.","ExperimentalDrugs":"[\"combination product: intra-arterial thrombolysis as adjunct to endovascular treatment\",\"other: standard medical treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":34,"Phase":"PHASE3","lastUpdateDate":"2026-04-14"},{"nctId":"NCT07111559","OrgName":"Nippon Medical School","Titlefull":"A Multicenter Randomized Controlled Trial Comparing Tissue Plasminogen Activator With Dual Antiplatelet Therapy for Patients With Hyperacute Single Perforating Artery Infarction","BriefSummary":"The goal of this clinical trial is to learn if a combination of antiplatelet drugs works better than intravenous tissue plasminogen activator to treat small ischemic stroke (lacunar stroke). The main questions it aims to answer are:\n\nIs a combination of antiplatelet drugs non-inferior to the current standard tissue plasminogen activator treatment? Does a combination of antiplatelet drugs reduce the bleeding complications than tissue plasminogen activator?\n\nResearchers will compare a combination of antiplatelet drugs to tissue plasminogen activator to see if a combination of antiplatelet drugs works to treat small ischemic stroke (lacunar stroke).\n\nParticipants will:\n\nTake a combination of antiplatelet drugs or be given intravenous tissue plasminogen activator Check the neurological status 3 months after stroke, in-person, by phone, or by mail.","ExperimentalDrugs":"[\"rt-pa\",\"dapt\"]","Allcountries":"[\"Japan\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"mRS at 90 days","total_Score":23,"Phase":"PHASE4","lastUpdateDate":"2026-06-04"},{"nctId":"NCT07220538","OrgName":"Dr. Willmar Schwabe GmbH & Co. KG","Titlefull":"Pragmatic Open-label, Parallel-group Clinical Trial on the Effectiveness of Extract of Ginkgo Biloba Leaves Tablets as add-on to Standard of Care in Participants With Cognitive Impairment After an Acute Ischemic Stroke (GiCIIS)","BriefSummary":"The goal of this clinical trial is to learn if Extract of Ginkgo Biloba Leaves Tablets help improve thinking and memory in people aged 55 years and older who had an ischemic stroke (a type of stroke caused by a blocked blood vessel in the brain). It will also look at how safe the Extract of Ginkgo Biloba Leaves Tablets are.\n\nThe main questions it aims to answer are:\n\n* Do the Extract of Ginkgo Biloba Leaves Tablets help people with memory or thinking problems after an ischemic stroke?\n* What medical problems do people have when taking the Extract of Ginkgo Biloba Leaves Tablets ? Researchers will compare people who take the Extract of Ginkgo Biloba Leaves Tablets along with their usual post-stroke treatment to people who only receive their usual post-stroke treatment.\n\nParticipants will:\n\n* Have had an ischemic stroke confirmed by MRI (Magnet Resonance Imaging, a magnetic scan that helps seeing inside the body in great detail) 7 to 14 days before joining the study\n* Take Extract of Ginkgo Biloba Leaves Tablets (240 mg per day) in addition to usual post-stroke treatment for 12 months, or receive only usual post-stroke treatment for 12 months\n* Be treated initially at hospitals across China\n* Visit the clinic 4, 26, and 52 weeks following the baseline for checkups and tests, and receive follow-up calls after 12 and 38 weeks.","ExperimentalDrugs":"[\"extract of ginkgo biloba leaves tablets 240 mg (2 x 40 mg, t.i.d.)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Other","total_Score":19,"Phase":"PHASE4","lastUpdateDate":"2026-04-22"},{"nctId":"NCT06113939","OrgName":"Hospital San Carlos, Madrid","Titlefull":"A Randomized Controlled Pilot Trial Comparing 2 Non-invasive Airway Clearance Methods for the Prevention of Early-onset Ventilator-associated Pneumonia.","BriefSummary":"Severe trauma, head trauma, stroke and resuscitated cardiac arrest patients requiring endotracheal intubation and mechanical ventilation are at high risk of early-onset ventilator-associated pneumonia (EO-VAP). A short course of systemic antibiotic is recommended for prophylaxis.\n\nThis study intends to assess the safety and efficacy of 2 alternative mechanical non-invasive airway clearance techniques in the prevention of EO-VAP in an open label randomized pilot trial of 20 subjects per study group i.e., 60 cases. The interventions will be in place for 7 days and the observational periods will be 14 days.","ExperimentalDrugs":"[\"device: airway clearance\"]","Allcountries":"[\"Spain\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":8,"Phase":"NA","lastUpdateDate":"2025-03-05"},{"nctId":"NCT06949228","OrgName":"ProMedica Health System","Titlefull":"Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial","BriefSummary":"The study objective is to evaluate the safety and efficacy of Intra arterial (IA) Tenecteplase (TNK) as an adjunctive therapy in acute ischemic stroke (AIS) patients with large vessel occlusions (LVO) in the anterior circulation of Internal Carotid Artery (ICA), Middle Cerebral Arteries (M1 and M2) who achieve a reperfusion grade of Modified Treatment in Cerebral Ischemia Scale (mTICI) 2b or higher post-mechanical thrombectomy using Food and Drug Administration (FDA) approved devices.","ExperimentalDrugs":"[\"tenecteplase\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":32,"Phase":"PHASE2","lastUpdateDate":"2026-01-20"},{"nctId":"NCT07163702","OrgName":"Dongzhimen Hospital, Beijing","Titlefull":"Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke (EXACT): a Multi-center, Randomized, Double-blinded, Dose-exploration Ⅱa Trial","BriefSummary":"This is a Ⅱa clinical trial. The purpose of this study is to preliminarily explore the optimal dosage of Xinglou Chengqi Granules in the treatment of acute ischemic stroke and to evaluate the efficacy and safety of Xinglou Chengqi Granules for acute ischemic stroke.","ExperimentalDrugs":"[\"high-dose xinglou chengqi granules\",\"low-dose xinglou chengqi granules and placebo\"]","Allcountries":"[\"Canada\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Early efficacy","total_Score":18,"Phase":"PHASE2","lastUpdateDate":"2025-09-02"},{"nctId":"NCT05691244","OrgName":"Pharmazz, Inc.","Titlefull":"A Multicentric, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke.","BriefSummary":"Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair in later stages of stroke. Several trials have been conducted and are in progress using different pharmacological agents, but none of the studies involve the stimulation of ETB receptors to treat cerebral ischemic stroke. Sovateltide (IRL-1620, PMZ-1620) has been effective in animal models of cerebral ischemic stroke. Its safety and tolerability have been demonstrated in a human phase I study with 7 subjects. Clinical phase II and III results indicate that sovateltide is a novel, first-in-class, highly effective drug candidate for treating cerebral ischemic stroke. Safety and significant efficacy in improving the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin scale (mRS), and Barthel index (BI) obtained in phase II and III studies in patients with cerebral ischemic stroke in India are convincing and encouraged us to investigate its safety and efficacy in cerebral ischemic stroke patients in the United States. Therefore, the plan is to conduct a phase III clinical study to evaluate the safety and efficacy of sovateltide therapy along with standard of care in patients of acute ischemic stroke.","ExperimentalDrugs":"[\"drug: normal saline\",\"sovateltide\"]","Allcountries":"[\"Germany\",\"Spain\",\"United Kingdom\",\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"mRS at 90 days","total_Score":31,"Phase":"PHASE3","lastUpdateDate":"2026-06-10"},{"nctId":"NCT07151677","OrgName":"Syracuse University","Titlefull":"Pre-Frontal tDCS as a Novel Intervention to Reduce Effects of Post-Stroke Fatigue While Improving Language and Attention in Aphasia","BriefSummary":"The goal of this clinical trial is to determine if electrical brain stimulation applied to the front parts of the brain can help people who have had a stroke improve their fatigue, language, and attention. The main question it aims to answer is:\n\n* Does transcranial direct current stimulation (tDCS) administered to the pre-frontal areas of the brain improve post-stroke fatigue and aphasia?\n* What kinds of participant characteristics are associated with better improvement of post-stroke fatigue and aphasia?\n\nResearchers will compare active electrical stimulation to sham stimulation to see if the active stimulation does a better job at reducing fatigue and language deficits after stroke. Participants will be asked to complete fatigue, language, and cognitive testing before and after receiving 10 sessions of tDCS plus speech and language therapy.","ExperimentalDrugs":"[\"device: tdcs (active)\",\"behavioral: attention-focused sentence comprehension treatment\",\"behavioral: sentence comprehension treatment\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":11,"Phase":"NA","lastUpdateDate":"2025-08-25"},{"nctId":"NCT06994975","OrgName":"Huashan Hospital","Titlefull":"CHinese ischEmic Stroke Beyond 4.5 Hours With TeNecteplase Under Optimized Non-Contrast CT Selection","BriefSummary":"The CHESTNUT trial is a multicenter, open-label, blinded-endpoint, randomized, controlled, phase 3 trial. The primary objective of this study is to explore the efficacy and safety of the dose of 0.25 mg/kg tenecteplase (TNK) in Chinese acute ischemic stroke (AIS) patients without substantial infarction on non-contrast computed tomography (NCCT) in an extended time window.","ExperimentalDrugs":"[\"0.25mg/kg tnk\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"mRS at 90 days","total_Score":27,"Phase":"PHASE3","lastUpdateDate":"2025-12-22"},{"nctId":"NCT07294209","OrgName":"Southwest Hospital, China","Titlefull":"Efficacy and Safety of Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients: A Prospective, Multicenter, Randomized Controlled Study","BriefSummary":"The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.","ExperimentalDrugs":"[\"low-dose tenecteplase intravenous thrombolysis\",\"standard-dose tenecteplase intravenous thrombolysis\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT mandatory; EVT optional","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"PHASE4","lastUpdateDate":"2026-04-22"},{"nctId":"NCT06954155","OrgName":"Beijing Tiantan Hospital","Titlefull":"Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND--A Multicenter, Prospective, Randomized, Open Label, Blinded-endpoint (PROBE) Controlled Trial of Tenecteplase Versus Standard Medical Treatment for Acute Ischemic Stroke Due to Intracranial Vessel Occlusion With Perfusion Mismatch 24 to 72 Hours of Symptom Onset","BriefSummary":"The benefit-risk profile of thrombolysis for acute ischemic strokes beyond 24 hours has never been investigated. We initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to assess the safety and efficacy of tenecteplase (0.25mg/kg, max 25mg) versus standard medical treatment in acute ischemic stroke due to intracranial vessel occlusion between 24-72 hours of symptom onset (including wake-up stroke and unwitnessed stroke).","ExperimentalDrugs":"[\"tenecteplase (0.25mg/kg)\",\"standard medical treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":30,"Phase":"PHASE3","lastUpdateDate":"2026-03-27"},{"nctId":"NCT07095790","OrgName":"Second Affiliated Hospital of Soochow University","Titlefull":"Tirofiban With Sequential Dual Antiplatelet Therapy Versus Dual Antiplatelet Therapy Alone in Mild Acute Ischemic Stroke (TiMIS): A Multicenter, Open-Label, Blinded-Endpoint, Parallel-Controlled, Randomized Clinical Trial","BriefSummary":"This study aims to evaluate whether initiating intravenous tirofiban within 48 hours of onset (with a 48-hour infusion), followed by sequential DAPT, can improve the likelihood of excellent functional outcomes (modified Rankin Scale score 0-1) in mild stroke patients, compared with standard DAPT therapy based on current guidelines.","ExperimentalDrugs":"[\"tirofiban+oral dual antiplatelet therapy\",\"oral dual antiplatelet therapy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":22,"Phase":"PHASE4","lastUpdateDate":"2025-07-23"},{"nctId":"NCT06711302","OrgName":"Beijing Tiantan Hospital","Titlefull":"Remote Ischemic Conditioning for Efficacy in Patients With Aneurysmal Subarachnoid Hemorrhage: a Multi-center, Randomized, Double-blind, Sham-controlled, Parallel-group Trial","BriefSummary":"Several recent large-scale clinical trials aimed at improving subarachnoid hemorrhage(SAH) outcomes have concluded with negative results, failing to enhance the prognosis for these patients. Consequently, there is an urgent demand for novel treatment strategies and approaches to address the challenges posed by SAH.\n\nRemote ischemic conditioning(RIC) has gained considerable attention in the treatment of stroke, particularly ischemic stroke, with numerous studies demonstrating its potential to enhance neurological outcomes compared to conventional treatments alone.RIC for the treatment of SAH is an investigative strategy in its initial stages. The neuroprotective effects of RIC, particularly its potential to preserve cranial nerve function and ameliorate neurological deficits, confer significant value in the treatment of SAH patients.\n\nThe precise manner in which SAH patients may benefit from RIC treatment, and the mechanisms by which it improves neurological function, remain to be fully understood. Consequently, randomized controlled trials are necessary to validate the efficacy of RIC in this patient population and to delineate the optimal therapeutic protocols for its application.\n\nBased on the above discussion, this study aims to explore the efficacy and safety of RIC in the treatment of SAH.","ExperimentalDrugs":"[\"device: remote ischemic conditioning treatment instrument\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":14,"Phase":"NA","lastUpdateDate":"2025-07-07"},{"nctId":"NCT07105917","OrgName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","Titlefull":"Sodium-dependent Glucose Transporters 2 Inhibitor for Neuroprotection in Patients With Acute Ischemic Stroke","BriefSummary":"Stroke is a leading cause of disability and mortality globally. With population aging, ischemic stroke (80% of cases) has become China's primary cause of adult disability. Sodium-dependent glucose transporters 2 inhibitors （SGLT2i） demonstrate cardiovascular protection beyond glycemic control, even in patients without diabetes.\n\nPreclinical studies suggest neuroprotective effects via improving cerebral glucose metabolism, anti-inflammatory/antioxidant actions, and reducing neuronal apoptosis. Therefore, the investigators aim to evaluate whether SGLT2i could improve 3-month functional outcomes (mRS scores) in AIS patients compared to standard care.","ExperimentalDrugs":"[\"sglt-2 inhibitors\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":22,"Phase":"PHASE3","lastUpdateDate":"2025-08-06"},{"nctId":"NCT06799312","OrgName":"Assiut University","Titlefull":"Comparative Effectiveness of Ipsilesional High-frequency rTMS, Contralesional Continuous Burst Theta rTMS, and Sham rTMS, Each Combined With Physiotherapy, in Subacute Ischemic Stroke Upper Limb Recovery : Clinical, Neurophysiological and Radiological: A Double-blinded Randomized Clinical Trial","BriefSummary":"To compare the efficacy of lesional high-frequency rTMS, contralesional cTBS, and sham stimulation in improving motor and cognitive recovery in post-stroke patients undergoing physiotherapy.","ExperimentalDrugs":"[\"device: ipsilesional high frequency rtms combined with physiotherapy\",\"device: contralesional continuous burst theta rtms (ctbs) + physiotherapy\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-03-02"},{"nctId":"NCT06841965","OrgName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","Titlefull":"Th Efficacy and Safety of Intravenous Thrombolysis in Acute Ischemic Stroke with Cancer","BriefSummary":"The primary hypothesis being tested in this trial is that ischemic stroke patients with active cancer will have improved clinical outcomes when given intravenous thrombolysis compared to standard care.","ExperimentalDrugs":"[\"intravenous thrombolysis\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"mRS at 90 days","total_Score":31,"Phase":"PHASE3","lastUpdateDate":"2025-02-20"},{"nctId":"NCT07030621","OrgName":"RenJi Hospital","Titlefull":"Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial","BriefSummary":"The trial will be a randomized, double-blind, controlled, single-center trial. The purpose of this trial is to determine the efficacy and safety of semaglutide in improving neurological outcomes after endovascular thrombectomy for acute ischemic stroke. The patients in the treatment group will receive a subcutaneous injection of 0.5 mg semaglutide into the abdomen during endovascular thrombectomy. The patients in the control group will receive a similar-looking placebo. Patients will be randomized to the treatment or control group by the pharmacy, eliminating the selection bias. The patient and evaluator will be blind to the allocation of patients, further minimizing the bias.","ExperimentalDrugs":"[\"semaglutide 0.5 mg\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":33,"Phase":"PHASE3","lastUpdateDate":"2025-06-12"},{"nctId":"NCT06890481","OrgName":"Fondazione Don Carlo Gnocchi Onlus","Titlefull":"Collaborative Development of a Virtual Reality Scenario, Integrated Into a Robotic Upper Limb Rehabilitation Device, for the Treatment of Unilateral Spatial Negligence (NSU) Through Mutisensory Stimulation: Feasibility and Usability Pilot Study","BriefSummary":"The goal of this pilot clinical trial is to develop an integrated motor and cognitive rehabilitation program and evaluate the usability and acceptability of a new virtual reality scenario designed for the MOTORE device. This study will focus on the rehabilitation of the upper limbs in post-stroke patients with plegia and left-sided hemi-inattention. The main questions it aims to answer are:\n\n* The evaluation of the usability and acceptability of the newly developed scenario\n* The evaluation of the effects of the new scenario on patients' hemi-inattention\n* The evaluation of changes in upper limb functional parameters\n\nParticipants will undergo a total of 13 rehabilitation sessions, each lasting 45 minutes, using the new scenario, including an initial and final assessment.","ExperimentalDrugs":"[\"device: upper-limb planar robotic intervention\"]","Allcountries":"[\"Italy\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":5,"Phase":"NA","lastUpdateDate":"2025-03-31"},{"nctId":"NCT06904664","OrgName":"Xuanwu Hospital, Beijing","Titlefull":"Individualized Temperature Health Risk Early Warning and Risk Factor Management App for Reducing the Recurrence Risk of Stroke: A Multicenter, Randomized Controlled Trial Study","BriefSummary":"This study employs individualized temperature health risk early warning and risk factor management interventions for stroke, and explores their actual intervention effects. This enables patients to promptly understand their own risk levels and take corresponding protective measures, thereby enhancing the management outcomes and quality of life. The study also promotes the interdisciplinary integration of environmental epidemiology and clinical intervention management, providing new ideas and methodological support for future relevant research.","ExperimentalDrugs":"[\"other: individualized temperature health risk early warning and risk factor management\",\"other: temperature health risk early warning\",\"other: risk factor management\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":8,"Phase":"NA","lastUpdateDate":"2025-09-02"},{"nctId":"NCT07202143","OrgName":"First Affiliated Hospital of Fujian Medical University","Titlefull":"Methylprednisolone as Adjunct to Endovascular Thrombectomy for Acute Ischemic Stroke With Large Infarct Core and Post-stroke Lymphocytopenia -A Multicenter, Randomized, Double-blind, Placebo-controlled, Non-inferiority Trial","BriefSummary":"The efficacy and safety of early adjunctive methylprednisolone therapy in acute ischemic stroke patients with large infarct cores (ASPECTS score \\< 6) and post-stroke lymphocytopenia remain unclear. These immunocompromised patients face higher mortality rates and poorer clinical outcomes, with limited effective treatment options currently available. This multicenter, randomized, double-blind, placebo-controlled, non-inferiority trial aims to demonstrate that early methylprednisolone administration combined with reperfusion therapy is non-inferior to placebo in terms of survival and functional outcomes at 90 days.","ExperimentalDrugs":"[\"methylprednisolone sodium succinate\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Late efficacy","total_Score":27,"Phase":"PHASE3","lastUpdateDate":"2025-09-23"},{"nctId":"NCT07089355","OrgName":"Toro Neurovascular, Inc.","Titlefull":"Open-Label, Single-Arm Study Evaluating Toro 88 Super Bore Aspiration Catheter Safety and Efficacy in Mechanical Thrombectomy for Acute Ischemic Stroke in France","BriefSummary":"The goal of this pilot study is to evaluate the safety and efficacy of the Toro 88 Super Bore Aspiration Catheter in acute ischemic stroke patients.","ExperimentalDrugs":"[\"device: toro 88 super bore aspiration catheter\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Safety","total_Score":29,"Phase":"NA","lastUpdateDate":"2025-07-20"},{"nctId":"NCT06927206","OrgName":"Riphah International University","Titlefull":"Combined Effects of Segmental Vibrator With Neuromuscular Electrical Stimulation for Dorsiflexors on Lower Limb Function in Subacute Stroke","BriefSummary":"Stroke is one of the world's leading causes of death and disability. It can cause a variety of motor disorders, such as apraxia, sensory deficits, abnormal muscle tone, inadequate weight transfer, lack of fine motor skills, incoordination, and balance deficit. These disorders can have a significant negative impact on a person's quality of life.","ExperimentalDrugs":"[\"other: experimental group a: segmental vibrator only on dorsiflexor\",\"other: experimental group b: segmental vibrator + electrical stimulation on dorsiflexors\"]","Allcountries":"[\"Pakistan\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":14,"Phase":"NA","lastUpdateDate":"2025-08-18"},{"nctId":"NCT06863571","OrgName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","Titlefull":"Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Ischemic Stroke","BriefSummary":"Large ischemic stroke is a severe subtype of acute ischemic stroke (AIS), often leading to malignant cerebral edema, elevated intracranial pressure, and poor functional outcomes. Despite early aggressive treatment, malignant cerebral edema remains a major determinant of prognosis, even in cases of successful recanalization. Preclinical studies suggest that a pharmacological cocktail (PPA) may alleviate cerebral edema by modulating extracellular potassium balance, maintaining aquaporin-4 expression, and enhancing lymphatic drainage.\n\nThis multicenter, randomized controlled trial (RCT) aims to assess the safety and efficacy of PPA in reducing cerebral edema and improving outcomes in patients with large ischemic stroke. The study will enroll 68 patients with MCA-territory infarction (80-300 mL infarct volume or ASPECTS 1-5), who are not undergoing decompressive craniectomy. Participants will be randomized to receive PPA therapy or standard treatment. The primary outcome is cerebral edema at 5-7 days, with secondary outcomes including 90-day functional outcomes (mRS) and safety assessments.","ExperimentalDrugs":"[\"ppa intervention\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":18,"Phase":"PHASE3","lastUpdateDate":"2025-04-15"},{"nctId":"NCT07236216","OrgName":"Mahidol University","Titlefull":"Effects of Transcranial Electrical Stimulation (tES) Combined With Cognitive-motor Dual-task Gait Training on Cortical Activity, Spinal Motoneuron Excitability, Cognition and Motor Performance in Stroke Individuals","BriefSummary":"The present study will use transcranial electrical stimulation (tES) which are transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS) combined with conventional physical therapy and cognitive-motor dual task gait training in sub-acute (at least 2 weeks after stroke onset) to chronic (within 5 years post-stroke) to investigate the effect on cortical activity, spinal motoneuron excitability, cognition and motor performance. The findings may enhance the evidence to support usages of tES for improvimg cognition, motor performance as well as cortical activity and spinal motoneuron excitability in a clinical setting.","ExperimentalDrugs":"[\"device: high-definition transcranial direct current stimulation (active)\",\"other: cognitive-motor dual task gait training\",\"other: conventional physical therapy\",\"device: high-definition transcranial alternating stimulation (active)\"]","Allcountries":"[\"Thailand\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":14,"Phase":"NA","lastUpdateDate":"2026-02-19"},{"nctId":"NCT06943885","OrgName":"Beijing Emergency Medical Center","Titlefull":"Comparison of 5G Mobile Stroke Unit to Standard Management by Emergency Medical Services For Acute Ischemic Stroke Treatment：A Multicenter, Prospective, Open-label, Blinded Endpoint , Week-wise Randomized, Controlled Trial","BriefSummary":"While Mobile Stroke Units (MSUs) are considered as a relatively new model for acute stroke treatment, 5G Mobile Stroke Units (5G MSUs) have already come into service for stroke treatment in some parts of China. Since limited evidence has been found to suggest their advantages over conventional Emergency Medical Services (EMS), well-conducted clinical studies are required to further assess their effectiveness and safety. This study aims to evaluate whether 5G MSUs outperform standard management (SM) by EMS in terms of functional outcomes of acute ischemic stroke (AIS) patients within 4.5 hours after symptom onset in urban and rural areas of China.","ExperimentalDrugs":"[\"other: 5g mobile stroke unit management\",\"other: standard management\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":20,"Phase":"NA","lastUpdateDate":"2025-05-11"},{"nctId":"NCT07205328","OrgName":"Shaanxi Micot Pharmaceutical Technology Co., Ltd.","Titlefull":"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of MT200605 in Patients With Acute Ischemic Stroke.","BriefSummary":"MT200605 is an agonist of the receptor tyrosine kinase B (TrkB). It exerts brain-derived neurotrophic factor (BDNF)-like effects, protecting the structure and function of neural tissues in the brain. Simultaneously, it enhances ATP synthesis in the mitochondria of the striatum and bolsters antioxidant and free radical-scavenging capabilities.\n\nMT200605 is anticipated to confer pharmacological benefits including the reduction of neuronal apoptosis, antioxidant/free radical scavenging activity, anti-inflammatory effects, modulation of neuronal excitability, and amelioration of cerebral ischemic injury in patients with ischemic stroke.\n\nThis Phase II exploratory study will be conducted across 32 research centers in China. It plans to enroll 360 patients diagnosed with acute ischemic stroke within 24 hours of onset. Subjects will be randomized to receive either a high, medium, or low dose of MT200605 or a placebo, in addition to standard medical care. The primary efficacy endpoint is the proportion of subjects achieving a modified Rankin Scale (mRS) score of ≤1 at 3 months post-stroke. Secondary efficacy endpoints include the reduction in the National Institutes of Health Stroke Scale (NIHSS) score from baseline at day 14, among others.","ExperimentalDrugs":"[\"mt200605\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"PHASE2","lastUpdateDate":"2025-09-25"},{"nctId":"NCT07233070","OrgName":"Fujian Shengdi Pharmaceutical Co., Ltd.","Titlefull":"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of HRS-7450 Injection in Patients With Acute Ischemic Stroke.","BriefSummary":"This study plans to enroll a total of 208 patients with Acute Ischemic Stroke (AIS) who present within 4.5 to 24 hours of symptom onset and meet the specified imaging criteria.","ExperimentalDrugs":"[\"hrs-7450 injection\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"PHASE2","lastUpdateDate":"2025-11-18"},{"nctId":"NCT07277283","OrgName":"Haseki Training and Research Hospital","Titlefull":"Time to Target Blood Pressure Before Reperfusion Therapy in Acute Ischemic Stroke: Nicardipine Versus Labetalol","BriefSummary":"In this ED-based study, the investigators compared the time to reach target blood pressure (BP) between hypertensive patients with acute ischemic stroke (AIS) undergoing intravenous (IV) thrombolysis and/or mechanical thrombectomy who received IV nicardipine versus labetalol. Additionally, the investigators evaluated the rate of early neurological improvement (ENI), length of hospital stay (LOS), in-hospital mortality, and adverse event profiles between the two treatment groups.","ExperimentalDrugs":"[\"nicardipine intravenous\",\"labetalol intravenous\"]","Allcountries":"[\"Turkey (Türkiye)\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"COMPLETED","Add_on":"Other","Endpoint":"Early efficacy","total_Score":12,"Phase":"PHASE4","lastUpdateDate":"2025-12-02"},{"nctId":"NCT06910163","OrgName":"University of Puerto Rico","Titlefull":"Direct-to-angio Approach From loCal hOspitals Based on a PoInt-of-care bLOod Test for LVO (COPILOT): an Effectiveness Cluster Randomized Crossover Trial","BriefSummary":"Direct-to-angio approach from loCal hOspitals based on a PoInt-of-care bLOod Test for LVO (COPILOT) is a multi-center, prospective, cluster-randomized crossover trial that will evaluate if the triage assessment to thrombectomy puncture time is shorter after performing the LVOne testing compared to current management standards in patients with suspected large vessel occlusion.","ExperimentalDrugs":"[\"diagnostic test: diagnostic standard of care\",\"diagnostic test: lvone test\"]","Allcountries":"[\"Puerto Rico\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT optional","Endpoint":"Other","total_Score":14,"Phase":"NA","lastUpdateDate":"2025-03-27"},{"nctId":"NCT06700824","OrgName":"Organ, Tissue, Regeneration, Repair and Replacement","Titlefull":"MATRISS-II. Matrix Therapy to Reduce Ischemic Stroke Sequelae-II. a Randomized-double Blinded- Placebo Controlled Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients with Acute Ischemic Stroke","BriefSummary":"The MaTRISS 2 study is a phase 2 randomized, double-blinded and placebo-controlled trial aimed at recruiting 60 subjects (30 placebo and 30 active) from 15 stroke centers in France. The main objective will be to assess the efficacy of OTR4132-MD in patients with anterior ischemic stroke after endovascular thrombectomy. One dose will be tested (2 mg) against placebo. The main outcomes will be NIHSS (neurological score) at 24 hours, rate of intracranial hemorrhages at 24 hours, MRI lesion volume at 3 months and neurological scores at 3 months.","ExperimentalDrugs":"[\"device: otr4132\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"NIHSS","total_Score":23,"Phase":"PHASE2","lastUpdateDate":"2024-11-22"},{"nctId":"NCT07081568","OrgName":"Nanchang University Affiliated Rehabilitation Hospital","Titlefull":"Research on Binaural Synchronous Vagus Nerve Regulation of Sensorimotor Disorders After Cerebral Infarction","BriefSummary":"The aim of this study is to determine the efficacy and safety of binaural synchronous vagus nerve regulation in the treatment of patients with sensory and motor dysfunction after cerebral infarction through a randomized controlled clinical study, and to provide high-quality evidence support for binaural synchronous vagus nerve regulation in the treatment of cerebral infarction.","ExperimentalDrugs":"[\"device: transcutaneous auriculai vagus nerve stimulation\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"NIHSS","total_Score":14,"Phase":"NA","lastUpdateDate":"2025-10-02"},{"nctId":"NCT06823999","OrgName":"Chiayi Christian Hospital","Titlefull":"Effect of Vitamin C in the Prevention and Treatment for Bruises in Patients With Ischemic Stroke: A Double-blind Randomized Control Trial","BriefSummary":"Background Over the past few decades, significant advances have been made in the diagnosis and treatment of strokes. Most studies focus on functional recovery in stroke patients. In addition to motor function, there are many symptoms may affect function and quality of life in stroke patients. Bruises are caused by damage to the skin that causes blood to drain out of the capillaries and accumulate in the connective tissue of the skin or subcutaneous tissue. The study on non-motor syndrome in ischemic stroke patients found that 25.8% of ischemic stroke patients had bruises and 17.7% of bruises were unexplained bruises. In addition to the physiological and emotional effects on stroke patients, bruises may increase infection risk and affect stroke patient outcomes. Vitamin C is a natural antioxidant discovered in 1747 to treat and prevent scurvy. Vitamin C can reduce gum bleeding and prevent colon bleeding after a polypectomy. Vitamin C has been reported to reduce brain edema around brain injury and decrease mortality in patients with traumatic brain injury. Dehydroascorbic acid decreases infarct volume in mice with middle cerebral artery occlusion. Investigators hypothesized that administration of vitamin C to patients with acute ischemic stroke patients would decrease the risk of bleeding and enhance its resolution. Investigators also hypothesized that vitamin C injection could minimize infarct volume and improve outcomes in ischemic stroke patients. The aims of the study include: 1. To investigate whether vitamin C injections can reduce bruising risk and enhance bruising resolution. 2. To explore whether vitamin C injections in the acute phase of stroke can improve the prognosis of ischemic stroke patients.\n\nMethods This is a prospective, double-blind, randomized controlled study. All patients admitted to the hospital under the diagnosis of ischemic stroke and stroke was confirmed by Magnetic Resonance imaging (MRI) or brain computed imaging (CT) and aged between 20 and 85 years were invited to participate in the study. Investigators excluded patients who had these diseases: cancer receiving chemotherapy, end stage renal disease receiving dialysis, autoimmune disease, hematological disease, Glucose-6-phosphatase disease, gouty arthritis, and a lack of informed consent.\n\nDuring the study period, all patients who met the inclusion and exclusion criteria were invited to participate in the study. After informed consent, participants were randomly assigned to the experimental group or the control group. All participants underwent NIHSS evaluation and a detailed dermatological examination on the day of hospitalization. After enrollment, the experimental group received 4 mg Vitamin C injection per day for 4 days, while the control group received the same volume of normal saline injection per day for 4 days. Researchers evaluate participant skin condition (including bruises number and size, color) every day during hospitalization, and up to 1 month after stroke. Investigators evaluate NIHSS at discharge and follow-up functional outcome (mRS) up to 3 months after stroke onset.\n\nAnalysis Rate shows bruise percentage. Chi square or Fisher exact test was applied to compare the difference in bruises between two groups. Logistic regression was used to compare bruise risk between groups. Wilcoxon rank sign test was used to analyze stroke severity and outcome between two groups.","ExperimentalDrugs":"[\"ascorbic acid (vitamin c)\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":12,"Phase":"PHASE4","lastUpdateDate":"2025-02-11"},{"nctId":"NCT06904911","OrgName":"University of Pennsylvania","Titlefull":"Intra-Arterial Tenecteplase to Improve the Microvascular Hemodynamics After Mechanical Thrombectomy","BriefSummary":"This is a prospective, single-arm, open-label study to evaluate the efficacy of intra-arterial tenecteplase in improving microvascular reperfusion following successful large vessel recanalization. Acute ischemic stroke patients with large anterior circulation large vessel occlusion will receive a single weight-based dose of intra-arterial tenecteplase after achieving successful large vessel recanalization (defined as TICI ≥ 2b) via standard of care mechanical thrombectomy. Microvascular flow will be assessed by quantitative angiography before and after the intra-arterial drug administration in order to quantify the impact of targeted thrombolysis on microvascular reperfusion. Reperfusion will be secondarily assessed with 24-hour imaging, final infarct volume will be quantified 72 hours following treatment, and functional outcome will be assessed in the short-term by the NIHSS and in the long-term by the 90-day modified Rankin Scale.","ExperimentalDrugs":"[\"intra-arterial tenecteplase administration\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"Other","total_Score":26,"Phase":"PHASE2","lastUpdateDate":"2026-01-07"},{"nctId":"NCT07143786","OrgName":"Xuanwu Hospital, Beijing","Titlefull":"Human Induced Neural Stem Cell-derived Exosomes for Treating Acute Ischemic Stroke: an Exploratory Clinical Trial","BriefSummary":"A phase I/IIa clinical trial investigating the safety and preliminary efficacy of intravenous administration of human induced neural stem cell-derived exosomes for acute ischemic stroke","ExperimentalDrugs":"[\"insc-ev01\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":22,"Phase":"PHASE1","lastUpdateDate":"2025-08-19"},{"nctId":"NCT06992596","OrgName":"Neuralink Corp","Titlefull":"UAE-PRIME: A Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices","BriefSummary":"The UAE-PRIME Study is a feasibility study designed to assess the initial clinical safety and functionality of the Neuralink N1 Implant and R1 Robot. This study involves participants who have tetraparesis, tetraplegia, or a diagnosis that may lead to these conditions.\n\nThe N1 Implant is a wireless, rechargeable device mounted on the skull, connected to electrode threads that are inserted into the brain by the R1 Robot, which is a robotic device specifically designed for this procedure.","ExperimentalDrugs":"[]","Allcountries":"[\"United Arab Emirates\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":11,"Phase":"NA","lastUpdateDate":"2025-06-03"},{"nctId":"NCT07047014","OrgName":"Beijing Tiantan Hospital","Titlefull":"Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke","BriefSummary":"Results from recent several trials provided data showing limits to the effectiveness of thrombectomy for ischemic stroke due to medium vessel occlusions.The benefit-risk profile of thrombolysis for these patients has never been investigated. We initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of tenecteplase (0.25mg/kg, maximum dose 25mg) compared to standard medical care for patients with acute ischemic stroke due to medium vessel occlusion (MeVO) within 4.5 to 24 hours from symptom onset.","ExperimentalDrugs":"[\"tenecteplase (0.25mg/kg)\",\"standard medical treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"mRS at 90 days","total_Score":27,"Phase":"PHASE3","lastUpdateDate":"2026-03-27"},{"nctId":"NCT07056907","OrgName":"University of Zurich","Titlefull":"Evaluating the Neuroprotective Effects of Continuous Lumbar Drainage on the Cerebral Perfusion in Patients With an Acute Ischemic Stroke and Hemodynamic Failure Type 2: a Pilot Study","BriefSummary":"This pilot interventional study investigates whether continuous cerebrospinal fluid (CSF) drainage via lumbar drain can improve cerebrovascular reactivity (CVR) in patients with acute ischemic stroke and hemodynamic failure, as assessed by blood oxygenation level dependent (BOLD) MRI.\n\nPatients with acute ischemic stroke frequently exhibit impaired cerebral autoregulation and reduced vascular reserve. In such cases, a low BOLD-CVR response is associated with a high (\\~40%) risk of recurrent ischemic stroke despite optimal medical therapy. Hemodynamic failure stage 2 (HF2), defined by severely reduced CVR (hemispheric BOLD-CVR ≤ 0.1041), indicates exhausted compensatory capacity and poor perfusion.\n\nEvidence from other neurological conditions suggests that CSF drainage via lumbar drain may transiently lower intracranial pressure, improve perfusion, and enhance autoregulatory function. This study aims to apply these findings to acute stroke patients with hemodynamic compromise.\n\nEligible patients will undergo BOLD-CVR MRI to assess cerebrovascular reserve. Those meeting HF2 criteria and without contraindications will be offered inclusion. After informed consent (or proxy consent), a lumbar drain will be placed, and continuous CSF drainage performed over \\~48 hours. A follow-up BOLD-CVR MRI will assess changes in CVR. In addition, 20 ml of CSF will be extracted to evaluate acute effects on CVR. A historical cohort will be used to control for spontaneous CVR variation over 48 hours.\n\nPrimary Objective:\n\nTo determine whether continuous CSF drainage improves BOLD-CVR in patients with HF2 following acute ischemic stroke.\n\nSecondary Objectives:\n\nTo compare longitudinal BOLD-CVR changes to a historical cohort. To evaluate safety and feasibility of lumbar drainage in this setting. To assess short-term clinical outcomes (NIHSS, mRS) and recurrent events. To assess BOLD-CVR change after 20 ml CSF extraction.\n\nStudy Design:\n\nSingle-center, open-label, prospective pilot study. Participants serve as their own control, with pre- and post-intervention imaging to evaluate physiological effects. Safety and exploratory clinical data will also be collected.\n\nThis proof-of-concept trial aims to generate preliminary evidence for a potential therapeutic strategy in high-risk stroke patients with poor autoregulation. Positive findings could inform future randomized controlled trials.","ExperimentalDrugs":"[\"procedure: lumbar drain placement\"]","Allcountries":"[\"Switzerland\"]","FirstAdminInter":"Within first 2 days","TreatDur":"3 days or less","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":11,"Phase":"NA","lastUpdateDate":"2025-06-27"},{"nctId":"NCT07292675","OrgName":"Delta University for Science and Technology","Titlefull":"The Effect of Low Intensity Training With Blood Flow Restriction Versus Traditional Resistance Exercise on Lower Extermity Isokinetic Torque and Balance in Ischemic Stroke Patients","BriefSummary":"To compare the effects of low-intensity resistance training with blood flow restriction (BFR) versus traditional resistance training on lower limb isokinetic torque and dynamic balance in ischemic stroke survivors.","ExperimentalDrugs":"[\"other: low-intensity resistance training with blood flow restriction\",\"other: high intensity resistance training\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":10,"Phase":"NA","lastUpdateDate":"2025-12-06"},{"nctId":"NCT05743101","OrgName":"The First Hospital of Jilin University","Titlefull":"Safety and Efficacy Study of Levofloxacin Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation","BriefSummary":"The purpose of this study is to determine the efficacy and safety of levofloxacin combined with endovascular thrombectomy in treating acute ischemic stroke due to large vessel occlusion of anterior circulation.","ExperimentalDrugs":"[\"levofloxacin\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"NIHSS","total_Score":21,"Phase":"NA","lastUpdateDate":"2024-10-01"},{"nctId":"NCT07212738","OrgName":"University of Calgary","Titlefull":"Post-stroke REhabilitation Start Evaluation for Reducing Vascular Events (PRESERVE)","BriefSummary":"The purpose of this research study is to better understand when to start rehabilitation therapies after acute ischemic stroke to prevent further harm to the brain and to improve outcomes for stroke survivors.\n\nStroke is the second leading cause of death and reduced quality of life worldwide, with one Canadian diagnosed with stroke every five minutes. The most common subtype, ischemic stroke, occurs when a blood vessel in the brain is blocked. Hyperacute treatments aim to remove these blockages to restore blood flow and improve deficits, but in some cases, this is not achieved and leads to persistent large or medium intracranial vessel occlusion.\n\nAfter stroke, early medical and physical care can reduce physical and cognitive impairment and improve long-term functional outcomes. Prolonged immobilization can cause secondary complications and make recovery more difficult. Other research studies have demonstrated varying results with both benefit and no difference in the long-term level of functional independence when starting physical activity between 24 to 48 hours after acute ischemic stroke. The optimal timing for mobilization is unclear especially for patients with persistent vessel occlusion large stroke size, or intracranial hemorrhage, where starting active therapy too soon can cause additional harm by damaging the brain further.\n\nIn this research study, the investigators aim to evaluate the feasibility and effect of delayed mobilization (DeM), defined as physical therapy starting on or after day 3 from stroke symptom onset, on stroke volume growth and functional outcomes in patients with persistent vessel occlusion. The investigators think that individuals who still have evidence of persistent blockage in their arteries may benefit from waiting until day 3 after stroke to begin rehabilitation.\n\nImproving care strategies for stroke survivors will ultimately benefit individuals, their families, and healthcare systems. This study may guide the optimal timing of initiating stroke rehabilitation in patients with persistent vessel occlusion and ischemia to improve recovery times and reduce long-term disabilities.","ExperimentalDrugs":"[\"other: delayed mobilization (dem)\",\"other: standard care (in control arm)\"]","Allcountries":"[\"Canada\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Other","total_Score":16,"Phase":"NA","lastUpdateDate":"2025-10-01"},{"nctId":"NCT06414499","OrgName":"Beijing Tiantan Hospital","Titlefull":"TNK-tPA Treatment for Acute Minor Ischemic Stroke：A Randomized, Double-blind, Double-dummy Controlled Trial","BriefSummary":"The purpose of this study is to evaluate the efficacy and safety of intravenous tenecteplase (0.25 mg/kg) compared with standard therapy in patients with acute ischemic stroke presenting with mild symptoms-defined as a National Institutes of Health Stroke Scale (NIHSS) score ≤5 accompanied by persistent unilateral limb weakness or speech impairment within 4.5 hours of onset.","ExperimentalDrugs":"[\"rhtnk-tpa\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":32,"Phase":"PHASE3","lastUpdateDate":"2025-07-20"},{"nctId":"NCT07288385","OrgName":"King Saud University","Titlefull":"Investigating the Feasibility of Combining Virtual Reality and Bilateral Transcranial Direct Stimulation to Improve Upper Limb Recovery in Patients With Stroke","BriefSummary":"Following a stroke, the function of the distal upper limb, especially hand and finger movements, is often severely compromised, significantly restricting the ability to carry out daily activities. It is estimated that 55-75% of stroke survivors suffer from motor dysfunction, with upper limb impairments affecting up to 85% of them (Tang et al., 2024). Current rehabilitation approaches, while beneficial, often produce limited gains in hand function, particularly in patients with chronic stroke. Virtual reality (VR) training has emerged as a promising tool in neurorehabilitation, providing repetitive, task-specific, and engaging practice environments that can promote motor learning (Cameirão et al., 2012). tDCS has also shown potential to enhance motor recovery when combined with motor practice (Kang et al., 2016). To date, no studies have directly compared the effectiveness of Bi-tDCS with VR for improving upper limb function after stroke.","ExperimentalDrugs":"[\"device: transcranial direct current stimulation combined with virtual reality\"]","Allcountries":"[\"Saudi Arabia\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":14,"Phase":"NA","lastUpdateDate":"2025-12-29"},{"nctId":"NCT07197996","OrgName":"Firstkind Ltd","Titlefull":"MonitoRing the Effect of Intermittent Pneumatic Compression and TRAnscutaneous Functional electrIcal Stimulation of the Common Peroneal Nerve Using the Geko® Device on Cerebral Haemodynamics in Patients With Ischaemic Strokes (The RETRAIN Trial Phase 2)","BriefSummary":"Ischaemic strokes, caused by a disruption in the brain's blood supply, are the second leading cause of death and disability in the United Kingdom. This single-center prospective randomised study aims to measure cerebral blood flow and oxygen delivery in patients who have recently suffered an ischaemic stroke and are using either the geko® neuromuscular electrostimulation device or an intermittent pneumatic compression (IPC) device as part of their routine clinical care.\n\nThe geko® device stimulates a nerve in the lower leg, inducing muscle contractions that enhance blood circulation. The IPC device applies controlled external pressure through compressed air and a pump, cyclically inflating and deflating chambers in a sleeve worn on the leg. This mimics the action of calf muscles to promote blood flow.\n\nThe primary objective of this study is to assess the effect of the geko® and IPC devices on cerebral blood flow in stroke patients, specifically during the hyperacute phase (within 36 hours) following an ischaemic stroke. Both devices will be used as part of standard care for VTE prevention. Cerebral blood flow will be measured using functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG).","ExperimentalDrugs":"[\"device: intermittent pneumatic compression\",\"device: geko® t3\"]","Allcountries":"[\"United Kingdom\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":17,"Phase":"NA","lastUpdateDate":"2025-09-25"},{"nctId":"NCT05367362","OrgName":"State University of New York at Buffalo","Titlefull":"Efficacy of Minocycline in Improving Neurological Outcomes of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke","BriefSummary":"The study will be a prospective, randomized, double- blinded placebo, single center pilot clinical trial. Patients with acute ischemic stroke due to large vessel occlusion undergoing endovascular thrombectomy will be included. The treatment group will receive 200 mg intravenous/oral minocycline hydrochloride in addition to endovascular thrombectomy for a total of 21 days. The control group will receive standard medical and endovascular care along with a similar looking placebo. Patients will be randomized to the treatment or control group by the Pharmacy eliminating the selection bias. The patient and evaluator will be blind to the allocation of patients further minimizing the bias. Through randomization we expect to achieve two groups that are comparable in their baseline clinical characteristics.","ExperimentalDrugs":"[\"minocyclin\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"WITHDRAWN","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"PHASE2","lastUpdateDate":"2026-03-04"},{"nctId":"NCT05940350","OrgName":"Akdeniz University","Titlefull":"The Effect of Telerehabilitation-Based Coaching Interventions (TeleSCoP) on Self-Efficacy, Modifiable Risk Factors, and Repeated Hospitalizations in Patients With Ischemic Stroke","BriefSummary":"Ischemic stroke has high morbidity and mortality worldwide. Stroke patients experience physical, psychological, and social problems, and require rehabilitation. The aim of stroke rehabilitation is to support patients in optimizing their physical, functional, mental, social, and occupational aspects. Telerehabilitation-based coaching interventions are among the individualized interventions applied to patients. This study aimed to examine the effects of telerehabilitation-based coaching interventions on self-efficacy, modifiable risk factors, and repeated hospitalizations in patients with ischemic stroke. It is predicted that discharge education in disease management and telerehabilitation-based coaching interventions will increase self-efficacy, reduce modifiable risk factors (blood pressure, cholesterol, triglyceride, HbA1c levels, body mass index, smoking, and alcohol use), and reduce repeated hospitalizations. With an education booklet prepared for ischemic stroke patients and primary care providers, one-on-one face-to-face education is planned while patients are in the clinic on the fourth or fifth day of stroke. Determination of individual goals with motivational interview, sending educational videos prepared in cooperation with the multidisciplinary health team to the phones or e-mails of the patients, providing telerehabilitation-based coaching a total of seven times for three months after discharge, monitoring the targets set weekly and monthly, and monthly follow-up after three months. It is planned to support patients with practices such as achieving their goals, maintaining healthy lifestyle changes such as diet and physical activity, and monitoring metabolic parameters. The evaluation form of the education booklet, videos prepared with the cooperation of the multidisciplinary team, and phone call evaluation form will be evaluated by 10 experts. The preliminary application will be tested with 6 patients, and the final form will be provided. The second phase of the study was designed as a single-center, single-blind (participant), randomized controlled study. The study will be carried out with a total of 60 patients with ischemic stroke, 30 in the intervention group and 30 in the control group, who continued to be followed up and treated at the Neurology Clinic of Akdeniz University Hospital.","ExperimentalDrugs":"[\"behavioral: telerehabilitation stroke coaching of program (telescop) group\"]","Allcountries":"[\"Turkey (Türkiye)\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":9,"Phase":"NA","lastUpdateDate":"2025-12-11"},{"nctId":"NCT06477016","OrgName":"University of Pennsylvania","Titlefull":"A Randomized Pilot Study of the Efficacy of the OsciPulse System for the Reduction of Serum D-dimer","BriefSummary":"Pilot, randomized, non-blinded clinical trial to generate preliminary data to evaluate the impact of the OsciPulse system on serum d-dimer levels compared to standard of care intermittent compression therapy for DVT prophylaxis in patients admitted in the neuro ICU or intermediate neurological care unit with acute ischemic stroke.","ExperimentalDrugs":"[\"device: oscipulse\",\"device: intermittent pneumatic compression\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"ACTIVE_NOT_RECRUITING","Add_on":"IVT excluded ; EVT optional","Endpoint":"Other","total_Score":17,"Phase":"NA","lastUpdateDate":"2026-05-28"},{"nctId":"NCT07162064","OrgName":"Tongji Hospital","Titlefull":"Effectiveness and Safety of Heparinization for Radial Artery Occlusion After Transradial Cerebral Angiography in Patients With Acute Ischemic Stroke - A Multicenter, Prospective, Double-blind, Randomized Trail","BriefSummary":"Cerebral angiography is a critical diagnostic tool in neurology, serving as the \"gold standard\" for evaluating cerebrovascular stenosis, hemodynamics, aneurysms, and arteriovenous malformations. Compared to the traditional transfemoral approach, transradial cerebral angiography (TRA) offers advantages such as preserved patient privacy, immediate post-procedure mobility, shorter hospitalization, and fewer access-site complications. Consequently, TRA has gained increasing acceptance among patients and clinicians as the preferred vascular access . However, radial artery occlusion (RAO) remains a common complication post-TRA, with reported incidence rates varying widely (1%-33%). RAO is particularly concerning as the radial artery serves as a key access for both cardiac and neurovascular interventions; its occlusion limits future procedural options.Evidence from interventional cardiology suggests that intra-arterial heparin administration significantly reduces RAO risk.However, patients undergoing transradial cerebral angiography are predominantly those with cerebrovascular diseases, including acute ischemic stroke (AIS)-a population at potential risk for hemorrhagic transformation.Although the 2022 Chinese Expert Consensus on Neurointerventional Diagnosis and Treatment via Transradial Access recommends intra-sheath heparin injection to prevent RAO, this recommendation is largely extrapolated from coronary intervention data. While several studies indicate that low-dose heparin is safe in moderate-to-severe AIS patients without increasing intracranial hemorrhage risk , high-level evidence specific to neurointerventional procedures-particularly in AIS patients-remains lacking.This multicenter, double-blind, randomized controlled trial (RCT) aims to: Evaluate the efficacy of intra-arterial heparin in preventing RAO following TRA cerebral angiography.Assess the safety of heparin in AIS patients, with a focus on hemorrhagic complications. By addressing these questions, the study will provide evidence-based guidance to optimize TRA outcomes, balancing RAO prevention with bleeding risk in neurovascular interventions. Its findings hold significant clinical value for improving the safety and efficacy of transradial cerebral angiography.","ExperimentalDrugs":"[\"heparin - therapeutic dosage\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"COMPLETED","Add_on":"Other","Endpoint":"Safety","total_Score":19,"Phase":"PHASE3","lastUpdateDate":"2026-03-23"},{"nctId":"NCT06990867","OrgName":"Corxel Pharmaceuticals","Titlefull":"Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of JX10 in Acute Ischemic Stroke With Late Presentations","BriefSummary":"The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours.\n\nThe main question the study aims to answer are:\n\n1. JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS.\n2. Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS.\n\nDuring Part 1, participants will be randomized to JX 10 (1mg/kg, 3 mg/kg) or placebo. During Part 2, participants will receive JX10 (optimal dose chosen from Part 1) or placebo.","ExperimentalDrugs":"[\"jx10\"]","Allcountries":"[\"Belgium\",\"Bulgaria\",\"Canada\",\"China\",\"France\",\"Germany\",\"Greece\",\"Italy\",\"Japan\",\"Latvia\",\"Lithuania\",\"Malaysia\",\"Portugal\",\"Serbia\",\"South Korea\",\"Spain\",\"Thailand\",\"United States\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":31,"Phase":"PHASE2","lastUpdateDate":"2026-03-11"},{"nctId":"NCT07035405","OrgName":"Beijing Tiantan Hospital","Titlefull":"Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX): a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial","BriefSummary":"The role of colchicine in the secondary prevention of ischemic stroke has not been determinded. This multicenter, randomized, double-blind, placebo-controlled, event-driven clinical trial of CHANCE-3 EX was aimed to assess the efficacy and safety of low-dose colchicine versus placebo on reducing the risk of recurrent ischemic stroke, myocardial infarction and vascular death in patients with minor-to-moderate ischemic stroke.","ExperimentalDrugs":"[\"colchicine 0.5 mg\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":15,"Phase":"PHASE3","lastUpdateDate":"2025-06-24"},{"nctId":"NCT07167550","OrgName":"Tatchempharmpreparaty, JSC","Titlefull":"Multicenter, Randomized, Double-blind, Placebo-controlled Comparative Study of the Efficacy and Safety of the Drug Dimephosphon®, Concentrate for Solution for Intravenous Administration, 1 g, in Acute Ischemic Stroke Patients","BriefSummary":"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Dimephosphon® in acute ischemic stroke","ExperimentalDrugs":"[\"dimephosphon®\"]","Allcountries":"[\"Russia\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Early efficacy","total_Score":25,"Phase":"PHASE3","lastUpdateDate":"2025-09-10"},{"nctId":"NCT06788626","OrgName":"The First Affiliated Hospital of University of Science and Technology of China","Titlefull":"Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment","BriefSummary":"The goal of this clinical trial is to learn if semaglutide works to treat acute ischemic stroke (AIS). It will also learn about the safety of semaglutide in AIS. The main question it aims to answer is: Does semaglutide improve the 90-days functional outcome in participants with acute large vessel occlusion who receive the endovascular treatment (EVT)? Researchers will compare semaglutide injection to non-injection to see if semaglutide works to improve the functional outcome in participants with EVT.\n\nParticipants will:\n\n* Receive 0.5mg semaglutide injection before (Day 0) and 1 week (Day 7) after EVT , or EVT alone.\n* Have additional blood test before and after EVT.\n* Receive neurological assessment before EVT, Day 1, Day 3, Day 5-7 after EVT or on hospital discharge (whichever earlier), Day 90±14 after EVT. Audio or video of the assessment may be recorded if possible.\n* Receive brain CT + CT angiogram + CT perfusion and MRI after EVT, where the CT scan may be repetitive.","ExperimentalDrugs":"[\"semaglutide 0.5 mg\",\"other: standard medical treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":27,"Phase":"PHASE3","lastUpdateDate":"2025-01-21"},{"nctId":"NCT06940635","OrgName":"VASCage GmbH","Titlefull":"Cross-Stroke Therapy Effects With BCI and FES Stimulation: A Pilot Study","BriefSummary":"The goal of this neurorehabilitation explorative study is to investigate how a closed-loop Brain-Computer Interface Functional Electrical Stimulation (BCI-FES) therapy, used within the intended purpose for hand rehabilitation, may impact swallowing difficulties (dysphagia) and language disorders (aphasia) in post-stroke patients.","ExperimentalDrugs":"[\"device: closed-loop bci-fes device\"]","Allcountries":"[\"Austria\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":14,"Phase":"NA","lastUpdateDate":"2025-11-25"},{"nctId":"NCT07023770","OrgName":"University Hospital, Grenoble","Titlefull":"Rehabilitation Program Dedicated to Post-stroke Lateropulsion Including Exoskeleton Assisted Exercises","BriefSummary":"Lateropulsion is a deficit in the body orientation with respect to the vertical in the coronal plane, defined by the presence of one of the three signs: lateral body tilt, active pushing from the sound limbs, and resistance to passive corrections. The lateral body tilt is the cardinal sign, the frequency of the 2 other signs increasing with lateropulsion severity (most dramatic forms called pusher syndrome in the past). Lateropulsion is frequent after stroke, and represents the main factor underpinning balance and gait disorders at the subacute phase. After hemisphere stroke lateropulsion is caused by a bias in the internal model of the verticality in the frontal plane, individuals unconsciously aligning their body posture on a tilted verticality representation. Pilot studies suggested the possibility to recalibrate the internal model of verticality, biased by stroke, and to improve individuals' uprightness. The investigators expect that a specific rehabilitation program combining technics devoted to lateropulsion, and comprising exoskeleton (Atalante) assisted balance exercises could help recalibrate the internal model of verticality and alleviate lateropulsion. The primary objective is to test the hypothesis that a 3-week specific lateropulsion rehabilitation program (15 sessions of 30 minutes including exoskeleton and a rehabilitation focused on the vertical body orientation in the frontal plane) improves the visual vertical (VV), the most used test to assess verticality perception.","ExperimentalDrugs":"[\"behavioral: specific lateropulsion rehabilitation program (exoskeleton + specific physiotherapy orientation rehabilitation)\",\"behavioral: conventional physiotherapy without without exercises dedicated to lateropulsion or verticality representation alleviation\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":10,"Phase":"NA","lastUpdateDate":"2025-06-13"},{"nctId":"NCT07047326","OrgName":"Capital Medical University","Titlefull":"A Dose-Escalation Safety Study of Urokinase for Thrombolysis in Patients With Acute Ischemic Stroke","BriefSummary":"According to the Chinese Guidelines for the Diagnosis and Treatment of Ischemic Stroke, intravenous thrombolysis with urokinase, administered at doses of 1-1.5 million IU within 6 hours of symptom onset, has been shown to be both safe and effective for patients with acute ischemic stroke. Compared to alteplase, urokinase offers considerable cost advantages while maintaining comparable therapeutic efficacy. However, current dosing protocols in clinical practice largely rely on the empirical judgment of physicians rather than evidence-based standardization. Therefore, the development of a weight-adjusted dosing regimen for urokinase is of significant clinical importance in optimizing treatment outcomes and ensuring patient safety. The purpose of this study is to determine the maximum tolerated dose of urokinase thrombolytic treatment in patients with acute ischemic stroke and to develop an optimal weight-adjusted dosing regimen.","ExperimentalDrugs":"[\"urokinase thrombolysis\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 6 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"Safety","total_Score":19,"Phase":"NA","lastUpdateDate":"2025-11-21"},{"nctId":"NCT06870448","OrgName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","Titlefull":"Methylprednisolone With Endovascular Thrombectomy for Large Ischemic Stroke (MATCH): A Randomized Controlled Trial","BriefSummary":"It is uncertain whether intravenous methylprednisolone improves outcomes for acute anterior circulation large vascular occlusion (LVO) patients with a large infarct core. In this study, the investigators assume that methylprednisolone plus endovascular thrombectomy (EVT) might be superior to EVT alone for patients who have evidence of a large infarct volume. The objective of the study was to establish the efficacy and safety of methylprednisolone with EVT in patients presenting with symptoms of acute ischemic stroke from LVO in the anterior circulation and having a large infarct volume.","ExperimentalDrugs":"[\"methyprednisolone sodium succinate\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"PHASE3","lastUpdateDate":"2025-03-06"},{"nctId":"NCT06834750","OrgName":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","Titlefull":"The Application of Kinesio Taping Technique in the Early Upper Limb Functional Activities Induction of Hemiplegic Patients After Stroke","BriefSummary":"1. To observe the inducing and promoting effect of kinesio taping technique on the recovery of upper limb function in early-stage stroke patients.\n2. To compare the different effects of kinesio tape and sports white tape on the induction and promotion of limb function in patients.\n3. To verify that kinesio taping technique is a safe and promotable technical means for stroke patients.","ExperimentalDrugs":"[\"other: experimental group\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-03-20"},{"nctId":"NCT07172789","OrgName":"General Hospital of Shenyang Military Region","Titlefull":"Head dOwn Position Before Endovascular Treatment for Large veSsel Occlusion (HOPES5): a Prospective, Randomized, Open Label, Blinded-end Point, Multi-center Study","BriefSummary":"Recent studies suggest that head-down positioning (HDP) intervention may improve outcomes in ischemic stroke. In the era of reperfusion therapy, a key protective strategy is to administer neuroprotective interventions before recanalization to reduce the loss of the ischemic penumbra, thereby salvaging more penumbral tissue after revascularization and ultimately improving clinical outcomes. Based on this concept, and considering the neuroprotective effects of HDP, the investigators hypothesize that HDP intervention prior to endovascular therapy (EVT) in patients with large vessel occlusion could improve clinical outcomes. This hypothesis is further supported by a recent clinical study (NCT03728738), which demonstrated that compared to a sitting up position (30°), a flat supine position (0°) before EVT significantly reduced the incidence of neurological deterioration prior to the procedure. Building on the above rationale, this trial aims to investigate the efficacy and safety of HDP intervention prior to EVT in patients with large vessel occlusion.","ExperimentalDrugs":"[\"other: head down position\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":26,"Phase":"NA","lastUpdateDate":"2025-09-08"},{"nctId":"NCT07241897","OrgName":"Second Affiliated Hospital of Soochow University","Titlefull":"DPP4 Inhibitor on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes Mellitus (DISC-DM): Multicentre, Double Blind, Randomised, Placebo Controlled Trial","BriefSummary":"Post-stroke cognitive impairment (PSCI) increases the risk of disability and mortality in stroke patients, thereby exacerbating the disease burden of stroke. Type 2 diabetes is a major risk factor for PSCI, and stroke patients with type 2 diabetes have a higher risk of developing PSCI. Despite the high incidence and severe impact of PSCI, effective intervention methods are still lacking. Identifying safe and effective drugs to improve cognitive function in stroke patients and reduce the risk of PSCI, especially for those with type 2 diabetes, is of significant importance and could help reduce the burden of stroke.\n\nDipeptidyl peptidase-4 (DPP4) inhibitors are first-line antidiabetic drugs, and several studies have shown that DPP4 inhibitors provide benefits beyond glucose control, including significantly improving cognitive function in patients with type 2 diabetes or slowing the progression of cognitive impairment. Our previous research found a significant negative correlation between baseline plasma soluble DPP4 (sDPP4) levels and the 90-day PSCI risk in ischemic stroke patients. Moreover, some studies indicate that DPP4 inhibitors can increase plasma sDPP4 levels. Based on this, we hypothesize that DPP4 inhibitors could be effective for PSCI intervention and may improve cognitive function post-stroke.\n\nThis project aims to conduct a multicenter, randomized, double-blind, placebo-controlled study. We will include patients with mild ischemic stroke combined with type 2 diabetes and provide continuous intervention with DPP4 inhibitors or a placebo for 180 days. Cognitive function in both groups will be assessed before and after intervention to determine if DPP4 inhibitors can improve cognitive function and reduce the risk of PSCI in ischemic stroke patients with type 2 diabetes. Clinical blood samples and imaging data will also be used to preliminarily explore potential mechanisms.","ExperimentalDrugs":"[\"sentagliptin phosphate - single dose\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":18,"Phase":"PHASE3","lastUpdateDate":"2025-11-18"},{"nctId":"NCT07135310","OrgName":"Shanghai Minhang Central Hospital","Titlefull":"STROKE 120 ACTION: a National Cluster Randomized Controlled Trial","BriefSummary":"Stroke is the main cause of death and disability in China, but it is preventable and treatable. For the most common type, acute ischemic stroke (AIS), initiating reperfusion therapy with intravenous thrombolysis (IVT) with or without mechanical thrombectomy (MT) within several hours of the onset of symptoms can significantly improve the chances of surviving free of major disability, and earlier the intervention is given the better the outcome. Thus, whether patients can achieve timely arrived at hospital, ideally within the critical 4.5-hour golden window, is pivotal to achieving high rates of recanalization and optimal functional outcome. To this end, it is important to note that the overall pre-hospital delay for patients with AIS is currently 24 hours in China.\n\nWe plan to conduct STROKE 120 ACTION, a national cluster randomized controlled trial, to determine whether implementing a STROKE 120 multifaceted intervention campaign can reduce pre-hospital delay in AIS, increase the 4.5-hour hospital arrival rate, and improve survival, disability, and healthcare costs. The STROKE 120 ACTION trial will recruit 16 community units across 8 regions in China, with each region enrolling 2 community units with a residential population of at least 110,000 and comparable demographic characteristics. To avoid cross-contamination, the participating community clusters will maintain a physical distance of more than 20 kilometers. Within each region, the 2 community units will be randomly assigned at a 1:1 ratio to receive the intervention (12-month usual health policy plus STROKE 120 multifaceted intervention campaign; 3-month intensive period and 9-month maintenance period) or control (12-month usual health policy alone). The study outcomes and related data on incident AIS cases within each participating community unit will be collected after the implementation of STROKE 120 multifaceted intervention campaign (from month 1 to month 12 of multifaceted intervention campaign). The primary outcome is proportion of hospital arrival within 4.5 hours after symptom onset within participating community units. Secondary outcomes include time from onset to hospital admission, time from onset to action, use of 120 emergency ambulances, IVT, MT, total hospitalization costs, out-of-pocket costs, composite outcome of death or major disability (modified Rankin scale score \\[mRS\\] ≥3) at 3 months, ordinal 7-level mRS score at 3 months, all-cause mortality within 3 months. The sample size was calculated according to the following estimates: (1) a significance level of 0.05 for a 2-sided test; (2) statistical power of 85%; (3) 4.5-hour hospital arrival rate of 10% for AIS patients in control group; (4) 4.5-hour hospital arrival rate of 20% among AIS patients in intervention group; (5) intra-class correlation coefficient of 0.03; and (6) a 10% loss to follow-up. The estimated sample size is 3,312 incident AIS patients from 16 community units with an average cluster size of 207 patients per community unit. The annual incidence of AIS is 195 per 100,000 people, and the sample size of participants in each community unit will be 106,000. Thus, the total sample size of the present study will be 1,696,000 participants from 16 community units.\n\nThe STROKE 120 ACTION trial will address the critical issue of long pre-hospital delay in AIS in China, and provide profound implications for global stroke prevention and control strategies.","ExperimentalDrugs":"[\"behavioral: stroke 120 multifaceted intervention campaign\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":6,"Phase":"NA","lastUpdateDate":"2025-08-27"},{"nctId":"NCT06639360","OrgName":"Xijing Hospital","Titlefull":"Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke","BriefSummary":"This is a multicenter, randomized, double-blind, sham-controlled trial, to determine the efficacy and safety of cTBS in treating patients with acute ischemic stroke after endovascular treatment.","ExperimentalDrugs":"[\"device: transcranial magnetic stimulation active\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"EVT mandatory; IVT optional","Endpoint":"Early efficacy","total_Score":17,"Phase":"NA","lastUpdateDate":"2025-11-26"},{"nctId":"NCT07092709","OrgName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","Titlefull":"Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users (PEARL-DOAC): A Multicenter, Prospective, Randomized, Double-blinded, Placebo-controlled Trial","BriefSummary":"An investigator-initiated, multicenter, randomized, placebo-controlled, double-blind trial to determine the efficacy and safety of intravenous tenecteplase thrombolysis in acute ischemic stroke (AIS) patients with recent direct oral anticoagulants (DOACs) intake in improving the 90-day functional outcome.","ExperimentalDrugs":"[\"tenecteplase (tnk) (0.25 mg/kg, to maximum of 25mg)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"mRS at 90 days","total_Score":32,"Phase":"PHASE3","lastUpdateDate":"2025-12-08"},{"nctId":"NCT06658197","OrgName":"Xuanwu Hospital, Beijing","Titlefull":"Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusive Stroke(TNK-LVO) :a Phase 3, Multicentre, Open-label, Randomised Controlled Trial","BriefSummary":"A phase III, multicentre, prospective, randomised, open-label, blinded-endpoint clinical trial will evaluate two thrombolytic agents for the treatment of acute large vessel occlusion stroke within 4.5 hours from symptoms onset: intravenous tenecteplase bridging mechanical thrombectomy vs. intravenous alteplase bridging mechanical thrombectomy.","ExperimentalDrugs":"[\"tenecteplase\",\"alteplase\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":34,"Phase":"PHASE3","lastUpdateDate":"2026-04-08"},{"nctId":"NCT06770426","OrgName":"Yonsei University","Titlefull":"CompARing Between CO2 Phenylephrine and Phenylephrine Only Treatment in Patients With proGrEssing Cerebral infarctioN(CARBOGEN Trial)","BriefSummary":"Progressing stroke is associated poor functional outcome and neurological deficit.\n\nCurrently, no treatment for progressing stroke is recommended on the guideline.\n\nCarbogen is a mixture of 5% CO2 with 95% O2. Carbogen is safe and it is used for the treatment of sudden sensory neural hearing loss or ocular ischemia.\n\nCO2 dilate cerebral arteriole and concentration of CO2 is correlated with cerebral blood flow.\n\nIncreased cerebral blood flow following dilation of cerebral arteriole by CO2 might halt and revert progressing stroke.\n\nInduced hypertension is alternative treatment of progressing stroke. Increasing blood pressure also induce cerebral blood flow. Phenylephrine is an α1 agonist, phenylephrine act on peripheral artery and little effect on cerebral artery or heart. Several studies reported that the effectiveness of phenylephrine on progressing stroke.\n\nTherefore, this study will compare the effectiveness of carbogen + phenyleprhine versus phenlyephrine in progressing stroke patients.","ExperimentalDrugs":"[\"carbogen with or without phenyleprhine\",\"phenylephrine\"]","Allcountries":"[\"South Korea\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":16,"Phase":"PHASE3","lastUpdateDate":"2025-01-16"},{"nctId":"NCT06822140","OrgName":"Rheinburg-Klinik","Titlefull":"Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Motor and Cognitive Deficits After Ischemic Stroke","BriefSummary":"The goal of this clinical trial is to learn if transcutaneous auricular vagus nerve stimulation (taVNS) works to treat motor and neurocognitive deficits after ischemic stroke when applied within 30 days after onset of stroke.\n\nThe main questions it aims to answer are:\n\n* Does tVNS improve motor deficits measured by the Fugl-Mayer assessment after ischemic stroke?\n* Does tVNS ameliorate stroke-related cognitive impairment? Researchers will compare tVNS to a placebo (sham stimulation, i.e. an electrode is fixed on the ear without applying electrical impulses ) to see if tVNS works to treat motor and cognitive deficits after stroke .\n\nParticipants will:\n\n* Receive tVNS or sham stimulation for 30 minutes 5 days a week during 5 weeks after ischemic stroke\n* Receive smotor and cognitive training during the tVNS or sham stimulation\n* Will take part on a standardized stroke rehabilitation program during the 5 weeks in a rehabilitation clinic.","ExperimentalDrugs":"[\"device: transcutaneous auricular vagus nerve stimulation\"]","Allcountries":"[\"Switzerland\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-02-16"},{"nctId":"NCT06613074","OrgName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","Titlefull":"Ali Pay Intelligent Navigation Applet-aided Pre-hospital Triage for Non-emergency Medical Service Patients With Acute Ischemic Stroke: A Step-wedge Cluster Randomized Controlled Trial","BriefSummary":"According to the Bigdata Observatory platform for Stroke of China (BOSC), the proportion of patients with acute ischemic stroke (AIS) receiving intravenous thrombolysis or endovascular treatment in China is 5.64% and 1.45% respectively. One of the important reasons for the low treatment rate is the prolonged pre-hospital and in-hospital delay. Besides, for patients receiving reperfusion therapy, the prolonged pre-treatment delay is associated with unfavorable functional outcomes.\n\nAlthough tons of efforts have been made to improve the efficiency of emergency medical system in the transportation of patients with AIS, little attention has been paid to patients who arrived at hospitals on their owns, which occupying approximately 2/3 of emergency patients. This leaves a huge gap in the pre-hospital management of patietns with AIS.\n\nTherefore, the investigators plan to develop an intelligent navigation system for patients with AIS. For the convenience of public use, this system was carried on the applet of Ali Pay, which has over 1.1 billion users in China. This system comprises of three functional modules, namely stroke knowledge education, stroke recognition and hospital recommendation. The investigators aim to explore whether this intelligent navigatino system could shorten pre-hospital delay and improve functional outcomes of patients with AIS undergoing reperfusion therapy.","ExperimentalDrugs":"[]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":15,"Phase":"NA","lastUpdateDate":"2025-08-06"},{"nctId":"NCT06660719","OrgName":"Shin Poong Pharmaceutical Co. Ltd.","Titlefull":"A Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase III Clinical Study to Evaluate Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Requiring Thrombolytic Therapy as Standard of Care","BriefSummary":"This clinical study is designed to evaluate the efficacy and safety of the combination therapy of SP-8203 (otaplimastat) and thrombolytic standard of care in acute ischemic stroke patient.\n\nAs a standard of care, thrombolytic therapy (for instance, recombinant tissue plasminogen activator) will be administered. When reperfusion is not achieved in spite of thrombolytic therapy, endovascular therapy can be performed.","ExperimentalDrugs":"[\"sp-8203\"]","Allcountries":"[\"South Korea\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"3 days or less","Status":"RECRUITING","Add_on":"IVT mandatory; EVT optional","Endpoint":"mRS at 90 days","total_Score":34,"Phase":"PHASE3","lastUpdateDate":"2025-03-04"},{"nctId":"NCT06837311","OrgName":"University Hospital, Bordeaux","Titlefull":"Medical Benefit of Digital Monitoring Using apTeleCare for Secondary Prevention in Patients With a Recent Transient Ischemic Attack or Stroke","BriefSummary":"Stroke is the second leading cause of death and a major cause of disability worldwide. In 2019, Disability-Adjusted Life-Years (DALYs) related to stroke was estimated to have reached 143 million. Modifiable stroke risk-factors, which include poor lifestyle habits (tobacco, alcohol and illicit drug abuse, dietary patterns at risk, low physical activity), account for 90 % of the risk of stroke. Stroke complications and the risk of stroke recurrence is highly dependent on the control of these risk factors. Thus, the secondary prevention of stroke requires profound lifestyle modifications including substance use cessation and diet changes. National guidelines for stroke clinical practice advocate an immediate cessation of consumption of all substances but without recommendations on specific therapeutic regimens. Moreover, none address the management of poor coping with stress or mood problems though they are major population attributable risk factors of stroke and constitute major barriers of behavior changes achievement. Yet, post-stroke emotional impairments are frequent, post-stroke depression and anxiety being the most frequent (prevalence is 30% and 25%, respectively). Importantly, independently from stroke, emotional impairments or disorders and Substance Related and Addiction Disorders (SRADs) are frequent comorbid conditions (dual disorders) with debilitating consequences and the interplay between the two conditions makes rehabilitation more complex. This suggests that taking into account stroke patients' mental health status might improve not only the management of post-stroke emotional impairments but also the control of stroke vascular risk factors.\n\nRegarding secondary prevention programs focusing on behavioral changes among Cardiovascular and Cerebrovascular Disease (CVD) patients, the literature is sparse and studies on smoking cessation are the most widely documented. Despite the risk of smoking after a myocardial infarct or a stroke/Transient Ischemic Attack (TIA), less than half of patients quit smoking after the event or achieve long-term abstinence.\n\nTo increase treatment adherence and efficacy, besides systematically screening lifestyle habits and evaluating the patients' mental health and motivation to change in clinical routine, experts in the domain emphasize the need to:\n\n* start delivering treatment as early as possible, ideally during hospitalization;\n* tailor the intensity of the treatment (combination of pharmacological medications +/- behavioral intervention; frequency of the follow-up/contacts) according to the risk profile of each patient, particularly depending on the level of dependence and the presence of comorbid emotional difficulties/psychiatric disorders.\n\nAfter hospital discharge, in standard care, the follow-up visit is scheduled 4 to 6 months post-stroke. Knowing that the vast majority of smoking relapses occur in the weeks following stroke, it appears that this period is of high risk for missing the goal of stroke secondary prevention. Therefore, new approaches are urgently needed that would allow for the day-to-day examination of clinical change in the immediate days and weeks following discharge from the stroke acute-care unit to optimize the patient's recovery and quality of life.\n\nThe potential pivotal role of eHealth development has been advocated by the World Health Organization, which considers e-Health as a cost-effective and secure use of information and communication technologies (ICT). Used in the context of stroke secondary prevention, eHealth technologies should give each patient the opportunity to describe his/her own experiences and symptoms and the contexts of daily life in which they occur that may constitute negative factors for post-stroke recovery. Post-stroke management would thus be optimized through a person-centered, intense and multidisciplinary care program.\n\nInvestigators believe apTeleCare would allow for such a day-to-day examination of clinical change in the immediate days and weeks following discharge from the stroke acute-care unit. It offers the possibility not only to closely monitor patients' experiences and symptoms and the contexts of daily life in which they occur, but also to inform the clinical team in real-time via specific alerts that depend on the type and level of difficulties the patients encounter for adopting the expected changes in their lifestyle","ExperimentalDrugs":"[\"device: ecological momentary assessment (ema)\",\"biological: biological assessment\",\"behavioral: psychological examination and substance use symptomatology\",\"other: treatment as usual (tau)\",\"diagnostic test: expired carbon monoxide (co)\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":6,"Phase":"NA","lastUpdateDate":"2025-07-18"},{"nctId":"NCT07011095","OrgName":"Population Health Research Institute","Titlefull":"A Pilot Trial to Assess the Feasibility of a Multicentre, Phase IV, Prospective, Randomized, Open-label, Two-arm Study With Blinded-endpoint Evaluation to Investigate Vitamin K Antagonist (VKA) Therapy Compared With Direct Oral Anticoagulant (DOAC) Therapy in Male and Female Participants With Atrial Fibrillation and Recent Ischemic Stroke While on a DOAC","BriefSummary":"People with atrial fibrillation who have a stroke while receiving a DOAC are at increased risk of experiencing another stroke. Physicians do not know the best medication to prevent another stroke in this group of people. Options include continuing the same DOAC, switching to another DOAC or switching to warfarin.\n\nThe investigators of the SWITCH-AF trial are trying to find out whether switching to warfarin or continuing a DOAC is better for preventing stroke.\n\nThe purpose of this study, called a pilot study, is to test the study plan and to find out whether enough participants will join a larger study that answers the question. A pilot study involves a small number of participants and it is not expected to tell us which treatment is better.","ExperimentalDrugs":"[\"vka\",\"direct oral anticoagulant (doac)\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":15,"Phase":"EARLY_PHASE1","lastUpdateDate":"2025-06-04"},{"nctId":"NCT06832579","OrgName":"University of Leipzig","Titlefull":"Pilot Study for SmartWatch-driven AF Detection in Stroke Patients","BriefSummary":"Unrecognized atrial fibrillation (AF) is a common cause of ischemic stroke. Implantable event monitors (ICM) are the gold standard for continuous heart rhythm monitoring but they have been implemented in very few patients after stroke due to high invasiveness and high costs.\n\nIn this trial, patients with implanted ICMs (Medtronic Reveal LINQ Insertable Cardiac Monitor) will be randomized to use one of two wearables (1:1 Apple Watch or PulseOn) for continuous monitoring. The aim is to compare the probability of detecting an episode of AF with a wearable versus the gold standard ICM.\n\nBoth groups will use the wearable for 12 weeks. If the wearables detect an arrhythmic pulse curve, this is communicated by vibration. By laying the other hand on the device, a 1-channel ECG is performed. ECG data will be transferred regularly to the CoreLab (Universityhospital Leipzig) for analysis.\n\nAfter 12 weeks, the patients will visit the site and answer questions regarding the usability, compliance and satisfaction with the wearables.","ExperimentalDrugs":"[\"device: wearable\"]","Allcountries":"[\"Germany\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"ACTIVE_NOT_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":8,"Phase":"NA","lastUpdateDate":"2026-04-28"},{"nctId":"NCT03669653","OrgName":"The First Hospital of Jilin University","Titlefull":"Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Ischemic Stroke","BriefSummary":"he purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for acute ischemic stroke.","ExperimentalDrugs":"[\"procedure: remote ischemic conditioning\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 12 hours","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":22,"Phase":"NA","lastUpdateDate":"2024-10-01"},{"nctId":"NCT07406971","OrgName":"Instituto Mexicano del Seguro Social","Titlefull":"Safety of Transmucosal Capsaicin for Chemical Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke Within 24 Hours of Symptom Onset: A Randomized Double-Blind Placebo-Controlled Trial","BriefSummary":"This study will evaluate the safety and tolerability of a dissolvable oral film containing a very small dose of capsaicin (the compound that produces the \"hot\" sensation in chili peppers) in adults with acute ischemic stroke. The film is designed to stimulate nerves in the mouth that may activate the sphenopalatine ganglion, a structure involved in regulating blood flow to the brain. The main purpose of this study is to determine whether the capsaicin film can be given safely to patients with acute ischemic stroke when started within 24 hours of symptom onset.\n\nParticipants will be randomly assigned (like flipping a coin) to receive either the capsaicin oral film or a placebo film that looks and tastes similar but contains no capsaicin. Neither the participants nor the clinical team will know which film is given (double-blind). All participants will continue to receive standard medical care for acute ischemic stroke.\n\nAfter administration of the study film, participants will be closely monitored for side effects and changes in vital signs (blood pressure, heart rate, respiratory rate, temperature, and oxygen saturation) at prespecified time points up to 72 hours. The primary outcome is the frequency of adverse events related to the study product within 72 hours after treatment begins. Participants will also be followed clinically up to 3 months as part of usual stroke care.\n\nThe results of this study will help determine whether this approach is safe and feasible, and whether further studies are warranted.","ExperimentalDrugs":"[\"capsaicin transmucosal oral film\"]","Allcountries":"[\"Mexico\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":19,"Phase":"PHASE2","lastUpdateDate":"2026-02-12"},{"nctId":"NCT06987305","OrgName":"Xinqiao Hospital of Chongqing","Titlefull":"Intravenous rhTNK-tPA Versus Placebo Before Endovascular Thrombectomy For Stroke Patient With Large Vessel Occlusion In The Extended Time Window: the BRIDGE-TNK EXTEND Randomized, Placebo-controlled, Double-blind Trial","BriefSummary":"This randomized, double-blind, placebo-controlled phase III clinical trial aims to evaluate the efficacy and safety of intravenous recombinant human tenecteplase (rhTNK-tPA) in acute ischemic stroke patients with large vessel occlusion presenting 4.5-24 hours after last known well. The study will address two primary questions: 1) Whether rhTNK-tPA enhances pre-thrombectomy reperfusion rates and improves 90-day functional outcomes compared to placebo; 2) Whether rhTNK-tPA increases the risk of symptomatic intracranial hemorrhage and mortality.\n\nParticipants will be randomized to receive either a single bolus of rhTNK-tPA (0.25 mg/kg, max 25 mg) or matching placebo administered intravenously over 5 seconds. Key assessments include repeat neuroimaging (CT/CTA or MRI/MRA) at 24 hours post-treatment to evaluate reperfusion, NIH Stroke Scale score at day 5-7, and modified Rankin Scale score assessment at 90 days. Safety monitoring will focus on hemorrhagic transformation and mortality events throughout the study period.","ExperimentalDrugs":"[\"intravenous rhtnk-tpa\",\"procedure: endovascular thrombectomy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"PHASE3","lastUpdateDate":"2025-12-24"},{"nctId":"NCT05536895","OrgName":"University of Wisconsin, Madison","Titlefull":"C-arm Cone Beam CTP Guided Cerebrovascular Interventions: Evaluating Predictability and Accuracy for the Treatment of Acute Cerebral Ischemia in the Angiography Suite","BriefSummary":"The study objective for the Phase 2 of this research is to demonstrate and confirm the substantial time savings that can be obtained using cone beam computed tomography (CB-CT) for both complete image acquisition and rapid image reconstruction in a Direct to Angio paradigm (One Stop Shop) for selected acute ischemic stroke (AIS) patients.","ExperimentalDrugs":"[\"diagnostic test: c-arm cone beam computed tomography\",\"diagnostic test: multi-detector computed tomography\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"WITHDRAWN","Add_on":"Other","Endpoint":"Other","total_Score":12,"Phase":"NA","lastUpdateDate":"2025-04-01"},{"nctId":"NCT06518902","OrgName":"National Engineering Center of Cell Products","Titlefull":"A Single Arm, Open Label Exploratory Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of Mesenchymal Stem Cells (Umbilical Cord) Injection in the Treatment of Acute Ischemic Stroke (AIS) Patients","BriefSummary":"The goal of this clinical trial is to learn if drug mesenchymal stem cells (umbilical cord) injection works to treat acute ischemic stroke in adults. It will also learn about the safety and efficacy of drug mesenchymal stem cells (umbilical cord) injection . The main questions it aims to answer are:\n\nIdentify the dose-limiting toxicity (DLT) of drug mesenchymal stem cells (umbilical cord) injection in acute ischemic stroke patients.\n\nDose the drug mesenchymal stem cells (umbilical cord) injection improves the mRS score, NIHSS score, Fugl-Meyer score and and Barthel index of acute ischemic stroke patients? What is the pharmacokinetic characteristics and immunogenic response of mesenchymal stem cells (umbilical cord) injection in the treatment of acute ischemic stroke patients.\n\nWhat is the the possible molecular mechanisms of mesenchymal stem cells (umbilical cord) injection in the treatment of acute ischemic stroke patients.\n\nParticipants will:\n\nTake drug drug mesenchymal stem cells (umbilical cord) injection once or once a week for three consecutive weeks.\n\nAfter receiving the corresponding dose of mesenchymal stem cells (umbilical cord) injection, the subjects entered a 6-month safety, efficacy observation and further safety evaluation period. Long term efficacy and survival follow-up up to 2 years.","ExperimentalDrugs":"[\"mesenchymal stem cells (umbilical cord) injection\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":14,"Phase":"PHASE1","lastUpdateDate":"2024-07-19"},{"nctId":"NCT06295900","OrgName":"Nigde Omer Halisdemir University","Titlefull":"The Effect of Aromatherapy Massage Applied to Intensive Care Patients on Sleep Quality","BriefSummary":"Sleep disturbance is one of the most common complaints of patients admitted to ICU. Insufficient sleep in intensive care units may be associated with environmental reasons such as excessive light at night, loud warning sounds and mechanical ventilation alarms, as well as non-environmental factors, including the situation at the time of admission. Sleep assessment is subjective in nature, so it is difficult to perform in the ICU. Since communication with the patient is prevented, clear information about perceived rest and disturbing factors cannot be provided. For this reason, night rest is an issue that is often forgotten and ignored. This study applied a mixture of lavender, medicinal chamomile and neroli oil (in 20 ml of sweet almond oil; lavender oil 2 drops, medicinal chamomile 4 drops, neroli oil 6 drops) to patients who were monitored in intensive care on high-flow and oxygen, once a day for three days. This study will be conducted to determine the effect of aromatherapy massage applied for a total of 30 minutes on sleep quality.","ExperimentalDrugs":"[\"other: intervention 1 group\"]","Allcountries":"[\"Turkey (Türkiye)\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Other","total_Score":1,"Phase":"NA","lastUpdateDate":"2024-02-28"},{"nctId":"NCT07044830","OrgName":"Hospital das Clínicas de Ribeirão Preto","Titlefull":"Obstructive Sleep Apnea Treatment From Acute to Chronic Phase of Stroke - A Randomized Clinical Trial","BriefSummary":"The study aims to evaluate whether early treatment of obstructive sleep apnea with continuous positive airway pressure in ischemic stroke patients has a favorable effect on functional recovery.","ExperimentalDrugs":"[\"device: cpap\"]","Allcountries":"[\"Brazil\"]","FirstAdminInter":"Within 12 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":20,"Phase":"NA","lastUpdateDate":"2025-06-21"},{"nctId":"NCT06696820","OrgName":"Tongji Hospital","Titlefull":"Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke (CAPTAIN)--A Multicenter, Prospective, Randomized Trial","BriefSummary":"This study is an investigator-initiated, multicenter, prospective, open-label, endpoint-blinded, randomized controlled trial (PROBE design) that includes patients with moderate or severe symptomatic intracranial large vessel atherosclerotic stenosis (sICAS) who present with acute ischemic stroke within 48 hours of symptom onset.\n\nPatients will be centrally randomized in a 1:1 ratio into two groups:\n\nExperimental Group: A single subcutaneous injection of 420 mg evolocumab upon admission, combined with standard doses of atorvastatin 20 mg or rosuvastatin 10 mg, along with other standard guideline-based medical treatments.\n\nControl Group: Standard doses of atorvastatin 20 mg or rosuvastatin 10 mg, with the remainder of treatment based on current guidelines.\n\nThe primary objective of the study is to evaluate whether early combination therapy with a PCSK9 inhibitor and statins within 48 hours of symptom onset can reduce the incidence of early neurological deterioration in patients with symptomatic intracranial atherosclerotic stenosis (sICAS). The secondary objectives include comparing the effects of early PCSK9 inhibitor and statin combination therapy versus statin monotherapy on the 90-day neurological outcomes of AIS patients, improving early neurological recovery, and reducing the recurrence rate of stroke at 30 and 90 days. The safety objective is to assess whether the combination of early PCSK9 inhibitors and statins, compared to statin monotherapy, increases the incidence of moderate-to-severe systemic bleeding within 3 days post-randomization (based on the GUSTO scale), any type of intracranial hemorrhage (according to the ECASS III criteria), and all-cause mortality within 90 days.","ExperimentalDrugs":"[\"pcsk9 inhibitors combined with atorvastatin/rosuvastatin\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Other","Status":"COMPLETED","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Early efficacy","total_Score":20,"Phase":"PHASE2","lastUpdateDate":"2026-06-07"},{"nctId":"NCT06391502","OrgName":"Affiliated Hospital of Nantong University","Titlefull":"Effect of Multi-component Exercise Intervention Program on the Degree of Frailty in Hospitalized Patients After Venous Hemolysis in Acute Ischemic Stroke","BriefSummary":"Physical exercise is an effective strategy to maintain functional ability and improve debilitating symptoms in the elderly.In addition to functional enhancement, exercise is considered a cornerstone for enhancing cognitive function in debilitated older adults with cognitive impairment and dementia.The investigators evaluated the effect of the Vivifrail exercise intervention on the degree of debilitation in elderly hospitalized patients after venous hemolysis in acute ischemic stroke","ExperimentalDrugs":"[\"behavioral: multi-component exercise intervention program\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Late efficacy","total_Score":4,"Phase":"NA","lastUpdateDate":"2024-05-30"},{"nctId":"NCT06328894","OrgName":"Chao Phya Abhaibhubejhr Hospital","Titlefull":"A Randomized Controlled Trial to Explore the Effect of Different Feeding Modes on Psychological Condition and Experience in Stroke Patients","BriefSummary":"The goal of this clinical trial is to compare the differences on Psychological Condition and Experience in ischemic stroke patients using Intermittent Oro-esophageal Tube and Nasogastric Tube. Patients will be randomly divided into an observation group and a control group, all receiving routine rehabilitation treatment. On this basis, the observation group will use Intermittent Oro esophageal Tube for enteral nutrition support, while the control group will use Nasogastric Tube. Researchers will compare Psychological Condition and Experience of two groups.","ExperimentalDrugs":"[\"device: intermittent oro-esophageal tube feeding\",\"behavioral: comprehensive rehabilitation therapy\",\"device: nasogastric tube feeding\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"Other","Endpoint":"Other","total_Score":3,"Phase":"NA","lastUpdateDate":"2026-05-05"},{"nctId":"NCT06301412","OrgName":"University of Freiburg","Titlefull":"Combination of Targeted Temperature Management and Thrombectomy After Acute Ischemic Stroke (COTTIS-2) - a Randomised Controlled Study","BriefSummary":"The goal of this clinical trial is to test the combination of hypothermia and endovascular treatment in acute stroke patients with large vessel occlusion.\n\nThe main question it aims to answer is: does an additional cooling to 35°C result in a benefit on clinical outcome ? Participants receive immediate cooling using a noninvasive transnasal cooling technique (RhonoChill) and are maintained at 35°C for 6 hours after reopening of the vessel using surface cooling, and then slowly rewarmed.\n\nResearchers will compare the intervention group (hypothermia and endovascular treatment and best medical treatment including iv thrombolysis) and control group (only endovascular treatment and best medical treatment including iv thrombolysis) to see if additional hypothermia leads to a better outcome after 3 months without relevant complications.","ExperimentalDrugs":"[\"device: hypothermia\"]","Allcountries":"[\"Germany\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"PHASE3","lastUpdateDate":"2025-01-02"},{"nctId":"NCT06752096","OrgName":"Navigantis Inc.","Titlefull":"Robot-assisted Neurovascular Intervention for Patients Indicated for Angiography, Cerebral Artery Embolization, and Thrombectomy: Exploratory Study to Compare to Existing Interventional Procedures","BriefSummary":"Patients scheduled for neurovascular interventions may be eligible to have their procedure done robotically.","ExperimentalDrugs":"[\"procedure: cerebral angiography, arterial embolization, thrombectomy\",\"device: cerebral angiogram using robotic device\",\"device: meningioma embolization using robotic device.\",\"device: mechanical thrombectomy for stroke using a robotic device.\"]","Allcountries":"[\"South Korea\"]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":18,"Phase":"NA","lastUpdateDate":"2026-01-14"},{"nctId":"NCT06202755","OrgName":"Kafrelsheikh University","Titlefull":"Ticagrelor Versus Cilostazol in Ischemic Stroke","BriefSummary":"Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever large-vessel ischemic stroke compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.","ExperimentalDrugs":"[\"ticagrelor 90 mg\",\"cilostazol 100 mg\"]","Allcountries":"[\"Egypt\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT optional","Endpoint":"Late efficacy","total_Score":28,"Phase":"PHASE3","lastUpdateDate":"2024-08-16"},{"nctId":"NCT05611242","OrgName":"Mercy Health Ohio","Titlefull":"Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial","BriefSummary":"The primary objective is to establish the efficacy of intra-arterial (IA) mechanical thrombectomy (MT) with extracranial proximal carotid artery acute stenting versus non-stenting approaches in patients with acute ischemic stroke (AIS) from intracranial vessel occlusion (IVO) in the anterior circulation and have a proximal carotid occlusive disease (occlusion or severe stenosis).","ExperimentalDrugs":"[\"procedure: mt+cat with po-ap\",\"procedure: mt+cas with iv-ap\",\"procedure: mt+cas with po-ap\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":33,"Phase":"PHASE3","lastUpdateDate":"2025-12-11"},{"nctId":"NCT06485583","OrgName":"Shalamar Institute of Health Sciences","Titlefull":"Comparison Between the Efficacy of CIMT and NDT Along With Conventional Physiotherapy Treatment on Upper Extremity Rehabilitation Among Patients of Stroke","BriefSummary":"To compare the efficacy of CIMT and NDT among stroke patients To study the phenomena of transfer of training To study relationship between the MMSE score and stroke rehabilitation","ExperimentalDrugs":"[]","Allcountries":"[\"Pakistan\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2024-07-02"},{"nctId":"NCT06121219","OrgName":"University of Rochester","Titlefull":"Effect of Visual Retraining on Visual Loss Following Cortical Damage","BriefSummary":"This project is intended to collect data using standard clinical tests and psychophysics to quantify the effect of visual cortical damage on the structure of the residual visual system, visual perception, spatial awareness, and brain function. The investigators will also assess the effect of intensive visual retraining on the residual visual system, processing of visual information and the use of such information in real-world situations following damage. This research is intended to improve our understanding of the consequences of permanent visual system damage in humans, of methods that can be used to reverse visual loss, and of brain mechanisms by which visual recovery is achieved.","ExperimentalDrugs":"[\"device: training in the blind field\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":11,"Phase":"NA","lastUpdateDate":"2025-07-10"},{"nctId":"NCT06331494","OrgName":"First Affiliated Hospital, Sun Yat-Sen University","Titlefull":"Efficacy of Butylphthalide on Symptomatic Atherosclerotic Stenosis in Middle Cerebral Artery (SICAS): a Prospective, Randomized, Double-blinded, Placebo-controlled, Multiple-center Trial.","BriefSummary":"Ischemic stroke with high incidence, mortality, disability and recurrence rate, has become the leading threat to the health worldwide. Intracranial atherosclerotic stenosis (ICAS) is commonly associated with ischemic stroke, especially in Chinese residents. Patients with severe ICAS are subject to a very high risk of recurrent stroke events, despite best medical therapy available. Unstable or complex atherosclerotic plaques can lead to plaque ruptures and distal embolisms, thereby increasing the risk of ischemic stroke recurrence. Studies have shown that activation of inflammatory states may play a driving role in the formation and development of atherosclerosis. So far, it remains unclear which are the best treatments for this condition, especially for high-risk patients. Dl-3-n-butylphthalide (NBP) is a Class I novel drug independently developed in China and was officially approved for use in acute ischemic stroke. Preclinical data showed that NBP can act multiple effects of anti-inflammation, antioxidation and anti-apoptosis by suppressing pro-inflammatory factors and upregulating the expression of anti-inflammatory factors. It is still undetermined whether combined therapy with NBP could enhance the curative effect of intracranial atherosclerosis. The primary purpose of this trial is to evaluate the efficacy of butylphthalide in reducing the degree of arterial stenosis and stabilizing plaques in patients with severe symptomatic middle cerebral artery stenosis.","ExperimentalDrugs":"[\"butylphthalide\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Other","total_Score":13,"Phase":"NA","lastUpdateDate":"2024-03-19"},{"nctId":"NCT06041581","OrgName":"Indiana University","Titlefull":"Strengthening Hearts by Addressing DisruptEd Sleep (SHADES) Mechanistic Trial","BriefSummary":"Cardiovascular disease (CVD) is common, deadly, and costly, and adults with insomnia represent a large group of people at elevated risk of developing CVD in the future. This clinical trial will determine if our updated insomnia treatment, called the SHADES intervention, improves CVD factors thought to explain how insomnia promotes CVD and if these improvements are due to positive changes in sleep factors. A total of 200 primary care patients with insomnia and CVD risk factors will be randomized to 6 months of the SHADES intervention (internet, telephonic, and/or face-to-face cognitive-behavioral therapy for insomnia) or the active control condition (sleep education/hygiene, symptom monitoring, and primary care for insomnia). Before and after treatment, participants will complete measurements of the CVD factors (systemic inflammation, autonomic dysfunction, metabolic dysregulation, proinflammatory gene expression) and the sleep factors (insomnia symptoms, sleep onset latency, wake after sleep onset, sleep efficiency). Researchers will test whether the SHADES intervention produces greater improvements in the CVD factors than the active control condition.","ExperimentalDrugs":"[\"behavioral: sleep healthy using the internet (shuti)\",\"behavioral: telephonic cbt-i\",\"behavioral: face-to-face cbt-i\",\"other: active control: sleep education/hygiene, symptom monitoring, and usual primary care\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"ENROLLING_BY_INVITATION","Add_on":"Other","Endpoint":"Other","total_Score":7,"Phase":"NA","lastUpdateDate":"2025-07-09"},{"nctId":"NCT06374277","OrgName":"University of Tennessee","Titlefull":"Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations","BriefSummary":"Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.","ExperimentalDrugs":"[\"other: med aaaction intervention\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":5,"Phase":"NA","lastUpdateDate":"2026-01-27"},{"nctId":"NCT07121569","OrgName":"Universitas Sebelas Maret","Titlefull":"Efficacy of Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: A Randomized Controlled Trial Evaluating Inflammatory Biomarkers, TCD Results, and Clinical Outcomes","BriefSummary":"This randomized, double-blind, placebo-controlled trial aims to evaluate the effect of oral DLBS1033 as adjunctive therapy on inflammatory biomarkers (IL-6, TNF-α, MMP-9, D-dimer), transcranial Doppler (TCD) parameters, and clinical outcomes in patients with acute ischemic stroke. Fifty-two eligible patients admitted to RSUD Dr. Moewardi Surakarta will be randomly assigned to receive either DLBS1033 (490 mg, DISOLF film-coated tablet, Dexa Medica, 2 tab t.i.d.) or placebo for 28 days, in addition to standard therapy between July 2024 to March 2025. The study was conducted in the inpatient ward, with follow-up at the outpatient clinic of the Neurology Department, Dr. Moewardi General Hospital, Surakarta, Central Java, following full ethical approval from the hospital's Health Research Ethics Committee. Primary outcomes include changes in inflammatory markers; secondary outcomes include changes in NIHSS and Barthel Index scores and TCD profiles.","ExperimentalDrugs":"[\"oral lumbrokinase dlbs1033\",\"placebo\"]","Allcountries":"[\"Indonesia\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"Other","Endpoint":"Other","total_Score":11,"Phase":"PHASE4","lastUpdateDate":"2025-08-12"},{"nctId":"NCT06214494","OrgName":"MedStar National Rehabilitation Network","Titlefull":"Effects of Blood Flow Restricted High Intensity Treadmill Training on Independently Ambulating Chronic Ischemic CVA Survivors: A Pilot Study","BriefSummary":"Individuals surviving Chronic Ischemic Stroke have lingering walking deficits long after their infarct. The main goal of this study is to compare two high intensity treadmill walking programs to see which improves walking more. The main question we aim to answer is: How does blood flow restricted high-intensity treadmill training impact walking function? Participants will be randomly separated into two groups. One group will perform the high intensity treadmill training with blood flow restriction on their Stroke affected leg, while the second group performs high intensity treadmill training only. Every week participants will be asked to walk on the treadmill for a total of 75 minutes during 2x 1-hour sessions. On visit 1, participants will undergo strength, balance, and walking testing. They will then be treated 2x weekly for 4 weeks (visit 2-9) and be re-tested to track progress on visit 10. Participants will again be treated 2x weekly for 4 more weeks (visit 11-18) and be tested to see the end results on visit 19. Researchers will then compare both groups to see if blood flow restriction training changes walking function, strength, and balance.","ExperimentalDrugs":"[\"other: blood flow restricted high intensity treadmill training\",\"other: hitt\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Late efficacy","total_Score":9,"Phase":"NA","lastUpdateDate":"2024-03-01"},{"nctId":"NCT06452888","OrgName":"Beijing Tiantan Hospital","Titlefull":"Improvement of Medical Quality and Outcomes Through Intelligent Management and Decision System of Cerebrovascular Diseases Based on Hospital Information System - A Multicenter, Open-label, Cluster-Randomized Controlled Study","BriefSummary":"This study applied a cerebrovascular disease organizational management and decision system based on hospital information system, aiming to verify the effect of intervention and management after stroke on improving the functional outcomes of acute ischemic cerebrovascular disease through a cluster randomized controlled study.","ExperimentalDrugs":"[\"behavioral: clinical decision support system.\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":10,"Phase":"NA","lastUpdateDate":"2024-06-06"},{"nctId":"NCT06654375","OrgName":"Tianjin Huanhu Hospital","Titlefull":"Thrombectomy Versus Best Medical Management in Large Vessel Occlusion Stroke Patients Presenting Beyond 24 Hours and With Presence of Collateral Flow on CT Angiography: A Multicentre, Open-label, Registry-linked, Randomised Controlled Trial","BriefSummary":"The goal of this clinical trial is to investigate if endovascular treatment (EVT) can effectively treat patients with large vessel occlusion (LVO) who present beyond the typical 24-hour window after symptom onset. The main questions it aims to answer are:\n\n* Can EVT improve functional independence at 90 days for patients treated after 24 hours?\n* What is the safety profile of EVT in this delayed treatment group compared to best medical management (BMM)? Researchers will compare EVT outcomes in patients presenting after 24 hours to those receiving BMM to see if EVT offers significant benefits.\n\nParticipants will:\n\n* Receive either EVT or BMM based on their eligibility.\n* Undergo CT angiography to assess collateral circulation and to confirm the presence of LVO.\n* Be followed for 90 days to evaluate functional outcomes and safety measures.","ExperimentalDrugs":"[\"procedure: endovascular thrombectomy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"NA","lastUpdateDate":"2024-10-22"},{"nctId":"NCT06578117","OrgName":"University of Rochester","Titlefull":"Statistical Learning as a Novel Intervention for Cortical Blindness","BriefSummary":"This project aims to develop a novel visual training paradigm for use in visually-intact participants and those sufferings from stroke-induced visual impairments. Our task design is built upon theories of statistical learning to reduce the overall training burden while still producing profound improvements to visual abilities. Efficacy will be first established in visually-intact controls before testing in stroke survivors to assess the feasibility of this form of learning in the damaged visual system.","ExperimentalDrugs":"[\"device: vision training and learning task\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"ENROLLING_BY_INVITATION","Add_on":"Other","Endpoint":"Other","total_Score":6,"Phase":"NA","lastUpdateDate":"2026-01-28"},{"nctId":"NCT06085378","OrgName":"First Affiliated Hospital, Sun Yat-Sen University","Titlefull":"Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus (TK-SEEK): a Prospective, Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Study","BriefSummary":"This study is a multicenter, randomized, double-blind, placebo parallel control study, aim to evaluate the efficacy and safety of human urinary kallidinogenase in the treatment of acute ischemic stroke with type 2 diabetes.","ExperimentalDrugs":"[\"urinary kallidinogenase for injection\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":20,"Phase":"NA","lastUpdateDate":"2023-10-13"},{"nctId":"NCT06649240","OrgName":"Seoul National University Hospital","Titlefull":"Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke (SVO70)","BriefSummary":"Lipid-lowering therapy constitutes a cornerstone of secondary prevention in ischemic stroke; however, current stroke guidelines remain deficient in providing optimal target low-density lipoprotein (LDL)-cholesterol levels tailored to the stroke subtypes. Most clinical trials on LDL-cholesterol management have not differentiated between stroke subtypes or have primarily focused on large artery atherosclerosis (LAA) stroke, leaving a gap in evidence for managing LDL-cholesterol in other stroke subtypes, e.g., small vessel occlusion (SVO) stroke. While hypertension is the leading risk factor for SVO strokes, the link between elevated LDL-cholesterol and SVO stroke is also recognized. Establishing optimal LDL-cholesterol targets for SVO stroke would significantly enhance secondary prevention strategies and improve patient outcome. Thus, the investigators aim to compare intensive versus standard lipid-lowering in patients with SVO stroke. SVO70 is a multicenter, prospective, randomized, open, blinded-endpoint clinical trial. Adult participants with objectively confirmed SVO stroke within 180 days of randomization will be included. Exclusion criteria include those with predefined LDL-cholesterol targets for other conditions, statin contraindications, or women who are pregnant, breastfeeding, or planning pregnancy during the study period. Eligible participants will be randomized 1:1 to target LDL-cholesterol \\<70 mg/dL (intensive group) or 90-110 mg/dL (standard group). The trial plans to enroll 4,016 participants, with the primary outcome being major adverse cardiovascular events-cardiovascular death, stroke, and acute coronary syndrome-during a follow-up period of at least 4 years. This study would provide valuable information for determining the optimal LDL-cholesterol target for patients with SVO stroke.","ExperimentalDrugs":"[\"statins and/or ezetimibe\",\"pcsk9 inhibitor\"]","Allcountries":"[\"South Korea\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":11,"Phase":"NA","lastUpdateDate":"2025-05-17"},{"nctId":"NCT06663657","OrgName":"Riphah International University","Titlefull":"Effects of Cognitive Sensorimotor Exercises Versus Task Oriented Training on Balance ,Gait and Activities of Daily Living in Chronic Stroke Patients.","BriefSummary":"To determine effects of cognitive sensorimotor exercises versus task oriented training on balance, gait and activities of daily living in chronic stroke patients.","ExperimentalDrugs":"[\"other: cognitive sensorimotor exercises\",\"other: task oriented training group\"]","Allcountries":"[\"Pakistan\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"Other","Endpoint":"Late efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2025-02-20"},{"nctId":"NCT06663631","OrgName":"Capital Medical University","Titlefull":"The Safety and effiCacy of HIbernation-Like Therapy Combining recanaLization in Ischemic Stroke: a Phase 1, Dose-escalation Study","BriefSummary":"The goal of this clinical trial is to learn whether chlorpromazine and promethazine（C+P）is safe in Acute Ischemic Stroke（AIS) patients and determine the maximum dosage. It will also evaluate the preliminary efficacy of C+P in AIS. The main questions it aims to answer are:\n\nWhat is the optimal dosage of C+P that is safe without causing adverse effects in AIS patients? What is the optimal dosage of C+P that potentially works to treat AIS? Researchers will compare C+P with placebo (saline solution without C+P) to see if C+P is safe and effective in treating Acute Ischemic Stroke.\n\nParticipants will:\n\nReceive C+P or placebo at the same time as endovascular thrombectomy begins. Patients will be observed for 72 hours to see if there were any adverse effects related to C+P. Infarct volumes will be evaluated using Computed Tomography. Functional outcomes will be assessed at 90 days.","ExperimentalDrugs":"[\"chlorpromazine and promethazine\",\"procedure: endovascular thrombectomy\",\"rt-pa\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Day 1 only","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Safety","total_Score":27,"Phase":"PHASE1","lastUpdateDate":"2024-12-18"},{"nctId":"NCT07643337","OrgName":"State University of New York at Buffalo","Titlefull":"The Impact of Vagus Nerve Stimulation Paired With Rehabilitation on Lower Limb and Gait Functions After Ischemic Stroke","BriefSummary":"This is a prospective, double-blinded, randomized controlled study to evaluate the impact of Vagus Nerve Stimulation (VNS) therapy on lower limb function.","ExperimentalDrugs":"[\"device: vagus nerve stimulation therapy\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":14,"Phase":"NA","lastUpdateDate":"2026-06-08"},{"nctId":"NCT06561867","OrgName":"Kafrelsheikh University","Titlefull":"Ticagrelor Versus Cilostazol in Moderate and Moderate-to-severe Ischemic Stroke, a Randomized Controlled Trial","BriefSummary":"Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever moderate and moderate to severe ischemic stroke compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.","ExperimentalDrugs":"[\"ticagrelor 90 mg\",\"cilostazol 100 mg\"]","Allcountries":"[\"Egypt\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT optional","Endpoint":"Late efficacy","total_Score":28,"Phase":"PHASE3","lastUpdateDate":"2024-08-16"},{"nctId":"NCT06616831","OrgName":"Medical University of South Carolina","Titlefull":"Development of At-Home Transcutaneous Auricular Vagus Nerve Stimulation for Post-Stroke Rehabilitation","BriefSummary":"Early evidence suggests the benefits of post-stroke motor rehabilitation may be enhanced by applying electrical stimulation to the ear. This study aims to test the new approach of pairing ear stimulation with motor rehabilitation in the home setting in stroke survivors with upper limb motor function deficits.","ExperimentalDrugs":"[\"device: remote transcutaneous auricular vagal nerve stimulation paired with task-specific training\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-05-15"},{"nctId":"NCT05995600","OrgName":"Seoul National University Hospital","Titlefull":"Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)","BriefSummary":"Antiphospholipid syndrome (APS) has a close association with ischemic stroke; however, the optimal treatment strategy for APS-related stroke has yet to be established. The clinical guidelines suggest using warfarin for APS-related stroke, but these suggestions are largely based on retrospective studies from the 1990s and expert opinion, rather than high-quality clinical trials. Moreover, the evidence on the role of antiplatelet drugs other than aspirin (e.g., clopidogrel) in APS-related stroke is particularly limited. Considering the relatively young age of patients with APS and the high clinical burden of using warfarin, it is necessary to verify whether warfarin is essential. Thus, the investigators aim to compare clopidogrel-based antiplatelet therapy and warfarin as a secondary preventive medication for patients with APS-related stroke. APS-STROKE is an exploratory, multicenter, prospective, randomized, open, blinded-endpoint clinical trial. Adult patients with definite APS who have a history of ischemic stroke will be included. Patients with high-risk APS (triple positivity or persistently high titers of anti-cardiolipin or anti-β2-glycoprotein I antibodies), systemic lupus erythematous, or indications for continued antiplatelet or anticoagulant therapy will be excluded. Eligible patients will be 1:1 randomized to receive clopidogrel-based antiplatelet therapy or warfarin. Patients assigned to the clopidogrel-based antiplatelet therapy group will be permitted to use additional antiplatelet drugs other than clopidogrel at the investigator's discretion. The primary outcome is a composite of any death, major adverse cardiovascular events, systemic thromboembolic events, and major bleeding during a follow-up period of at least 4 years. This study would provide valuable information for determining the optimal secondary prevention strategy for APS-related stroke.","ExperimentalDrugs":"[\"antiplatelet drug\",\"warfarin\"]","Allcountries":"[\"South Korea\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":11,"Phase":"PHASE4","lastUpdateDate":"2024-10-13"},{"nctId":"NCT07641998","OrgName":"Beijing Tiantan Hospital","Titlefull":"A Phase I, Open-Label, Single-Arm Study of Robot-Assisted Stereotactic Minimally Invasive Hematoma Aspiration Followed by Intrahematoma Tenecteplase in Patients With Symptomatic Supratentorial PH2 Hemorrhagic Transformation After Reperfusion Therapy for Acute Ischemic Stroke","BriefSummary":"The purpose of this phase I trial is to evaluate the safety and feasibility of robot-assisted stereotactic minimally invasive hematoma aspiration, followed when eligible by intrahematoma tenecteplase administration, in patients who develop symptomatic supratentorial PH2 hemorrhagic transformation after reperfusion therapy for acute ischemic stroke. The main study questions are whether this strategy is associated with an acceptable early rebleeding risk and whether it can achieve clinically meaningful hematoma reduction with accurate catheter placement and relief of hematoma-related mass effect.","ExperimentalDrugs":"[\"robot-assisted stereotactic hematoma aspiration plus intrahematoma tenecteplase\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Early efficacy","total_Score":20,"Phase":"PHASE1","lastUpdateDate":"2026-06-06"},{"nctId":"NCT05976685","OrgName":"Insel Gruppe AG, University Hospital Bern","Titlefull":"Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic StrokE Despite Anticoagulation Therapy","BriefSummary":"Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and cardioembolic stroke due to AF is its major complication. Direct oral anticoagulants (DOAC) reduce the risk of cardioembolism in patients with AF. Despite DOAC therapy, there is a significant residual stroke risk of 1-2%/year. Recent data from the Swiss Stroke Registry found 38% of patients with AF and ischemic stroke were on prior anticoagulant therapy (approximately 400 patients per year in Switzerland). The investigators found in a prior observational study, that patients with AF who have ischemic stroke despite anticoagulation are at increased risk of having another ischemic stroke (HR 1.6; 95% confidence interval, CI 1.1-2.1). Combining observational data from 11 international stroke centres, the investigators found that the majority of ischemic strokes despite anticoagulation in patients with AF is \"breakthrough\" cardioembolism (76% of patients) and only a minority of 24% is related to other causes unrelated to AF. Optimal secondary prevention strategy is unknown. The investigators have conducted two independent observational studies including together \\>4000 patients but did not identify any strategy (e.g. switch to different DOAC, additional antiplatelet therapy) that seems superior. A recent randomized controlled trial on surgical occlusion of the left atrial appendage (LAAO) found that LAAO may provide additional protection from ischaemic stroke in addition to oral anticoagulation. Triggered by this finding, the investigators performed a matched retrospective observational study and found that patients with AF and stroke despite anticoagulation who received a combined mechanical-pharmacological therapy (DOAC therapy + LAAO) had lower rates of adverse outcomes compared to those with DOAC therapy alone. Therefore, the investigators hypothesize that in patients with AF and ischemic stroke despite anticoagulant therapy, LAAO in addition to anticoagulation with a DOAC is superior to DOAC therapy alone. The investigators propose an international, multi-center randomized controlled two-arm trial to assess the effect of LAAO in patients with AF suffering from strokes despite anticoagulation therapy and without competing stroke etiology. The investigators will use the PROBE design with blinded endpoint assessment. The investigators will enrol patients with non-valvular AF and a recent ischemic stroke despite anticoagulation therapy at stroke onset. Patients will be randomized 1:1 to receive LAAO + DOAC therapy (experimental arm) or DOAC therapy alone (standard treatment arm). The primary endpoint is the first occurrence of a composite outcome of recurrent ischemic stroke, systemic embolism and cardiovascular death during follow-up. Secondary outcomes include individual components of the primary composite outcome, safety outcomes (i.e. symptomatic intracranial haemorrhage, major extracranial bleeding, serious device- or procedure-related complication), functional outcome (modified Rankin Scale) and patient-oriented outcomes. The minimum follow-up is 6 months and all patients will receive follow-ups every 6 months until end of study, the maximal follow-up will be 48 months. Based on prior observational data from the investigators' group and others (5 observational studies, \\>5000 patients), the investigators estimate the proportion of patients with the primary outcome in the standard treatment arm to be 18% in the first year and 9% in the second year (=cumulative 27% after 2 years). A relative risk reduction of 40% at 2 years would be clinically relevant. Based on these assumptions and a log-rank test, the investigators would need 98 events for a power of 80% at an alpha-level of 5%. Assuming a recruitment rate of 52, 118, 156 and 156 patients in years 1 to 4, an additional 6 months of follow-up (mean follow-up time of 2.1 years) and a uniform drop-out rate of 7.5% per year, 482 patients would need to be enrolled. How to treat patients with an ischemic stroke despite anticoagulation is a major yet unresolved clinical dilemma. This trial has the potential to answer the question whether LAAO plus DOAC therapy is superior to current standard of care for patients with AF who have ischemic stroke despite anticoagulation.","ExperimentalDrugs":"[\"procedure: left atrial appendage occlusion\",\"doac\"]","Allcountries":"[\"Belgium\",\"Germany\",\"New Zealand\",\"Spain\",\"Switzerland\",\"United Kingdom\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":11,"Phase":"NA","lastUpdateDate":"2026-06-16"},{"nctId":"NCT05875389","OrgName":"Ottawa Hospital Research Institute","Titlefull":"Virtual Intervention Stroke Initiative by Ottawa Neurology","BriefSummary":"The goal of this clinical trial is to determine if patients admitted to a primary stroke centre, such as the general internal medicine service of the Ottawa Hospitals General Campus, for acute ischemic stroke would benefit from a scheduled virtual assessment with a stroke neurologist to review investigations, results, and evaluations to identify stroke etiology, propose appropriate therapy, and guide decision-making and multidisciplinary assessment, similar to services provided to patients admitted to comprehensive stroke centres, such as the Civic Campus of the Ottawa Hospital.","ExperimentalDrugs":"[\"other: virtual assessment\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Other","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Late efficacy","total_Score":9,"Phase":"NA","lastUpdateDate":"2024-04-02"},{"nctId":"NCT06316570","OrgName":"Beijing Tiantan Hospital","Titlefull":"Efficacy and Safety of Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis in Patients With Ischemic Stroke (TAPIS): a Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Trial","BriefSummary":"Early antiplatelet therapy is promising for further improvement of functional prognosis on the basis of intravenous thrombolytic therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of the early dual antiplatelet therapy (within 6 hours of onset ) of ticagrelor with aspirin combined with intravenous thrombolysis in improving good functional outcome (mRS score 0-1) at 90 days inpatients with ischemic stroke.","ExperimentalDrugs":"[\"early dual antiplatelet therapy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 6 hours","TreatDur":"Other","Status":"COMPLETED","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":26,"Phase":"PHASE3","lastUpdateDate":"2026-01-21"},{"nctId":"NCT06447415","OrgName":"Fujian Shengdi Pharmaceutical Co., Ltd.","Titlefull":"Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled, Single Dose Incremental Phase Ib Clinical Trial","BriefSummary":"This study is a multi-center, randomized, double-blind, double-dummy, placebo-controlled, single dose escalation study aimed at evaluating the overall safety, tolerability, and preliminary efficacy of HRS-7450 in patients with acute ischemic stroke.","ExperimentalDrugs":"[\"hrs-7450\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Other","Status":"COMPLETED","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Safety","total_Score":20,"Phase":"PHASE1","lastUpdateDate":"2025-09-26"},{"nctId":"NCT06299579","OrgName":"Beijing Tiantan Hospital","Titlefull":"Phase III Clinical Trial of GD-11 for Injection in the Treatment of Acute Ischemic Stroke","BriefSummary":"Phase III Clinical Trial of GD-11 for Injection in the Treatment of Acute Ischemic Stroke - A Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase III Clinical Study with the primary objective of evaluation of the efficacy and safety of GD-11 for injection in the treatment of acute ischemic stroke patients within 48 hours. The subject has a clinical diagnosis of acute ischemic stroke, within 48 hours from stroke onset to start of study treatment, with a National Institutes of Health Stroke Scale (NIHSS) between 6 and 20, had a total score of upper and lower limbs on motor deficits ≥ 2. The primary outcome is the proportion of subjects with mRS score ≤ 1 at 90 days after treatment.","ExperimentalDrugs":"[\"gd-11 for injection test group\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Longer than 3 days","Status":"UNKNOWN","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":22,"Phase":"PHASE3","lastUpdateDate":"2024-03-12"},{"nctId":"NCT06265779","OrgName":"People's Hospital of Zhengzhou University","Titlefull":"Therapeutic Effect of Transcranial Direct Current Stimulation Combined With Intermittent Oral to Esophageal Feeding on Swallowing Disorders in Patients With Cerebral Infarction: Double Blind Randomized Controlled Study","BriefSummary":"The study is a double-blind randomized controlled trial, lasting for 15 days for each participant. Patients with post-stroke dysphagia who receive treatment at the Rehabilitation Department are selected as the study subjects. The patients are randomly assigned to either the experimental group or the placebo group. All patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using Intermittent Oro-esophageal Tube. In addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.","ExperimentalDrugs":"[\"behavioral: comprehensive rehabilitation therapy\",\"device: intermittent oro-esophageal tube feeding\",\"device: transcranial direct current stimulation\"]","Allcountries":"[\"South Korea\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Early efficacy","total_Score":9,"Phase":"NA","lastUpdateDate":"2024-03-02"},{"nctId":"NCT06314308","OrgName":"Columbia University","Titlefull":"Community Health Worker Assisted Task Specific and Cognitive Therapy at Home With Exposure After Stroke","BriefSummary":"CATCHES is a novel intervention for preliminary testing, integrating Task Specific Therapy at home guided by Community Health Workers (CHW) under supervision of a licensed Physical Therapist (PT) guided by telehealth based Cognitive Behavioral Therapy (CBT) to reduce task specific fears through repetitive exposure and adaptive behavioral activation strategies and facilitate engagement in physical activity.\n\n1. To integrate and establish feasibility of CATCHES intervention. Hypothesis: A multidisciplinary team providing home based TST with exposure therapy tailored to an underserved urban setting will inform a patient-centered behavioral intervention to reduce fear of falling (FOF) among post-acute stroke patients returning home. Feasibility outcomes will include recruitment, retention, and fidelity of implementation.\n2. Test effects of the intervention on hypothesized treatment mechanism of fear of falling. Hypothesis: Therapy will reduce task specific fear of falling Primary outcome will be change in Activities-specific Balance Confidence Scale.\n3. Explore physical activity measures subjectively and objectively. Exploratory outcomes include pre and post Timed Up and Go test, patient reported outcome surveys and activity as measured by wearable devices.","ExperimentalDrugs":"[\"behavioral: catches\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"Other","Endpoint":"Other","total_Score":5,"Phase":"NA","lastUpdateDate":"2026-04-07"},{"nctId":"NCT06005233","OrgName":"Technical University of Munich","Titlefull":"Smartwatches for Detection of Atrial Fibrillation (AFib) in Secondary Prevention of Cryptogenic Stroke - WATCH AFib A Prospective, Intraindividual-controlled, Multicenter Clinical Study","BriefSummary":"Scientific Background: In secondary prevention of ischemic stroke, detection of atrial fibrillation (AFib) and subsequent anticoagulation therapy reduce the risk of recurrent stroke by approximately 60%. Prolonged electrocardiogram (ECG) monitoring up to 6 months significantly increases detection of AFib in cryptogenic stroke. Wearables like smartwatches have recently been shown to adequately detect AFib in the general population. Thus, prolonged ECG monitoring after cryptogenic ischemic stroke or transient ischemic attack (TIA) using a smartwatch could lead to a reduction of recurrent stroke by prompting adequate anticoagulation therapy and may constitute a cost-effective, non-invasive, and broadly-available alternative to the current standard of care.\n\nHypothesis: The investigators hypothesize that AFib detection via smartwatch in patients with cryptogenic TIA or ischemic stroke is accurate compared to an implantable event recorder.\n\nMethods: The investigators introduce a prospective, intraindividual-controlled, multicentre clinical study in patients with cryptogenic ischemic stroke or TIA. In addition to an implanted event recorder as indicated by clinical standard, included patients receive a smartwatch for detection of AFib. ECG-data from smartwatches will be continuously monitored by two independent cardiologists. As soon as AFib is confirmed, a doctoral appointment is set to evaluate start of anticoagulation. The follow-up period will be six months. The study consists of four study visits: a baseline visit, two phone visits at one and three months, and an end of trial visit at six months.\n\nPrimary Objective: To compare smartwatch and event recorder based analysis for sensitivity and specificity of AFib detection per patient after six months","ExperimentalDrugs":"[\"device: smartwatch\"]","Allcountries":"[\"Germany\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":6,"Phase":"NA","lastUpdateDate":"2024-12-09"},{"nctId":"NCT03814850","OrgName":"University of Miami","Titlefull":"Remote Ischemic PreConditioning Provides Neuroprotection: A Phase 2, Single Center, Randomized, Double-Blind, Sham-Controlled, Safety and Efficacy Study Evaluating the Use of Remote Ischemic Preconditioning in Patients Undergoing Endovascular Repair of Brain Aneurysms","BriefSummary":"The purpose of this study is to learn about protecting the brain from low blood flow (ischemia) with limb preconditioning. From human studies the investigators know that the brain can be protected from dangerous low blood flow by reducing the blood flow to an arm or leg for just a short period of time. This is called limb preconditioning. The investigators are studying the safety and feasibility of preconditioning and their effect of protecting the brain from ischemia in two different groups. This is a Phase 2, randomized, double-blind, sham-controlled, design. Up to 50 male and female patients undergoing elective endovascular repair of unruptured brain aneurysm who are randomized to the remote ischemic preconditioned or sham group will be enrolled. This study consists of one 3-9 month study period for each patient plus up to 14 days for enrollment activities. Subjects are required to return between 3-9 months for end-of-study procedures.","ExperimentalDrugs":"[\"device: standard manual aneroid sphygmomanometer\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Day 1 only","Status":"WITHDRAWN","Add_on":"Other","Endpoint":"Safety","total_Score":8,"Phase":"NA","lastUpdateDate":"2023-12-01"},{"nctId":"NCT06615726","OrgName":"Capital Medical University","Titlefull":"Regular Physical Exercise in Patients With Symptomatic Intracranial Arterial Stenosis: a Prospective Randomized Open-label Blinded Endpoint Trial","BriefSummary":"The objective of this study is to evaluate the effectiveness and safety of regular physical exercise in preventing ischemic stroke events in patients with symptomatic intracranial arterial stenosis.","ExperimentalDrugs":"[\"behavioral: regular physical exercise\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"ACTIVE_NOT_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":16,"Phase":"PHASE3","lastUpdateDate":"2025-11-22"},{"nctId":"NCT06540417","OrgName":"Xidian University","Titlefull":"Study of the Neuroprotection and Rehabilitation Promotion of the Non-invasive Trigeminal Nerve Stimulation on Ischemic Stroke Patients","BriefSummary":"In patients with ischemic stroke, the primary focus revolves around enhancing the neuroprotective and rehabilitative effects of external trigeminal nerve stimulation (eTNS) and elucidating its underlying central mechanisms. Through clinical trials and neuroimaging studies, this research endeavors to 1) investigate the clinical impact of TNS on brain protection and 2) rehabilitation acceleration in ischemic stroke patients, while concurrently exploring the potential central nervous mechanisms involved. The ultimate aim is to contribute a novel therapeutic approach to the clinical management of acute ischemic stroke.","ExperimentalDrugs":"[\"device: external trigeminal nerve stimulation\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"COMPLETED","Add_on":"Other","Endpoint":"NIHSS","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-07-16"},{"nctId":"NCT06010628","OrgName":"General Hospital of Shenyang Military Region","Titlefull":"Intravenous Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2): a Prospective, Randomized, Open Label, Blinded Endpoint, and Multi-center Study","BriefSummary":"To date, the benefit of intravenous thrombolysis is confined within 4.5 hours of onset for acute ischemic stroke (AIS) patients without advanced neuroimaging selection. Unpublished pilot EXIT-BT (EXtending the tIme window of Thrombolysis by ButylphThalide up to 6 Hours after onset) suggest the safety, feasibility and potential benefit of intravenous tenecteplase (TNK) in AIS within 4.5 to 6 hours of onset. The current study aims to investigate the efficacy and safety of TNK for AIS within 4.5 to 6 hours of onset.","ExperimentalDrugs":"[\"tenecteplase\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 6 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"PHASE4","lastUpdateDate":"2025-08-20"},{"nctId":"NCT06495671","OrgName":"University of Melbourne","Titlefull":"Australasian Nanoparticle-mediated Magnetically Enhanced Diffusion for Ischemic Stroke (AusNanoMED)","BriefSummary":"Rapidly restoring blood flow to the brain in patients with stroke caused by a blocked blood vessel in the brain is the key to reducing disability. Current treatments often leave small blocked arteries that cannot be safely opened with mechanical clot removal devices. Furthermore, stagnant flow limits access of clot-dissolving medication to the clot. This trial tests iron nanoparticles (similar to iron infused to replace low body stores but injected directly into the brain artery upstream of the blockage) combined with an external rotating magnet that draws the nanoparticles towards the clot, overcoming stagnant blood flow. The aim is to bring fresh blood which contains naturally-occurring clot-dissolving substances, and any clot-dissolving medication that may be circulating, to the surface of the clot with the aim of restoring blood flow to the brain. The trial will recruit up to 30 patients. All will receive injection of nanoparticles via an angiogram (small tube inserted into a leg or arm artery and fed up into the brain artery under Xray control). The procedure takes 30min and the degree of success in opening the artery at the end of procedure is the primary outcome, combined with an absence of symptomatic brain bleeding at 24h.","ExperimentalDrugs":"[\"device: magnetically enhanced diffusion\"]","Allcountries":"[\"Australia\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Day 1 only","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":20,"Phase":"NA","lastUpdateDate":"2024-07-07"},{"nctId":"NCT06494202","OrgName":"University of Sao Paulo","Titlefull":"Stroke Rehabilitation: A Systemized and Hierarchized Rehabilitation Program for the Brazilian Unified Health System","BriefSummary":"The goal of this clinical trial is to systemize and hierarchize a rehabilitation program for the Brazilian Unified Health System in patients with stroke above 18 years of age and of both sexes. The main question it aims to answer is:\n\n* Do patients with ischemic first episode of stroke have central nervous systems consequences due to peripheral and central nervous system sensibilization?\n* Can stroke patients benefit from a systemized and hierarchized rehabilitation program with desensibilization interventions combined with multidisciplinary and educational programs?\n\nWe will randomize 60 patients, 30 in each study arm.\n\nResearchers will compare the intervention group with an active control whose treatment is the institutional conventional program to see if innovative desensibilization strategies yield superior results. Authors will also investigate the role of genetic polymorphism and ancestrality in the outcome measures.\n\nParticipants will undertake an innovative or conventional rehabilitation program, according to the randomization.","ExperimentalDrugs":"[\"other: conventional rehabilitation program.\",\"other: innovative rehabilitation\"]","Allcountries":"[\"Brazil\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":8,"Phase":"NA","lastUpdateDate":"2024-07-29"},{"nctId":"NCT06559436","OrgName":"The First Affiliated Hospital of University of Science and Technology of China","Titlefull":"Extending the Time Window for Intravenous Tenecteplase in Patients With Distal Medium Vessel Occlusions Stroke-a Randomised, Controlled, Multicentre Study","BriefSummary":"To assess the safety and efficacy of beyond time window TNK intravenous thrombolysis for distal Medium Vessel Occlusion (MeVO) related stroke in a prospective randomized clinical trial.","ExperimentalDrugs":"[\"intravenous thrombolysis\",\"other: standard medical management\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":23,"Phase":"NA","lastUpdateDate":"2024-10-22"},{"nctId":"NCT06472921","OrgName":"Xiangya Hospital of Central South University","Titlefull":"Effect of Early Initiation of Butylphthalide on Neural Function in Patients With Acute Ischemic Stroke -A Prospective, Multicenter, Randomized, Open-label, Blinded End Trial","BriefSummary":"This study is a prospective, multicenter, randomized, open-label, blinded-endpoint trial designed to evaluate the difference in efficacy of Butylphthalide Sodium Chloride Injection treatment initiated early (\\&lt;3 hours) versus late (3-6 hours) in patients with acute ischemic stroke. The aim is to determine the optimal timing window for neuroprotective therapy.","ExperimentalDrugs":"[\"behavioral: butylphthalide treatment initiation time\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":22,"Phase":"PHASE2","lastUpdateDate":"2025-11-20"},{"nctId":"NCT06645405","OrgName":"Shanghai Jiao Tong University Affiliated Sixth People's Hospital","Titlefull":"Segmentation and Modeling for Accurate Reconstruction of CT Angiography of Intracranial Large Vessel Occlusion with Artificial Intelligence: a Stepped-wedge, Cluster-randomized Controlled Trial","BriefSummary":"Acute ischemic stroke (AIS) caused by intracranial large vessel occlusion (LVO) in the anterior circulation significantly contributes to stroke-related disability and mortality. Recent randomized controlled trials have demonstrated substantial benefits of endovascular thrombectomy (EVT) when patients are appropriately triaged beforehand. However, accurately orienting the 'missed segment' during EVT remains challenging. Guide-wires often fail to navigate through the occlusion or are mistakenly directed into the small tranches or even cause vessel rupture. To address this clinical need, the investigators developed an artificial intelligence (AI) algorithm to automate the reconstruction of CT angiography (CTA), focusing on the occluded LVO segment. To evaluate the clinical utility of this AI algorithm, the investigators propose a prospective, stepped-wedge cluster-randomized study to determine whether integrating our AI algorithm into AIS care flow can reduce the time for first pass of the thrombus by improving the visualization of the occluded segment on CTA. Physicians will assess patient eligibility for thrombectomy, and all selected patients will receive standard care according to current guidelines. This approach is expected to enhance patient treatment outcomes for endovascular thrombectomy by leveraging readily available data.","ExperimentalDrugs":"[\"behavioral: ai algorithm\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":14,"Phase":"NA","lastUpdateDate":"2024-10-15"},{"nctId":"NCT06722677","OrgName":"Beijing Pins Medical Co., Ltd","Titlefull":"A Multi-Center, Triple-Blind, Randomized, Sham-Controlled Trial Assessing the Efficacy and Safety of Rehabilitation Paired with Vagus Nerve Stimulation for Upper Extremity Motor Function in Patients with Ischemic Stroke (Repair Study)","BriefSummary":"The goal of this clinical trial is to investigate the efficacy and safety of vagus nerve stimulation (VNS) paired with rehabilitation for enhancing upper extremity motor function after ischemic stroke.\n\nResearchers will compare the outcomes of active VNS paired with rehabilitation against sham VNS (the actual intensity is 0 mA) also paired with rehabilitation, in order to assess improvements in arm motor function post-stroke.\n\nParticipants in this study will undergo a surgical procedure to implant the VNS system and will subsequently recieve a 6 weeks in-clinic therapy, followed by an additional 6 weeks home exercise. During the final 6 weeks, participants will either recieve in-clinic therapy or maintain their home exercise, depending on their assigned group.","ExperimentalDrugs":"[\"device: vns\",\"other: rehabilitation\",\"device: sham vns\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":18,"Phase":"NA","lastUpdateDate":"2024-12-09"},{"nctId":"NCT05857046","OrgName":"Coordinación de Investigación en Salud, Mexico","Titlefull":"Cerebroprotective Effect of Melatonin in Acute Ischemic Stroke","BriefSummary":"Stroke is a leading cause of mortality and disability in Mexico and worldwide. Although current treatment strategies focus on removing oclussion, they do not interrupt the signaling cascade of neuronal damage. Thus, the search for a cerebroprotective agent that can protect the entire brain. Melatonin has been proposed as a potential cerebroprotective agent due to its antioxidant, anti-inflammatory, antiapoptotic, and immunomodulatory effects, which oppose the pathophysiological mechanisms of cerebrovascular disease. Melatonin has the potential to improve stroke outcomes and reduce the risk of disability and mortality, making it a promising therapeutic option for stroke patients.\n\nTo assess the efficacy of melatonin in patients with acute ischemic CVD, improve clinical outcome, and infarct volume.","ExperimentalDrugs":"[\"melatonin 10 mg\",\"other: placebo\"]","Allcountries":"[\"Mexico\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"UNKNOWN","Add_on":"IVT excluded ; EVT optional","Endpoint":"Late efficacy","total_Score":23,"Phase":"PHASE3","lastUpdateDate":"2024-03-01"},{"nctId":"NCT06335641","OrgName":"University of Calgary","Titlefull":"Head COOLing in IscHemic Stroke Patients Undergoing EndovAscular Thrombectomy: a Feasibility and Safety StuDy","BriefSummary":"This is an investigator-initiated, prospective, open-label, single-arm, non-randomized study to assess the safety and feasibility of external active conductive head cooling during endovascular thrombectomy procedures.","ExperimentalDrugs":"[\"device: external active conductive head cooling\"]","Allcountries":"[\"Canada\",\"New Zealand\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"ACTIVE_NOT_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":14,"Phase":"NA","lastUpdateDate":"2024-12-24"},{"nctId":"NCT06656442","OrgName":"Ain Shams University","Titlefull":"\"The Effect of Trimetazidine on the Clinical Outcome of Acute Ischemic Stroke Patients\"","BriefSummary":"The investigators need to test the effect of Trimetazidine on the pro-inflammatory marker Interleukin - 18 , NIHSS score, and mRs score of acute ischemic stroke patients.","ExperimentalDrugs":"[\"trimetazidine\"]","Allcountries":"[\"Egypt\"]","FirstAdminInter":"Within 12 hours","TreatDur":"Other","Status":"COMPLETED","Add_on":"IVT excluded ; EVT optional","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"PHASE3","lastUpdateDate":"2025-08-30"},{"nctId":"NCT06352619","OrgName":"The George Institute","Titlefull":"Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL_ENCHANTED3/MT)","BriefSummary":"Several clinical trials have produced variable conclusions regarding the effects of intensive blood pressure (BP) lowering in post-EVT acute ischaemic stroke (AIS) patients. Although two trials indicate harm from very intensive target-based treatment (SBP \\<130 mmHg), the others neutral effects in the SBP range 140-160 mmHg. The ENCHANTED3/MT domain of the ACT-GLOBAL platform trial aims to test different approaches to the treatment of elevated SBP in post-EVT AIS patients to find an optimal BP management strategy. ENCHANTED3/MT will randomize (1:1:1) up to 2,000 patients with SBP ≥150 mmHg post-EVT to conservative (no or minimal SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP \\[≥180mmHg\\]), moderate (SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP \\[150-160mmHg\\]), or intensive (SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher) BP management.","ExperimentalDrugs":"[\"other: conservative sbp control\",\"other: moderate sbp control\",\"other: intensive sbp control\"]","Allcountries":"[\"Australia\",\"Canada\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"NA","lastUpdateDate":"2024-11-18"},{"nctId":"NCT06753006","OrgName":"Neurotechnika","Titlefull":"A Study of Neurorehabilitation Based on Robotics, Brain-Computer Interface (BCI) and Virtual Reality (VR) in Patients with Upper Limb Paresis Due to Stroke in the Early Rehabilitation Period","BriefSummary":"This clinical trial aims to investigate the effectiveness of a novel neurorehabilitation technology for treating stroke in adults. The study will evaluate a simulator that combines robotic orthosis, a non-invasive brain-computer interface (BCI), and a virtual reality (VR) display. The goal of this trial is to advance stroke rehabilitation by exploring the potential benefits of these cutting-edge technologies.\n\nKey Research Questions:\n\nEfficacy: Does the new simulator significantly improve arm function compared to standard rehabilitation techniques?\n\nBCI Technology: Which approach - motor imagery of only the paretic arm or both the paretic and healthy arm - yields greater functional improvements?\n\nVR Contribution: How does the integration of VR enhance rehabilitation outcomes?\n\nSafety and Tolerability: What potential side effects or adverse events may arise from using the new simulator?\n\nParticipants who have suffered a stroke will undergo a standard rehabilitation course, during which 10-12 sessions will take place using the innovative simulator: a robotic device moves a patient's paralyzed arm at the command of a non-invasive brain-computer interface to perform a game task resembling real-life activities, augmented by a virtual reality display.\n\nResearchers will assess the impact of the new technology on arm function to determine its efficacy in promoting recovery.","ExperimentalDrugs":"[\"procedure: standard course\",\"device: neurorehabilitation simulator\"]","Allcountries":"[\"Russia\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":18,"Phase":"NA","lastUpdateDate":"2024-12-31"},{"nctId":"NCT06576466","OrgName":"Fundació d'investigació Sanitària de les Illes Balears","Titlefull":"Effect of Supplementation With Creatine on the Early Recovery of Ischemic Stroke: A Randomized Clinical Trial","BriefSummary":"Stroke is a leading cause of disability and the second leading cause of death worldwide. Most strokes are ischemic, caused by acute arterial occlusion. Post-stroke treatment focuses on secondary prevention and rehabilitation, but few treatments address functional recovery. Creatine, a supplement known for improving physical performance, may aid in the recovery of stroke patients, reducing sarcopenia and improving strength among other effects. This pilot study will investigate the effectiveness of creatine supplementation in enhancing physical and functional recovery in ischemic stroke patients. The study will involve a randomized, double-blind clinical trial comparing creatine monohydrate to a placebo.","ExperimentalDrugs":"[\"dietary supplement: creatine monohydrate\"]","Allcountries":"[\"Spain\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-07-02"},{"nctId":"NCT06330051","OrgName":"Beijing Tiantan Hospital","Titlefull":"The Improve Acute Reperfusion Treatment Quality for Ischemic Stroke Through Spatiotemporal Computing in China (IMPROVE-II ) -A Multicenter, Evaluator-Blind, Cluster-Randomized Controlled Study","BriefSummary":"This study intends to construct the goal-oriented integrated intervention model for AIS in-hospital procedure through the spatiotemporal positioning and the P-D-C-A cycle for continuous improvement (FAST model). Then a multicenter, evaluator-blind, cluster-randomized controlled study aims to verify the validity and safety of this FAST model.","ExperimentalDrugs":"[\"behavioral: improvement acute reperfusion treatment quality for stroke through spatiotemporal computing\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2025-06-07"},{"nctId":"NCT06286020","OrgName":"People's Hospital of Zhengzhou University","Titlefull":"A Randomized Controlled Study to Explore the Effect of Virtual Reality Therapy on Dysphagia in Wallenberg Syndrome","BriefSummary":"The goal of this clinical trial is to learn about on dysphagia in wallenberg syndrome. The main questions it aims to answer are:\n\nthe efficacy of Virtual Reality Therapy in the rehabilitation of patients with dysphagia in Wallenberg syndrome.\n\nParticipants received conventional dysphagia treatment and Virtual Reality Therapy once a day for 14 days. Researchers compared the control group to see the effect and mechanism of Virtual Reality Therapy.","ExperimentalDrugs":"[\"device: virtual reality therapy\",\"behavioral: conventional dysphagia treatment\"]","Allcountries":"[\"Taiwan\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Early efficacy","total_Score":8,"Phase":"NA","lastUpdateDate":"2024-03-02"},{"nctId":"NCT06243133","OrgName":"Sichuan Provincial People's Hospital","Titlefull":"Pair Antiplatelet THerapy in Ischemic Stroke With Intracranial Artery Stenosis","BriefSummary":"The goal of this clinical trial is to learn about efficacy and safety of dual antiplatelet therapy in ischemic stroke with intracranial artery stenosis. The main question it aims to answer are:\n\nwhether aspirin combined with clopidogrel for 3 month is better than 1 months for patients with non-cardiogenic cerebral infarction with intracranial artery stenosis.\n\nParticipants will get dual antiplatelet therapy (aspirin plus clopidogrel) for 1 month or 3 months within 7 days of the first stroke.\n\nResearchers will compare experimental group (3 months dual antiplatelet therapy) with comparison group (1 month dual antiplatelet therapy), to see if experimental group would reduce stroke recurrence or mortality, and increase bleeding and other adverse prognosis.","ExperimentalDrugs":"[\"clopidogrel for 30 days combined with aspirin for 90 days\",\"clopidogrel for 90 days combined with aspirin for 90 days\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Late efficacy","total_Score":17,"Phase":"PHASE4","lastUpdateDate":"2024-06-17"},{"nctId":"NCT06629116","OrgName":"Zhangzhou Municipal Hospital","Titlefull":"Study on the Role of Human Serum Albumin in Large Acute Ischemic Stroke of Anterior Circulation After Thrombectomy: A Prospective, Multicenter, Open-label, Endpoint-blinded, Randomized Controlled Trial","BriefSummary":"This project intends to explore the therapeutic efficacy of human serum albumin in mitigating postoperative cerebral edema and enhancing clinical outcomes following mechanical thrombectomy in patients with acute anterior circulation large-core ischemic stroke.","ExperimentalDrugs":"[\"patients with ais receive intravascular therapy, and within 10 minutes after the surgery, they are administered 100ml of 20% human albumin intravenously (infused within 30 minutes).\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"NA","lastUpdateDate":"2024-10-04"},{"nctId":"NCT06211712","OrgName":"Huashan Hospital","Titlefull":"Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion: A Prospective, Randomized, Double-blind, Placebo-controlled, Multi-center Study","BriefSummary":"The purpose of this study is to evaluate the safety and efficacy of Human Urinary Kallidinogenase combined with endovascular therapy in acute ischemic stroke (AIS) patients with large vessel occlusion.","ExperimentalDrugs":"[\"experimental: human urinary kallidinogenase\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":23,"Phase":"NA","lastUpdateDate":"2024-12-01"},{"nctId":"NCT06265805","OrgName":"People's Hospital of Zhengzhou University","Titlefull":"A Randomized Controlled Trial to Explore the Effect of Different Feeding Modes on Psychological Condition and Experience in Stroke Patients","BriefSummary":"The goal of this clinical trial is to compare the differences on Psychological Condition and Experience in ischemic stroke patients using Intermittent Oro-esophageal Tube and Nasogastric Tube. Patients will be randomly divided into an observation group and a control group, all receiving routine rehabilitation treatment. On this basis, the observation group will use Intermittent Oro esophageal Tube for enteral nutrition support, while the control group will use Nasogastric Tube. Researchers will compare Psychological Condition and Experience of two groups.","ExperimentalDrugs":"[\"behavioral: comprehensive rehabilitation therapy\",\"device: intermittent oro-esophageal tube feeding\",\"device: nasogastric tube feeding\"]","Allcountries":"[\"Taiwan\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Other","total_Score":1,"Phase":"NA","lastUpdateDate":"2024-03-02"},{"nctId":"NCT06134622","OrgName":"The First Affiliated Hospital of University of Science and Technology of China","Titlefull":"Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT)","BriefSummary":"To assess the efficacy and safety of tirofiban administration after intravenous thrombolysis for patients with AIS.","ExperimentalDrugs":"[\"intravenous thrombolysis plus tirofiban\",\"intravenous thrombolysis plus placebo\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Day 1 only","Status":"COMPLETED","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":30,"Phase":"PHASE3","lastUpdateDate":"2025-05-01"},{"nctId":"NCT06613282","OrgName":"Siberian Scientific Research and Test Center for Biomedical Engineering","Titlefull":"A Randomized Single-blind Study of LI-TMS and AVS for Stroke Recovery in Healthy Participants with the Evaluation of the Effect on the Subject Using EEG and the Following Testing.","BriefSummary":"This randomized, controlled, single-blind clinical pilot study investigates the therapeutic potential of low-intensity repetitive transcranial magnetic stimulation (LI-TMS) and audio-visual stimulation (AVS) and newly offered interventional protocols in healthy participants for further research on stroke rehabilitation and therapeutic effects.\n\nThe goal of this clinical trial is to learn if the intervention can be used in the future treatment of patients recovering after stroke. It will also learn about the safety of low-intensity repetitive transcranial magnetic stimulation and audio-visual stimulation.\n\nThe main questions it aims to answer are:\n\nDoes intervention with LI-TMS and AVS influence the parameter Work Efficiency (WE) of the participant? Does intervention with LI-TMS and AVS influence the parameter Warming-up work indicator (WU) of the participant? Does intervention with LI-TMS and AVS influence the parameter Psychological Stability (PS) of the participant? Does intervention with LI-TMS and AVS influence the parameter Perceptual Accuracy (Tv) of the participant? Does intervention with LI-TMS and AVS affect changes in the participants electroencephalogram parameters? The researchers will compare the results of LI-TMS and AVS intervention to a control group that received no intervention but only underwent an examination to evaluate the effects of the interventions.\n\nParticipants will:\n\nReceive interventions from LI-TMS and AVS every day for 2 weeks with a weekend break on Saturday and Sunday.\n\nAttend the clinic 3 times during the trial and undergo testing and screening. The first clinic visit is before the intervention course. The second clinic visit will be the day immediately following the end of the two-week intervention course. The third visit will be two weeks after the second visit.","ExperimentalDrugs":"[\"device: low intensity transcranial magnetic stimulation\",\"device: auditory and visual stimulation\"]","Allcountries":"[\"Russia\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"ENROLLING_BY_INVITATION","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2024-09-23"},{"nctId":"NCT05648812","OrgName":"Turku University Hospital","Titlefull":"Contrast Enhanced Ultrasound and Elastography of the Neonatal Brain","BriefSummary":"The aim of our study is to investigate changes of brain perfusion and elasticity in neonates during the time that a neonate is adapting to live outside the womb and during diseases that are suspected to affect neonatal brain perfusion. We use contrast enhanced ultrasound (sulphur hexafluoride) and ultrasound-assisted elastography to evaluate the state of brain perfusion. We will study neonates recruited from the Neonatal Units of Turku University Hospital.","ExperimentalDrugs":"[\"diagnostic test: brain contrast enhanced ultrasound, brain ultrasound elastography\",\"sulfur hexafluoride\"]","Allcountries":"[\"Finland\"]","FirstAdminInter":"Not AIS","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":14,"Phase":"PHASE3","lastUpdateDate":"2026-01-13"},{"nctId":"NCT06679998","OrgName":"Jiangsu Kanion Pharmaceutical Co., Ltd","Titlefull":"A Dose-increasing, Randomized, Double-blind, Placebo-controlled, Single-dose/multiple-dose Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection in Healthy Chinese Subjects.","BriefSummary":"This is a Phase I clinical to evaluate the safety and tolerability of single and multiple intravenous infusions of AAPB at different doses over 7 consecutive days.","ExperimentalDrugs":"[\"single dose, aapb by injection, intravenous drip.\",\"multiple dosing, aapb for injection, intravenous drip\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":17,"Phase":"PHASE1","lastUpdateDate":"2024-11-06"},{"nctId":"NCT06403267","OrgName":"NoNO Inc.","Titlefull":"A Multicentre, Prospective, Randomized, Open Label, Blinded-Endpoint, Placebo-controlled, Single-dose Trial to Determine the Efficacy and Safety of NoNO-42 in Participants With Acute Ischemic Stroke Selected for Thrombolysis With or Without Endovascular Thrombectomy (ACT-42 Trial)","BriefSummary":"ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632).\n\nThis trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial.\n\nA total of up to 600 male and female participants aged ≥ 18 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 4.5 hours of stroke onset/last known well.","ExperimentalDrugs":"[\"nono-42\"]","Allcountries":"[\"Canada\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT mandatory; EVT optional","Endpoint":"mRS at 90 days","total_Score":35,"Phase":"PHASE2","lastUpdateDate":"2025-07-10"},{"nctId":"NCT05880524","OrgName":"Ludwig-Maximilians - University of Munich","Titlefull":"Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD)","BriefSummary":"The goal of this (monocentric, randomised, placebo-controlled single-blinded; phase 2) clinical trial is to test the hypothesis that DNase 1 administration leads to a reduction in systemic immune response measured in patients after acute ischaemic stroke compared to control treatment.\n\nParticipants will receive intravenous DNase 1 (500 µg/kg) or placebo (NaCl 0.9%) twice within 24±6 hours after symptom onset (last seen well). Blood samples will be taken at baseline, day 1 and 3. Personal visits will occur on baseline, day 1, 3 and discharge date. A telephone interview will be conducted on day 30±3.","ExperimentalDrugs":"[\"dornase alfa\"]","Allcountries":"[\"Germany\"]","FirstAdminInter":"Within 12 hours","TreatDur":"Other","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Other","total_Score":18,"Phase":"PHASE2","lastUpdateDate":"2024-03-18"},{"nctId":"NCT06560203","OrgName":"Capital Medical University","Titlefull":"Safety and Efficacy of Endovascular Treatment for Acute Basilar Artery Occlusion in the Extended Time Window -a Prospective, Multicenter, Randomized Controlled, Open-label Clinical Trial","BriefSummary":"A prospective, multi-center, randomized, controlled, open-label, blinded-endpoint trial to evaluate the safety and efficacy of endovascular mechanical thrombectomy for acute basilar artery occlusion in the extended time window","ExperimentalDrugs":"[\"procedure: mechanical thrombectomy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"NA","lastUpdateDate":"2024-09-10"},{"nctId":"NCT06775028","OrgName":"Heart Care Foundation","Titlefull":"AFFIRMO - Atrial Fibrillation Integrated Approach in Frail, Multimorbid and Polymedicated Older People","BriefSummary":"The study will verify if a structured multidisciplinary approach (called iABC), aimed to improve the appropriate management of elderly AF patients with multimorbidity (the i-ABC group), would provide a clear evidence of an improvement in clinical conditions and quality of life compared to usual clinical care. The i-ABC group in AFFIRMO will follow the ABC pathway, focused on three domains: avoid stroke with anticoagulation (with optimized VKA or label-adherent DOAC use); better symptom management; and optimized management of associated cardiovascular and non cardiovascular comorbidities.\n\nThe study will be conducted in Bulgaria, Denmark, Italy, Romania, Serbia and Spain .","ExperimentalDrugs":"[\"other: iabc platform use\"]","Allcountries":"[\"Bulgaria\",\"Denmark\",\"Italy\",\"Romania\",\"Serbia\",\"Spain\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":10,"Phase":"NA","lastUpdateDate":"2025-01-09"},{"nctId":"NCT05780905","OrgName":"University of Washington","Titlefull":"Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes","BriefSummary":"A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The study will randomize subjects with diabetes to either semaglutide or matching placebo. Magnetic resonance images will be primary endpoint measured at baseline and at one year to assess effect of this FDA approved medication.\n\nGiven the available evidence supporting the neuroprotective effect of this drug class and stroke reduction with semaglutide, and the investigators preliminary data showing that T2D had significantly reduced total number of distal arterial branches in the brain than non-T2D, the investigators expect treatment with semaglutide will be associated with improved intracranial blood flow condition.","ExperimentalDrugs":"[\"semaglutide auto-injector\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":6,"Phase":"PHASE4","lastUpdateDate":"2024-06-04"},{"nctId":"NCT04677777","OrgName":"Prolong Pharmaceuticals","Titlefull":"A Randomized, Phase 1, Contemporaneously Controlled, Multicenter Study to Assess the Safety of PP-007 in Subjects With Acute Ischemic Stroke (HEMERA-1)","BriefSummary":"The HEMERA-1 Extension (Part III) is a prospective, open-label, multicenter study to evaluate safety of two doses of PP-007 in Acute Ischemic Stroke (AIS) subjects receiving Intravenous Thrombolysis (IVT) or mechanical thrombectomy (MT) or IVT+MT as standard of care (SOC). Subjects will receive two doses of PP-007 infusion 24 ± 6 hours apart in addition to the site-specific SOC protocol. PP-007 is PEGylated bovine carboxyhemoglobin and will be administered via IV infusion. The effects on collateral flow, infarct size and functional outcomes will be evaluated.","ExperimentalDrugs":"[\"biological: pp-007 (two doses administered 24±6 hours apart) + soc (ivt or mt or ivt+mt)\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"3 days or less","Status":"COMPLETED","Add_on":"IVT optional; EVT optional","Endpoint":"Safety","total_Score":26,"Phase":"PHASE1","lastUpdateDate":"2025-11-13"},{"nctId":"NCT06179017","OrgName":"Zhangzhou Municipal Hospital","Titlefull":"Endovascular Treatment for Mild Stroke With Acute Anterior Circulation Large Vessel Occlusion：a Multicenter Randomized Controlled Trail","BriefSummary":"Exploring the Efficacy and Safety of Emergent Endovascular Treatment in Patients with Mild Ischemic Stroke Caused by Acute Anterior Circulation Large Vessel Occlusion based on Perfusion Imaging Screening","ExperimentalDrugs":"[\"other: experimental group:intervention group\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"ACTIVE_NOT_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"NA","lastUpdateDate":"2026-04-26"},{"nctId":"NCT06170944","OrgName":"General Hospital of Shenyang Military Region","Titlefull":"Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke (RICAS): a Prospective, Randomized, Blind Endpoint, Multicenter Study","BriefSummary":"The goal of this clinical trial is to explore the influence of chronic RIC on collateral status evaluated by DSA in ischemic stroke patients with LAA etiology.","ExperimentalDrugs":"[\"device: remote ischemic preconditioning\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Late efficacy","total_Score":17,"Phase":"NA","lastUpdateDate":"2026-04-22"},{"nctId":"NCT06143488","OrgName":"First Affiliated Hospital of Wannan Medical College","Titlefull":"Endovascular Therapy Versus Best Medical Treatment for Acute Large Vessel Occlusion Stroke With Low NIHSS","BriefSummary":"Patients presenting with mild symptoms of acute ischemic stroke are common and account for approximately half of all acute ischemic stroke. About 30% of patients with minor stroke have a 90-day functional disability. Radiologically proven a large vessel occlusion (LVO) in patients with minor stroke is a well-established predictor of poor outcomes, while the poor outcomes following best medical management in patients with minor stroke with the underlying presence of a LVO are mainly driven by the occurrence of early neurological deterioration (END).\n\nConsidering the well-known strong association between lack of arterial recanalization and END, endovascular therapy (EVT) appears as an attractive option to improve functional outcomes for LVO-related patients with stroke with mild symptoms. Whether EVT is safe and effective in patients with mild stroke with an LVO is currently debated, since these patients were typically excluded from the pivotal EVT trials.\n\nThe current study aimed to further test the hypothesis that endovascular therapy would be superior to medical management with respect to functional recovery among low NIHSS patients caused by acute large-vessel occlusion in the anterior circulation.","ExperimentalDrugs":"[\"procedure: endovascular therapy\",\"best medical management\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"NA","lastUpdateDate":"2026-04-27"},{"nctId":"NCT06393218","OrgName":"Chao Phya Abhaibhubejhr Hospital","Titlefull":"The Impact of Diaphragm Training on Dysphagia in Bulbar Palsy After Ischemic Stroke: A Randomized Controlled Study","BriefSummary":"This was a prospective multicenter study. the patients after stroke with were randomly divided into the observation group and the control group. All patients were given comprehensive rehabilitation therapy. During the treatment, enteral nutrition support was provided for the two groups by Intermittent Oro-esophageal tube feeding. The observation group will be given Diaphragm Training Nutritional status, dysphagia, quality of life and depression before and after treatment were compared.","ExperimentalDrugs":"[\"device: intermittent oro-esophageal tube feeding\",\"behavioral: diaphragm training\",\"behavioral: routine rehabilitation\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Early efficacy","total_Score":7,"Phase":"NA","lastUpdateDate":"2024-04-27"},{"nctId":"NCT06569121","OrgName":"Baylor Research Institute","Titlefull":"Efficacy of an Evidence-based Telehealth-delivered Weight-loss Intervention to Enhance Access and Reach Underserved Groups After Stroke","BriefSummary":"Investigators will conduct a randomized controlled trial (RCT) to assess intervention efficacy of telehealth delivery of the GLB-CVA (tGLB-CVA) compared to a 6-month wait-list control (WLC) in partnership with a diverse group of patient partners and peer mentors.","ExperimentalDrugs":"[\"behavioral: group lifestyle balance for people post stroke (glb-cva)\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":11,"Phase":"NA","lastUpdateDate":"2026-01-19"},{"nctId":"NCT05049109","OrgName":"Columbia University","Titlefull":"Integrated Telehealth After Stroke Care","BriefSummary":"In this pilot trial, the investigator will compare early post-stroke BP management using an integrated Telehealth After Stroke Care (iTASC), to usual care with a primary outcome of BP control defined by the mean 24-hr blood pressure through remote monitoring at 3 months and survey patient reported outcomes.\n\nAs this is a preliminary trial with a small sample, estimates derived will be used to plan the subsequent larger confirmatory trial. Descriptive statistics will characterize the randomized patients completing surveys and outcome assessments. The study will evaluate the primary clinical outcome (BP \\<140/90 mmHg) 90 days post-discharge as a function of treatment and adjusted for from baseline BP. Change from baseline BP will also be assessed as an outcome. Change in activity level and duration, as well as trends in sedentary time will be compared between arms, and pre- and post-intervention with visual tailored infographics in the intervention arm. Moderating effects of demographics will also be evaluated. Decisions regarding the pursuit of a subsequent trial will use the primary outcome, and analysis of all other measures will be hypothesis generating.","ExperimentalDrugs":"[\"behavioral: integrated telehealth after stroke care\",\"behavioral: usual post-stroke follow-up care\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"WITHDRAWN","Add_on":"Other","Endpoint":"Other","total_Score":4,"Phase":"NA","lastUpdateDate":"2024-06-10"},{"nctId":"NCT06034847","OrgName":"Centre hospitalier de l'Université de Montréal (CHUM)","Titlefull":"Treatment of Persistent Distal Occlusion After Successful Proximal Recanalization in Thrombectomy","BriefSummary":"In stroke patients, mechanical thrombectomy is now the standard of care when the stroke is due to large proximal cerebral vessel occlusion. The purpose of the 2BE3 trial is to test whether adjunct rescue treatment of persisting distal occlusions after successful proximal recanalization of the large vessel occlusion can be proposed as an additional intervention to restore reperfusion of affected stroke tissue and improve clinical outcomes.\n\nThe rescue therapies will be either mechanical (small stent retrievers and/or small aspiration catheters) or pharmacological (infusion of intra-arterial thrombolytics).\n\nPatients will be randomized to conservative management (mechanical thrombectomy with or without IV thrombolytics of large proximal vessels) or rescue therapy (mechanical or pharmacological interventions in distal vessels in addition to conservative management). Each patient will be followed for 3 months post-intervention.\n\nThe data collected will be clinical assessments and angiographic imaging to evaluate the reperfusion state.","ExperimentalDrugs":"[\"device: mechanical thrombectomy in proximal large vessels\",\"device: rescue mechanical thrombectomy in distal vessels\"]","Allcountries":"[\"Canada\"]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"WITHDRAWN","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":21,"Phase":"NA","lastUpdateDate":"2026-04-24"},{"nctId":"NCT06307743","OrgName":"Shanghai Jiao Tong University Affiliated Sixth People's Hospital","Titlefull":"A Multicenter, Open Label, Blind Endpoint, Clinical Trial to Evaluate the Efficacy and Safety of Rapid Local Ischemic Postconditioning in Acute Ischemic Stroke Patients Received Successful Thrombectomy Reperfusion","BriefSummary":"The objective of this clinical trial is to determine whether rapid local ischemic postconditioning (RL-IPostC) is effective in preventing brain edema and safe in acute ischemic stroke (AIS) patients treated with mechanical thrombectomy. In this trial, researchers will block antegrade cerebral blood flow temporarily by the way of balloon inflation/deflation in AIS patients immediately after revascularization. It makes the ischemic reperfusion brain tissue have a capacity of adaptation through intermittent blood flow restoration. Researchers will evaluate the protective role and safety of different duration of balloon inflation/deflation. The optimal postconditioning intervention dose will be determined for further confirmative investigation.","ExperimentalDrugs":"[]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"UNKNOWN","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":22,"Phase":"NA","lastUpdateDate":"2024-03-09"},{"nctId":"NCT06961487","OrgName":"Stanford University","Titlefull":"Endovascular Therapy for Large Core Patients With Uncertain Response to Thrombectomy (OUTER LIMITS)","BriefSummary":"The purpose of this study is to assess the safety and efficacy of endovascular thrombectomy in both an early and extended time window in patients with large strokes due to large artery occlusion.","ExperimentalDrugs":"[]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"ENROLLING_BY_INVITATION","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"NA","lastUpdateDate":"2025-04-29"},{"nctId":"NCT06370182","OrgName":"Anaconda Biomed S.L.","Titlefull":"A Prospective, Randomized, Dual-arm Multi-center Study to Assess the Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter in Combination With a Stent Retriever","BriefSummary":"The objective of this study is to assess the safety and effectiveness of mechanical thrombectomy (MT) using the ANA funnel catheter in its intended use, which is to facilitate the navigation and deployment of other neurovascular devices and to allow flow arrest during mechanical thrombectomy procedures performed in subjects experiencing acute ischemic stroke (AIS) secondary to large vessel occlusion (LVO) and treated within 24 hours of symptom onset.","ExperimentalDrugs":"[\"device: ana funnel catheter\",\"device: control\"]","Allcountries":"[\"France\",\"Hungary\",\"Spain\",\"Turkey (Türkiye)\",\"United States\"]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Safety","total_Score":25,"Phase":"NA","lastUpdateDate":"2025-12-05"},{"nctId":"NCT06899399","OrgName":"Beijing Tiantan Hospital","Titlefull":"Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery Stenosis","BriefSummary":"This study is a multicenter, prospective, open-label, endpoint-blinded, randomized controlled trial designed to evaluate the safety and efficacy of endovascular stenting combined with optimal medical therapy versus optimal medical therapy alone in patients with asymptomatic severe stenosis (70-99%) of the internal carotid artery. The study plans to enroll 982 patients aged 40-80 years who have had no ipsilateral carotid artery-related neurological symptoms in the past six months and who have declined carotid endarterectomy. The primary endpoints include stroke, myocardial infarction, or death within 30 days post-procedure/enrollment, as well as the incidence of ipsilateral stroke from 30 days to one year post-procedure/enrollment. Secondary endpoints include procedural success rate, restenosis rate, changes in cognitive function, and others. The study results will provide high-level evidence-based medical evidence for the treatment selection of patients with asymptomatic carotid artery stenosis.","ExperimentalDrugs":"[\"procedure: endovascular treatment\",\"best medical treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-03-21"},{"nctId":"NCT06557135","OrgName":"The First Affiliated Hospital with Nanjing Medical University","Titlefull":"Brachial vErsus Femoral Access for carotId Artery sTenting: a Multicenter Randomized Clinical Trial (BEFIT)","BriefSummary":"Study purpose:\n\nA multicenter, prospective and randomized study is planned to compare the clinical outcomes of carotid artery stenting via brachial artery access and femoral artery access.\n\nEligible participants will be randomly assigned 1:1 to the brachial artery group or the femoral artery group.\n\nPrimary endpoint: surgical success rate.\n\nSecondary endpoints:\n\n1. Operation time (time from first arterial puncture to last angiography)\n2. Serious adverse events (SAE) within 90 days;\n3. Access puncture complications;","ExperimentalDrugs":"[\"procedure: carotid artery stenting (cas)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":17,"Phase":"NA","lastUpdateDate":"2025-07-15"},{"nctId":"NCT05004233","OrgName":"Centre Hospitalier Universitaire de Saint Etienne","Titlefull":"Transmission Electron Microscopy Images for Platelet Ultrastructural Criteria Before and After the Onset of an Antiplatelet Agent","BriefSummary":"The aim of the pilot study is to collect all the ultrastructural platelet characteristics by transmission electron microscopy before and after the onset of an antiplatelet treatment in patients hospitalized for an ischemic stroke ; and to assess recurrence of Ischemic Cerebral Accident (ICA) at 6 months in patients hospitalized for Ischemic stroke.","ExperimentalDrugs":"[\"biological: blood collection before antiplatelet treatment\",\"biological: blood collection after antiplatelet treatment\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":7,"Phase":"NA","lastUpdateDate":"2025-08-04"},{"nctId":"NCT05874596","OrgName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","Titlefull":"Whole-process Quality Improvement of Patients With Acute Ischemic Stroke Undergoing Endovascular Treatment Based on an Artificial Intelligence-aided Clinical Feedback System","BriefSummary":"A clustered randomized control trial to evaluate whether multi-aspect intervention based on an AI-aided clinical feedback system could improve the quality of EVT and functional outcome of patients.","ExperimentalDrugs":"[\"behavioral: ai-aided clinical feedback system coupled with multi-aspect intervention basd on behaviour change wheel model\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"COMPLETED","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":23,"Phase":"NA","lastUpdateDate":"2025-11-17"},{"nctId":"NCT05210088","OrgName":"University Hospital, Grenoble","Titlefull":"PLAsticity, Security and Tolerance to Intermittent Hypoxic Conditioning Following Stroke","BriefSummary":"By inducing endogenous neuroprotection, hypoxic post-conditioning following stroke may represent a harmless and efficient non-pharmacological innovative neuro-therapeutic modality aiming at inducing neuroplasticity and brain repair, as supported by many preclinical studies.\n\nThe investigators thus hypothesize that hypoxic post-conditioning represents a safe therapeutic strategy post-stroke. The investigators further hypothesize that hypoxic conditioning could enhance neuroplasticity and function in combination with conventional rehabilitative care.\n\nThe primary study endpoint will be safety. Safety will be assessed through the clinical review of the adverse events over the duration of the study, every 48 hours by a trained evaluator, blinded for the therapeutic intervention.\n\nThe investigators will further investigate the potential functional benefits of such a therapeutic approach on motor function, gait, balance, and cognition. The neurophysiological substrates of hypoxic conditioning-triggered neuroplasticity at a subacute delay post-stroke will also be investigated, based on biological and imagery markers.","ExperimentalDrugs":"[\"hypoxia, intermittent\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"WITHDRAWN","Add_on":"Other","Endpoint":"Safety","total_Score":7,"Phase":"PHASE1","lastUpdateDate":"2024-06-03"},{"nctId":"NCT06187025","OrgName":"University Hospital, Bordeaux","Titlefull":"Addiction in the Secondary Prevention of Stroke","BriefSummary":"Modifiable stroke risk-factors, which include poor lifestyle habits, account for 90 % of the risk of stroke. Disability Adjusted Life Years (DALYs) related to cerebrovascular disorders rely on three main factors, including the severity of stroke-related symptoms, the occurrence of stroke complications, and stroke recurrences.\n\nStroke complications and the risk of stroke recurrence are highly dependent on the control of vascular risk factors. Thus, the secondary prevention of stroke involves profound lifestyle modifications including substance use cessation and diet changes.","ExperimentalDrugs":"[]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":8,"Phase":"NA","lastUpdateDate":"2025-07-18"},{"nctId":"NCT05847699","OrgName":"Fondation Ophtalmologique Adolphe de Rothschild","Titlefull":"Radiohistological Correlation of Thrombohemorrhagic Remodeling in the Acute Phase of Ischemic Stroke Managed by Decompressive Hemicraniectomy","BriefSummary":"Recent years have witnessed a change in the therapeutic paradigm of stroke with the advent of mechanical thrombectomy as the reference treatment.\n\nHowever, despite the achievement of effective proximal recanalization in nearly 80% of patients, nearly half of these patients have an unfavorable functional outcome. Several causes can be mentioned, such as the extent of the initial ischemic damage, the occurrence of complications related to reperfusion treatments or the occurrence of thrombosis of the downstream microvascularization. The latter is a phenomenon that has been known and studied increasingly over the last twenty years. It is the result of multiple cellular remodeling following ischemia and at the origin of an endoluminal filling by platelets, inflammatory cells and fibrin. This phenomenon introduces the fundamental difference between recanalization, i.e. the removal of the obstruction by the thrombus, and reperfusion, which translates into a satisfactory supply of oxygen to the ischemic tissues and therefore the expected result of these treatments. However, not all recanalization is necessarily accompanied by reperfusion, which is the phenomenon of no-reflow. This last situation could be explained by downstream microvascular thrombosis. Studies have shown the interest of intravenous thrombolysis associated with mechanical thrombectomy to preserve this vascular bed and improve cerebral reperfusion. More recently, a study has also shown the value of adding intra-arterial thrombolysis after mechanical thrombectomy. Nevertheless, there is currently no clinical evidence of the reality and prognostic importance of downstream microvascular thrombosis.\n\nAdvances in imaging have allowed the development of susceptibility weighted imaging (SWI) sequences with millimeter resolution, allowing a precise study of vascular damage and the appearance of previously unseen remodeling. Among them, the existence of cortical or juxta-cortical microinfarcts whose remnographic characteristics differed by the presence of a SWI hyposignal. The hypothesis evoked is that of a hemorrhagic remodeling consecutive to the barrier rupture. However, in view of the pathophysiology explained so far and the hypointense character of the thrombi on the SWI sequences, these remodeling could in fact be not microbleeding but rather markers of thrombosis in the downstream microcirculation. MRI would allow to identify the presence and the importance of microvascular thrombosis and thus to bring arguments to specifically target this microvascular component, consequence of cerebral ischemia, by antithrombotic or thrombolytic treatments.\n\nThe objective of our project is therefore to carry out a study focused on a better description and understanding of cortical and basal ganglia SWI hyposignals with a histopathological correlation and with the clinical prognosis.","ExperimentalDrugs":"[]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":14,"Phase":"NA","lastUpdateDate":"2026-01-16"},{"nctId":"NCT06308952","OrgName":"Zhujiang Hospital","Titlefull":"Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation: Protocol of a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial","BriefSummary":"APICES trial is an investigator-initiated, multicenter, multicenter, randomized, double-blind, placebo-controlled clinical trial that plans to enroll 396 patients with a 1-year follow-up, including a neurovascular imaging examination \\[digital subtraction angiography (DSA), CT angiography (CTA) or magnetic resonance angiography (MRA)\\] at 6 months after index treatment. It was designed in compliance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. The study was approved by the Ethics Committee of Zhujiang Hospital of South Medical University (2024-KY-032-02) and registered at ClinicalTrials.gov (NCT06308952). The participants will be recruited from twelve advanced stroke centers in China.","ExperimentalDrugs":"[\"atorvastatin 20mg\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":11,"Phase":"PHASE4","lastUpdateDate":"2026-02-27"},{"nctId":"NCT06577662","OrgName":"Chiang Mai University","Titlefull":"Effects of an Individual and Family Self-Management of Fall Prevention Program on Balance Ability and Fall-related Self-efficacy Among Chinese Post-Stroke Individuals","BriefSummary":"This study is about exploring the effectiveness of individual and family self-management (IFSM) fall prevention programs on balance ability and fall-related self-efficacy in post-stroke people. The main intervention measures were developed based on the risk and protective factors of fall prevention in post-stroke people, including exercise, environment safety, assistant technology, medication review, and safety in daily activities. The intervention was implemented in 10 weeks for both patients and their family members. By mastering these skills, post-stroke people may reduce the number of falls after discharge to home.","ExperimentalDrugs":"[\"behavioral: individual and family self-management (ifsm) fall prevention program\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"ACTIVE_NOT_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":11,"Phase":"NA","lastUpdateDate":"2025-06-26"},{"nctId":"NCT05907694","OrgName":"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval","Titlefull":"Medical Treatment With or Without Transcatheter Patent Foramen Ovale CloSure for Older Patients With CrypTogenic StrOke and Patent Foramen Ovale. The STOP Trial","BriefSummary":"Patent foramen ovale PFO closure has been shown to reduce the risk of stroke in patients with recurrent stroke. However, the majority of existing clinical studies in this field excluded patients over the age of 60 years. Data in older patients is limited and since the population ages and stroke remains a major cause of death and morbidity, randomized clinical trials are needed to better assess the benefit of PFO closure in this elderly population. Therefore, this study proposal sought to determine the efficacy of PFO closure for the prevention of recurrent stroke in older patients with PFO and cryptogenic stroke.","ExperimentalDrugs":"[\"procedure: transcatheter pfo closure\",\"optimal medical treatment\"]","Allcountries":"[\"Canada\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-03-23"},{"nctId":"NCT06319846","OrgName":"Beijing Tiantan Hospital","Titlefull":"A Multicenter, Double-blind, Double-dummy, Randomized Clinical Trial Comparing the Efficacy and Safety of Tirofiban Versus Placebo in Preventing Recurrence of Stroke for Patients With Intracranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）","BriefSummary":"This is a multicenter, double-blind, double-dummy, randomized clinical trial comparing the efficacy and safety of tirofiban versus placebo in preventing recurrence of stroke for patients with intracranial artery stenosis and high-risk acute non-disabling cerebrovascular events.","ExperimentalDrugs":"[\"tirofiban\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Late efficacy","total_Score":23,"Phase":"PHASE3","lastUpdateDate":"2024-07-11"},{"nctId":"NCT05899036","OrgName":"RapidPulse, Inc","Titlefull":"PULSE-C: Early Feasibility Study of RapidPulseTM Aspiration System as Frontline Approach for Patients With Acute Ischemic Stroke Due to Large Vessel Occlusions","BriefSummary":"The goal of this clinical trial is to assess the initial safety and performance of the RapidPulseTM Aspiration System in patients experiencing acute ischemic stroke within 24 hours since the onset of stroke symptoms, or last known normal. Subject will undergo mechanical thrombectomy (a procedure to remove a clot in the brain which is preventing blood flow), with the RapidPulseTM Aspiration System. Participating in the trial is for 5-7 days or hospital discharge (whichever is earlier).","ExperimentalDrugs":"[\"device: rapidpulsetm aspiration system\"]","Allcountries":"[\"Paraguay\",\"Turkey (Türkiye)\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"COMPLETED","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":27,"Phase":"NA","lastUpdateDate":"2025-01-20"},{"nctId":"NCT06498934","OrgName":"Beijing Municipal Administration of Hospitals","Titlefull":"Deep Brain Stimulation of Cerebellar Dentate Nucleus Promotes Upper Limb Motor Function Recovery After Ischemic Stroke: a Randomized, Double-blind, Sham-controlled Trial","BriefSummary":"The goal of this clinical trial is to learn if deep brain stimulation of the dentate nucleus (DN-DBS) works to promote chronic post-stroke upper limb motor function in adults. It will also learn about the safety of DN-DBS. The main questions it aims to answer are:\n\nDoes DN-DBS paired with rehabilitation improve the upper limb motor function of participants more than rehabilitation only? What medical problems do participants have when using DN-DBS for post-stroke rehabilitation?\n\nResearchers will compare real DN-DBS+rehabilitation to sham DN-DBS+rehabilitation (electrodes will be implanted, but no electrical current is given) to see if DN-DBS works to promote chronic post-stroke upper limb motor function.\n\nParticipants will:\n\nUndergo unilateral DN-DBS surgery Take real DN-DBS+rehabilitation or sham DN-DBS+rehabilitation as treatment for 6 months Visit the clinic every month during the DN-DBS+rehabilitation (treatment) period for programing, checkups and tests Visit the clinic at Day 1, 30, 90 and 365 after treatment period for checkups and tests","ExperimentalDrugs":"[\"device: deep brain stimulation\",\"other: rehabilitation\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2024-07-17"},{"nctId":"NCT06666764","OrgName":"Capital Medical University","Titlefull":"Adjuvant Normobaric Hyperoxia in Acute Ischemic Stroke Patients Transferred for Thrombectomy","BriefSummary":"The primary objective of this study is to estimate the efficacy and safety of NBO on 3-month functional outcome after acute ischemic stroke","ExperimentalDrugs":"[\"other: nbo\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 12 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"PHASE3","lastUpdateDate":"2025-12-04"},{"nctId":"NCT06224426","OrgName":"Beijing Tiantan Hospital","Titlefull":"Oxygenation Targets for Endovascular Therapy in Acute Ischemic Stroke Patients (Oxy-TARGET)","BriefSummary":"The goal of this clinical trial is to compare the effects of different concentrations of normobaric oxygen on early neurological improvement in acute ischemic stroke (AIS) patients receiving endovascular therapy (EVT). The main questions it aims to answer are:\n\n* Evaluating the impact of normobaric high-concentration oxygen versus low-concentration oxygen on early neurological function after EVT.\n* Evaluating the safety of high and low normobaric oxygen concentration in patients with ischemic stroke.\n\nParticipants will (1) receive EVT under general anesthesia; (2) be randomly assigned 1:1 to receive oxygen therapy with FiO2=80% or FiO2=30% through endotracheal intubation during the operation, and the gas flow rate was set at 4L /min.","ExperimentalDrugs":"[\"other: normobaric high-concentration oxygen\",\"other: normobaric low-concentration oxygen\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Day 1 only","Status":"RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":21,"Phase":"NA","lastUpdateDate":"2024-11-27"},{"nctId":"NCT06341881","OrgName":"Khyber Medical University Peshawar","Titlefull":"Understanding the Need and Feasibility of Transitional Care Training Program Among Family Caregivers of Geriatric Stroke Survivors in Pakistan","BriefSummary":"The main intention of the study is to understand the need and feasibility of transitional care training program among family caregivers of geriatric stroke survivors in Pakistan","ExperimentalDrugs":"[\"behavioral: transitional care training program\"]","Allcountries":"[\"Pakistan\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"COMPLETED","Add_on":"Other","Endpoint":"Other","total_Score":4,"Phase":"NA","lastUpdateDate":"2025-06-23"},{"nctId":"NCT06484036","OrgName":"Assistance Publique - Hôpitaux de Paris","Titlefull":"Effectiveness of Periodontitis Treatment on the Metabolic Activity of Symptomatic Carotid Atherosclerotic Plaque Responsible for Ischemic Stroke: a Multicenter Randomized Controlled Trial: a Multicenter Randomized Controlled Trial","BriefSummary":"Cardiovascular disease is the world's leading cause of death. Atherothrombosis is a common cause of ischemic stroke.\n\nA strong epidemiological link has been established between periodontitis and the risk of stroke. It shares common risk factors with atherothrombosis, and its severe form is associated with low-grade systemic inflammation and daily low-intensity bacteremia. Atherothrombosis is a frequent cause of ischemic stroke.\n\nPeriodontal bacteria have been found within atheromatous plaques, correlated with a greater risk of rupture.\n\nThus, periodontitis could be a modifiable risk factor for atherothrombosis and future vascular events: its early diagnosis and treatment could have a major impact on cardiovascular prevention.\n\nHypothesis: In patients with periodontitis who have had an ischemic stroke, periodontal treatment may reduce atherosclerotic plaque activity.","ExperimentalDrugs":"[\"procedure: periodontal treatment strategy\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":5,"Phase":"NA","lastUpdateDate":"2024-06-28"},{"nctId":"NCT06320431","OrgName":"University of Calgary","Titlefull":"A Multicentre, Prospective, Randomized, Open Label, Blinded-endpoint Trial to Optimize the Use of Intravenous Tenecteplase in Participants With Acute Ischemic Stroke (ACT-GLOBAL THROMBOLYSIS (ACT WHEN-001) Within A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL) NCT06352632","BriefSummary":"This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design. Up to 4,000 patients with presumed acute ischemic stroke (AIS) will be followed for 90 days (or until death, if prior to 90 days). The end of the trial is defined as the date that all participants have completed their Day 90 assessment.\n\nThis domain aim is to efficiently, reliably, and simultaneously, determine the comparative effectiveness of intravenous thrombolysis (IVT) using standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) in all patients who present to hospital with acute ischemic stroke and are considered for intravenous thrombolysis. In addition, this domain also seeks to study standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) vs. no TNK upfront with rescue IA TNK if necessary (in those eligible for emergency EVT) and no TNK upfront in those who have taken DOACs during the preceding 48 hours. This domain therefore seeks to generate more robust randomized evidence to guide clinicians in their decisions over the balance of risks and treatment with intravenous thrombolysis with tenecteplase wherever such evidence is currently insufficient.\n\nThis domain will currently evaluate four research questions in relation to the use of IVT with tenecteplase:\n\n1. In patients with recent (48 hours) intake of a standard-dose direct oral anticoagulant (DOAC), how should IVT be used? - Use standard-dose (0.25 mg/kg body weight) or low-dose tenecteplase (0.18 mg/kg) or not at all.\n2. In patients planned to be treated with endovascular thrombectomy, how should tenecteplase be used? -Treat with IV tenecteplase (standard- or low-dose) or not at all.\n3. In any patient receiving IVT, what is the optimal dose of tenecteplase? - use standard-dose (0.25 mg/kg body weight) or low-dose tenecteplase (0.18 mg/kg).\n4. To what extent is the treatment effect of standard- vs. low-dose tenecteplase modified by key patient characteristics, such as diabetes, prior antiplatelet therapy, renal failure, or frailty, old age or having a heavy burden of cerebral small vessel disease on brain imaging.","ExperimentalDrugs":"[\"tenecteplase\"]","Allcountries":"[\"Australia\",\"Canada\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT mandatory; EVT optional","Endpoint":"mRS at 90 days","total_Score":33,"Phase":"PHASE3","lastUpdateDate":"2025-09-11"},{"nctId":"NCT06584812","OrgName":"Tianjin Institute of Pharmaceutical Research Co., Ltd","Titlefull":"A Phase I Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety in Healthy Subjects with Multiple Administration of Tiprogrel","BriefSummary":"This study is designed to evaluate the pharmacokinetics, pharmacodynamics and safety in healthy subjects with multiple administration of Tiprogrel.","ExperimentalDrugs":"[]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"Other","Endpoint":"Other","total_Score":5,"Phase":"PHASE1","lastUpdateDate":"2025-01-02"},{"nctId":"NCT06352632","OrgName":"The George Institute","Titlefull":"A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL)","BriefSummary":"Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.","ExperimentalDrugs":"[\"standard-dose intravenous tenecteplase\",\"low-dose intravenous tenecteplase\",\"other: no intravenous tenecteplase\",\"other: conservative blood pressure control\",\"other: moderate blood pressure control\",\"other: intensive blood pressure control\",\"other: placebo\",\"nono-42\",\"other: no deferoxamine mesylate and no colchicine\",\"deferoxamine mesylate only\",\"colchicine only\",\"both deferoxamine mesylate and colchicine\"]","Allcountries":"[\"Australia\",\"Canada\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":20,"Phase":"PHASE3","lastUpdateDate":"2024-11-18"},{"nctId":"NCT06313710","OrgName":"General Hospital of Shenyang Military Region","Titlefull":"Head Down Position for Successful Recanalization of Anterior Circulation Large Vessel Occlusion (HOPES3): a Prospective, Randomized, Open Label, Blinded-end Point, Single-center Study","BriefSummary":"This is a prospective, randomized, open label, blinded-end point, single-center study, aiming to investigate the effect of head down position in anterior circulation large vessel occlusion patients with successful recanalization after endovascular treatment.","ExperimentalDrugs":"[\"other: head down position\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"COMPLETED","Add_on":"IVT optional; EVT mandatory","Endpoint":"NIHSS","total_Score":26,"Phase":"NA","lastUpdateDate":"2025-11-18"},{"nctId":"NCT06755944","OrgName":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","Titlefull":"A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled, Dose-exploration Phase Ⅱb/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke","BriefSummary":"The investigators invite participants to participate in a clinical study, which is a multicenter, randomized, double-blind, placebo parallel-controlled phase II.b/III. clinical study to evaluate the efficacy and safety of XY03-EA tablets in the treatment of acute ischemic stroke. After non-clinical pharmacodynamic and pharmacological studies, XY03-EA has a clear effect on the treatment of acute ischemic stroke, with low toxicity and high activity. XY03-EA significantly improves neurological function impaired by cerebral ischemia. In this phase of the study, 360 subjects are planned to be recruited and randomly assigned to four trial groups and placebo groups in a ratio of 1:1:1:1:1.\n\nIf participants choose to participate in this trial, participants will be assessed for compliance with the requirements of the study, and participants will be asked to cooperate in completing the screening visit and returning to the hospital within the required time as required by the investigators. During the test, participants will follow the steps described above to have participantsr blood taken for laboratory tests; Participantsr blood sample will be collected at a specified time point for a pharmacokinetic study, and participants will be compensated accordingly. During the study period, participants need to follow the instructions of the study doctor, take the medicine or treatment according to the doctor's instructions, and the doctor will tell participants the time, method, and precautions for the follow-up visit in detail. The main adverse reactions in the clinical trials of XY03-EA tablets are the abnormalities of laboratory examination items, including the increase in alanine aminotransferase, the increase in γ-glutamyl transferase, the increase in aspartate aminotransferase, etc., and the vast majority of AEs are grade 1\\~2, which can be recovered without treatment, and there are no serious and uncontrollable adverse events.\n\nIf participants experience any discomfort during the study, or new changes in participantsr condition, or any unexpected situation, whether it is related to drugs or not, please inform participantsr study doctor in time, and he/she will make corresponding judgments and treatment according to participantsr condition to protect participantsr health and interests. If an adverse event occurs in a clinical trial, the study physician will take action and determine whether it is related to the trial drug. Participants have the right to withdraw from the trial at any time at any stage without discrimination or retaliation, and participantsr medical treatment and rights will not be affected.","ExperimentalDrugs":"[\"xy03-ea\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Other","Status":"ENROLLING_BY_INVITATION","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"PHASE2","lastUpdateDate":"2024-12-31"},{"nctId":"NCT06155032","OrgName":"First Affiliated Hospital of Wannan Medical College","Titlefull":"Study of Rescue Endovascular Therapy for Progressive Acute Mild Ischemic Stroke With Large Vascular Occlusion--- A Multi-centered, Prospective, Open-label, Blind Endpoint, Randomized Controlled Trial (RESCUE END-LOW)","BriefSummary":"Endovascular therapy (EVT) added on best medical management is currently recommended in acute large vascular occlusion (LVO) stroke patients with National Institutes of Health Stroke Scale (NIHSS) score \\>5. Thus, a sizeable fraction of patients with a minor stroke that do not undergo cerebrovascular screening may experience an early neurological deterioration (END) due to LVO, possibly leading to poor long-term functional outcome. However, whether these patients may still benefit from a rescue EVT is unknown, especially in a late window (\\>24 hours). In this study, the investigators assume that best medical management plus EVT might be superior than best medical management alone in a late window for minor stroke patients who have experienced an LVO and END. The primary objective of the study was to establish the safety and efficacy of EVT in a late window for minor stroke patients in the anterior circulation who experienced an LVO and END.","ExperimentalDrugs":"[\"procedure: endovascular therapy\",\"best medical management\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":20,"Phase":"NA","lastUpdateDate":"2026-04-27"},{"nctId":"NCT06286800","OrgName":"The Methodist Hospital Research Institute","Titlefull":"Personalized Transcranial Direct Current Stimulation in Stroke Recovery","BriefSummary":"The central objective of this application is to explore the neural substrate of personalized tDCS (ptDCS) and to determine whether the paradigm for each stroke patient can predict the amount of sustained clinical improvement through increased connectivity as measured by a biomarker of plasticity.","ExperimentalDrugs":"[\"device: transcranial direct current stimulation (tdcs) with ot\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":11,"Phase":"NA","lastUpdateDate":"2026-02-27"},{"nctId":"NCT06679322","OrgName":"Beijing Tiantan Hospital","Titlefull":"A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIb Clinical Trial of Androtriol Injection for the Treatment of Acute Ischemic Stroke","BriefSummary":"This is a prospective, multicenter, randomized, double-blind, placebo-controlled, phase IIb clinical trial of Androtriol injection for the treatment of acute ischemic stroke. The goal of this trial is to explore the efficacy and safety of different doses of Androtriol injection in patients with acute ischemic stroke (AIS) who received vascular recanalization treatment within 24 hours of symptom onset.\n\nParticipants will receive a low-dose Androtriol injection (100 mg BID), a high-dose Androtriol injection (300 mg BID), or a placebo intravenously within 24 hours of stroke onset. They will be treated twice daily (every 12 hours) for 7 days, with a total of 14 doses over the course of the study. Each infusion will last approximately 30±5 minutes.","ExperimentalDrugs":"[\"androtriol injection (high-dose group)\",\"androtriol injection (low-dose group)\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":26,"Phase":"PHASE2","lastUpdateDate":"2024-11-06"},{"nctId":"NCT06733246","OrgName":"Ceretrieve Ltd.","Titlefull":"Evaluation of the Safey & Performance of the Ceretrieve Device Designed for Thrombus Removal in Intracranial Arteries Using an Aspiration Technique in Patients Suffering an Acute Ischemic Stroke (AIS)","BriefSummary":"The main objective of this clinical trial is to evaluate of the safety \\& efficacy of the Ceretrieve device within 24 hours post thrombectomy procedure. This means to assess that the use with the Ceretrieve neuro-thrombectomy device that is designed to treat acute ischemic stroke patients raises no safety concerns and that it is found to be effective when it is used according to its intended purpose, which is revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (involving the internal carotid artery, middle cerebral artery- M1 and M2 segments, basilar, and vertebral arteries).\n\nThe study researchers will compare the efficacy and safety results of this study to data derived from the literature of FDA approved neuro-thrombectomy devices. The study hypothesis is that The Ceretrieve device would achieve successful reperfusion performance shall be similar to the safety \\& performance derived from the literature.\n\nThe primary outcomes that will be measures are:\n\nPerformance:\n\nSuccessful reperfusion, defined as core laboratory-adjudicated modified Thrombolysis in Cerebral Ischemia (mTICI) score 2b-3 within three passes of the Ceretrieve system without any rescue.\n\nSafety:\n\nSymptomatic intra-cranial hemorrhage within 24 (18-36) hours of the study procedure.\n\nPatients who will participate in this study will be followed for a time period of 3 months. After discharge from the medical center, they will be asked to arrive to a one visit at the clinic for safety data collection and evaluation.","ExperimentalDrugs":"[\"device: aspiration 0\"]","Allcountries":"[\"Germany\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":28,"Phase":"NA","lastUpdateDate":"2026-03-22"},{"nctId":"NCT05484154","OrgName":"ZZ Biotech, LLC","Titlefull":"A Phase 3 Study to Evaluate the Efficacy and Safety of 3K3A-APC in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy, or Both in Subjects with Moderate to Severe Acute Ischemic Stroke","BriefSummary":"The purpose of this study is to evaluate the efficacy and safety of intravenous doses of 3K3A-APC, a recombinant variant of human activated protein C (APC), in the treatment of acute ischemic stroke following treatment with thrombolysis, mechanical thrombectomy or both.","ExperimentalDrugs":"[\"biological: 3k3a-apc\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"WITHDRAWN","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":23,"Phase":"PHASE3","lastUpdateDate":"2024-09-26"},{"nctId":"NCT06157502","OrgName":"Beijing Tiantan Hospital","Titlefull":"Efficacy and Safety of Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Trial","BriefSummary":"Shuxuening injection is a multi-target neuroprotective agent, it is expected to play a neuroprotective role on the basis of intravenous thrombolysis therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of Shuxuening injection in the treatment with intravenous thrombolysis in patients with ischemic stroke.","ExperimentalDrugs":"[\"shuxuening injection\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 6 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT mandatory; EVT optional","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"PHASE3","lastUpdateDate":"2025-07-21"},{"nctId":"NCT06726941","OrgName":"Afyonkarahisar Health Sciences University","Titlefull":"Effect of Exercise on Neuroplasticity-Related Gene Expression and Histone Modifications in Patients With Hemiplegia","BriefSummary":"The aim of this study is to demonstrate the effect of routine exercise program on neuroplasticity through histone acetylation and gene expression changes in acute stroke survivors from an epigenetic perspective and to investigate the correlation of epigenetic effects with its effects on motor function and quality of life.","ExperimentalDrugs":"[\"other: physiotherapy and rehabilitation practices\"]","Allcountries":"[\"Turkey (Türkiye)\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":11,"Phase":"NA","lastUpdateDate":"2025-11-22"},{"nctId":"NCT06657235","OrgName":"Syntrillo, Inc","Titlefull":"Improved Risk Factor Control Through a Transitional Care Program for Stroke Survivors","BriefSummary":"The goal of this clinical trial is to evaluate whether our transitional care program helps stroke survivors better manage their risk factors for stroke to lower the risk of a repeat stroke. The main question it aims to answer is:\n\n\\- Does the program help participants meet the targets set by the American Heart Association clinical guidelines for control of risk factors associated with stroke?\n\nResearchers will compare participants enrolled right after being discharged from the hospital to participants enrolled around 3-5 months after being discharged to examine whether timing differences in enrollment affect the efficacy of the program.\n\nParticipants will:\n\n* Keep track of their medications, their exercise, and their health information using smart devices provided by the study\n* Answer questions about their health and lifestyle\n* Meet with our team of healthcare providers","ExperimentalDrugs":"[\"other: transitional care program\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":6,"Phase":"NA","lastUpdateDate":"2025-05-28"},{"nctId":"NCT04974138","OrgName":"Shenzhen Ausa Pharmed Co.,Ltd","Titlefull":"Comparative Efficacy of Amlodipine Folic Acid vs. Amlodipine on the Risk of First Ischemic Stroke Among Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype: A Multi-center, Randomized, Double-blind, Double-dummy, Controlled Clinical Trial","BriefSummary":"This is a multi-center, randomized, double-blind, double-dummy, controlled clinical trial. This trial will include 32,000 Chinese men and women with hypertension (H-type hypertension), MTHFR 677 CC or CT genotype, elevated plasma total homocysteine (tHcy ≥10µmol/L), and insufficient serum folate levels (\\<12ng/mL).\n\nThe participants will be first stratified by their MTHFR 677 genotype (CC vs. CT), then randomized to one of two treatment groups in a 1:1 ratio.\n\nGroup A: amlodipine tablet (5mg), taken orally, once daily, serving as active comparator.\n\nGroup B: amlodipine folic acid 5.8mg tablet (5mg amlodipine and 0.8mg folic acid), taken orally, once daily.\n\nThe treatment period is five years and primary endpoint is first ischemic stroke.","ExperimentalDrugs":"[\"amlodipine besylate\",\"amlodipine-folic acid placebos\",\"amlodipine besylate and folic acid\",\"amlodipine placebos\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":18,"Phase":"PHASE4","lastUpdateDate":"2025-02-24"},{"nctId":"NCT06737549","OrgName":"The Third Affiliated hospital of Zhejiang Chinese Medical University","Titlefull":"Effect of Specific Mode Electroacupuncture Stimulation Combined with NGF on Dysphagia After Ischaemic Stroke: a Pilot Randomized Controlled Trial","BriefSummary":"Ischemic stroke is a common clinical disease, often accompanied by dysphagia. At present, clinical treatment for patients with dysphagia after ischemic stroke is limited. The emergence of NGF has surprised the field of neurorehabilitation, but the clinical effect is not satisfactory. The main problem is that NGF is a macromolecular material with a molecular weight of 13.4 KD, which is difficult to penetrate the blood brain barrier. A large number of previous studies in our team have found that electroacupuncture with specific stimulation mode can open the blood brain barrier and induce NGF into the brain. Therefore, the purpose of this study is to investigate the effect of specific mode electroacupuncture stimulation combined with NGF treatment on patients with dysphagia after ischemic stroke and to explore the mechanism of this combination therapy to improve brain function, which creates a new method and theoretical basis for nerve rehabilitation of integrated traditional Chinese and Western medicine.","ExperimentalDrugs":"[\"nerver growth factor (ngf) injection\",\"device: ea intervention\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":15,"Phase":"PHASE4","lastUpdateDate":"2024-12-12"},{"nctId":"NCT06511934","OrgName":"Massachusetts General Hospital","Titlefull":"Intuitive, Complete Neural Control of Tablet Computers for Communication","BriefSummary":"People with brainstem stroke, advanced amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease), or other disorders can become unable to move or speak despite being awake and alert. In this project, the investigators seek to further translate knowledge about interpreting brain signals related to movement, and to further develop an intracortical brain-computer interface (iBCI) that could restore rapid and intuitive use of communication apps on tablet computers by people with paralysis.","ExperimentalDrugs":"[\"device: braingate neural interface system\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":7,"Phase":"NA","lastUpdateDate":"2025-11-26"},{"nctId":"NCT06492239","OrgName":"Beijing Tiantan Hospital","Titlefull":"Emergency Stroke Unit for Acute Cerebrovascular Events--A Prospective, Multicenter, Week-wise Randomized, Controlled Trial ( ESU-ACE-A )","BriefSummary":"To compare the door-to-needle time of patients with hyperacute ischemic stroke (within 4.5 hours after the onset of symptoms) managed in a standard stroke unit adherent to guidelines versus managed in Emergency Stroke Unit (a new stroke unit based on low-field magnetic resonance imaging).","ExperimentalDrugs":"[\"combination product: emergency stroke unit based on 0.23-t mri\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Other","Status":"COMPLETED","Add_on":"IVT mandatory; EVT optional","Endpoint":"Other","total_Score":20,"Phase":"PHASE2","lastUpdateDate":"2025-03-02"},{"nctId":"NCT06226805","OrgName":"Basking Biosciences, Inc.","Titlefull":"A Multicenter, Double-blinded, Placebo-controlled, Single Ascending Dose, Two-part, Randomized, Phase 2 Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BB-031 in Acute Ischemic Stroke Patients","BriefSummary":"The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset.\n\nParticipants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 228 patients are planned in this study.","ExperimentalDrugs":"[\"bb-031\"]","Allcountries":"[\"Australia\",\"Canada\",\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"Safety","total_Score":29,"Phase":"PHASE2","lastUpdateDate":"2026-05-13"},{"nctId":"NCT06202807","OrgName":"People's Hospital of Zhengzhou University","Titlefull":"A Randomized Controlled Trial to Explore the Effect of Intermittent Oro-esophageal Tube vs. Nasogastric Tube on Feeding Amount in Dysphagic Patients After Ischemic Stroke","BriefSummary":"The goal of this clinical trial is to compare the differences in feeding amount and nutritional status between ischemic stroke patients using Intermittent Oro-esophageal Tube and Nasogastric Tube. Patients will be randomly divided into an observation group and a control group, all receiving routine rehabilitation treatment. On this basis, the observation group will use Intermittent Oro esophageal Tube for enteral nutrition support, while the control group will use Nasogastric Tube. Researchers will compare changes in daily intake and nutritional status of two groups of patients before and after the study to see if Intermittent Oro-esophageal Tube can improve the feeding amount and nutritional status between ischemic stroke patients compared to Nasogastric Tube","ExperimentalDrugs":"[\"device: intermittent oro-esophageal tube feeding\",\"behavioral: comprehensive rehabilitation therapy\",\"device: nasogastric tube feeding\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"WITHDRAWN","Add_on":"Other","Endpoint":"Other","total_Score":7,"Phase":"NA","lastUpdateDate":"2024-03-02"},{"nctId":"NCT06344390","OrgName":"The First Hospital of Hebei Medical University","Titlefull":"Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke and Its Mechanism of Brain Electricity and Brain Metabolism","BriefSummary":"Pentoxifylline can improve cognitive impairment after ischemic stroke, possibly by improving the level of cerebral blood flow, affecting the content of blood oxygen and metabolic substances in the brain, and then playing a protective role in the transmission of nerve electrical signals, and ultimately improving cognitive function. The patients with cognitive impairment and non-dementia PSCIND after ischemic stroke were randomly divided into two groups. In addition to the basic drugs of ischemic stroke, the patients were given pentothemine sustained release tablets and blank control respectively to observe the effects of pentothemine on cognitive function and neuronal electrical signals in the patients with ischemic PSCIND. It is expected to explore the possible internal biological mechanism by using transcranial Doppler, oxygen-dependent functional magnetic resonance imaging and craniocerebral magnetic resonance pop analysis. Finally, statistical correlation analysis was used to elucidate the specific mechanism of pentoxifylline in improving cognitive function of non-dementia patients with cognitive impairment after ischemic stroke.","ExperimentalDrugs":"[\"pentoxifylline\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Other","total_Score":8,"Phase":"PHASE1","lastUpdateDate":"2024-03-27"},{"nctId":"NCT06328569","OrgName":"Chao Phya Abhaibhubejhr Hospital","Titlefull":"Effect of Virtual Reality Therapy on Dysphagia in Wallenberg Syndrome: A Randomized Controlled Study","BriefSummary":"The goal of this clinical trial is to learn about on dysphagia in wallenberg syndrome. The main questions it aims to answer are:\n\nthe efficacy of Virtual Reality Therapy in the rehabilitation of patients with dysphagia in Wallenberg syndrome.\n\nParticipants received conventional dysphagia treatment and Virtual Reality Therapy once a day for 14 days. Researchers compared the control group to see the effect and mechanism of Virtual Reality Therapy.","ExperimentalDrugs":"[\"device: virtual reality therapy\",\"behavioral: conventional dysphagia treatment\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Other","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Early efficacy","total_Score":2,"Phase":"NA","lastUpdateDate":"2024-03-18"},{"nctId":"NCT06696703","OrgName":"First Affiliated Hospital of Harbin Medical University","Titlefull":"Effect of Human Urinary Kallidinogenase on Inflammatory Factors in Acute Ischemic Stroke: a Single-center, Randomized, Open Label, Blinded-endpoint, Controlled Study(KIF-AIS)","BriefSummary":"The goal of this clinical trial is to explore the changes in the expression levels of inflammatory factors before and after the early treatment of Human Urinary Kallidinogen (HUK) in the acute ischemic stroke. It will also learn about the correlation between inflammatory factors and AIS prognosis, in order to clarify the efficacy and safety of Urinary Kallidinogen in the acute phase of AIS.","ExperimentalDrugs":"[\"human urinary kininogenase(huk)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":18,"Phase":"NA","lastUpdateDate":"2024-11-19"},{"nctId":"NCT06677970","OrgName":"Yonsei University","Titlefull":"Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)","BriefSummary":"Though intravenous thrombolysis has been shown to improve symptoms in acute ischemic stroke patients, the recanalization rate remains low (22.6%) and only around 30% of patients benefit from the treatment. Recently, endovascular thrombectomy using stent retrievers or catheters has proven to be more effective, with a success rate of nearly 80%. However, only 50% of patients experience clinical improvement, highlighting the need for new treatment strategies to enhance outcomes. Current guidelines recommend maintaining systolic blood pressure (BP) below 180 mmHg after thrombectomy, but there is a lack of evidence regarding optimal blood pressure management post-reperfusion.\n\nFour randomized clinical trials, including the OPTIMAL-BP trial, have examined blood pressure control following thrombectomy. Meta-analyses showed that intensive BP lowering did not reduce symptomatic hemorrhage and was associated with worse functional outcomes at 3 months. Specifically, lowering BP too aggressively after successful reperfusion could worsen outcomes by reducing perfusion to the ischemic penumbra. Therefore, this study will investigate whether a more targeted blood pressure elevation strategy could improve patient prognosis compared to standard BP control in patients with sustained systolic blood pressure (SBP) \\<150 mmHg on successive measurements obtained less than 10 minutes apart within 3 hours after reperfusion.\n\nThis is a prospective, randomized, open-label trial with blinded endpoint assessment (PROBE) design, aimed at comparing intensive and standard BP control strategies in acute ischemic stroke patients. Participants will be randomized 1:1 into either an intensive BP control group (targeting a 20% systolic BP increase, capped at less than 160 mmHg) or a standard BP control group (systolic BP at or below 180 mmHg).","ExperimentalDrugs":"[\"bp lowering drugs (nicardipine, labetalol, urapidil)\",\"bp raising drug (phenylephrine) or bp lowering drugs (nicardipine, labetalol, urapidil)\"]","Allcountries":"[\"South Korea\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"PHASE3","lastUpdateDate":"2026-02-10"},{"nctId":"NCT06250608","OrgName":"OBELAB, Inc.","Titlefull":"Evaluation of Cerebral Oxygen Saturation(rSO2) Measurements Between Frontal Lesion Area and Normal Area of Brain by Pulse Oximetry(NIRSITX) Using Near-infrared Spectroscopy in Acute Ischemic Stroke Patients, Prospective, Multi-center, Non-randomized, Open-label, Exploratory Clinical Trial.","BriefSummary":"The clinical trial is for acute ischemic stroke patients measuring cerebral oxygen saturation (rSO2) values using pulse oximeter of near-infrared spectroscopy in the frontal lesion area and normal area of brain. The purpose of the clinical trial is to compare differences in cerebral oxygen saturation values, and the efficacy and safety are evaluated through additional exploratory clinical trials.","ExperimentalDrugs":"[\"device: pulse oximeter, nirsitx\"]","Allcountries":"[\"South Korea\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"COMPLETED","Add_on":"IVT optional; EVT optional","Endpoint":"Other","total_Score":11,"Phase":"NA","lastUpdateDate":"2026-04-15"},{"nctId":"NCT06446960","OrgName":"Institut National de la Santé Et de la Recherche Médicale, France","Titlefull":"The Role of Peripheral Afferents in Modulating Post-stroke Central Pain","BriefSummary":"Central post-stroke pain (CPP) is extremely difficult to relieve and responds very poorly to analgesics targeting neuropathic pain, probably because the mechanisms underlying this pain remain poorly understood.\n\nStroke pain is traditionally considered to be of central origin and related to changes in the spinal cord and/or brain nociceptive systems. However, a recent study in a small cohort of patients has suggested that the peripheral nervous system (PNS) may have a role in the initiation and persistence of APD.\n\nThe main objective of this prospective randomised controlled bicentric study (Raymond Poincaré and Ambroise Paré) in double blind and parallel groups against placebo (3 arms) will be to evaluate the efficacy of two peripheral nerve blocks performed 14 days apart on spontaneous neuropathic pain after stroke. The active treatments used for the blocks will be either lidocaine 20 mg/ml or levobupivacaine 1.25 mg/ml or placebo (saline)","ExperimentalDrugs":"[\"lidocaine 20mg/ml\",\"levobupivacaine hydrochloride 1.25 mg/ml\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":15,"Phase":"PHASE3","lastUpdateDate":"2026-04-17"},{"nctId":"NCT03223220","OrgName":"Lower Merion Neurology Research Foundation","Titlefull":"Quelling of Excitotoxicity in Acute Stroke With Ketamine","BriefSummary":"The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.","ExperimentalDrugs":"[\"ketamine\",\"midazolam injection\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"PHASE2","lastUpdateDate":"2023-12-14"},{"nctId":"NCT05906602","OrgName":"University of Illinois at Chicago","Titlefull":"Motor and Neurophysiological Changes After Ischemic Conditioning in Individuals With Stroke","BriefSummary":"The goal of this clinical trial is to test ischemic conditioning (blood flow restriction) as a neuromodulatory technique to improve gait function in stroke. Neuromodulation is emerging as a promising adjunct strategy to facilitate changes in brain activity and improve motor behavior following a neurological injury such as stroke.\n\nThe main questions this trial aims to answer are:\n\n* Can ischemic conditioning produce neuromodulatory changes in the lower limb primary motor cortex?\n* Can ischemic conditioning be used as a neuromodulatory technique to improve strength and motor control in individuals with stroke when compared to sham ischemic conditioning?\n\nParticipants will take part in two sessions of ischemic conditioning where a cuff (similar to ones that measure blood pressure) will be placed around the thigh and inflated to one of two blood flow restriction pressures (real ischemic conditioning (real IC) and sham ischemic conditioning (sham IC)). Each participant will experience measures of brain activity and motor behavior testing before and after both sessions (real IC and sham IC).\n\nResearchers will investigate ischemic conditioning as neuromodulation modality in stroke to see if ischemic conditioning can produce beneficial changes in brain activity and improvements on subsequent motor behavior tasks.","ExperimentalDrugs":"[\"device: real ischemic conditioning\",\"device: sham ischemic conditioning\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"Other","Endpoint":"Early efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2026-04-27"},{"nctId":"NCT06538844","OrgName":"Capital Medical University","Titlefull":"Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Reperfusion Therapy","BriefSummary":"The objective of this study is to evaluate the effectiveness and safety of endovascular therapy combined with 25% human albumin in the treatment of acute large vessel occlusive stroke.","ExperimentalDrugs":"[\"intravenous infusion of human albumin\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"COMPLETED","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":23,"Phase":"PHASE2","lastUpdateDate":"2025-03-27"},{"nctId":"NCT06469801","OrgName":"Children's Mercy Hospital Kansas City","Titlefull":"Low-Field Bedside MRI for Detection of Acute Brain Injury in Pediatric Extracorporeal Membrane Oxygenation","BriefSummary":"The primary objective is to characterize the prevalence and type of ABI following cannulation for pediatric patients who require ECMO support. The secondary objective is to describe the time course and rates of ABI using ultralow-field bedside MRI relative to both duration of ECMO support and clinical imaging obtained in routine care of pediatric ECMO patients.","ExperimentalDrugs":"[\"device: hyperfine\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":7,"Phase":"NA","lastUpdateDate":"2025-08-12"},{"nctId":"NCT06421337","OrgName":"Fundació Institut Germans Trias i Pujol","Titlefull":"Somatosensory Evoked Potential (SEP) N20 Monitoring With BraiN20® Medical Device for Prediction of Functional Independence Defined as Rankin Scale Score 0-2 in Global Patients With Suspected Acute Stroke.","BriefSummary":"Time is Brain company (http://www.tibtimeisbrain.com/about\\_us/) developed BraiN20®, a medical device to assess the presence and characteristics of the N20 signal of SEP. Investigators have demonstrated a high prognostic accuracy of N20 on functional recovery of patients with acute ischemic stroke (AIS) due to large vessel occlusion (LVO) undergoing endovascular thrombectomy (EVT), the gold standard treatment. The aim if this new project is to validate BraiN20® in global patients presenting with suspected acute ischemic or hemorrhagic stroke in three comprehensive stroke centers in Spain. The primary objective is to establish the predictive performance of the presence of the N20 SEP over functional recovery as the primary outcome measure (likelihood of having a modified Rankin Scale (mRS) score 0-2 at 3 months evaluated by blinded independent raters). The effect will be measured by the metrics sensitivity, specificity, and predictive values, and compared with clinical and imaging predictive models by Receiving Operating Characteristics (ROC) curve analysis in the global population, stroke subtype and stroke mimics. Secondary aims are: 1) to determine the area under the curve (AUC) of the presence of the N20 SEP as biomarker of functional recovery in small subcortical infarctions and in patients with cortical infarctions and no large vessel occlusion; 2) to characterize N20 SEP signal in hemorrhagic stroke and stroke mimics; and 3) to evaluate the discriminant capacity of an explanatory new algorithm combining pre-hospital clinical variables and N20-SEP signal characteristics between ischemic, hemorrhagic and stroke mimics.\n\nThis project would represent the first pilot study to validate the ability of BraiN20® to predict the functional recovery in the different types of acute stroke but also its ability to discriminate between stroke subtypes. Thus, BraiN20® monitoring could arise as a paradigm shift in acute stroke management, since it would standardize and accelerate patient triage, enable real time monitoring, increase access to EVT treatment and improve its outcome The trial is sponsored by Time is Brain S.L. and started in March 2024. Primary endpoint results are expected by the end of the 2024.\n\nBraiN20® could be a useful medical device aiding stroke subtype diagnosis and functional recovery.","ExperimentalDrugs":"[\"device: brain20(r)\"]","Allcountries":"[\"Spain\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"UNKNOWN","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":13,"Phase":"NA","lastUpdateDate":"2024-05-17"},{"nctId":"NCT04647292","OrgName":"University College Dublin","Titlefull":"European Blood Pressure Intensive Control After Stroke - Pilot Trial","BriefSummary":"Stroke is the third most common cause of death worldwide and the leading cause of disability. High blood pressure is an important risk factor for stroke. Lowering a person's blood pressure reduces the risk of future stroke or heart attack, and current guidelines recommend treatment to a target of \\<130mmHg for secondary prevention.\n\nHome blood pressure measurement and telemonitoring are acceptable to patients, but there is uncertainty over the use of out of office blood pressure measurements in stroke patients in guidelines.\n\nThis is a study designed to establish the feasibility of a larger clinical trial, comparing home blood pressure monitoring, telemonitoring and medication titration with standard care. The study hypothesis is that home BP measurement and telemonitoring with medication titration may lead to improved BP control compared to standard of care clinical practice.","ExperimentalDrugs":"[\"other: anti-hypertensive, home blood pressure measurement, telemonitoring and medication titration\",\"other: standard of care blood pressure management with antihypertensives\"]","Allcountries":"[\"Ireland\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":14,"Phase":"PHASE2","lastUpdateDate":"2024-07-09"},{"nctId":"NCT05982015","OrgName":"Capital Medical University","Titlefull":"Multicenter, Randomized, Double-blind, Pseudo Treatment-controlled Clinical Study on the Efficacy and Safety of Remote Ischemic Conditioning in Preventing Stroke-associated Pneumonia","BriefSummary":"Verifying whether remote ischemic adaptation can reduce the occurrence of stroke related pneumonia in acute stroke patients within 24 hours of onset","ExperimentalDrugs":"[\"device: remote ischemic conditioning\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"COMPLETED","Add_on":"Other","Endpoint":"Early efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2024-12-20"},{"nctId":"NCT05603897","OrgName":"University of Miami","Titlefull":"Utility of Non-standardized Clinical Swallow Evaluation vs. Standardized Swallow Evaluation to Identify the Presence of Dysphagia and Risk for Aspiration in Patients Post-ischemic Stroke in Acute Inpatient Rehabilitation","BriefSummary":"The purpose of this study is to compare two different screening tests for detecting dysphagia (difficulty swallowing) as well as the risk for aspiration (silent swallowing of liquids/solids into the lungs) in patients after an ischemic stroke (when a blood clot blocks or narrows an artery leading to the brain).","ExperimentalDrugs":"[\"other: mann assessment of swallowing ability (masa) (dysphagia screening tool)\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":11,"Phase":"NA","lastUpdateDate":"2026-04-23"},{"nctId":"NCT06549582","OrgName":"Beijing Electric Power Hospital","Titlefull":"Effect of Taohong Tongluo Xiaoban Prescription on Reprogramming of Lipid Metabolism and Endothelial Injury for Cerebral Infarction Patients：a Randomized Controlled Clinical Trial","BriefSummary":"This study is a prospective, open-label, randomized control trial. It is planning to include 160 cerebral infarction patients which will be randomized in a 1﹕1 fashion to receive Chinese herbal medicines combined basic medicine treatment, or to receive standard basic medicine treatment within 3 months after inclusion. Follow-up will be performed after the treatment for 3 months to evaluate the incidence and disability rates of limb impairment, language impairment, cognitive impairment, and emotional disorders. The primary outcome is modified Rankin Scale Score, which is measured by the overall distribution from 0 (no symptoms) to 6 (death). The secondary outcome include the Evaluation of Neurological Function Deficit score (National Institute of Health stroke scale scoring) and carotid atherosclerotic plaque score (Crouse scoring system for neck carotid atherosclerotic plaque scoring). Additional outcomes include laboratory indicator to analysis the reprogramming of lipid metabolism and endothelial Injury, Chinese medicine symptom and sign scoring system and biological indicators. The investigators will perform the intention-to-treat analysis for withdrawal and missing data, and estimate the health economic value.","ExperimentalDrugs":"[\"other: taohong tongluo xiaoban prescription\",\"other: fundamental medical treatment\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":15,"Phase":"NA","lastUpdateDate":"2024-08-11"},{"nctId":"NCT06064734","OrgName":"Beijing Tiantan Hospital","Titlefull":"Low-Frequency REpetitive TRanscranial Magnetic Stimulation in ACute Ischemic StrokE Within 48 Hours (RETRACE-I): A Randomized, Open-label, Evaluator-blinded, Phase 2 Pilot Trial","BriefSummary":"This is a multicenter, open-label, evaluator-blinded, investigator-initiated, randomized clinical trial, to evaluate the clinical efficacy and safety of LF-rTMS in reducing infarct size, reducing disability rate and improving functional outcome in patients with acute ischemic stroke within 48 hours after stroke onset.","ExperimentalDrugs":"[\"device: lf-rtms\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"3 days or less","Status":"COMPLETED","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Other","total_Score":17,"Phase":"NA","lastUpdateDate":"2026-04-10"},{"nctId":"NCT06203860","OrgName":"Odense University Hospital","Titlefull":"Cardiovascular Protection in Patients With Type 2 Diabetes and Established Heart or Vascular Disease - The Cardio-Metabolic Clinic","BriefSummary":"This study aims to investigate whether a Cardio-Metabolic Clinic can protect the cardiovascular health of patients with both diabetes and cardiovascular disease.\n\n* At the Cardio-Metabolic Clinic, patients will receive a specialized and comprehensive care. This includes applying a systematic approach, considering their whole health based on the latest knowledge in the field, and administering aggressive treatment with heart protective medications.\n* The ProtecT-2-D trial will compare the effects of care at the Cardio-Metabolic Clinic to usual care to see if there are any differences in cardiovascular illness and death.","ExperimentalDrugs":"[\"other: cardio-metabolic clinic\"]","Allcountries":"[\"Denmark\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":10,"Phase":"NA","lastUpdateDate":"2025-07-02"},{"nctId":"NCT06133179","OrgName":"Assistance Publique - Hôpitaux de Paris","Titlefull":"Pilot Study of the Characterization of Subacute Ischemic Cerebrovascular Accidents in the Region of the Middle Cerebral Artery by 3D Ultrasound Localization Microscopy (ULM) with a Research Ultrasound System and Non-marketed 2D Matrix Probe.","BriefSummary":"The goal of this proof of concept study is to determine if the visualization of the middle cerebral artery and its perforators, through 3D transtemporal ultrasound imaging, is possible thanks to an off-line analysis by 3D ultrasound localization microscopy. Visualization of these vessels would allow us to conclude on the presence, or absence, of an ischemic stroke in the region of the middle cerebral artery.\n\nTo answer the question asked, 20 participants who suffered a stroke will carry out a transtemporal ultrasound examination specifically for research in the 7 days following his stroke. The data obtained will be analyzed by the CNRS medical imaging laboratory, in order to characterize the presence of a stroke and to compare the data obtained with that of standard examinations (CT and MRI).","ExperimentalDrugs":"[\"procedure: transtemporal ultrasound with contrast product (sonovue)\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":6,"Phase":"NA","lastUpdateDate":"2024-09-03"},{"nctId":"NCT06344312","OrgName":"Peking University Third Hospital","Titlefull":"Effectiveness of Yangxue Qingnao Granules in Preventing Post Thrombolytic Hemorrhage Transformation in Patients With Acute Cerebral Infarction: a Randomized Controlled Study","BriefSummary":"Evaluate the effectiveness of Yangxue Qingnao Granules in preventing post thrombolytic hemorrhage transformation in patients with acute cerebral infarction, and explore its possible mechanism","ExperimentalDrugs":"[\"yangxue qingnao granules\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Longer than 3 days","Status":"UNKNOWN","Add_on":"IVT mandatory; EVT optional","Endpoint":"mRS at 90 days","total_Score":19,"Phase":"NA","lastUpdateDate":"2024-04-01"},{"nctId":"NCT06645522","OrgName":"The First Hospital of Jilin University","Titlefull":"Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial","BriefSummary":"The purpose of this study is to determine the efficacy and safety of edaravone dexborneol in treating acute ischemic stroke.","ExperimentalDrugs":"[\"edaravone dexborneol\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":21,"Phase":"PHASE4","lastUpdateDate":"2024-10-15"},{"nctId":"NCT06517173","OrgName":"Beijing Tiantan Hospital","Titlefull":"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Y-3 in Chinese Subjects with Acute Ischemic Stroke","BriefSummary":"This trial aims to evaluate the effectiveness and safety of Y-3 for injection in the treatment of patients with acute ischemic stroke within 48 hours of onset","ExperimentalDrugs":"[\"y-3 for injection\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"PHASE3","lastUpdateDate":"2024-09-04"},{"nctId":"NCT06140888","OrgName":"The First Hospital of Jilin University","Titlefull":"Effect of Ginkgo Biloba Extract on Cognitive Function in Acute Ischemic Stroke: a Multicentre, Randomised, Open-label, Blinded-Endpoint Trial","BriefSummary":"The purpose of this study is to determine the effect of ginkgo biloba extract on cognitive function in acute ischemic stroke.","ExperimentalDrugs":"[\"ginkgo biloba extract\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Late efficacy","total_Score":16,"Phase":"NA","lastUpdateDate":"2024-02-25"},{"nctId":"NCT06559475","OrgName":"The First Affiliated Hospital of University of Science and Technology of China","Titlefull":"A Multicenter, Randomized Controlled Clinical Investigation to Evaluate the Safety and Effectiveness of the Super-Bore 8/7F Aspiration Catheters in the Treatment of Acute Intracranial Large Vessel Occlusion","BriefSummary":"To Evaluate the Safety and Efficacy of the Super-Bore 8/7F Thrombosis Aspiration Catheter in the Treatment of Acute Intracranial Large Vessel Occlusion.","ExperimentalDrugs":"[\"procedure: super-bore thrombosis aspiration catheter treatment group\",\"procedure: conventional thrombectomy device treatment group\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":26,"Phase":"NA","lastUpdateDate":"2024-12-14"},{"nctId":"NCT06242366","OrgName":"Mahidol University","Titlefull":"Effects of Transitional Care Program in Stroke Patients on Self-care Behavior, Quality of Life, and Hospital Readmission: A Randomized Controlled Trial.","BriefSummary":"This study examines the effects of a transitional care program in stroke patients on self-care behavior, quality of life, and hospital readmission.\n\nThe research conceptual framework is based on the Transitional Care Model by Naylor. Sixty participants with stroke patients at Charoenkrung Pracharak Hospital will be recruited. These participants are stratified by block randomization using NIHSS score and divided into 2 groups; a control group (n=30) and an intervention group (n=30).\n\nThe program consisted of 2 phases: 1) Phase I during hospital admission and 2) Phase II following hospital discharge","ExperimentalDrugs":"[\"behavioral: intervention group\"]","Allcountries":"[\"Thailand\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2024-11-19"},{"nctId":"NCT06758609","OrgName":"Guangdong Second Provincial General Hospital","Titlefull":"Local Hypothermia and Endovascular Recanalization for Acute Large Artery Occlusive Stroke-A Multicenter, Prospective, Open-label, Blinded-Endpoint, Randomized Controlled Trial","BriefSummary":"A multicenter, prospective, open-label, blinded-endpoint, randomized controlled trial to assess the effectiveness and safety of catheter-based focal intracranial hypothermia combined with endovascular reperfusion therapy for patients with acute anterior circulation large artery occlusion.","ExperimentalDrugs":"[\"procedure: mechanical thrombectomy\",\"4°c saline infusion\",\"normothermic saline infusion\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"NA","lastUpdateDate":"2024-12-27"},{"nctId":"NCT06526429","OrgName":"Shanghai Jiao Tong University Affiliated Sixth People's Hospital","Titlefull":"RAPID Local Ischemic Postconditioning in Acute Ischemic Stroke pAtients receiVEd Successful Thrombectomy Reperfusion","BriefSummary":"This study aims to determine the safety and optimal dose of rapid local ischemic postconditioning in acute ischemic stroke(AIS) patients received successful thrombectomy reperfusion. In this trial, investigators will halt antegrade cerebral blood flow temporarily by the way of balloon guiding catheter (BGC) inflation/deflation in AIS patients immediately after revascularization. It makes the ischemic reperfusion brain tissue have a capacity of adaptation through intermittent blood flow restoration. The optimal postconditioning intervention dose will be determined for further investigation.","ExperimentalDrugs":"[\"procedure: rapid local ischemic postconditioning\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"COMPLETED","Add_on":"IVT optional; EVT mandatory","Endpoint":"Safety","total_Score":25,"Phase":"NA","lastUpdateDate":"2025-11-24"},{"nctId":"NCT06400407","OrgName":"Beijing Tiantan Hospital","Titlefull":"Lesion Network Mapping Navigated Continuous Theta-burst Stimulation for Motor Recovery in Acute Ischemic Stroke:A Randomized, Double-Blind, Sham-Controlled, Phase 2 Pilot Trial","BriefSummary":"This is a multicenter, sham-controlled, double-blind, randomized clinical trial to evaluate the efficacy and safety of lesion network mapping navigated cTBS in improving motor function in patients with acute ischemic stroke within 14 days of symptom onset.","ExperimentalDrugs":"[\"device: continuous theta-burst stimulation\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"Other","Endpoint":"Early efficacy","total_Score":15,"Phase":"PHASE2","lastUpdateDate":"2026-04-03"},{"nctId":"NCT05884762","OrgName":"Rennes University Hospital","Titlefull":"earlY Upper Limb Rehabilitation WIth EEG-Neurofeedback After Stroke","BriefSummary":"The aim of this study is to evaluate the effect of early rehabilitation treatment by electroencephalographic neurofeedback on upper limb motor function after stroke.\n\nResearchers will compare :\n\nInterventional group: electroencephalographic neurofeedback + traditional reference rehabilitation programme Control group: SHAM electroencephalographic neurofeedback + traditional reference rehabilitation programme","ExperimentalDrugs":"[\"other: electroencephalographic neurofeedback\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Late efficacy","total_Score":16,"Phase":"NA","lastUpdateDate":"2026-02-26"},{"nctId":"NCT06214091","OrgName":"Tianjin Medical University General Hospital","Titlefull":"Safety and Efficacy of Early Gastrointestinal Decompression for Patients With Acute Severe Ischemic Stroke","BriefSummary":"Acute severe ischemic stroke is a life-threatening subtype of stroke. Due to stress ulcer and gastric reflux in acute stage, patients with severe ischemic stroke are always complicated with stomach bleeding and pulmonary infections, resulting in poor prognosis and even death. Reducing stomach acidity and avoiding gastric reflux play a pivotal role on controlling serious complications after austere ischemic attack. Gastrointestinal decompression is an cheap, safe, effective and acknowledgemented strategy for treating stomach bleeding and preventing gastric reflux in clinical settings. Early gastrointestinal decompression seems to be an available method to reduce stomach acidity and avoid gastric reflux after severe ischemic stroke. Therefore, we aimed to evaluate the safety and efficacy of early gastrointestinal decompression in patients with acute severe ischemic stroke.","ExperimentalDrugs":"[\"procedure: gastrointestinal decompression\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"UNKNOWN","Add_on":"IVT optional; EVT excluded","Endpoint":"Late efficacy","total_Score":16,"Phase":"NA","lastUpdateDate":"2024-01-18"},{"nctId":"NCT06383390","OrgName":"Eli Lilly and Company","Titlefull":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease","BriefSummary":"The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.","ExperimentalDrugs":"[\"retatrutide\"]","Allcountries":"[\"Argentina\",\"Australia\",\"Austria\",\"Belgium\",\"Brazil\",\"Canada\",\"Czechia\",\"Denmark\",\"France\",\"Germany\",\"Greece\",\"Hungary\",\"India\",\"Israel\",\"Italy\",\"Mexico\",\"Netherlands\",\"New Zealand\",\"Poland\",\"Puerto Rico\",\"Romania\",\"Slovakia\",\"Spain\",\"Turkey (Türkiye)\",\"Ukraine\",\"United Kingdom\",\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"ACTIVE_NOT_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":19,"Phase":"PHASE3","lastUpdateDate":"2026-06-16"},{"nctId":"NCT06360458","OrgName":"First Affiliated Hospital of Fujian Medical University","Titlefull":"Methylprednisolone as Adjunct to Endovascular Thrombectomy for Patients With Acute Ischemic Strokes With Large Infarct: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial (MIRACLE)","BriefSummary":"The efficacy and safety of methylprednisolone in acute ischemic stroke patients with large infarct cores (ASPECTS score \\< 6 or infarct volume ≥50 mL) due to anterior circulation large vessel occlusion have not been clearly established. This is a multi-center, randomized, double-blind, placebo-controlled trial to investigate early combination therapy with methylprednisolone for reperfusion in acute large core infarction.","ExperimentalDrugs":"[]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 12 hours","TreatDur":"Other","Status":"ACTIVE_NOT_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Late efficacy","total_Score":27,"Phase":"PHASE3","lastUpdateDate":"2025-11-25"},{"nctId":"NCT06591338","OrgName":"Kafrelsheikh University","Titlefull":"Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA, a Randomized Controlled Trial","BriefSummary":"Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel minor stroke or TIA compared to 300 mg clopidogrel were assessed through NIHSS, mRS, and possible adverse effects.","ExperimentalDrugs":"[\"ticagrelor 90 mg\",\"aspirin 75 mg oral tablet\",\"clopidogrel\"]","Allcountries":"[\"Egypt\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Late efficacy","total_Score":26,"Phase":"PHASE3","lastUpdateDate":"2025-08-30"},{"nctId":"NCT06388148","OrgName":"Xinqiao Hospital of Chongqing","Titlefull":"Efficacy and Safety of Endovascular Thrombectomy Plus Medical Management Versus Medical Management Alone in Acute Ischemic Stroke Patients With Large Vessel Occlusion and Extra-Large Infarct Core: A Multicenter, Randomized Controlled Trial","BriefSummary":"The role of endovascular thrombectomy in patients with extra-large ischemic burden is still unclear. The XL STROKE-2 randomized trial is aiming to investigate the efficacy and safety of mechanical thrombectomy in acute extra-large ischemic stroke patients with large vessel occlusion.","ExperimentalDrugs":"[\"medical management\",\"procedure: endovascular thrombectomy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"EVT mandatory; IVT optional","Endpoint":"mRS at 90 days","total_Score":21,"Phase":"NA","lastUpdateDate":"2025-12-18"},{"nctId":"NCT06210516","OrgName":"Saglik Bilimleri Universitesi","Titlefull":"Effect of Respiratory Muscle Training on Diaphragm Function and Activity Performance in Subacute Ischemic Stroke Patients: A Single-blind Randomised-controlled Trial","BriefSummary":"Stroke, which can occur due to many different reasons and is one of the most common neurological conditions, is one of the leading causes of disability worldwide. The most common disorders that occur after stroke are motor disorders. In addition, these patients may be accompanied by respiratory problems such as changes in breathing patterns and decreased ventilation function. Respiratory problems are an important risk factor for the development of long-term mortality for both cardiovascular diseases and stroke. With all these changes, there is a serious decrease in the activity performance of the patients. While stroke rehabilitation focuses on motor function losses, problems in pulmonary functions do not receive the necessary attention. Evaluating and treating patients from every aspect in stroke rehabilitation will further increase the effectiveness of the treatments applied.\n\nUltrasonography (USG), which has been used in the field of healthcare for more than 40 years, works with a mechanism based on the principle of sound waves traveling and reflecting at different speeds in tissues of different densities. USG is a very useful and effective imaging method used by modern medicine as a part of examination and patient care, based on its advantages such as sound waves being harmless to living beings because they are non-ionizing, the image being real-time and being viewable at the time of the procedure, being a non-invasive method, and being inexpensive. This study will be included in the literature as an original study in terms of examining both the development of the patients and the effectiveness of the treatment in many aspects, with many parameters obtained by ultrasonography in subacute stroke patients who will receive respiratory muscle training.","ExperimentalDrugs":"[\"device: powerbreathe\",\"other: conventional physiotherapy\"]","Allcountries":"[\"Turkey (Türkiye)\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"Other","Endpoint":"Other","total_Score":10,"Phase":"NA","lastUpdateDate":"2024-10-17"},{"nctId":"NCT05948566","OrgName":"Translational Sciences, Inc.","Titlefull":"Strategy for Improving Stroke Treatment Response (SISTER) Trial","BriefSummary":"SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.","ExperimentalDrugs":"[\"biological: ts23\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Other","total_Score":20,"Phase":"PHASE2","lastUpdateDate":"2026-06-01"},{"nctId":"NCT05604638","OrgName":"Second Affiliated Hospital of Guangxi Medical University","Titlefull":"Safety and Efficacy of Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke","BriefSummary":"The purpose of this study is to assess the safety and efficacy of early administration of tirofiban in patients treated with tenecteplase for acute ischemic stroke.","ExperimentalDrugs":"[\"tirofiban hydrochloride\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":22,"Phase":"PHASE3","lastUpdateDate":"2025-12-17"},{"nctId":"NCT06728592","OrgName":"Chinese University of Hong Kong","Titlefull":"Emergency Stroke Unit for Acute Cerebrovascular Events: A Prospective, Single-arm Trial With a Historical Control Group","BriefSummary":"Background Reperfusion therapies, i.e., intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT), are most effective treatments in the management of acute ischemic stroke (AIS) patients. The benefits of reperfusion therapies, however, may be reduced by treatment delays due to tests and examinations and logistic issues. Emergency Stroke Unit (ESU), a new concept of stroke unit locating at the Accident and Emergency Department (AED), equipped with a mobile, low-field MR imaging (lfMRI) scanner for fast diagnosis of ischemic stroke, differentiation of intracranial hemorrhage and identification of large vessel occlusion (LVO), is being tested in Mainland China. It may shorten the door-to-needle time (DNT) for IVT and door-to-groin puncture time (DPT) for EVT, which may hance associate with improved functional outcomes of AIS patients.\n\nThis is a prospective, single-center, open-label, non-randomized, single-arm study aims to evaluate the safety and efficacy of the ESU workflow using lfMRI in shortening the DNT/DPT and improving functional outcomes in AIS patients, who are potentially eligible for IVT and/or EVT and can be treated within 6 hours after onset, compared with standard practice in Hong Kong; to reveal the changes in the ischemic lesions over a few days after IVT/EVT in these patients, with serial follow-up lfMRI exams.","ExperimentalDrugs":"[\"device: portable magnetic resonance imaging\"]","Allcountries":"[\"Hong Kong\"]","FirstAdminInter":"Within 6 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Early efficacy","total_Score":19,"Phase":"NA","lastUpdateDate":"2025-05-25"},{"nctId":"NCT06339411","OrgName":"Chang Gung Memorial Hospital","Titlefull":"Examining the Efficacy of Cerebrolysin-Augmented Extended Time Window Thrombectomy in Acute Ischemic Stroke: An In-depth Study of Blood-brain Barrier Biomarkers and Imaging Indicators","BriefSummary":"Background:\n\nStroke is a leading cause of mortality and disability globally, with acute ischemic strokes(AIS) due to Large Vessel Occlusion (LVO) presenting significant treatment challenges. Mechanical thrombectomy (MT) has emerged as an effective intervention for AIS within an 8-hour window from symptom onset. However, the potential to extend this window up to 24 hours for select patients could revolutionize outcomes for those arriving late at comprehensive stroke centers. This study investigates the efficacy and safety of Cerebrolysin as an adjunct therapy to MT in extended time window and improving patient recovery.\n\nMethods:\n\nWe conducted a multi-center, prospective, randomized study within the Chang Gung Memorial Hospital system in Taiwan, targeting 100 AIS patients eligible for MT beyond the traditional 8-hour window. Participants were randomized to receive either standard care or Cerebrolysin post-MT, initiated within 24 hours of stroke onset and continued for 14 days. The study assessed neurological, neuropsychological, and biomarker outcomes at multiple time points post-stroke to evaluate the effects of Cerebrolysin on recovery.\n\nResults:\n\nThe primary outcome will measure the proportion of patients achieving favorable functional outcomes (modified Rankin Scale 0-2) at 90 days. Secondary outcomes include the impact of Cerebrolysin on secondary hemorrhagic transformation, brain edema, mortality rates, and quality of life. The study aims to provide comprehensive data on the benefits of adding Cerebrolysin to the standard post-MT care, focusing on its potential to protect against reperfusion injuries and maintain blood-brain barrier integrity.\n\nConclusion:\n\nBy evaluating the role of Cerebrolysin in conjunction with MT, this study aims to extend the therapeutic window for AIS treatment, offering hope for improved outcomes for patients who would otherwise be ineligible for current reperfusion therapies. The findings may pave the way for new guidelines in stroke management, emphasizing the importance of integrated care approaches in enhancing patient recovery.","ExperimentalDrugs":"[\"cerebrolysin\"]","Allcountries":"[]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":19,"Phase":"EARLY_PHASE1","lastUpdateDate":"2024-03-31"},{"nctId":"NCT06646601","OrgName":"Assistance Publique Hopitaux De Marseille","Titlefull":"A Preventive, Multidisciplinary Primary Care Intervention Organized Around a Therapeutic Garden: Acceptability to Patients Suffering from Cardio-neurovascular Pathology and to Those Involved in the Action.","BriefSummary":"A preventive, multidisciplinary primary care intervention organized around a therapeutic garden: Acceptability to patients suffering from cardio-neurovascular pathology and to those involved in the action.","ExperimentalDrugs":"[\"other: intervention of prevention\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":7,"Phase":"NA","lastUpdateDate":"2024-10-15"},{"nctId":"NCT06273475","OrgName":"Odense University Hospital","Titlefull":"The Effect of Robot-Assisted Versus Standard Training on Motor Function Following Subacute Rehabilitation After Ischemic Stroke - a Randomised Controlled Trial Nested in a Prospective Cohort.","BriefSummary":"The aim of this randomised controlled trial (RCT) nested in a prospective cohort, is to investigate the superior effect of late-phase robot-assisted versus standard training on motor function, physical function, fatigue, and quality of life in a moderately-to-severely impaired chronic stroke population following subacute rehabilitation.\n\nThe main hypothesis of the study is:\n\nRobot-assisted training has a superior effect on motor function (Fugl-Meyer Lower Extremity Assessment; primary outcome), physical function, fatigue, and quality of life in moderately-to-severely impaired chronic stroke-affected individuals in comparison to standard training.","ExperimentalDrugs":"[\"other: robot-assisted training\",\"other: standard training\"]","Allcountries":"[\"Denmark\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":14,"Phase":"NA","lastUpdateDate":"2025-11-17"},{"nctId":"NCT06221371","OrgName":"Beijing Tiantan Hospital","Titlefull":"Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion: a Multi-center, Prospective, Randomized, Open-label, Blinded Endpoint (PROBE), Phase 3 Trial","BriefSummary":"The purpose of this study is to investigate the safety and efficacy of endovascular treatment with or without preceding intravenous Tenecteplase in patients with late-window (4.5-24 hours of symptom onset) acute ischemic stroke due to middle cerebral artery (MCA) M1 or proximal M2 occlusion.","ExperimentalDrugs":"[\"tenecteplase\",\"device: direct evt\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Only once","Status":"COMPLETED","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"PHASE3","lastUpdateDate":"2025-11-21"},{"nctId":"NCT05892510","OrgName":"University of Melbourne","Titlefull":"Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke (EXTEND-AGNES TNK)","BriefSummary":"Multicentre, prospective, Multi-arm Multi-stage (MAMS) seamless phase 2b/3 interventional randomized placebo-controlled double-blinded parallel-assignment (2 arms with 1:1 randomization) efficacy and safety trial to test intra-arterial tenecteplase at the completion of thrombectomy versus best practice in participants with anterior circulation LVO receiving mechanical thrombectomy within 24 hours of symptoms onset.","ExperimentalDrugs":"[\"intra-arterial tenecteplase injection at the completion of thrombectomy\"]","Allcountries":"[\"Australia\",\"New Zealand\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":32,"Phase":"PHASE2","lastUpdateDate":"2026-05-14"},{"nctId":"NCT03252626","OrgName":"The First Hospital of Jilin University","Titlefull":"Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke","BriefSummary":"Ischemic stroke has a variety of treatments and currently drug therapy is one of the main treatments.A number of clinical studies have proved that alprostadil (PGE1) has pharmacological effects of significant dilation of blood vessels, inhibition of plate aggregation, anti-atherosclerosis and increased cerebral blood flow.Evaluate the 90-days efficacy by comparing two groups of patients'(one with alprostadil,another with placebo) mRS.","ExperimentalDrugs":"[\"alprostadil\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"UNKNOWN","Add_on":"IVT excluded ; EVT optional","Endpoint":"mRS at 90 days","total_Score":23,"Phase":"PHASE4","lastUpdateDate":"2024-03-29"},{"nctId":"NCT06261606","OrgName":"Rajaie Cardiovascular Medical and Research Center","Titlefull":"Feasibility of a Multifaceted Intervention to Mitigate the Cardiovascular Adverse Effects of Air Pollution: The COATED-AIR Feasibility Trial","BriefSummary":"The main goal of this clinical trial is to evaluate the feasibility of conducting a large-scale clinical trial testing a program containing several aspects for reducing the effects of air pollution on cardiovascular health (which is named the hybrid program hereafter) in adult patients (18 years or older) with atherosclerotic cardiovascular disease. Furthermore, we seek to answer how much patients adhere to and are satisfied with implementing the hybrid program, and what problems executing this program will bring for patients.","ExperimentalDrugs":"[\"other: hybrid strategy\"]","Allcountries":"[\"Iran\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Other","total_Score":1,"Phase":"NA","lastUpdateDate":"2024-03-01"},{"nctId":"NCT06265753","OrgName":"Pamukkale University","Titlefull":"Effects of Gastrocinemius Function Massage on Lower Extemity Spasticity, Spatio- Temporal Gait Variables and Fall Risk ın Patients With Stroke","BriefSummary":"This study aimed to investigate gastrocinemius function massage on physical parameters of stroke patients.","ExperimentalDrugs":"[\"other: gastrocinemius function massage\"]","Allcountries":"[\"Turkey (Türkiye)\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Other","total_Score":6,"Phase":"NA","lastUpdateDate":"2024-02-11"},{"nctId":"NCT05832762","OrgName":"University Hospital, Montpellier","Titlefull":"Evaluation of Acute Endovascular Treatment in Symptomatic Isolated Cervical Internal Carotid Artery Occlusion","BriefSummary":"Our main hypothesis is that acute EVT associated with best medical treatment is superior to best medical treatment alone, for improving clinical outcomes at 90 days, in patients with mild or severe acute ischemique stroke and diffusion-perfusion or clinical-imaging mismatch, secondary to CICAO.","ExperimentalDrugs":"[\"procedure: endovascular treatment (evt) + best medical treatment (bmt)\",\"procedure: best medical treatment (bmt)\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"NA","lastUpdateDate":"2026-01-26"},{"nctId":"NCT06443008","OrgName":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","Titlefull":"Objective To Investigate the Effect of Myoelectric Biofeedback Therapy Combined With Comprehensive Rehabilitation Training on Upper Extremity Motor Function in Elderly Patients With Hemiplegia With Cerebral Infarction","BriefSummary":"The purpose of this clinical trial is to investigate the effect of myoelectric biofeedback therapy on upper limb function in elderly patients with cerebral infarction, and to analyze the adjustment of stroke condition and quality of life.The main questions it aims to answer are:\n\n1. Does myoelectric biofeedback therapy promote the restoration of upper limb function in elderly patients with cerebral infarction?\n2. What medical problems do participants have with myoelectric biofeedback therapy?","ExperimentalDrugs":"[\"device: observation group\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-02-14"},{"nctId":"NCT06843356","OrgName":"First Affiliated Hospital of Wannan Medical College","Titlefull":"Trial of Rescue Endovascular Treatment for Progressive Acute Mild Ischemic Stroke With Basilar Artery Occlusion With Extended Time Window","BriefSummary":"A prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial to evaluate whether best medical management (BMM) combined with endovascular therapy (EVT) improves neurological outcomes compared to BMM alone in patients with progressive acute mild ischemic stroke due to basilar artery occlusion within an extended time window.","ExperimentalDrugs":"[\"procedure: endovascular treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"NA","lastUpdateDate":"2025-04-13"},{"nctId":"NCT07200661","OrgName":"University of Phayao","Titlefull":"The Effects of Transcranial Direct Current Stimulation on Improving Impairment and Functional Activity in Individuals With Stroke: A Randomized Controlled Trial","BriefSummary":"Stroke patients often experience impaired balance and weight-bearing due to muscle weakness and neurological deficits. Motor rehabilitation is a crucial goal in their recovery, and transcranial direct current stimulation (tDCS) has emerged as a promising therapeutic approach. When combined with motor training, tDCS can enhance walking and balance abilities. However, there is a lack of research exploring the combination of unstable surfaces training, cognitive function, and tDCS for stroke rehabilitation","ExperimentalDrugs":"[\"device: experimental a tdcs: transcranial direct current stimulation.\",\"device: experimental c tdcs: transcranial direct current stimulation.\"]","Allcountries":"[\"Thailand\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"COMPLETED","Add_on":"Other","Endpoint":"Late efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2025-09-22"},{"nctId":"NCT06010641","OrgName":"General Hospital of Shenyang Military Region","Titlefull":"Trendelenburg Position for Acute Anterior Circulation Ischemic Stroke With Large Artery Atherosclerosis Etiology (HOPES 3): a Prospective, Randomized, Open-label, Blinded-endpoint, Multi-center Trial","BriefSummary":"The effect of head position as a nonpharmacological therapy on acute ischemic stroke (AIS) remains inconclusive. Recent HOPES2 (Head dOwn-Position for acutE moderate ischemic Stroke with large artery atherosclerosis) suggest the safety, feasibility, and potential benefit of the head-down position (HDP) in acute ischemic stroke. The current study aims to investigate the efficacy and safety of HDP in acute moderate ischemic stroke patients with large artery atherosclerosis.","ExperimentalDrugs":"[\"other: head-down position\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":19,"Phase":"NA","lastUpdateDate":"2026-04-22"},{"nctId":"NCT06381089","OrgName":"Sinop University","Titlefull":"The Effect of Robotic Rehabilitation and Vagus Nerve Stimulation in Addition to Robotic Rehabilitation on the Patient's Functional Level and Autonomic Nervous System in Patients With Ischemic Stroke","BriefSummary":"This study was conducted in patients with ischemic stroke; This study was conducted to examine the effect of robotic rehabilitation and transcutaneous auricular vagal nerve stimulation applied in addition to robotic rehabilitation on the patient's functional level and autonomic nervous system.\n\n40 people over the age of 18 participated in the study. They were randomly divided into two groups: robotic rehabilitation and transcutaneous auricular vagal nerve stimulation applied in addition to robotic rehabilitation. While the robotic rehabilitation group received Lokomat and neurological rehabilitation, the other group received stimulation with the Vagustim device, which is applied non-invasively through the ear, in addition to Lokomat and neurological rehabilitation. Spasticity, autonomic nervous system, walking speed, motor function, quality of life, muscle activity and pain were evaluated in both groups before starting treatment and six weeks after treatment. In the study, significance was evaluated at p\\<0.05 level.","ExperimentalDrugs":"[\"device: robotic rehabilitation\",\"device: transcutaneous auricular vagal nerve stimulation\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Early efficacy","total_Score":9,"Phase":"NA","lastUpdateDate":"2024-04-19"},{"nctId":"NCT06559241","OrgName":"Capital Medical University","Titlefull":"Safety and Efficacy of Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy (RECAST-MT): A Multicenter, Randomized, Controlled, Open-label, Blinded Endpoint Trial","BriefSummary":"For patients with acute ischemic stroke caused by large vessel occlusion, endovascular thrombectomy has been demonstrated to be the most effective therapy, as approximately 90% of the occluded vessels can be recanalized. However, less than 50% of patients could achieve functional independence, and over 15% died 90 days after stroke. Although the mismatch of successful recanalization with poor prognosis can be attributed to many factors, the infarct core formed during thrombectomy and reperfusion injury after thrombectomy may be among the most important and effective neuroprotective strategies urgently needed.\n\nRemote ischemic conditioning (RIC) is a noninvasive strategy in which one or more cycles of brief and transient limb ischemia confer protection against prolonged and severe ischemia in distant organs. In the transient focal cerebral ischemia-reperfusion model, the application of remote ischemic conditioning before reperfusion or both before and after reperfusion reduces reperfusion injuries and the final infarct size. Because patients with acute ischemic stroke who are treated with endovascular thrombectomy can achieve a high rate of recanalization after focal ischemia, this patient population is akin to the model of transient focal cerebral ischemia-reperfusion. Furthermore, a pilot study has determined the safety and feasibility of remote ischemic conditioning in patients undergoing endovascular thrombectomy. However, whether remote ischemic conditioning could provide clinical benefits to patients with acute ischemic stroke who are treated with endovascular thrombectomy urgently needs investigations.\n\nThis study aims to investigate the safety and efficacy of remote ischemic conditioning in improving functional outcomes of patients with acute ischemic stroke treated with endovascular thrombectomy and explore the effect of treatment duration on the treatment outcome of remote ischemic conditioning.","ExperimentalDrugs":"[\"device: 14-day remote ischemic conditioning\",\"procedure: endovascular thrombectomy\",\"best medical management\",\"device: 30-day remote ischemic conditioning\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"PHASE3","lastUpdateDate":"2025-12-03"},{"nctId":"NCT06175715","OrgName":"Pirogov Russian National Research Medical University","Titlefull":"The Study is Planned to Evaluate the Effectiveness and Safety of Two Types of Anesthesia (Regional and General) for Carotid Endarterectomy in 100 Patients With Acute Stage of Stroke: 50 Patients Will be Operated Under Regional Anesthesia and the Remaining 50 Patients Under General Anesthesia.","BriefSummary":"The study is planned to evaluate the effectiveness and safety of two types of anesthesia (regional and general) for carotid endarterectomy in 100 patients with acute stage of stroke: 50 patients will be operated under regional anesthesia and the remaining 50 patients under general anesthesia.\n\nPatient inclusion criteria:\n\n1. Ischemic stroke in the middle cerebral artery territory\n2. Ipsilateral stenosis of the internal carotid artery more than 50%\n3. Neurological deficit at the time of surgical treatment: the modified Rankin scale (mRs) score of 0-4 and the US National Institutes of Health (NIHSS) stroke scale score no more than 12\n4. The size of the ischemia focus: no more than 1/3 in the territory of the middle cerebral artery brain supply\n5. Terms of operation: from 1 to 28 days from the moment of ischemic stroke\n\nThe primary intra-hospital and/or 30-day study endpoints:\n\n1. Perioperative ipsilateral ischemic stroke.\n2. Any stroke: contralateral ischemic or any hemorrhagic stroke.\n3. Myocardial infarction.\n4. Hemorrhagic complications that required surgical revision of the operating wound or transfusion of blood components.\n5. Surgical site infection\n6. Death\n7. Main adverse cardiovascular events (stroke + myocardial infarction + death).","ExperimentalDrugs":"[\"procedure: carotid endarterectomy\"]","Allcountries":"[\"Russia\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":18,"Phase":"NA","lastUpdateDate":"2026-03-23"},{"nctId":"NCT06405750","OrgName":"University Hospital Bispebjerg and Frederiksberg","Titlefull":"Left Atrial Appendage Arrhythmogenic and Thrombogenic Substrate","BriefSummary":"The purpose of the project is to elucidate whether it is possible to identify which patients are at risk of forming blood clots that can cause stroke based on analysis of the electrocardiogram.\n\nIn connection with the operation, the small pouch known as the auricle of the heart is closed, which can be completely removed after closing. This procedure is common in patients with atrial fibrillation to protect the brain from stroke. In the project, all patients will have this auricle closed if they agree to participate in the project.\n\nAfter closure, the auricle is usually discarded. We will analyze the blood and the auricle tissue taken (if available) in connection with the operation itself, together with the analysis of the electrocardiogram recorded before the planned heart operation.","ExperimentalDrugs":"[]","Allcountries":"[\"Denmark\"]","FirstAdminInter":"Not AIS","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-01-14"},{"nctId":"NCT06047782","OrgName":"Centre Hospitalier Universitaire Dijon","Titlefull":"Impact of Atrial Fibrosis Surface Area on the Occurrence of Atrial Fibrillation in Patients With Ischemic Stroke of Undetermined Origin: a Prospective Cardiac MRI Pilot Study.","BriefSummary":"Atrial fibrillation is a cardiac arrhythmia most often originating in the left atrium, causing anarchic electrical activity and thus a loss of atrial contraction. This increases the risk of stroke through clot formation in the atrium, but also of heart failure. Atrial fibrillation is a major cause of stroke, accounting for more than 25% of all strokes. In addition, a quarter of ischemic strokes remain without an obvious cause at the end of hospitalization, and it is recommended that atrial fibrillation be detected intensively with long-term heart rhythm recording. Implantable loop recorders can detect 30% of atrial fibrillation cases over the 3-year battery life of these devices, after a stroke of undetermined origin. However, these devices require a small operation to implant them under the skin, and they are expensive.\n\nThe hypothesis of this study is that MRI imaging of the left atrium would enable better selection of patients to receive an implantable loop recorder. MRI can quantify the proportion of the left atrium with scar tissue, which is likely to favour the onset of atrial fibrillation. If the results confirm this hypothesis, the number of patients requiring an implantable loop recorder could be reduced, and perhaps an anticoagulation strategy based on MRI data could be introduced.\n\nIn addition to the usual follow-up by cardiologists and neurologists, participation in this study involves a cardiac MRI (with contrast agent) within 3 months of the stroke.","ExperimentalDrugs":"[]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Please provide the JSON structured object containing the Arm intervention module for the clinical trial you would like me to analyze.","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":6,"Phase":"NA","lastUpdateDate":"2026-01-16"},{"nctId":"NCT06628817","OrgName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","Titlefull":"The Intensive Care Bundle with Mortality Reduction in Acute Ischemic Stroke Trial","BriefSummary":"Ischemic stroke, also known as cerebral infarction, accounts for as high as 60% to 80% of all stroke cases, and it is characterized by high morbidity, high disability rate, and high mortality rate. In recent years, acute ischemic stroke (AIS) has risen to the top of the list of causes of death in Chinese people, bringing a heavy burden on families, society and the country. In the process of continuous accumulation of evidence-based evidence, the management of stroke has gradually become systematic, and the demand for multi-disciplinary collaboration has become increasingly prominent, thus the concept of organized medical care has emerged.\n\nImproving the prognosis of stroke faces multiple challenges, including timely identification of stroke patients, intravenous thrombolysis after clinical doctors evaluate indications and contraindications, reducing in-hospital stroke complications, accurately diagnosing the cause of stroke and implementing precise prevention. In the past, there were relatively few clinical trials on reducing mortality. The 2023 Dutch PRECIOUS study used metoclopramide, ceftriaxone and acetaminophen to prevent aspiration, infection and fever in elderly patients with acute stroke. The results showed that there was no significant difference in acute 90-day good functional outcomes and reduced mortality. The INTERACT3 trial results showed that for patients with acute cerebral hemorrhage, compared with conventional medical care, the use of a new combination management plan, namely early intensive blood pressure management, strict control of blood sugar elevation, body temperature control and anticoagulation therapy, can significantly reduce the risk of 6-month adverse functional prognosis in patients, improve the survival rate and quality of life of patients, and the possibility of patients being discharged within 7 days. Therefore, the use of a new combination management plan, including improving the efficiency of reperfusion therapy, reducing the occurrence of stroke complications, and carrying out precise etiological treatment, may reduce the mortality rate of patients.\n\nThe Zhejiang Stroke Online Platform can monitor the comprehensive information of treatment and management in the process of clinical doctors receiving AIS patients in real time. According to the self-feedback of each unit of the online platform, the provincial center conducts multi-level new combined management intervention on it. The purpose of this study is to explore whether the new combined management intervention measures can reduce the mortality rate of AIS patients on the basis of the implementation of stroke online platform monitoring.","ExperimentalDrugs":"[\"radiation: the intensive care bundle with mortality reduction\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"mRS","total_Score":8,"Phase":"NA","lastUpdateDate":"2024-10-04"},{"nctId":"NCT06091332","OrgName":"Huashan Hospital","Titlefull":"Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: a Randomized, Placebo-controlled Pilot Trial","BriefSummary":"The aim of this pilot phase trial is to assess the safety and tolerability, and estimate the efficacy of sirolimus in reducing the incidence of ICH during high-risk periods for rebleeding, compared to placebo. This pilot trial will inform the design of a future definitive clinical trial on sirolimus treatment for CCM.","ExperimentalDrugs":"[\"sirolimus\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":15,"Phase":"PHASE2","lastUpdateDate":"2024-12-17"},{"nctId":"NCT06489925","OrgName":"University Hospital Sestre Milosrdnice","Titlefull":"Cerebrolysin as an Add-On Therapy to Standard Treatment of Posterior Circulation Stroke Secondary to Basilar Artery Occlusion","BriefSummary":"The standard therapy for acute ischemic posterior circulation stroke (PCS) often leads to poor functional outcomes and high mortality rates, despite all advances in reperfusion therapy. Recent trials have shown that adding Cerebrolysin, a cerebral neuroprotective agent, to standard therapy for patients with acute ischemic anterior circulation stroke is safe and leads to improved functional outcomes. The purpose of this study is to assess the effectiveness and safety of Cerebrolysin with standard treatment for patients with PCS secondary to basilar artery occlusion (BAO).\n\nThe plan is to conduct a prospective, single-center, single-arm, open-label study with 20 acute basilar artery occlusion patients and premorbid modified Rankin Score (mRS) ≤3, treated with standard treatment (mechanical thrombectomy ± intravenous alteplase or conservative treatment) and Cerebrolysin as add-on therapy, compared with historical controls. Besides standard acute stroke assessment, standard treatment, and rehabilitation, the participants who meet the eligibility criteria will receive Cerebrolysin in a single-day dosage of 30 ml intravenously for 14 consecutive days. The participants will be closely monitored, and neuroimaging findings and clinical outcomes will be obtained during the drug administration period, on discharge, one month, and 3 months after the treatment onset.\n\nThe primary endpoints are mRS (0-3) on day 90 and mortality rate 90 days after the stroke onset. The secondary endpoints are defined as a change in any type of intracerebral bleeding and a change of min. 2 points on the National Institutes of Health Stroke Scale 24 hours, 14 days, 30 days, and 90 days post-stroke.\n\nThe investigators hypothesize that adding Cerebrolysin to standard stroke treatment will improve clinical outcomes and reduce morbidity and mortality in patients with acute basilar occlusion compared to standard treatment alone.","ExperimentalDrugs":"[\"cerebrolysin\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":15,"Phase":"EARLY_PHASE1","lastUpdateDate":"2024-07-08"},{"nctId":"NCT06522269","OrgName":"Beijing Tiantan Hospital","Titlefull":"Emergency Stroke Unit for Acute Cerebrovascular Events--A Prospective, Multicenter, Week-wise Randomized, Controlled Trial ( ESU-ACE-C )","BriefSummary":"To compare the prognosis of patients with hyperacute ischemic stroke (who arrive at the emergency department within 4.5 hours of symptom onset) managed in a standard stroke unit adherent to guidelines versus managed in Emergency Stroke Unit (a new stroke unit based on low-field magnetic resonance imaging).","ExperimentalDrugs":"[\"combination product: emergency stroke unit based on 0.23-t mri\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Day 1 only","Status":"COMPLETED","Add_on":"IVT mandatory; EVT optional","Endpoint":"mRS at 90 days","total_Score":31,"Phase":"PHASE3","lastUpdateDate":"2025-08-17"},{"nctId":"NCT07435688","OrgName":"Istanbul University - Cerrahpasa","Titlefull":"Comparison of The Effectiveness Of Mirror Therapy And Mirror Mode of a Hand Robot in Upper Extremity Motor Recovery After Stroke","BriefSummary":"The goal of this clinical trial is to compare the effectiveness of conventional mirror therapy and robotic mirror mode training in promoting upper extremity motor recovery in adult patients with ischemic stroke during the early subacute phase. The main questions it aims to answer are:\n\nDoes mirror mode of a robotic hand device result in greater motor function recovery compared to conventional mirror therapy?\n\nAre there differences between the groups in somatosensory improvement and gross motor skill outcomes?\n\nDo both intervention modalities result in clinically significant improvements in motor and functional outcomes?\n\nResearchers will compare a conventional mirror therapy group and a robotic-assisted mirror mode group to determine which provides more significant gains in motor function, somatosensory input, and functional use of the paretic arm.\n\nParticipants will:\n\nReceive standard physiotherapy sessions for 6 weeks\n\nBe randomly assigned to either mirror therapy or robotic mirror mode intervention\n\nBe evaluated using Fugl-Meyer Assessment, ARAT, Box and Block Test, Wolf Motor Function Test and Tactile/proprioceptive sensory test using Fugl-Meyer Assessment Sensory subsection.","ExperimentalDrugs":"[\"device: therapy mirror\",\"device: hand robot mirror mode\"]","Allcountries":"[\"Turkey (Türkiye)\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"COMPLETED","Add_on":"Other","Endpoint":"Early efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2026-04-12"},{"nctId":"NCT06489470","OrgName":"University of Rostock","Titlefull":"Strokectomy in Malignant Cerebral Media Infarction: A Pilot Study","BriefSummary":"Decompressive hemicraniectomy (DC) is the standard procedure and life saving measure in case of malignant middle cerebral artery (MCA) infarction. However, there have been several studies reporting the neuroinflammatory cascade based on the necrotic tissue as one of the leading cause for the secondary brain damage, wherefore, strokectomy with resection of necrotic tissue has been proposed in some case series as an alternative surgical option. Thus, the aim of this study is to perform a pilot study by including patients with malignant MCA infarction and to check the feasibility of this specific surgical treatment.","ExperimentalDrugs":"[\"procedure: strokectomy/necrosectomy\"]","Allcountries":"[\"Germany\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":20,"Phase":"NA","lastUpdateDate":"2024-07-02"},{"nctId":"NCT06388954","OrgName":"Cairo University","Titlefull":"Effect of Trans-auricular Vagus Nerve Stimulation on Plasticity Biomarkers,Interleukin-6 and Motor Performance Post Stroke : A Randomized Controlled Clinical Trial","BriefSummary":"Seventy-eight clinically verified Egyptian patients from both sexes with ischemic stroke that occurred at least 6 months to 2 years before inclusion will be randomly assigned into 2 groups, control group (GA) and the experimental group (GB). Patients will be randomly assigned into two equal groups: the control group (GA) and the experimental group (GB). Patients in the control group (GA) will be treated with sham Vagus nerve stimulation (taVNS) immediately before a selected physical therapy program, while in the experimental group (GB), patients will receive real transcutaneous auricular Vagus nerve stimulation (taVNS) followed by the same selected physical therapy program as (GA). Plasma level of Brain-Derived Neurotrophic Factors (BDNF) and Interleukin-6 (IL-6), Box and Blocks Test (BBT), and modified Ashworth scale (MAS) will be assessed at baseline and immediately post-treatment.","ExperimentalDrugs":"[\"device: true transcutaneous auricular vagus nerve stimulation (tavns)\"]","Allcountries":"[\"Egypt\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Other","total_Score":7,"Phase":"NA","lastUpdateDate":"2025-05-08"},{"nctId":"NCT07331844","OrgName":"Fatih Sultan Mehmet Training and Research Hospital","Titlefull":"The Combined Effect of Botulinum Toxin Type A and Mirror Therapy in the Management of Chronic-Phase Upper Extremity Spasticity After Ischemic Stroke: A Double-Blind, Controlled Study","BriefSummary":"Stroke is one of the leading causes of disability worldwide, particularly affecting the upper extremities and thus negatively impacting patients' activities of daily living and quality of life. Upper extremity spasticity, characterized by increased muscle tone and tendon reflexes, leads to functional limitations. While Botulinum Toxin Type A (BTX-A) is widely used to manage spasticity and can temporarily alleviate symptoms, it does not directly support neuroplasticity and often requires repeated injections.\n\nMirror therapy (MT) has emerged as a promising rehabilitation approach with the potential to stimulate motor recovery and cortical reorganization. It is hypothesized that combining MT with BTX-A injections may more effectively reduce spasticity and improve upper extremity function.\n\nIn this study, a randomized, sham-controlled, double-blind, prospective design was employed to investigate the effects of adding MT to BTX-A treatment on spasticity and upper extremity motor function in stroke patients. A total of 30 patients, who received BTX-A injections, were divided into two groups: an experimental group receiving mirror therapy and a control group receiving sham therapy (using transparent glass). All patients also underwent a standardized conventional rehabilitation program, and the BTX-A injection protocol was kept consistent. Treatment efficacy was evaluated by comparing pre-injection measurements with those at six months post-injection, using the Brunnstrom Scale, Modified Ashworth Scale (MAS), Fugl-Meyer Scale, and a hand dynamometer. The findings are expected to shed light on the potential benefits of simultaneous MT and BTX-A administration, including reducing injection frequency, and to guide more comprehensive approaches in the rehabilitation of chronic stroke.","ExperimentalDrugs":"[\"botulinum toxin type a (botox®, allergan)\",\"procedure: mirror therapy\",\"procedure: sham mirror therapy\"]","Allcountries":"[\"Turkey (Türkiye)\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"COMPLETED","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-01-05"},{"nctId":"NCT06225752","OrgName":"First Affiliated Hospital of Wannan Medical College","Titlefull":"A Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial of Probucol in Reducing the Risk of Recurrent Stroke in Patients With Symptomatic Intracranial and Extracranial Large-artery Stenosis","BriefSummary":"This study is a multicenter, double-blind, placebo-controlled, randomized clinical trial that aims to evaluate the efficacy of probucol on the reduction of the risk of recurrent stroke in patients with symptomatic intracranial or extracranial arterial stenosis.","ExperimentalDrugs":"[\"probucol\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":19,"Phase":"PHASE3","lastUpdateDate":"2024-07-12"},{"nctId":"NCT06548971","OrgName":"Capital Medical University","Titlefull":"Safety and Efficacy of Treatment With Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT): A Multicenter, Randomized, Placebo-controlled, Clinical Trial","BriefSummary":"Stroke is the second leading cause of death worldwide, and ischemic stroke is the most frequent type. Intravenous thrombolysis with recombinant tissue plasminogen activator within 4.5 hours of symptom onset is the most effective therapy for patients with acute ischemic stroke. However, ischemic stroke progression and early reocclusion are not an uncommon phenomenon in patients after intravenous thrombolysis, resulting in neurological deterioration, which is associated with unfavorable functional outcomes. The underlying mechanism mainly involves the augmented platelet activation, triggered by the activated coagulation cascade during thrombolysis, which peaks within 2 hours of initiating rt-PA administration. Therefore, early antiplatelet therapy following intravenous thrombolysis represents a promising therapeutic approach to prevent neurological deterioration and improve the functional outcome of patients treated with intravenous thrombolysis.\n\nCurrently, guidelines recommend initiating antiplatelet therapy 24 hours after intravenous thrombolysis due to the potential risk of increased bleeding. The safety and efficacy of early antiplatelet treatment following intravenous thrombolysis in patients with acute ischemic stroke remain clear.\n\nThe study aims to test the hypothesis that in patients with acute ischemic stroke treated with intravenous thrombolysis, early administration of oral aspirin will improve functional outcomes without increasing the risk of intracranial hemorrhage.","ExperimentalDrugs":"[\"aspirin\",\"other: best medical management\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Other","Status":"RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":27,"Phase":"PHASE3","lastUpdateDate":"2025-12-14"},{"nctId":"NCT06845683","OrgName":"Riphah International University","Titlefull":"Effects of Dual-Task and Progressive Wall Squat Training on Cognition, Balance and Functional Mobility in Stroke Survivors","BriefSummary":"To determine the Effects of Dual-Task and Progressive Wall Squat Training on Cognition, Balance and Functional mobility in Stroke Survivors.","ExperimentalDrugs":"[\"other: group a\",\"other: group b\"]","Allcountries":"[\"Pakistan\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2025-04-07"},{"nctId":"NCT06322394","OrgName":"Biocells (Beijing) Biotech Co.,Ltd","Titlefull":"A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset","BriefSummary":"The purpose of this study was to evaluate the effectiveness of early administration of BXOS110 for injection in reducing overall disability in patients with acute ischaemic stroke.","ExperimentalDrugs":"[\"high-dose bxos110\",\"low-dose bxos110\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Only once","Status":"UNKNOWN","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":28,"Phase":"PHASE2","lastUpdateDate":"2024-03-19"},{"nctId":"NCT06319534","OrgName":"Chao Phya Abhaibhubejhr Hospital","Titlefull":"A Randomized Controlled Study to Explore the Effect of Stellate Ganglion Block in Dysphagic Patients With Bulbar Palsy After Ischemic Stroke","BriefSummary":"This is a randomized controlled study, including dysphagic patients with bulbar palsy after ischemic stroke who were received in the department of rehabilitation medicine in 3 hospitals in China. All patients are randomly allocated to the observation group or the control group. Both groups are provided with comprehensive rehabilitation. Besides, the observation group additionally undergoes the stellate ganglion block. At admission and after 10-day treatment, video fluoroscopic swallowing study, ultrasound diagnostic devices, and penetration-aspiration scale, Flexible laryngoscope are used to assess swallowing function.","ExperimentalDrugs":"[\"behavioral: comprehensive rehabilitation\",\"procedure: stellate ganglion block\",\"lidocaine hydrochloride\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"Other","Endpoint":"Late efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2026-05-05"},{"nctId":"NCT06374667","OrgName":"Beijing Tiantan Hospital","Titlefull":"The Efficacy and Safety of Y-3 Intracalvariosseous Injection Bypassing Blood-brain Barrier Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction（SOLUTION-2）","BriefSummary":"A pilot study confirmed the feasibility and safety of neuroprotectant Y-3 intracalvariosseous(ICO) injection in patients with malignant middle cerebral artery infarction (mMCAI), showing a trend in improving 90-day functional scores compared to conventional treatment. The aim of this trial is to further investigate the efficacy and safety of ICO injection of Y-3 compared to intravenous injection in patients with acute large hemispheric infarction(LHI) who has contraindications of reperfusion therapy or have got poor reperfusion therapy outcomes.","ExperimentalDrugs":"[\"procedure: y-3 ico injection\",\"other: conventional treatment\",\"y-3 intravenous injection\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"3 days or less","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":22,"Phase":"NA","lastUpdateDate":"2025-01-24"},{"nctId":"NCT06469619","OrgName":"Tampere University Hospital","Titlefull":"The Effect of Music Listening in Rehabilitation of Subacute Stroke","BriefSummary":"Music listening has many positive effects on the brain. This study aims to find out if people with stroke get better results with their rehabilitation if they listen to music during their passive hours. The study is a randomized controlled trial with people who are at a rehabilitation center care after stroke at Tampere University Hospital. The control group gets standard rehabilitation. Music group gets standard rehabilitation and in addition they listen to music one hour a day during four weeks. Physiotherapists, occupational therapists and speech therapists test how well the participant's walking, use of hand and speech improve. The main goal is to find out if the improvement is better with music listening. The study also monitors effects of music listening on mood in rehabilitation.","ExperimentalDrugs":"[\"behavioral: music listening\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2024-06-17"},{"nctId":"NCT04974151","OrgName":"Shenzhen Ausa Pharmed Co.,Ltd","Titlefull":"Comparative Efficacy of Amlodipine Folic Acid vs. Amlodipine on the Risk of First Ischemic Stroke Among Participants With Hypertension and MTHFR 677 TT Genotype: A Multi-center, Randomized, Double-blind, Triple-dummy, Controlled Clinical Trial","BriefSummary":"This is a multi-center, randomized, double-blind, triple-dummy, controlled trial in 24,000 Chinese men and women with hypertension and MTHFR 677 TT genotype.\n\nThe study participants will be randomized to one of the three treatment groups:\n\nGroup A: amlodipine tablet (5mg), taken orally, once daily, serving as active comparator.\n\nGroup B: amlodipine folic acid 5.8mg tablet (5mg amlodipine and 0.8mg folic acid), taken orally, once daily.\n\nGroup C: amlodipine folic acid 5.8mg tablet plus 5-methyltetrahydrofolate (5-MTHF, 0.4mg), taken orally, once daily.\n\nThe primary endpoint is first ischemic stroke.","ExperimentalDrugs":"[\"amlodipine besylate\",\"amlodipine folic acid placebo\",\"5-mthf placebos\",\"amlodipine besylate and folic acid\",\"amlodipine placebo\",\"5-methyltetrahydrofolate (5-mthf)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":18,"Phase":"PHASE4","lastUpdateDate":"2025-02-24"},{"nctId":"NCT05764122","OrgName":"Biogen","Titlefull":"A Multicenter, Operationally Seamless, Double-Blind, Dose-Ranging, Placebo-Controlled, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Intravenous BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well","BriefSummary":"The primary objective of the study is to evaluate the effects of BIIB131 on arterial revascularization (Part 1) and to determine if BIIB131 improves functional outcome as measured by the Modified Rankin Scale (mRS) when compared with placebo following acute ischemic stroke (AIS) (Part 2). The secondary objectives are to evaluate the effects of BIIB131 on angiographic reperfusion and infarct evolution, to determine if BIIB131 improves functional outcome, pharmacokinetic profile of BIIB131 (Part 1); to evaluate the effects of BIIB131 on acute and 90-day clinical outcomes (Part 2).","ExperimentalDrugs":"[\"biib131\"]","Allcountries":"[]","FirstAdminInter":"Between 4,5 to 24 hours","TreatDur":"Day 1 only","Status":"WITHDRAWN","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":27,"Phase":"PHASE2","lastUpdateDate":"2024-02-08"},{"nctId":"NCT06249776","OrgName":"Gravity Medical Technology, INC","Titlefull":"Gravity Stent-Retriever System For Reperfusion Of Large Vessel Occlusion Stroke Trial (GRASSROOT)","BriefSummary":"The study aims to evaluate the safety and efficacy of the Supernova stent retriever device, developed by Gravity Medical Technology, for treating acute ischemic stroke. The device is used to remove blood clots and restore blood flow to the brain .","ExperimentalDrugs":"[\"device: supernova revascularization device\"]","Allcountries":"[\"India\",\"Iran\",\"Pakistan\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"COMPLETED","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":27,"Phase":"NA","lastUpdateDate":"2026-05-20"},{"nctId":"NCT06580730","OrgName":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Titlefull":"Endovascular Treatment Post 1 Day （24 Hours）: a Randomized Controlled Clinical Trial on Efficacy and Safety for Stroke","BriefSummary":"Acute ischemic stroke (AIS) is one of the leading causes of disability and mortality worldwide. The treatment of this condition is time-critical, with the key to effective therapy being the early recanalization of the occluded vessel and restoration of blood flow to salvage the ischemic penumbra tissue. Currently, the time window for endovascular treatment in the anterior circulation can be extended up to 24 hours. Exploring endovascular treatments for patients beyond this time window (from 24 hours to 30 days) could mean hope for a greater number of AIS patients.","ExperimentalDrugs":"[\"procedure: endovascular treatment\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":23,"Phase":"NA","lastUpdateDate":"2024-08-31"},{"nctId":"NCT06427187","OrgName":"Assiut University","Titlefull":"Outcomes of Mechanical Thrombectomy of Acute Ischemic Stroke Anterior Circulation Distal Vessel Occlusion","BriefSummary":"Ischemic stroke continues to be of the leading causes of disability and death. Distal vessel occlusion one of most presenting and disabling varieties of ischemic stroke. Distal vessel occlusion stroke is a type of ischemic stroke that affects the small arteries in the brain, usually beyond the M2 segment of the middle cerebral artery. These strokes can cause various neurological symptoms depending on the location and size of the occluded vessel and the extent of the brain tissue damage","ExperimentalDrugs":"[\"device: an array of devices are used in thrombectomy. these include guide catheters, stent-retrievers, microcatheters, aspiration catheters, and aspiration pump systems\"]","Allcountries":"[]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":16,"Phase":"NA","lastUpdateDate":"2024-05-22"},{"nctId":"NCT05961293","OrgName":"NeuroGlove LLC","Titlefull":"Impact of Peripheral Sensory Stimulation of the Hand in the Treatment of Stroke: A Preliminary Functional MRI Study","BriefSummary":"This is a prospective, single center, interventional clinical study containing two cohorts the treatment cohort and control cohort. A total of 13 subjects will be enrolled. Three (3) healthy volunteers will be enrolled in the control cohort and undergo imaging only. Ten (10) subjects who have recently experienced a mild to moderate acute ischemic stroke will receive treatment using the NeuroGlove.","ExperimentalDrugs":"[\"device: neuroglove\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Safety","total_Score":13,"Phase":"NA","lastUpdateDate":"2024-08-26"},{"nctId":"NCT06653348","OrgName":"Mazandaran University of Medical Sciences","Titlefull":"De-Escalation of Dual Antiplatelet Therapy With Ticagrelor and Aspirin in Non-disabling Non-cardioembolic Ischemic Stroke or High Risk TIA Patients: A Randomized, Outcome Assessor Blind, Controlled Trial","BriefSummary":"This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for 6 months in reduce of non-disabling non-cardioembolic ischemic stroke or high risk TIA recurrence during first 12 months.","ExperimentalDrugs":"[\"ticagrelor 60 + aspirin\",\"ticagrelor 90 + aspirin\"]","Allcountries":"[\"Iran\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Late efficacy","total_Score":21,"Phase":"PHASE2","lastUpdateDate":"2025-04-23"},{"nctId":"NCT06443840","OrgName":"Association APPROCHE","Titlefull":"AUTONHOME: Impact of a Self-rehabilitation and Tele-rehabilitation Program on the Post-stroke Care Pathway : Preliminary Study","BriefSummary":"The AutonHome® clinical investigation, proposed by Dr Charles FATTAL (coordinator of this study), and carried out by the Association Approche (delegated promoter), aims to use the AutonHome® selfeducation device for the rehabilitation of patients who have suffered a Cerebrovascular Accident (CVA), and thus respond to the problems of therapeutic discontinuity highlighted today. Neuradom's AutonHome® device combines self-education and telecare. This device makes it possible to carry out personalised self-education programmes supervised by the therapist, enabling the therapeutic link with the patient to be maintained without the need for the patient to travel. This tool has already proved its usability and perceived usefulness in a previous clinical study, which demonstrated the feasibility of a self-education programme for hemiplegic patients, based on feedback. AutonHome® was considered by users to be a relevant, useful and safe complement to conventional rehabilitation.\n\nOn the basis of this feasibility study, the investigators wished to develop a second study around this AutonHome® device. In this second clinical investigation, in addition to perceived usefulness, the main objective is to demonstrate, in a population of stroke victims, that an experimental care pathway combining supervised self-education via AutonHome® with conventional re-education optimises the care pathway in terms of sensory-motor recovery, but also in terms of reduced length of stay and functional and medico-economic added value.\n\nThis clinical trial involves two parallel arms. Participants will be randomised into a control group, undergoing conventional in-centre rehabilitation, or into an experimental group, with self-rehabilitation and tele-rehabilitation in addition to conventional rehabilitation. The AutonHome study is a pilot study, with the aim of including 40 participants. Each centre will recruit 10 participants on a 1:1 randomisation basis, with 5 in the experimental group and 5 in the control group. Participants will be monitored for 15 weeks. This clinical investigation is multicentre, with 4 centres involved: the Centre Bouffard Vercelli (66962, Perpignan), the CMRRF de Kerpape (56275 Ploemeur), the association Saint-Hélier (35043, Rennes), and the Fondation ILDYS (29684 Roscoff).","ExperimentalDrugs":"[\"device: autonhome® device\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Late efficacy","total_Score":5,"Phase":"NA","lastUpdateDate":"2024-05-30"},{"nctId":"NCT05230914","OrgName":"Xinqiao Hospital of Chongqing","Titlefull":"Simple Imaging Versus Standard Imaging Selection in Stroke Patients for Endovascular Treatment: the NO-SELECT Randomized Trial","BriefSummary":"Several studies suggest that advanced multi-modal imaging with CTP should be used to screen late time window stroke patients for thrombectomy. However, NCCT is more accessible when comparing with CTP. It is unclear whether the NCCT-based ASPECTS can be used as an imaging criterion to screen patients for thrombectomy.\n\nThe newly published MR CLEAN-LATE and TENSION trials used NCCT or CTA, but still relied on ASPECTS scores to evaluate and select patients for endovascular therapy. However, different trials have different time windows. The aim of this trial was to assess the clinical outcomes of stroke patients with anterior large vessel occlusion who selected by simple imaging (NCCT) comparing via standard imaging screening strategy (CTP/MRI). The hypothesis is that simple imaging is non-inferior to standard imaging selection strategy in terms of achieving favorable outcomes.","ExperimentalDrugs":"[\"other: simplified imaging strategy\",\"other: standard imaging strategy\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":25,"Phase":"NA","lastUpdateDate":"2025-12-18"},{"nctId":"NCT06587347","OrgName":"Capital Medical University","Titlefull":"Effects of Tirofiban on Early Neurological Deterioration After Intravenous Thrombolysis in Patients With Acute Ischemic Stroke: an Open-label, Multicenter, Randomized Controlled Trial","BriefSummary":"A prospective, multicenter, randomized, controlled, open-label, blinded endpoint trial to evaluate the safety and efficacy of intravenous administration of tirofiban for preventing early neurological deterioration after intravenous thrombolysis in patients with acute ischemic stroke.","ExperimentalDrugs":"[\"tirofiban hydrochloride\",\"standard medical treatment (smt)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Day 1 only","Status":"NOT_YET_RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"Early efficacy","total_Score":25,"Phase":"PHASE2","lastUpdateDate":"2024-10-28"},{"nctId":"NCT06541691","OrgName":"Rajaie Cardiovascular Medical and Research Center","Titlefull":"Coated or Chewable Aspirin in Patients with Established Atherosclerotic Disease and a Hybrid Strategy to Mitigate the Adverse Effects of Air Pollution: the COATED-AIR Randomized Clinical Trial","BriefSummary":"Although both enteric-coated and plain formulations of aspirin are being used commonly, there are no high-quality comparisons between these formulations with respect to clinical efficacy outcomes in patients with atherosclerotic cardiovascular diseases (ASCVD). Air pollution is also a major contributor to the excess risk of cardiovascular events in many regions of the world. However, little is known about the effect of individual-level mitigation strategies against air pollution in reducing cardiovascular outcomes. The purpose of the first randomization is to compare the efficacy and safety of enteric-coated versus plain low-dose (81 mg) aspirin formulations in a double-blind fashion. The second randomization compares a multifaceted intervention including one-page educational flashcard, cell phone text messages alerting participants on polluted days, recommending them to stay indoors or wear KN-95 facemasks provided by the study team in case of necessary outdoor activity, and recommendation to consume citrus fruits on polluted days versus usual care. Both randomization are powered for clinical outcomes and the results will inform practice.","ExperimentalDrugs":"[\"enteric-coated aspirin\",\"plain aspirin\",\"other: hybrid strategy\"]","Allcountries":"[\"Iran\"]","FirstAdminInter":"Not AIS","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":10,"Phase":"NA","lastUpdateDate":"2025-03-14"},{"nctId":"NCT06373042","OrgName":"Xinqiao Hospital of Chongqing","Titlefull":"Efficacy and Safety of Tirofiban Versus Placebo After Successful Reperfusion With Endovascular Thrombectomy in Acute Ischemic Stroke Patients With Anterior Circulation Large Vessel Occlusion: a Multicenter, Double-Blind, Randomized Clinical Trial","BriefSummary":"Up to 50% of acute ischemic stroke patients with large vessel occlusion failed to achieve functional independence even after successful reperfusion therapy, a phenomenon that is referred to as \"futile recanalization\". The mechanism of futile recanalization is complex, and some studies have shown that it may be related to factors such as tissue no reflow, reocclusion, poor status of collateral circulation, hemorrhagic transformation, impaired cerebrovascular autonomic regulation, and low perfusion volume. Several studies suggested that maximizing the improvement of cerebral reperfusion is still the primary goal of acute large vessel occlusive stroke. Structural and functional alterations in the microvascular system may be a major obstacle to reperfusion. In animal models of cerebral ischemia, downstream microvascular thrombosis may occur in the early stage of cerebral ischemia and before vascular recanalization, which is the main factor leading to incomplete reperfusion and affecting the efficacy of endovascular thrombectomy.\n\nMechanical thrombectomy mainly addressed the occluded large arteries, and does not consider the distal arteries. However, the recanalization of occluded large arteries does not necessarily translate into successful reperfusion of the ischemic tissue supplied by the distal capillaries. Even with complete recanalization, impaired microcirculatory reperfusion may lead to poor clinical outcomes. Therefore, we speculate that at the end of endovascular thrombectomy, microthrombi remain present in the microcirculation of brain tissue in patients with complete or near-complete cerebral angiography, and that microthrombi is more likely to be dissolved than thrombus more proximal to the heart. Therefore, intra-arterial administration of pharmaceutical, such as tirofiban, may be the only possible option to ensure complete reperfusion of ischemic tissue. Tirofiban is a platelet glycoprotein IIb/IIIa receptor antagonist, which has been widely used in acute coronary syndrome, and its role in acute ischemic stroke has attracted more and more attention from stroke experts. Previous studies have suggested that tirofiban can further increase the incidence of successful recanalization, while reducing the reocclusion rate.\n\nWhether early administration of intraarterial and intravenous tirofiban can further improve the clinical outcomes of patients with large vessel occlusive stroke after successful mechanical thrombectomy remains unclear.","ExperimentalDrugs":"[\"intraarterial and intravenous tirofiban\"]","Allcountries":"[]","FirstAdminInter":"Within 24 hours","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":26,"Phase":"PHASE2","lastUpdateDate":"2024-05-13"},{"nctId":"NCT06360120","OrgName":"Kafrelsheikh University","Titlefull":"Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke, a Randomized Controlled Single-blinded Trial","BriefSummary":"Along with the current clinical trial, the impact of adding atorvastatin or rosuvastatin in the first 24 hours on the clinical outcomes of first-ever large-vessel ischemic stroke patients treated with clopidogrel assessed through NIHSS, mRS, and possible adverse effects.","ExperimentalDrugs":"[\"atorvastatin 40 mg oral tablet\",\"clopidogrel 75 mg oral tablet\",\"rosuvastatin 20mg\"]","Allcountries":"[\"Egypt\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":18,"Phase":"PHASE3","lastUpdateDate":"2025-08-30"},{"nctId":"NCT06483230","OrgName":"Weill Medical College of Cornell University","Titlefull":"A Pilot Study on Tolerance and Ease of Implementation of Intensive Visual Stimulation (IVS3) in Daily Practice for Upper Limb Motor Recovery in Outpatient Rehab Center","BriefSummary":"This study measures participant satisfaction and upper extremity function in outpatients with chronic stroke when exposed to the IVS3 device. Investigators hypothesize that treatment with the IVS3 device will be feasible and tolerable for use in the outpatient setting.","ExperimentalDrugs":"[\"device: intensive visual stimulation device\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":10,"Phase":"NA","lastUpdateDate":"2025-10-27"},{"nctId":"NCT06045156","OrgName":"The First Hospital of Jilin University","Titlefull":"Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial","BriefSummary":"The purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT","ExperimentalDrugs":"[\"tirofiban\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Day 1 only","Status":"RECRUITING","Add_on":"IVT mandatory; EVT excluded","Endpoint":"mRS at 90 days","total_Score":26,"Phase":"NA","lastUpdateDate":"2025-12-22"},{"nctId":"NCT06591377","OrgName":"Kafrelsheikh University","Titlefull":"Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA, a Randomized Controlled Trial","BriefSummary":"Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel minor stroke or TIA compared to 200mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.","ExperimentalDrugs":"[\"ticagrelor 90 mg\",\"aspirin 75mg\",\"cilostazol 100 mg\"]","Allcountries":"[\"Egypt\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT optional","Endpoint":"Late efficacy","total_Score":28,"Phase":"PHASE3","lastUpdateDate":"2025-09-12"},{"nctId":"NCT06262529","OrgName":"Centre Hospitalier Universitaire de Nice","Titlefull":"Trajectories of Neurocognitive Impairment After Ischemic Stroke in Young Subjects","BriefSummary":"Affecting more than 150,000 patients in France, stroke is a major public health issue and a leading cause of disability worldwide. In western countries, 80-85% of strokes are of ischemic subtype. This study will focus on young adults, aged 18-45, with a diagnosis of ischemic stroke.\n\nStudies assessing post-stroke cognition in young patients reported an alarming prevalence of cognitive impairment, affecting about 60% of stroke survivors between 4 and 12 months after the acute event. However, longitudinal data on neurocognitive trajectories (i.e., the evolution of cognitive impairment over time) in young patients with ischemic stroke are lacking. Collecting such data requires an exhaustive neuropsychological assessment and several functional evaluations, at different times, for the same patient.\n\nRepeated neurocognitive study of young patients with ischemic stroke will enable: a description of the prevalence of impaired global cognitive efficiency, an analysis of the specific neurocognitive domains affected, and the tracing of trajectories of recovery from cognitive impairment over time, in terms of global cognitive efficiency and as a function of specific neurocognitive domains (memory, executive, attentional, social cognition, instrumental functions, fatigability, etc.).\n\nUp to date, the clinic-radiological predictors and associated factors of neurocognitive impairment after ischemic stroke in young patients have not been studied. Ischemic stroke causes acute brain lesions of the gray matter (GM) and white matter (WM). Numerous studies suggest that cognitive health may be more closely linked to the integrity of WM than to GM. Magnetic resonance imaging (MRI), and in particular diffusion tensor imaging (DTI) sequences, analyze WM bundles. By using fiber tracking algorithms image analysis enable the WM fiber bundle reconstruction and allow quantifying the volume of lesions (pre-existing and ischemic stroke-induced) in the WM tract.\n\nThe aim of this study is to study whether the extension of pre-existing and acute white matter lesions is associated with poorer cognitive recovery after ischemic stroke, both in terms of global cognitive performance and impairment in specific neurocognitive domains.","ExperimentalDrugs":"[\"other: cerebral mri\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":10,"Phase":"NA","lastUpdateDate":"2025-03-18"},{"nctId":"NCT05983757","OrgName":"University of Pittsburgh","Titlefull":"A Phase III, Randomized, Multicenter, Investigational, Open Label Clinical Trial That Will Examine Whether Treatment With Endovascular Thrombectomy is Superior to Standard Medical Therapy Alone in Patients Who Suffer a Distal Medium Vessel Occlusion Ischemic Strokes.","BriefSummary":"A phase III, randomized, multi-center, investigational, open label clinical trial that will examine whether treatment with endovascular thrombectomy is superior to standard medical therapy alone in patients who suffer a Distal Medium Vessel Occlusion Ischemic Stroke within 12 hours from time last seen well","ExperimentalDrugs":"[\"other: standard medical management\",\"device: experimental: endovascular thrombectomy in patients who suffer a distal medium vessel occlusion\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Within 12 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"NA","lastUpdateDate":"2026-02-20"},{"nctId":"NCT06525168","OrgName":"Chendu DIAO Nine Hong Pharmaceutical Factory","Titlefull":"Phase I Clinical Study of the Safety, Tolerability, Food Effect and Pharmacokinetics of DA414 Granules After Single and Multiple Administration in Healthy Subjects","BriefSummary":"The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and Food Effects of DA414 Granules in Chinese healthy subjects with single and multiple doses.","ExperimentalDrugs":"[\"da414 granules\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Safety","total_Score":18,"Phase":"PHASE1","lastUpdateDate":"2024-07-23"},{"nctId":"NCT06485427","OrgName":"Beijing Shijitan Hospital, Capital Medical University","Titlefull":"Safety and Efficacy of Selective Intra-Arterial Cooling Infusion Combined With Endovascular Thrombectomy in Acute Ischemic Stroke: A Multicenter, Randomized Controlled, Subject- and Assessor-Blind Clinical Trials","BriefSummary":"This is a multicenter, randomized, controlled, subject- and assessor-blinded clinical trial. The research objective is to evaluate the safety and efficacy of selective intra-arterial cooling infusion combined with endovascular therapy in the treatment of acute anterior circulation large vessel occlusion stroke. This trial aims to enroll 258 subjects. Patients assigned to the control group will receive best medical management (BMM) and endovascular therapy (EVT). Those in the selective intra-arterial cooling infusion group (IA-SCI group) will undergo selective intra-arterial cold saline infusion, in addition to BMM and EVT. Subjects will be interviewed face-to-face at randomization, 24±6 hours, 48±6 hours after randomization, 7±2 days/discharge. Telephone interviews/ face-to face interviews will be performed at 30±3 days and 90±7 days after randomization. The primary outcome is the distribution of Modified Rankin Score at 90±7days after randomization.","ExperimentalDrugs":"[\"procedure: selective intra-arterial cooling infusion (ia-sci)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":29,"Phase":"NA","lastUpdateDate":"2025-04-02"},{"nctId":"NCT06474507","OrgName":"Tongji Hospital","Titlefull":"An Open Label Clinical Trial to Evaluate the Efficacy and Safety of Calculus Bovis Sativus (CBS) for Ischemic Cerebral Vascular Disease","BriefSummary":"The most common cause of death for Chinese patients is ischemic cerebrovascular diseases(ICVD), particularly cerebral infarction. It places a heavy burden on people, families, and society as a whole and poses considerable risks of death and disability. The disease known as CSVD has a subtle beginning, is difficult to identify, and is frequently detected only after it progresses to the point of vascular cognitive dysfunction. The primary ischemia necrosis of brain nerve cells and the activation of inflammatory cells are their pathologic processes.\n\nAccording to historical Chinese medical documents, bezoar possesses properties that can help prevent seizures, treat strokes, enhance cognitive function and mental well-being, and stimulate alertness. Calculus Bovis Sativus (CBS) is the most authentic formulation of bezoar ingredients compared to other bezoar products. It has received approval from the China Food and Drug Administration for the essential treatment of comatose patients. CBS consists of three primary constituents: bilirubin, bile acids, and taurine. Scientific evidence has demonstrated that all of these components possess anti-inflammatory, antioxidant, and neuroprotective properties.\n\nThe investigators' objective is to carry out an investigator-initiated clinical study to assess the efficacy of orally administered CBS in treating ischemic cerebrovascular diseases in humans.","ExperimentalDrugs":"[\"calculus bovis sativus (cbs)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":16,"Phase":"NA","lastUpdateDate":"2024-09-19"},{"nctId":"NCT06551727","OrgName":"Ruijin Hospital","Titlefull":"Antithrombotic Therapy With Regulation of Blood Pressure in Non-Cardioembolic Progressive Stroke","BriefSummary":"Stroke has become the leading cause of death in China, with acute ischemic stroke still progressing within one week of onset, known as progressive ischemic stroke (PIS), which has a high rate of disability and mortality, accounting for 23-43% of the incidence of stroke. Non-cardioembolic PIS is one of the common types, and the current treatment mainly focuses on antithrombotic therapy, but the therapeutic effect is not satisfactory. More and more evidence suggests that hypotension is an unfavorable factor for PIS, so this study intends to explore the efficacy and safety of antithrombotic therapy with regulation of blood pressure in non-cardioembolic PIS.","ExperimentalDrugs":"[\"other: control group\",\"other: intervention group\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"ENROLLING_BY_INVITATION","Add_on":"IVT optional; EVT excluded","Endpoint":"mRS at 90 days","total_Score":18,"Phase":"NA","lastUpdateDate":"2024-10-11"},{"nctId":"NCT06415734","OrgName":"The First Affiliated Hospital with Nanjing Medical University","Titlefull":"Repeated Transcranial Magnetic Stimulation (rTMS) Promotes Neural Function Recovery in Patients With Ischemic Stroke by Affecting Local Cerebral Blood Flow and Brain Network","BriefSummary":"The goal of this clinical trial is to learn if transcranial magnetic stimulation(rTMS) can improve neurological rehabilitation in patients with acute ischemic stroke. The main questions it aims to answer are:\n\nCan rTMS Promote Recovery of Limb Impairment in Patients with Acute Ischemia? Can rTMS Cause Changes in the Functional Connections of Brain Networks in Patients?\n\nResearchers will compare rTMS therapy to non-stimulation therapy to see if rTMS is effective in promoting neurological recovery from ischemic stroke.\n\nParticipants will:\n\nReceive rTMS or sham stimulation with LF-rTMS on the contralateral M1 of the brain lesion for 20 minutes, 1200 pulses, 120% RMT, and a treatment period of 5 days； Be evaluated on a scale before and after treatment","ExperimentalDrugs":"[\"device: rtms\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Early efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2024-06-16"},{"nctId":"NCT06059144","OrgName":"University Hospital, Bordeaux","Titlefull":"Induced Hypertension in Acute PRogrESsive Perforating Artery Stroke Using Peripheral Dilute noREpinephrine","BriefSummary":"PRESSURE is a multicenter, prospective, randomized, open, blinded end-point assessed (PROBE) trial, that aims to evaluate the efficacy and safety of drug-induced hypertension using peripheral dilute norepinephrine, in patients with acute ischemic stroke in a perforating artery territory and experiencing early neurological deterioration.","ExperimentalDrugs":"[\"peripheral intravenous norepinephrine\"]","Allcountries":"[\"France\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":24,"Phase":"PHASE3","lastUpdateDate":"2025-01-07"},{"nctId":"NCT06365463","OrgName":"University Rehabilitation Institute, Republic of Slovenia","Titlefull":"Telerehabilitation to Improve Balance and Mobility in Patients After Stroke: Group Physiotherapy Performed in Individuals' Homes","BriefSummary":"Telerehabilitation is an effective rehabilitation method that allows patients to receive physiotherapy remotely in their homes. The purpose of this study was to investigate the effects of home-based remote group training for balance and mobility on activities and body functions.","ExperimentalDrugs":"[\"behavioral: telerehabilitation\"]","Allcountries":"[\"Slovenia\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"COMPLETED","Add_on":"Other","Endpoint":"Early efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2024-10-08"},{"nctId":"NCT06238024","OrgName":"Suzhou Municipal Hospital of Anhui Province","Titlefull":"Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment: a Double-blind, Randomized, Placebo-controlled Trial","BriefSummary":"Tocilizumab may exert neuroprotective effects in patients with ischemic stroke undergoing endovascular treatment","ExperimentalDrugs":"[\"tocilizumab\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"COMPLETED","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":28,"Phase":"PHASE2","lastUpdateDate":"2024-09-23"},{"nctId":"NCT05967728","OrgName":"University of Calgary","Titlefull":"Testing of a System for Remote Ischemic Conditioning in Preparation for Clinical Trials in Cerebral Small Vessel Disease and Pre-hospital Stroke Care","BriefSummary":"This early phase trial will address the following key objectives:\n\n1. Completion of initial safety and tolerability testing of our viable prototype for remote ischemic conditioning (RIC) with patients with (a) CSVD and (b) acute ischemic stroke.\n2. Usability testing of the prototype with patients and healthcare professionals, with further optimization.\n\nApproximately 24 patients with CSVD will be recruited to use the RIC device daily for 60 days and provide feedback. They will be randomized in a 1:1 ratio to either true RIC therapy or sham control for the first 30 days, after which the sham group will cross over to receive true RIC for the remaining 30 days.\n\nFeasibility testing will be done in the mobile stroke unit on up to 10 patients with acute ischemic stroke.\n\nAn additional 10 stroke physicians and paramedics will conduct device usability testing and provide feedback.","ExperimentalDrugs":"[\"device: remote ischemic conditioning (ric) progammable device\"]","Allcountries":"[\"Canada\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"ENROLLING_BY_INVITATION","Add_on":"Other","Endpoint":"Other","total_Score":13,"Phase":"PHASE2","lastUpdateDate":"2024-12-28"},{"nctId":"NCT06241677","OrgName":"Chinese University of Hong Kong","Titlefull":"Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on Direct Oral Anticoagulants - A Prospective Multicenter Study","BriefSummary":"Direct oral anticoagulants (DOAC) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF). All four DOACs - apixaban, dabigatran, edoxaban, rivaroxaban - were associated with lower risks of major bleeding compared to warfarin. Listed as core essential medicines by the World Health Organization, DOAC prescriptions have been surging worldwide. In Hong Kong, approximately 80,000 patients received DOACs from January 2009 through December 2022 according to the Hospital Authority registry.\n\nThe widespread DOAC usage had created DOAC-specific clinical dilemmas that lack evidence-based treatment despite twenty years of prescribing experience. Ischemic stroke despite DOAC (IS-DOAC), in particular, may occur in up to 6% of DOAC users annually. Due to the in vivo anticoagulation effect, there had been concerns of intracerebral bleeding (ICH) with intravenous thrombolytic therapy (IVT) for acute IS-DOAC. Under the current guideline recommendations, most acute IS-DOAC are contraindicated to IVT (see Intravenous thrombolytic therapy), which resulted in only a small proportion of acute ISDOAC patients being able to receive IVT even if presented early. Nonetheless, our group found that majority of patients had a DOAC level of \\<50ng/mL only 24 hours after DOAC cessation (see work done by us), a level deemed clinically negligible and safe for thrombolytic therapy. Together with evolving clinical evidence discussed below, IS-DOAC patients maybe unnecessarily barred from IVT, thus compromised functional recovery.\n\nWith robust pharmacokinetic and retrospective clinical evidence to support, it is hypothesized that IVT are safe in IS-DOAC patient. The investigators hereby propose a prospective multicenter study to determine the efficacy and safety of IVT in acute IS-DOAC.","ExperimentalDrugs":"[\"alteplase or tenecteplase\"]","Allcountries":"[\"Hong Kong\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Only once","Status":"RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"mRS at 90 days","total_Score":27,"Phase":"NA","lastUpdateDate":"2026-02-21"},{"nctId":"NCT06358313","OrgName":"Kafrelsheikh University","Titlefull":"Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Small Vessel Stroke, a Randomized Controlled Single-blinded Trial","BriefSummary":"Along with the current clinical trial, the impact of adding atorvastatin or rosuvastatin in the first 24 hours on the clinical outcomes of first-ever small vessel stroke patients treated with clopidogrel and aspirin assessed through NIHSS, mRS, and possible adverse effects.","ExperimentalDrugs":"[\"atorvastatin 40mg\",\"rosuvastatin 20mg\"]","Allcountries":"[\"Egypt\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Late efficacy","total_Score":21,"Phase":"PHASE3","lastUpdateDate":"2026-04-20"},{"nctId":"NCT06807879","OrgName":"University of Lahore","Titlefull":"EFFECTS of OTAGO EXERCISES in ADDITION to ROUTINE PHYSICAL THERAPY on BALANCE and FUNCTIONAL ACTIVITIES in PATIENTS with STROKE.","BriefSummary":"Stroke is an extremely severe medical condition which is ranked as the second biggest cause of death worldwide as it claims an estimated 5.5 million lives per year. A stroke can result in enduring brain injury, prolonged disability, or fatality (Tsao et al., 2023) . There are two major types of stroke: Hemorrhagic stroke and Ischemic stroke. The most prevalent type is Ischemic, accounting for approximately 87% of strokes worldwide. It arises from a blockage in a blood vessel supplying the brain (Collaborators, 2022) . Also, the affected brain areas can result in functional limitations, cognitive changes, and emotional difficulties (Fihla, 2024) .\n\nMoreover, given the potential cost-effectiveness of OEP compared to more intensive rehabilitation methods, its implementation could offer a pragmatic solution to improving the quality of life for individuals grappling with the enduring consequences of ischemic stroke.\n\nTherefore, exploring the effectiveness of OEP in this specific population holds promise for advancing stroke rehabilitation strategies and potentially improving the lives of individuals living with the long-term effects of ischemic stroke.","ExperimentalDrugs":"[\"behavioral: modified otago exercise with routine care physical therapy\",\"behavioral: routine care physical therapy\"]","Allcountries":"[\"Pakistan\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"Other","Endpoint":"Late efficacy","total_Score":7,"Phase":"NA","lastUpdateDate":"2025-01-29"},{"nctId":"NCT06386874","OrgName":"BrainQ Technologies Ltd.","Titlefull":"The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (the \"EMAGINE 2.0\" Study)","BriefSummary":"This is a multicenter study that will be conducted at approximately 20 centers and up to 30 centers, if the sample size will be increased following interim assessment.\n\nThe Q Therapeutic System (BQ 3.0) is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery.\n\nThe Q Therapeutic System (BQ 3.0) is indicated for adjunctive use in a clinical facility or home setting, in addition to standard-of-care therapies.\n\n* In Stage 1 (starting 4-21 days after the index stroke event to day 90 post stroke), participants will be randomly assigned (1:1) to receive either active or the sham treatments, up to 5 times a week, and at least to a total of 45 treatments.\n* In Stage 2 (day 90 to day 180 post stroke), participants in both the active and the control group will be allowed to continue to receive active treatments, up to 5 times per week.\n* In stage 3 (day 180 to day 270 post stroke), participants will not receive any treatments and would be followed up until the final visit at day 270.\n\nEach session will last approximately 60 minutes, with stimulation activated for up to 40 minutes, in conjunction with a home-based exercise program. Treatments may be administered in the hospital, in the clinic or in a home setting.\n\nThe study will enroll 100-122 adult subjects who will be randomly assigned (1:1 allocation ratio) to either active or sham study intervention using the BQ 3.0 system.","ExperimentalDrugs":"[\"device: q therapeutic system (bq 3.0) - sham\",\"device: q therapeutic system (bq 3.0) - active\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":15,"Phase":"NA","lastUpdateDate":"2025-01-08"},{"nctId":"NCT06522282","OrgName":"Beijing Tiantan Hospital","Titlefull":"Emergency Stroke Unit for Acute Cerebrovascular Events--A Prospective, Multicenter, Week-wise Randomized, Controlled Trial ( ESU-ACE-D )","BriefSummary":"To compare the prognosis of patients with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) managed in a standard stroke unit adherent to guidelines versus managed in Emergency Stroke Unit (a new stroke unit based on low-field magnetic resonance imaging).","ExperimentalDrugs":"[\"combination product: emergency stroke unit based on 0.23-t mri\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 6 hours","TreatDur":"Day 1 only","Status":"RECRUITING","Add_on":"IVT excluded ; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":32,"Phase":"PHASE3","lastUpdateDate":"2024-09-27"},{"nctId":"NCT06752720","OrgName":"Hokkaido University Hospital","Titlefull":"Intracerebral Autologous Mesenchymal Stem Cell Transplantation Therapy for Patients with Ischemic Stroke in Chronic Phase: Phase 2a Clinical Trial","BriefSummary":"The goal of this clinical trial is to evaluate if autologous mesenchymal stem cell (HUNS001-01) transplantation therapy can provide neurological recovery in patients with chronic stage of stroke resulting in moderate to severe neurological sequelae. The main questions it aims to answer are:\n\nCan HUNS001-01 intracerebral transplantation demonstrate improvement in the mRS of disability for 1 year after intervention? Can HUNS001-01 intracerebral transplantation can be performed without any adverse events for 1 year after intervention?\n\nParticipants will receive the below interventions.\n\n* Screening for the eligibility to enroll the clinical trial (interview, blood test, imaging)\n* Harvest of platelet concentrates (PC)\n* Harvest of bone marrows (BM)\n* Receive intracerebral transplantation surgery of HUNS001-01\n* Post-operative rehabilitation\n* Follow-up studies (until 1 year or termination of the trial)","ExperimentalDrugs":"[\"stem cell transplantation\"]","Allcountries":"[\"Japan\"]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS","total_Score":22,"Phase":"PHASE2","lastUpdateDate":"2025-01-22"},{"nctId":"NCT06225076","OrgName":"People's Hospital of Zhengzhou University","Titlefull":"A Randomized Controlled Study to Explore the Effect of Stellate Ganglion Block in Dysphagic Patients With Bulbar Palsy After Ischemic Stroke","BriefSummary":"This is a randomized controlled study, including dysphagic patients with bulbar palsy after ischemic stroke who were received in the department of rehabilitation medicine in 3 hospitals in China. All patients are randomly allocated to the observation group or the control group. Both groups are provided with comprehensive rehabilitation. Besides, the observation group additionally undergoes the stellate ganglion block. At admission and after 20-day treatment, video fluoroscopic swallowing study, and penetration-aspiration scale, Functional Oral Intake Scale, Flexible laryngoscope are used to assess swallowing function.","ExperimentalDrugs":"[\"behavioral: comprehensive rehabilitation\",\"procedure: stellate ganglion block\",\"lidocaine hydrochloride\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"WITHDRAWN","Add_on":"Other","Endpoint":"Late efficacy","total_Score":11,"Phase":"NA","lastUpdateDate":"2024-03-02"},{"nctId":"NCT06127602","OrgName":"University of Illinois at Chicago","Titlefull":"NeuroMuscular Electrical Stimulation to Facilitate Perturbation-based REACtive Balance Training for Fall Risk Reduction Post-stroke: The REACTplusNMES Trial","BriefSummary":"The aim of this study is to compare the effectiveness of 6-weeks of reactive balance training (REACT) with and without neuromuscular electrical stimulation (NMES) to paretic lower limb muscles on biomechanical, clinical, neuromuscular and neuroplastic outcomes of reactive balance control. This project is a Phase-I study and incorporates a double-blinded, randomized controlled trial design.\n\nMethods: Forty-six individuals with chronic stroke will be recruited and screened for determining their eligibility for the study. Once enrolled, they will be randomized into either of the two groups: intervention group (23 participants) and control group (23 participants). Both groups will undergo series of pre-training assessments which includes a postural disturbance in the form of a slip- or trip-like perturbations and walking tests in laboratory environment. After the pre-training assessment, individuals will undergo 6-weeks of training (2 hour per session, 2 sessions per week). The intervention group will receive NMES with the REACT training and the control group will receive ShamNMES. NMES will be applied to the different muscle groups of the paretic lower limb using an advanced software which is able to synchronize muscle activation with the time of perturbation onset and according to the phases of gait. After training, both groups will again be tested on all the assessments performed pre training.\n\nThis study will help us understand the immediate therapeutic and mechanistic effects of REACT+NMES and inform stroke rehabilitation research and clinical practice. Our study will provide foundational evidence for future use of NMES to implement clinically applicable neuromodulation adjuvants to reactive balance training, which could be leveraged for designing more effective future interventions for fall-risk reduction.","ExperimentalDrugs":"[\"behavioral: reactive balance training with neuromuscular electrical stimulation\",\"behavioral: reactive balance training without neuromuscular electrical stimulation\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":11,"Phase":"NA","lastUpdateDate":"2025-07-31"},{"nctId":"NCT06459388","OrgName":"Riphah International University","Titlefull":"Effects of Stabilizing Reversal and Rhythmic Stabilization Versus Pelvic Proprioceptive Neuromuscular Facilitation on Trunk Control, Postural Stability and Mobility in Stroke Patients","BriefSummary":"The goal of this clinical trial is to compare the effects of stabilizing reversal and rhythmic stabilization versus pelvic proprioceptive neuromuscular facilitation on trunk control, postural stability and mobility in stroke patients. The main question it aims to answer is:\n\nIs there any difference in effects of stabilizing reversal and rhythmic stabilization versus pelvic proprioceptive neuromuscular facilitation on trunk control, postural stability and mobility in stroke patients?\n\nResearchers will compare stabilizing reversal and rhythmic stabilization to pelvic proprioceptive neuromuscular facilitation to see if there any difference in effects of stabilizing reversal and rhythmic stabilization versus pelvic proprioceptive neuromuscular facilitation on trunk control, postural stability and mobility in stroke patient.\n\nParticipants will be divided into two groups:\n\nGroup A will receive stabilizing reversals and rhythmic reversals technique. The patient will perform 3 sets with 15 repetitions in each session, 5 days per week for 8 weeks.\n\nGroup B will receive Pelvic PNF protocol. The treatment protocol will be followed 5 days a week for 8 weeks (i.e. 20 sessions) and each session will last for 30 minutes.","ExperimentalDrugs":"[\"other: stabilizing reversals and rhythmic stabilization\",\"other: pelvic proprioceptive neuromuscular facilitation\"]","Allcountries":"[\"Pakistan\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":14,"Phase":"NA","lastUpdateDate":"2024-12-20"},{"nctId":"NCT06042179","OrgName":"Medical University of South Carolina","Titlefull":"Impact of Intense Physical Therapy on Functional Mobility Outcomes in the Acute Stroke Population - Phase II","BriefSummary":"The Department of Physical Therapy in conjunction with the Comprehensive Stroke Center at the Medical University of South Carolina (MUSC) seeks support for developing an evidence-based approach for the mobilization of patients within the first 24 hours of admission for an acute stroke and for increasing the frequency and intensity of acute PT services while inpatient. This evidence will prepare physical therapists and guide practice in the delivery of acute stroke mobilization in the hospital setting to optimize length of stay, disposition planning, and enhance long term recovery outcomes.\n\nThis research hopes to challenge the clinical paradigm regarding the possibility of decreased functional outcomes with early mobilization post stroke. The investigators acknowledge that acute stroke patients may not be able to tolerate an extensive early mobility program but may benefit from shorter more frequent sessions of therapy early in their recovery. Throughout the literature, there are clinical practice guidelines for both the inpatient rehabilitation and outpatient therapy sectors and post stroke recovery. Little is known about the contribution of therapy services in the acute hospital setting and therapy's impact on long term functional gains. This study will compare outcomes (AM-PAC, PASS, length of stay and post discharge mRS) across four groups- 1) standard of care 2) increased frequency 3) increased intensity 4) combined increased frequency and intensity. The goal of this project is to determine the appropriate dosage of post stroke mobility in the acute care hospital setting.","ExperimentalDrugs":"[\"behavioral: frequent pt\",\"behavioral: intense pt\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Other","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"Other","Endpoint":"Late efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2026-03-24"},{"nctId":"NCT05955326","OrgName":"Pharmazz, Inc.","Titlefull":"A Prospective, Multicentric, Randomized, Double-blind, Parallel, Phase IV Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke","BriefSummary":"This is a prospective, multicenter, randomized, double-blind, parallel, phase IV study designed to evaluate the safety and efficacy of sovateltide (PMZ-1620, IRL-1620) as a potential treatment for cerebral ischemic stroke.","ExperimentalDrugs":"[\"sovateltide\"]","Allcountries":"[\"India\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"Safety","total_Score":24,"Phase":"PHASE4","lastUpdateDate":"2025-12-26"},{"nctId":"NCT06244914","OrgName":"National Cheng-Kung University Hospital","Titlefull":"Combining Closed-loop Transcutaneous Auricular Vagus Nerve Stimulation and Focal Transcranial Direct Current Stimulation as an Adjuvant Treatment for Acute and Subacute Strokes","BriefSummary":"Ischemic stroke, the most prevalent neurological disorder, is treated with medication and thrombectomy but with limited success, especially in chronic stages where traditional rehabilitation is the primary option. Stroke often leads to post-stroke autonomic imbalance, deteriorating functional outcomes and increasing recurrence risk. Emerging non-pharmacological treatments like Transcutaneous Auricular Vagus Nerve Stimulation (VNS) and Focused Transcranial Direct Current Stimulation (tDCS) offer new possibilities. VNS targets post-stroke tissue injury and promotes healing and neurogenesis, while tDCS aims to enhance motor learning by rebalancing brain activity. Both therapies seek to improve outcomes in both acute and chronic stroke stages.","ExperimentalDrugs":"[\"device: tdcs stimulation\",\"device: tavns stimulation\",\"device: sham tavns stimulation\",\"device: sham tdcs stimulation\"]","Allcountries":"[\"Taiwan\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":16,"Phase":"NA","lastUpdateDate":"2024-03-18"},{"nctId":"NCT06094478","OrgName":"University of Chicago","Titlefull":"Implementation of a Stroke Protocol for Emergency Evaluation and Disposition","BriefSummary":"Most stroke patients are initially evaluated at the closest hospital but some need to be transferred to a hospital that can provide more advanced care. The \"Door-In-Door-Out\" (DIDO) process at the first hospital can take time making transferred patients no longer able to get the advanced treatments. This study will help hospitals across the US \"stand up\" new ways to evaluate stroke patients, decide who needs to be transferred, and transfer them quickly for advanced treatment.","ExperimentalDrugs":"[\"behavioral: hi-speed protocol\"]","Allcountries":"[\"United States\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":5,"Phase":"NA","lastUpdateDate":"2026-05-18"},{"nctId":"NCT06137300","OrgName":"The First Hospital of Jilin University","Titlefull":"Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke：a Multicentre, Prospective, Randomised, Open-label, Blinded-Endpoint Trial","BriefSummary":"The purpose of this study is to evaluate the safety and efficacy of urinary kallidinogenase treatment in patients with large artery atherosclerotic acute ischemic stroke.","ExperimentalDrugs":"[\"urinary kallidinogenase for injection\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"mRS at 90 days","total_Score":20,"Phase":"NA","lastUpdateDate":"2024-02-25"},{"nctId":"NCT06492265","OrgName":"Beijing Tiantan Hospital","Titlefull":"Emergency Stroke Unit for Acute Cerebrovascular Events--A Prospective, Multicenter, Week-wise Randomized, Controlled Trial ( ESU-ACE-B )","BriefSummary":"To compare the door-to-puncture time of patients with hyperacute ischemic stroke (between 4.5-6 hours after the onset of symptoms) treated in a standard stroke unit adherent to guidelines versus treated in Emergency Stroke Unit (a new stroke unit based on low-field magnetic resonance imaging).","ExperimentalDrugs":"[\"combination product: emergency stroke unit based on 0.23-t mri\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 6 hours","TreatDur":"Day 1 only","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"Other","total_Score":26,"Phase":"PHASE2","lastUpdateDate":"2024-08-09"},{"nctId":"NCT06573840","OrgName":"NeuroGlove LLC","Titlefull":"A Functional MRI Study: Assessing Brain Function in Post Stoke Patients","BriefSummary":"This is a prospective, single center, observational clinical study containing two cohorts the healthy cohort and post stroke cohort. A total of 13 subjects will be enrolled. Three (3) healthy volunteers will be enrolled in the healthy cohort. Ten (10) subjects who have recently experienced a mild to moderate acute ischemic stroke will be enrolled in the post stroke cohort.","ExperimentalDrugs":"[\"device: neuroglove\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Only once","Status":"WITHDRAWN","Add_on":"Other","Endpoint":"Other","total_Score":12,"Phase":"NA","lastUpdateDate":"2024-08-26"},{"nctId":"NCT06315231","OrgName":"Simcere Pharmaceutical Co., Ltd","Titlefull":"Efficacy and Safety of Edaravone Dexborneol Sublingual Tablet for Post-stroke Cognitive Impairment in Patients With Acute Ischemic Stroke: a Multicenter, Randomized, Double-blind, Placebo-controlled, Exploratory Phase II Clinical Trial.","BriefSummary":"This is a multicenter, randomized, double-blind, placebo-controlled, exploratory Phase II clinical trial.\n\nThe goal of this clinical trial is to assess the safety and efficacy of edaravone dexborneol sublingual tablets for post-stroke cognitive impairment in patients with acute ischemic stroke.\n\nParticipants will be required to receive 24 weeks treatment of edaravone dexborneol sublingual tablets or placebo during this study. The safety and efficacy endpoints will be compared in the patients with edaravone dexborneol sublingual tablets or placebo.","ExperimentalDrugs":"[\"edaravone dexborneol sublingual tablet\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT optional; EVT excluded","Endpoint":"Other","total_Score":16,"Phase":"PHASE2","lastUpdateDate":"2025-09-01"},{"nctId":"NCT07119021","OrgName":"Beijing Tiantan Hospital","Titlefull":"Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)","BriefSummary":"EXCELLENT was a prospective, multicenter, randomized, double-blind, placebo-controlled clinical study in which participants were randomized participants were randomized (1:1) to receive either IV thrombolysis + edaravone or IV thrombolysis + matched placebo (same volume of tablets without drug components), and the primary outcome was the proportion of patients with transformed bleeding on MRI at 72 hours following revascularization therapy.","ExperimentalDrugs":"[\"intravenous thrombolysis + edaravone\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 4.5 hours","TreatDur":"Day 1 only","Status":"RECRUITING","Add_on":"IVT mandatory; EVT optional","Endpoint":"Safety","total_Score":22,"Phase":"PHASE4","lastUpdateDate":"2025-08-11"},{"nctId":"NCT06138210","OrgName":"Xuanwu Hospital, Beijing","Titlefull":"The Effect of Exosomes Derived From Human Induced Pluripotent Stem Cell (GD-iExo-003) in Acute Ischemic Stroke: an Exploratory Study.","BriefSummary":"This is a multicenter, randomized, double-blinded, placebo-controlled, dose-escalation trial. The objective of this study is evaluating safety and preliminary efficacy of intravenous exosomes derived from human induced pluripotent stem cell (GD-iExo-003) in acute ischemic stroke.","ExperimentalDrugs":"[\"exosomes derived from human induced pluripotent stem cell for injection\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"RECRUITING","Add_on":"IVT optional; EVT optional","Endpoint":"Safety","total_Score":17,"Phase":"PHASE1","lastUpdateDate":"2025-11-26"},{"nctId":"NCT06967025","OrgName":"Tianjin Huanhu Hospital","Titlefull":"Ischemic Postconditioning in Acute Stroke Patients Receiving Endovascular Thrombectomy: Mechanistic Exploration Through a Randomized Controlled Pilot Trial","BriefSummary":"This clinical trial will evaluate whether on-site ischemic postconditioning (IPostC) improves outcomes in acute stroke patients receiving endovascular thrombectomy (EVT) and explore its mechanisms. The investigators aim to answer: (1) Is on-site IPostC effective compared to EVT alone? (2) What molecular markers and cellular pathways does on-site IPostC influence? Participants will be randomized to EVT alone or EVT+IPostC (4 cycles of 2-minute balloon occlusion/reperfusion). The investigators will assess infarct size, functional outcomes, biomarkers (e.g., multi-omics, ELISA, and clinical laboratory parameters), and safety (e.g., mortality, procedure-related complications).","ExperimentalDrugs":"[\"procedure: endovascular thrombectomy\",\"procedure: ischemic postconditioning\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"COMPLETED","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":28,"Phase":"PHASE2","lastUpdateDate":"2025-12-07"},{"nctId":"NCT06064747","OrgName":"Beijing Tiantan Hospital","Titlefull":"Low-Frequency REpetitive TRanscranial Magnetic Stimulation Combined With Endovascular Treatment in ACute Ischemic StrokE (RETRACE-II): A Randomized, Double-Blind, Sham-Controlled, Phase 2 Pilot Trial","BriefSummary":"This is a multicenter, randomized, double-blind, sham-controlled, investigator-initiated clinical study, to evaluate the clinical efficacy and safety of LF-rTMS in rescuing the ischemic penumbra, reducing disability rate and improving functional outcome in patients with acute ischemic stroke receiving early endovascular recanalization (bridging or direct endovascular therapy)","ExperimentalDrugs":"[\"device: lf-rtms\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"3 days or less","Status":"COMPLETED","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":22,"Phase":"NA","lastUpdateDate":"2026-04-03"},{"nctId":"NCT06459349","OrgName":"Riphah International University","Titlefull":"Effects of Exteroceptive and Proprioceptive Sensory Stimulation Versus Sensorimotor Therapy on Spasticity, Motor Function and Activities of Daily Living in Patients With Stroke","BriefSummary":"To compare effects of exteroceptive and proprioceptive sensory stimulation versus sensorimotor therapy on spasticity, motor function and activities of daily living in patients with stroke","ExperimentalDrugs":"[\"other: exteroceptive and proprioceptive sensory stimulation training\",\"other: sensorimotor therapy group\"]","Allcountries":"[\"Pakistan\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"COMPLETED","Add_on":"Other","Endpoint":"Late efficacy","total_Score":12,"Phase":"NA","lastUpdateDate":"2024-10-28"},{"nctId":"NCT04916197","OrgName":"Beijing Chao Yang Hospital","Titlefull":"Effect of Postoperative Prolonged Sedation With Dexmedetomidine After Successful Reperfusion With Endovascular Thrombectomy on Long-term Prognosis in Patients With Acute Ischemic Stroke (PPDET)","BriefSummary":"Dexmedetomidine can attenuate the activity of the sympathetic nervous system under stress response and improve ischemia-reperfusion injury. The investigators hypothesized that the prolonged sedation of dexmedetomidine after successful reperfusion of endovascular thrombectomy may improve the clinical outcome of acute ischemic stroke patients.","ExperimentalDrugs":"[\"dexmedetomidine prolonged sedation\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Other","TreatDur":"Day 1 only","Status":"RECRUITING","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":21,"Phase":"PHASE4","lastUpdateDate":"2023-12-19"},{"nctId":"NCT06196320","OrgName":"Beijing Tiantan Hospital","Titlefull":"Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5 Improving Neurological Functional Outcomes in Basilar Artery Occlusion With Tenecteplase in Extended Time Window: Multicentre, Prospective, Open-label, Blinded Endpoint (PROBE), Phase 3, Randomized Controlled Trial","BriefSummary":"The trial is a multicentre, prospective, open-label, blinded endpoint (PROBE), phase 3, randomized controlled design. Patients with acute ischemic stroke due to basilar artery occlusion presenting within 24 hours will be randomized 1:1 to intravenous tenecteplase (0.25mg/kg, maximum 25mg) ± thrombectomy or 'best practice'which may be alteplase (0.9mg/kg) within 4.5 hours from stroke onset or standard care (no lysis) ± thrombectomy at treating clinician's discretion.","ExperimentalDrugs":"[\"tenecteplase\",\"best practice (which may include intravenous alteplase)\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Only once","Status":"COMPLETED","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":33,"Phase":"PHASE3","lastUpdateDate":"2025-11-21"},{"nctId":"NCT06765018","OrgName":"University Hospital Marburg","Titlefull":"Tongue Brush (Orabrush) for Reducing Aspiration Pneumonia in Stroke Patients","BriefSummary":"The investigators conduct a controlled prospective experimental intervention study to examine whether the use of a tongue brush (Orabrush) can improve the rate of aspiration pneumonia and dysphagia in patients with ischemic stroke. Secondary outcomes include the impact on bacterial tongue colonization, the Tongue Coating Index, and the length of stay of the patients.The patients will be recruited in the Stroke Unit of the Department of Neurology from November 2024 until approximately October 2026.","ExperimentalDrugs":"[\"device: tongue brush (orabrush)\"]","Allcountries":"[\"Germany\"]","FirstAdminInter":"Other","TreatDur":"3 days or less","Status":"COMPLETED","Add_on":"Other","Endpoint":"Early efficacy","total_Score":10,"Phase":"NA","lastUpdateDate":"2026-03-15"},{"nctId":"NCT06265051","OrgName":"Tongji Hospital","Titlefull":"Safety and Efficacy of Adjunct Tirofiban Treatment After Successful Mechanical Thrombectomy Recanalization in Acute Anterior Circulation Ischemic Stroke- A Multicenter, Prospective, Double-blind, Randomized Trial","BriefSummary":"Acute ischemic stroke with large vessel occlusion is a frequently occurring life-threatening condition. Although endovascular treatment can effectively open occluded vessels, the successful reperfusion rate exceeds 80%, but the rate of good prognosis is less than 50%. The current clinical focus is on how to improve futile recanalization. Tirofiban is widely used in the treatment of stroke, as it can effectively prevent vascular reocclusion and improve microcirculation perfusion. It has the potential to improve futile recanalization, but there is a lack of high-level evidence-based medical support. This multicenter, prospective, double-blind, randomized controlled trial was conducted to assess the effectiveness and safety of sequential tirofiban therapy following successful mechanical thrombectomy within 24 hours of onset.","ExperimentalDrugs":"[\"tirofiban\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within 24 hours","TreatDur":"Longer than 3 days","Status":"COMPLETED","Add_on":"IVT optional; EVT mandatory","Endpoint":"mRS at 90 days","total_Score":26,"Phase":"PHASE2","lastUpdateDate":"2026-03-08"},{"nctId":"NCT05104593","OrgName":"Complejo Hospitalario Universitario de Albacete","Titlefull":"An Integrated Solution for Sustainable Care for Multimorbid Elderly Patients With Mild Cognitive Impairment or Mild Dementia (CAREPATH)","BriefSummary":"The CAREPATH will conduct Technical Validation and Usability (TVU) study by involving ≥ 45 target end users (16 patients with MCI or mild dementia with their informal caregivers and 16 healthcare professionals from various disciplines) and Clinical Investigation (CI) study involving ≥ 200 patients (≥ 100 users to pilot the CAREPATH platform and ≥ 100 patients as reference cases). Both of these pilot studies will be coordinated in four European countries (Spain, Romania, Germany and UK) with diverse health and social care systems, ICT landscape/digital maturity of healthcare provision and dementia national programs, which will allow for strengthening the evidence base on health outcomes and efficiency gains.\n\nThe CAREPATH outcomes can be summarized as:\n\n1. An Integrated Care Platform that jointly addresses multimorbidity, dementia and diminished intrinsic capacity and optimally manages healthcare interventions for its users (patients, informal caregiver, healthcare providers, etc).\n2. Technical Validation and Usability (TVU) study involving over 45 users and Clinical Investigation (CI) involving over 200 patients that will be conducted in four European countries (Spain, Romania, Germany and UK) during two years and mobilizing the other necessary actors, such as caregivers and healthcare professionals, for the validation of healthcare interventions.\n3. Dementia / Multimorbidity Guidelines that will be conceived for best healthcare delivery.\n4. Health Economics Impact Assessment for healthcare cost effectiveness and care provision equalities. The incremental cost-effectiveness and the incremental cost-utility ratio would allow revealing the incremental cost (or the potential savings) per unit of benefit of switching from usual care to CAREPATH-an integrated patient-centred approach- in multimorbid elderly patients with dementia, and therefore, to determinate whether the CAREPATH approach would be considered as a cost-effective alternative.","ExperimentalDrugs":"[\"other: intervention tested (carepath)\"]","Allcountries":"[\"Spain\"]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"UNKNOWN","Add_on":"Other","Endpoint":"Other","total_Score":6,"Phase":"NA","lastUpdateDate":"2023-08-29"},{"nctId":"NCT07645560","OrgName":"Beijing Tiantan Hospital","Titlefull":"Lesion Network Mapping-Navigated Continuous Theta-Burst Stimulation for Motor Recovery in Acute Ischemic Stroke: A Randomized, Double-Blind, Sham-Controlled, Multicentre Phase 2b Trial: MASTRE-2","BriefSummary":"This Phase 2b study will evaluate whether lesion network mapping-guided continuous theta burst stimulation (cTBS) can improve recovery after acute ischemic stroke. The treatment uses each participant's brain imaging to identify individualized stimulation targets related to stroke symptoms. Participants will receive either active cTBS or a sham procedure in addition to standard stroke care. The study will assess the efficacy and safety of this personalized brain stimulation approach and support planning for future confirmatory trials.","ExperimentalDrugs":"[\"device: lnm-navigated ctbs\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":18,"Phase":"PHASE2","lastUpdateDate":"2026-06-12"},{"nctId":"NCT07644234","OrgName":"Sichuan Provincial People's Hospital","Titlefull":"Platelet Aggregation Function-Guided De-Escalation Antiplatelet Therapy in Patients With Acute Ischemic Stroke","BriefSummary":"This multicenter, prospective, open-label, randomized controlled trial will evaluate whether platelet aggregation function-guided de-escalation of antiplatelet therapy is non-inferior in efficacy and superior in safety compared with standard dual antiplatelet therapy in patients with acute minor ischemic stroke or high-risk transient ischemic attack who are sensitive to clopidogrel.\n\nParticipants who present within 48 hours of symptom onset and meet the eligibility criteria will receive loading doses of clopidogrel and aspirin, followed by platelet aggregation function testing. Eligible clopidogrel-sensitive participants will be randomized to receive either 7 days of dual antiplatelet therapy followed by clopidogrel monotherapy or standard 21-day dual antiplatelet therapy followed by single antiplatelet therapy. The primary efficacy outcome is new stroke within 90 days after randomization.","ExperimentalDrugs":"[\"clopidogrel\",\"aspirin\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Within first 2 days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"IVT excluded ; EVT excluded","Endpoint":"Late efficacy","total_Score":16,"Phase":"PHASE4","lastUpdateDate":"2026-06-08"},{"nctId":"NCT07645586","OrgName":"Beijing Tiantan Hospital","Titlefull":"Lesion Network Mapping-Navigated Continuous Theta-Burst Stimulation for Motor Recovery in Acute Ischemic Stroke: A Randomized, Double-Blind, Sham-Controlled, Multicentre Phase 3 Trial: MASTRE-3","BriefSummary":"This Phase 3 study will evaluate whether lesion network mapping-guided continuous theta burst stimulation (cTBS) can improve recovery after acute ischemic stroke. The treatment uses each participant's brain imaging to identify individualized stimulation targets related to stroke symptoms. Participants will receive either active cTBS or a sham procedure in addition to standard stroke care. The study will assess whether this personalized brain stimulation approach improves functional recovery and is safe for patients after ischemic stroke.","ExperimentalDrugs":"[\"device: lnm-navigated ctbs\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"mRS at 90 days","total_Score":20,"Phase":"PHASE3","lastUpdateDate":"2026-06-12"},{"nctId":"NCT06545734","OrgName":"Tianjin Huanhu Hospital","Titlefull":"Effectiveness and Biological Mechanism of Direct Ischemic Post-conditioning for Acute Stroke Patients Due to Large Vessel Occlusion: A Randomized Controlled Pilot Trial","BriefSummary":"The goal of this clinical trial is to determine if direct ischemic post-conditioning (IPostC) can alleviate ischemic-reperfusion injury (I/R) in patients who have undergone endovascular thrombectomy (EVT). Additionally, the study aims to explore the underlying mechanisms of direct IPostC.\n\nThe primary questions this trial seeks to answer are:\n\n1. Is direct IPostC effective for acute stroke patients with large vessel occlusion?\n2. What are the underlying mechanisms of direct IPostC?\n\nParticipants will be randomly assigned to one of two groups: an EVT alone group or an EVT plus direct IPostC group. Direct IPostC will be administered immediately after EVT through four cycles of mechanical interruptions of reperfusion. We will evaluate outcomes based on final infarct volume, infarct volume growth, clinical parameters, and I/R-related imaging and laboratory biomarkers. Additionally, an exploratory multi-omics analysis will be conducted to uncover the detailed mechanisms of direct IPostC.","ExperimentalDrugs":"[\"procedure: endovascular therapy\",\"procedure: direct ischemic post-conditioning\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Other","TreatDur":"Only once","Status":"COMPLETED","Add_on":"IVT optional; EVT mandatory","Endpoint":"Early efficacy","total_Score":23,"Phase":"PHASE2","lastUpdateDate":"2026-06-10"},{"nctId":"NCT07647666","OrgName":"Shanghai Pudong New Area Gongli Hospital","Titlefull":"Translational Application of an Oropharyngeal Flushing Suction Tube Combined With Laryngoscope for Improving Prognosis in Stroke-Associated Pneumonia: A Prospective Randomized Controlled Trial","BriefSummary":"Stroke-associated pneumonia is a common and clinically important complication after acute ischemic stroke, especially in non-intubated patients with impaired consciousness and reduced cough or swallowing reflexes. Conventional oral or nasal suction may be insufficient for removing deep oropharyngeal secretions. This prospective randomized controlled trial will evaluate whether a patented oropharyngeal flushing suction tube combined with direct laryngoscopy reduces the 28-day incidence of stroke-associated pneumonia compared with laryngoscope-guided standard suction and conventional oral/nasal suction.","ExperimentalDrugs":"[\"device: oropharyngeal flushing suction tube\",\"procedure: laryngoscope-guided oropharyngeal suction\",\"device: standard suction catheter\",\"procedure: conventional oral or nasal suction\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Other","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":9,"Phase":"NA","lastUpdateDate":"2026-06-17"},{"nctId":"NCT07651332","OrgName":"Capital Medical University","Titlefull":"Placebo-Controlled, Double-Blind, Phase 2 Trial of Probiotic Supplementation in Acute Ischemic Stroke","BriefSummary":"The primary objective of this study is to evaluate the effect of daily oral administration of the probiotic supplement OMNi-BiOTiC® SR-9 for 90 days, compared to placebo, on gut microbiome beta diversity in patients aged 60 years or older with acute ischemic stroke.","ExperimentalDrugs":"[\"dietary supplement: probiotic supplement omni-biotic® sr-9\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":13,"Phase":"PHASE2","lastUpdateDate":"2026-06-16"},{"nctId":"NCT07649135","OrgName":"University of Minnesota","Titlefull":"Feasibility of Engaging Stroke Survivors in a Brief Step Count Intervention During Chronic Stroke","BriefSummary":"The goal of this study is to explore the feasibility of a new approach to rehabilitation that focuses on step count. Participants will complete 6 telephone or Zoom-based sessions with an occupational therapist over 6 weeks and use a step count tracker during that time. They will also complete questionnaires, assessments, surveys, and physical activity measurements during study weeks 0 (baseline), 3 (mid-point), 7 (post-intervention) and 12 (follow-up).","ExperimentalDrugs":"[\"behavioral: physical activity chats after stroke (pa-chats)\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":10,"Phase":"NA","lastUpdateDate":"2026-06-16"},{"nctId":"NCT07654582","OrgName":"Cairo University","Titlefull":"Effect of Adding Augmented Cues to Physical Therapy Intervention on Hand Function Post Stroke Patients","BriefSummary":"This study aims to investigate the effect of adding augmented cues to conventional physical therapy intervention on hand function in patients with post-stroke hemiparesis. Fifty patients with subacute ischemic stroke will be randomly assigned to either a study group receiving augmented cue-based training in addition to conventional physical therapy or a control group receiving conventional physical therapy alone. Hand function will be assessed before and after the intervention period using the Nine-Hole Peg Test (NHPT), hand grip strength measured by a dynamometer, and pressure pain threshold measured by a pressure algometer. The findings of this study may provide evidence regarding the effectiveness of augmented cue-based rehabilitation strategies in improving hand function after stroke.","ExperimentalDrugs":"[\"other: conventional physical therapy\",\"device: musicgloves training\"]","Allcountries":"[]","FirstAdminInter":"Beyond two days","TreatDur":"Longer than 3 days","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-06-13"},{"nctId":"NCT07650110","OrgName":"Assistance Publique - Hôpitaux de Paris","Titlefull":"Collection Biologique de la Cohorte Des Maladies Rares Des Vaisseaux du Cerveau et de l'œil - 2","BriefSummary":"CERVCO is the French National Reference Centre for Rare Cerebrovascular and Retinal Diseases, accredited by the Ministry of Health since 2005. Since 2017, CERVCO has coordinated the MRVC cohort, a prospective cohort of patients with rare vascular diseases of the brain and retina, and established the associated B-MRVC biobank in 2020 to support translational research and biomarker discovery.\n\nDue to the rarity and heterogeneity of these disorders, centralized longitudinal collection of clinical data and biological samples is essential to improve understanding of disease mechanisms, identify biomarkers of progression and prognosis, and facilitate the development of new diagnostic and therapeutic approaches.\n\nThe present study aims to expand this longitudinal biobank, enable national and international collaborative research through controlled sample sharing, and establish reference control samples to support biomarker validation.","ExperimentalDrugs":"[]","Allcountries":"[]","FirstAdminInter":"Not AIS","TreatDur":"Other","Status":"NOT_YET_RECRUITING","Add_on":"Other","Endpoint":"Other","total_Score":4,"Phase":"NA","lastUpdateDate":"2026-06-10"},{"nctId":"NCT06049498","OrgName":"Dongzhimen Hospital, Beijing","Titlefull":"Efficacy and Safety of Mongolian Medicine ZhenBao Pills on Limb Function Recovery After Acute Ischemic Stroke: a Randomized Double-blinded Placebo-controlled Trial.","BriefSummary":"The trial was designed to test the hypothesis that treatment with Mongolian Medicine ZhenBao Pills has a positive effect on upper-limb motor recovery after acute ischemic stroke.","ExperimentalDrugs":"[\"mongolian medicine zhenbao pills\"]","Allcountries":"[\"China\"]","FirstAdminInter":"Beyond two days","TreatDur":"Other","Status":"COMPLETED","Add_on":"Other","Endpoint":"Late efficacy","total_Score":13,"Phase":"NA","lastUpdateDate":"2026-06-16"}]